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Abstract 
While the existence of protein was first described by Berzelius and Mulder back 
in 1838 and a single empirical formula noted (C400H620N100O120P1S1) (Vickery, 
1950, Brand, 1946), early protein-based research was limited to the analysis of 
proteins which could be easily purified in large quantities, such as those 
obtained from blood, egg whites and those obtainable from slaughterhouses, 
such as digestive and metabolic enzymes (Chapman, 2005). Indeed, despite the 
development of recombinant deoxyribonucleic acid technologies in the 1970s 
(enabling protein expression) and the increasing sensitivity of techniques which 
enable the identification and sequencing of proteins separated by gel 
electrophoresis (Patterson and Aebersold, 2003), it was not until the late 1980s, 
with the description of soft biomolecule ionisation that large scale proteomic 
analyses were undertaken, based upon the use of mass spectrometry (Guerrera 
and Kleiner, 2005). 
 
While early mass spectrometry-based proteomic analyses focussed on the 
systematic identification of a great number of proteins within a single organism, 
the field of proteomics is now becoming increasingly quantitative (Baak et al., 
2005), enabling the relative comparison of protein expression patterns between 
phenotypes, but also the targeted absolute quantification of specific proteins. 
 
During this project, a stable isotopically labelled internal standard based 
absolute quantitative technique, first described by Gerber and co-workers in 
2003 (S. A. Gerber et al., 2003), was applied to the absolute quantification of 
three families of multiple protein isoforms. This area of research is of particular 
scientific interest as it is thought that up to 95% of human multi-exon genes may 
be subject to alternative splicing, making alternative splicing the rule, not the 
exception (Pan et al., 2008a). Indeed alternative splicing has also been 
implicated as both a cause and a consequence of disease. This technique should 
therefore enable both the confirmation of disease, based upon the identification 
of a set of phenotype specific protein biomarkers, but also the mapping of a 
disease’s progression (Venables, 2004). 
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During this study, stable isotopically labelled internal standard peptides were 
selected for the absolute quantification of 11 confirmed protein isoforms, and 
two predicted protein isoforms. In addition, a separate MRM based LC-MS 
acquisition method was developed for the absolute quantification of each of the 
three families of protein isoforms (A-Raf, PDE4B and SERCA2) within a single 
analysis, and finally, these acquisition methods were applied to the absolute 
quantification of a range of immunoprecipitated, exogenously expressed protein 
isoforms. This project was, however, hindered by the sensitivity of the mass 
spectrometers available for use, preventing these acquisition methods from 
being applied to the absolute quantification of the endogenous levels of protein 
expression. 
 
While beyond the scope of this project, the further development of this 
quantitative technique should enable future researchers to: (i) Quantify each 
endogenously expressed protein isoform within a family of multiple protein 
isoforms. (ii) Assess any changes in the expression of each isoform in a range of 
cellular states, and (iii) Assess how a targeted drug treatment may affect the 
expression ratio of these protein isoforms. 
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Definitions / Abbreviations 
% Percent 
oC Degrees Celsius 
2D-LC 2D-liquid chromatography 
2DGE 2D-SDS-PAGE 
amu Atomic mass unit 
A-Raf WT A-Raf wild type 
AAA Amino acid analysis 
AKAP A-kinase anchoring protein 
ALS Acid labile surfactants 
AMBIC Ammonium bicarbonate 
ANOVA Analysis of variance 
AQUA Absolute quantification 
ARF6 ADP ribosylation Factor six GTPase 
ASK-1 Apoptosis signal-regulating kinase 1 
ATP Adenosine-5'-triphosphate 
BLAST Basic local alignment search tool 
cAMP 3'-5'-cyclic adenosine monophosphate  
C-terminal Carboxy-terminal 
Ca2+ Calcium 
cDNA Complementary DNA 
CoV Coefficient of variation 
CID Collision induced dissociation 
CO2 Carbon dioxide 
Cps Counts per second 
CR1 Conserved region one (Raf) 
CR2 Conserved region two (Raf) 
CR3 Conserved region three (Raf) 
CRD Cys-rich domain (Raf) 
dNTP Deoxyribonucleotide triphosphate 
DA-Raf-1 Deleted A-Raf 1 
DA-Raf-2 Deleted A-Raf 2 
DC Direct-current 
DEX Glucocorticoid dexamethasone 
DIGE  Difference gel electrophoresis 
DISC  Disrupted-in-Schizophrenia-1 
DMS  Dimethyl sulfide 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid  
DTT  Dithiothreitol 
eV  Electron volt 
ECD  Electron capture dissociation 
EDTA  Ethylenediaminetetraacetic acid 
EGF  Epidermal growth factor 
EPI  Enhanced product ion 
ER  Endoplasmic reticulum 
ERK  Extracellular signal-regulated kinases 
ESI  Electrospray ionisation 
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Fmoc  Fluorenylmethyloxycarbonyl 
FA  Formic acid 
FT-ICR Fourier transform-ion cyclotron resonance 
GDP  Guanosine-5'-triphosphate 
GTP  Guanosine-5'-triphosphate 
hnRNP H Heterogeneous nuclear ribonucleoprotein H 
H0  Null hypothesis 
H2O  Water 
HCCA  α-cyano-4-hydroxycinaminic acid 
HCl  Hydrochloric acid 
HPLC  High pressure liquid chromatography 
iTRAQ  Isobaric tags for relative and absolute quantitation 
IAA  Iodoacetamide 
ICAT  Isotope-coded affinity tags 
IP  Immunoprecipitate 
IPG  Immobilized pH gradient 
IRMPD  Infrared multiphoton dissociation 
IS  Internal standard 
LoD  Limit of detection 
LC  Liquid chromatography 
LIT  Linear ion trap 
LLOQ  Lower limit of quantification 
m/z  Mass to charge ratio 
min  Minute 
mRNA  Messenger ribonucleic acid 
M  Molar 
MeCN  Acetonitrile 
MeOH  Methanol 
MALDI  Matrix-assisted laser desorption / ionisation 
MAPK  Mitogen activated protein kinase 
MRM  Multiple reaction monitoring 
MS  Mass spectrometry 
MS/MS Tandem MS 
MST2  Mammalian sterile 20-like kinase 
MW  Molecular weight 
N-terminal Amino-terminal 
NaNO2  Sodium nitrite 
NO  Nitric oxide 
PCR  Polymerase chain reaction 
PDE  Phosphodiesterase 
PDGF  Platelet-derived growth factor  
PKA  Protein kinase A 
PMF  Peptide mass fingerprinting 
PSAQ  Protein standard absolute quantification 
PTM  Post-translational modifications 
QconCAT Quantitative concatamer 
Raf  Rapidly accelerated fibrosarcoma 
Ras  Rat sarcoma 
RBD  Ras-binding domain 
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RF  Radio-frequency 
RNA  Ribonucleic acid 
RP  Reversed phase 
siRNA  Small interfering RNA 
Src  Sarcoma (MAPK signal transduction protein) 
SDS  Sodium dodecyl sulphate  
SDS-PAGE SDS-poly-acrylamide gel electrophoresis 
SERCA  Sarcoplasmic /endoplasmic reticulum calcium ATPase 
SILAC  Stable isotope labelling by amino acids in cell culture 
SIN-1  3-Morpholinosydnonimine hydrochloride 
SISCAPA Stable isotope standards with capture by anti-peptide antibodies 
SNP  Single nucleotide polymorphism 
SnR  Signal to noise ratio 
SOE-PCR Splice overlap extension PCR 
SORI-CID Sustained off-resonance irradiation collision-induced dissociation 
SPPS  Solid-phase peptide synthesis 
ToF  Time-of-flight 
ToF/ToF Tandem ToF MS 
TBST  Tris-buffered saline with 0.05% Tween (v/v) 
TFA  Trifluoroacetic acid 
TMT  Tandem mass tags 
TNM  Tetranitromethane 
UCR1  Upstream conserved region one (PDE4) 
UCR2  Upstream conserved region two (PDE4) 
v  Volume 
V  Volt 
w  Weight 
XIC  Extracted ion chromatogram 
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1 Introduction 
As was briefly described in the abstract, this project details the development of 
a stable isotopically labelled internal standard based quantitative technique for 
the absolute quantification of three families of protein isoforms, through the use 
of mass spectrometry (MS). This chapter thus details the literature surrounding 
the development of proteomics as a field of scientific research, the various 
methods through which a protein may be quantified, the various types of mass 
spectrometers which are utilised in proteomics, and the methods which have 
been developed for the absolute quantification of proteins. 
 
1.1 The Birth of Proteomics 
While genomic based studies, such as the Human Genome Project (Venter et al., 
2001), have yielded vast amounts of sequence data, the “blueprints” of life 
(Mundy, 2001), these data have provided only a basis for evaluating what is 
possible within the cell, yet has yielded no information as to the biological 
activity, or phenotype, of a cell in a specific environment at a given point in 
time (Montpetit, 2003, Wasinger et al., 1995). Indeed, it is now understood that 
the levels of messenger ribonucleic acid (RNA) (mRNA) expressed within a cell, 
can give only a rough indication as to the rate at which a protein is produced 
(Duggan et al., 1999, Anderson and Seilhamer, 1997), which yields no 
information as to the final concentration of the protein, due to the varying rates 
at which a protein may be degraded. Furthermore, mRNA stability within the 
cell can be variable and the rate at which mRNA is translated into protein may 
also vary. mRNA expression yields no information as to the presence of post-
translational modifications (PTMs), which can be suggestive of cellular function 
(Unwin and Whetton, 2006) and current bioinformatic techniques cannot 
differentiate between genes and pseudogenes (Montpetit, 2003), cannot detect 
alternatively spliced proteins, nor do they take into account for the fact that 
many amino acid chains can be incorporated into a single protein, in the form of 
subunits (Godovac-Zimmermann et al., 2005).  
 
21 
 
It is thus understandable that the field of proteomics has received increased 
interest over the last decade (Dunn, 2007), initially being envisioned as a 
technique capable of characterising each of the proteins within an organism 
simultaneously (Zhang et al., 2010). This assumption presented proteomics with 
its first major challenge, addressing the dynamic nature of the proteome 
through independently analysing each organism under a range of conditions 
(Zhang et al., 2010). 
 
Further to the environment from which the organism was sampled, which will 
determine the protein expression pattern, it has been predicted that up to 74 
percent (%) of the 20,000 to 30,000 genes in the human genome may be subject 
to alternative splicing (Johnson et al., 2003), yielding an average of two or three 
transcripts per gene (M. Nakao et al., 2005), thereby greatly increasing the 
complexity of the proteome. Furthermore, it is also common for proteins to be 
post-translationally modified with one or more of some 200 PTMs, resulting in 
the number of modified and unmodified proteins within an organism generally 
being much larger than the number of genes identified (Zhang et al., 2010, 
Anderson et al., 2004b). 
 
The highly variable concentrations at which proteins are expressed are also a 
problem for proteomic based analyses. For example, the dynamic range of 
protein expression in yeast can vary by up to four orders of magnitude (Anderson 
and Anderson, 2002), and by up to 12 orders of magnitude in extra-cellular 
fluids, such as blood (Corthals et al., 2000). By way of an example of the scale of 
the problem, just 12 housekeeping proteins (required for cell survival, integrity 
or duplication, and thus are thought to be expressed in every cell at 
approximately the same level (Thorrez et al., 2008)) in human plasma have been 
found to account for up to 95% of the total protein mass (Zhang et al., 2010), 
and a single extracellular protein, albumin, being recorded so as to account for 
up to 50% of the total protein mass (Corthals et al., 2000). Were such a sample 
to be proteolytically digested and analysed via MS, the proteolytic peptides 
generated from those 12 most abundant proteins would compete during 
ionisation with those peptides generated from lower abundance proteins, 
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possibly masking their detection. Furthermore, during an information-dependent 
acquisition (IDA) based MS scan (a scan which monitors the MS spectrum until an 
ion which satisfies user specified MS/MS selection criteria is detected), an 
eluting peptide may be missed while another peptide undergoes tandem MS 
(MS/MS). This limitation can be reduced, however, through utilising an 
instrument with a shorter cycle time. It is thus clear that only after several 
stages of separation would it be possible to detect and analyse lower abundance 
proteins, or to assess the differences between cellular phenotypes (Klose, 1975, 
O’Farrell, 1975).  
 
1.2 Protein Separation 
It is indeed because of the vast range of concentrations at which proteins are 
expressed, the overwhelming number of modified, unmodified and alternatively 
spliced proteins within any given sample that the field of proteomics has 
required high sensitivity, high resolution, and high throughput techniques and 
technologies capable of delivering high-confidence protein identifications.  
 
Classically protein separations have been performed through two-dimensional 
sodium dodecyl sulphate (SDS) poly-acrylamide gel electrophoresis (SDS-PAGE) 
(2DGE) (Corthals et al., 2000, O’Farrell, 1975), coupled with spot picking, 
proteolytic digestion, and a matrix-assisted laser desorption/ionisation (MALDI) 
coupled with time-of-flight (ToF) based protein identification. In recent years, 
however, liquid chromatography (LC) based separations have offered scientists 
an automated, MS compatible, alternative (Link et al., 1999). 
 
1.2.1 2DGE 
While poly-acrylamide based gel electrophoresis was first employed to separate 
protein back in 1959 (Kwietny et al., 1959), it was not until 1974 that isoelectric 
focusing (IEF) was combined with SDS-PAGE to yield 2DGE, a development which 
heralded a new age for analytical protein separation (Corthals et al., 2000, 
O’Farrell, 1975).  
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Figure 1-1: A theoretical 2D gel based separation of five proteins. The image 
above depicts the steps required to separate a proteome based on 2DGE, the 
first step of which involves each protein migrating across an IPG strip, based on 
its isoelectric point (pI), until a neutral charge is achieved, at which point the 
proteins are further separated based on the number of bound SDS molecules, 
and thus their MW.  
 
The first dimension of 2DGE involves the proteome being separated based on the 
pI of each protein, where each protein will migrate across an immobilized pH 
gradient (IPG) until a neutral charge is achieved (Corthals et al., 2000, O’Farrell, 
1975). The second dimension separation step is then conducted, applying SDS to 
the sample, so as to impart a uniform negative charge to each protein. As 1.4 
grams of SDS binds to one gram of protein, each protein can be separated via 
electrophoresis at a rate approximate to its molecular weight (MW) (O’Farrell, 
1975), as is shown on Figure 1-1. At this stage, the separated proteins can be 
visualised through the application of a number of protein stains or dyes. Options 
include Coomassie brilliant blue, Sypro and silver stain. Which dye is selected 
will depend on the sensitivity required (0.05 – 500 nanograms (ng) per spot), the 
24 
 
requirement for reproducibility, and the optional requirement for compatibility 
with downstream protein characterization techniques (Klose, 1975, O’Farrell, 
1975), such as MS. 
 
While 2DGE has previously been seen as the “gold standard” in protein 
separation, this approach has many well-documented drawbacks. In terms of 
protein chemistry, proteins have an average pI range of between pH 3 and pH 
12. IPG strips can however only offer a pI range of between pH 3 and pH 10, with 
the majority of commercial IPG strips covering much smaller pI ranges. Should a 
protein fall outside the pI range it will migrate to the end of the IPG strip and 
precipitate. Likewise in the second dimension, SDS-PAGE gels are limited by 
their MW ranges, causing those proteins which are either too large or small to 
either fail to enter the gel or to proceed through and pass beyond the gel, 
respectively (Herbert et al., 2001). In terms of single analysis reproducibility, 
inter-gel variability has been well documented, preventing the direct 
comparison of varying proteomes on separate gels (Rabilloud, 1990). 
Furthermore, dissimilarities in protein migration, inefficiency during the loading 
of the IPG strip, limited sensitivity, limited dynamic range (Shen and Smith, 
2002) and problems with the transfer of protein between the first and second 
dimensions have limited the use of 2DGE, especially in comparative proteomic 
studies outside of difference gel electrophoresis (DIGE) (Rabilloud, 1990). By way 
of an example of the scale of the problem, it has recently been estimated that 
more than 50% of proteins in yeast are not suited to detection based upon the 
use of 2DGE (Gygi et al., 2000). 
 
Despite the shortcomings associated with 2DGE, this technique continues to 
provide analysts with a tool capable of separating protein isoforms. For example, 
in 1990 Kojima and co-workers utilised 2DGE and immunostaining to identify 
three C-protein isoforms, and to map their expression in both neonatal breast 
muscle and posterior latissimus dorsi muscle (Kojima et al., 1990). Furthermore, 
in 2006 Raikos and co-workers identified several ovalbumin and conalbumin 
isoforms in egg white, based upon the use of 2DGE and MALDI-ToF (Raikos et al., 
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2006). Finally, in 1994 Nakamura and co-workers detected seven α- and four β-
tubulin isoforms within the axoneme of Tetrahymena cilia, based upon the use 
of 2DGE and immunostaining (Nakamura et al., 1994).  
 
In addition to the separation of protein isoforms, 2DGE offers analysts a tool 
capable of separating hydrophobic membrane proteins, through solubilising the 
proteins in a range of non-MS compatible detergents, prior to separation, in-gel 
digestion and an MS based detection (Babu et al., 2004). 
 
1.2.2 Liquid Chromatography 
In seeking an alternative technique to separate the proteome, researchers have 
recently turned to LC (Shi et al., 2004). In addition to its compatibility with 
electrospray ionisation (ESI) based MS (Shen and Smith, 2002, Fenn et al., 1989), 
LC systems have been fitted with a wide array of stationary and mobile phases, 
so as to enable both high resolving power, and specificity, assuming a unique 
sub-set of the proteome is to be targeted (Shi et al., 2004). While currently most 
proteomic LC based separations are performed via reversed phase (RP), ion-
exchange, affinity and size-exclusion based chromatography may all be utilised 
(Zhang et al., 2010).  
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Figure 1-2: A theoretical LC based separation of five proteins. The image 
above depicts the steps required to separate a proteome based on RP-LC, the 
first step of which involves the sample being injected to the LC column in a 
highly polar solvent, causing the hydrophobic proteins to adsorb to the silica 
bound C18 chains. As the ratio of polar to organic solvent is gradually increased, 
the proteins or peptides are eluted based upon their hydrophobicity. 
 
In regards to the fundamentals of RP-LC, the stationary phase is generally 
composed of a silica bead packed column, derivatised with a layer of aliphatic 
carbon (most commonly C18, though C8 and C4 may be utilised for less 
hydrophobic samples). The sample is loaded onto the stationary phase in a polar 
solvent (water (H2O)), acidified with 0.1% (volume/volume (v/v)) formic acid 
(FA) (employed as both a source of protons and to prevent the carboxyl groups 
from dissociating, thereby preventing secondary interactions with the stationary 
phase), under which conditions the peptide or protein will adsorb to the 
stationary phase. The ratio of acidified organic solvent (most commonly 
Acetonitrile (MeCN) or Methanol (MeOH) acidified with 0.1% (v/v) formic acid) to 
polar solvent is then increased, and each peptide or protein eluted when the 
strength of organic solvent in the mobile phase is sufficient to compete with the 
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hydrophobic forces retaining the analyte (Shi et al., 2004), as is shown on Figure 
1-2. The term RP is applied to this technique as historically the sample was 
loaded to the silica stationary phase in an organic solvent based buffer, and the 
sample components eluted based upon a gradient of increasingly polar solvent.  
 
Where greater resolving power is required, two-dimensional liquid 
chromatography (2D-LC) may be utilised (Giddings, 1984). 2D-LC employs two 
orthogonal LC based separation steps, performed either on-line (with the eluant 
from the first column flowing directly into the second column, in series) or off-
line (utilising fraction collecting and subsequent re-injection), so as to offer the 
analyst unparalleled resolving power. To better explain, 2D-LC enables a 
complex proteome to be separated based upon the exploitation of two separate 
biochemical parameters, such as hydrophobicity, size, or the number of basic or 
acidic residues a protein may contain. 
 
1.3 MS Based Protein Identification 
While 2DGE based experiments have predominantly involved the spot or protein 
of interest being excised from the poly-acrylamide gel, proteolytically digested, 
and ionised/detected though the application of MALDI-ToF, LC based separation 
coupled with an ESI based MS detection can be conducted in one of two ways; 
top-down or bottom-up. 
 
1.3.1 Top-down Proteomics 
Top-down based proteomic analyses involve the separation of a complex mixture 
of proteins via LC and the detection of each intact protein molecule via MS (Wu 
et al., 2012, Loo et al., 1990, Kelleher et al., 1999). This technique offers 
several advantages over bottom-up based proteomic techniques, the first of 
which is the ability of top-down proteomics to detect which PTMs are present on 
a protein, or indeed if several PTMs are mutually exclusive (Jeffrey, 2012). 
Furthermore, top-down based proteomics offers the analyst reduced sample 
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preparation time and reduced sample complexity, thereby offering better 
separation. 
 
In terms of applications, top down based proteomics has been utilised in the 
verification of translational start and stop sites identified during genome based 
bioinformatic analyses (Ryan et al., 2010). In this application, however, accurate 
mass based detection alone can be complicated by the presence of PTMs and 
splice isoforms, significantly altering the mass of the protein from that predicted 
(Cui et al., 2011), indeed it has been noted that identifying a protein based upon 
intact mass alone is sufficient for only a limited number of proteins in an LC 
fraction (Wu et al., 2009), MS/MS is therefore a requirement of top-down based 
proteomics.  
 
Furthermore, top-down based proteomics offers researchers a tool for the 
detection and identification of protein isoforms. Through analysing the intact 
structure and fragmentation pattern of each protein, it is possible to obtain 
sequence data which may otherwise be lost (assuming the use of top-down based 
proteomics). One such top-down based proteomic analysis, recently performed 
by Tran and co-workers, identified 1,043 unique gene products from a cultured 
human cell lysate, which together yielded more than 3,000 unique protein 
species, including protein isoforms, unique proteins generated through the 
addition of PTMs and protein fragments generated via proteolysis, based upon 
the use of a novel four-dimensional separation system (Tran et al., 2011). 
 
Top-down based proteomics does suffer from several technological limitations 
though, for example, only proteins containing 500 or fewer amino acids (50 
kilodaltons (kDa) or less) can be detected, due to the limitations of current mass 
spectrometers (Cui et al., 2011). Furthermore, high resolution mass 
spectrometers are required to differentiate between multiple-charge states, 
instruments which are expensive to both purchase and operate. In addition, top-
down based proteomics has been shown to struggle with the detection of very 
hydrophobic or hydrophilic proteins, in addition to low copy number proteins 
within complex samples (Motoyama and Yates, 2008). Finally, the technique 
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through which MS/MS fragmentation is most commonly employed during top-
down based proteomics, electron capture dissociation (ECD) (Sleno and Volmer, 
2004), requires long ion accumulation, activation and detection times, limiting 
the applications of this technique to samples which are relatively pure. 
 
1.3.2 Bottom-up Proteomics 
In performing a bottom-up based proteomic analysis the complex mix of proteins 
is proteolytically digested prior to LC based separation and MS based detection 
(Wu et al., 2012, Fournier et al., 2007). In pre-digesting the target proteins, 
many of the problems associated with top-down based proteomic analyses are 
avoided, enabling the detection of a much larger range of protein species and 
PTMs. Bottom-up based proteomics has therefore become the technique of 
choice for large-scale protein studies (Zhang et al., 2010).  
 
In proteolytically digesting an already complex proteome however, hundreds of 
thousands of peptides are created, which to date, no single LC based separative 
technique has been capable of resolving (Zhang et al., 2010). This can result in 
multiple peptide ions eluting from the LC column simultaneously, overwhelming 
the detector and reducing the number of peptides potentially identified during 
an IDA based MS/MS scan. In addition to simply limiting the results obtained for a 
given sample, the limited resolution offered by single dimension LC in bottom-up 
based proteomics has also limited the reproducibility of this technique (Zhang et 
al., 2010). 2D-LC is therefore often employed in bottom-up based proteomics so 
as to increase the resolving power of the LC separation and therefore, through 
increasing the number of peptides detected, increasing the protein sequence 
coverages achieved. 
 
A fundamental flaw exists within bottom-up based proteomics, however, in that 
identical peptides can be generated through the digestion of several protein 
isoforms, or indeed multiple distinct proteins, leading to confusion over which 
protein is actually expressed, and indeed the accuracy of the protein sequence 
coverages or quantifications achieved (Cui et al., 2011). Because of this, top-
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down based proteomics has again begun to attract more attention in recent 
years (Collier et al., 2008, Ferguson et al., 2009, Liu et al., 2002, Tran et al., 
2011). 
 
1.4 Protein identification 
Prior to 1990 it was thought possible to sequence only the first 20 – 30 amino 
acids of a single, highly purified peptide or protein over a matter of hours or 
days. This was achieved based on the sequential cleavage and ultraviolet (UV) 
based identification of the peptide or proteins amino-terminal (N-terminal) 
amino acid through a technique known as Edman degradation (Steen and Mann, 
2004, Edman, 1949). So as to avoid the sequence length limitations of this 
technique, proteins were often proteolytically digested and purified via RP-LC 
prior to the sequencing of each peptide fraction. With the advent of soft 
ionisation techniques however, including ESI and MALDI, MS has become the 
method of choice for protein identification.  
 
Early MS based protein identifications were conducted following the completion 
of 2DGE; where each protein spot was picked, proteolytically digested, and the 
species identified based on MALDI-TOF MS coupled with peptide mass 
fingerprinting (PMF) (Pappin et al., 1993). In brief, PMF assumes that when a 
protein is digested it will yield a unique set of proteolytic peptides, thus when 
the masses of several such peptides are detected during an analysis, an identity 
for the target protein can be predicted. 
 
PMF does, however, suffer from several limitations, the first of which is the 
requirement for the digested protein to be relatively pure. Considering the 
complexity of the proteome this can be difficult to achieve, even when 2DGE has 
been utilised. Furthermore, for a proteins identity to be predicted, the target 
protein must already exist within the database being searched. As each database 
is species specific, however, and the data generated through the bioinformatic 
analysis of a sequenced genome, for a protein identification to be made, the 
target organism’s genome must thus first have been sequenced (Steen and Mann, 
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2004). Finally, many proteins will yield peptides with similar mass to charge 
ratios (m/z), which can lead to erroneous data, in addition to which, where a 
peptide contains a PTM the final mass of the peptide will be significantly altered 
(Mann and Wilm, 1994), possibly resulting in an incorrectly predicted identity 
being assigned to the protein. 
 
Alternative approaches have therefore been developed to enable the accurate 
identification of a protein based upon IDA scanning and MS/MS. The first of these 
techniques, termed de novo sequencing, involves the collection and 
interpretation of MS/MS spectra (Steen and Mann, 2004), assessing the distance 
between MS/MS fragmentation peaks, so as to predict the loss of a specific 
amino acid. Through assessing the m/z ratio of the MS/MS fragments, it is 
possible to piece together this sequence information, so as to determine the 
structure of the target peptide. While it is possible to determine the sequence 
of a peptide via de novo sequencing, this technique is often complicated by 
incomplete fragmentation and the presence of interfering peaks, originating 
both from the target peptide and external sources (Steen and Mann, 2004).  
 
At the beginning of the 1990s, however, it was realised that only an 
infinitesimally small fraction of all possible amino acid sequences actually occur 
in nature, and therefore, if even a limited MS/MS spectrum was obtained, in 
conjunction with the peptides’ m/z and the specificity of the protease utilised, 
that the sequence of the peptide/protein could accurately be predicted (Mann 
and Wilm, 1994, Rappsilber and Mann, 2002).  
 
As such, the most common mass spectrometry based technique for identifying a 
protein now involves: (i) proteolytically digesting the protein of interest and 
injecting the resulting peptide mix onto an LC-MS/MS system, (ii) ionising the 
target peptides, so as to obtain a m/z, or parent ion, for each peptide, (iii) 
having each parent ion selected for MS/MS, and (iv) deriving an MS/MS spectrum 
for each peptide. Finally, (v) each MS/MS spectra is compared to a genomically 
derived sequence database, so as to predict the identity of the target protein. 
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1.5 Mass Spectrometry 
The origins of mass spectrometry can be traced back to the late 1800s when J. J. 
Thomson (Thomas, 1910), in researching the transmission of electricity through 
gas, built a device capable of measuring the mass of charged particles (Griffiths, 
2008). This device utilised gas discharge tubes to generate ions, which were 
passed though parallel electric and magnetic fields, deflecting the ions into 
parabolic trajectories which were then detected on a photographic plate 
(Griffiths, 2008). 
 
1.5.1 Biomolecule Ionisation 
For a long time, however, many of the ion sources used in MS, for the chemical 
analysis of small molecules, employed energy rich chemical and electrical 
ionisation techniques which were not suited to the ionisation of large intact 
biomolecules, as they were found to decompose in an unpredictable manner 
(Sauer and Kliem, 2010). The application of MS was thus limited to the analysis 
of volatile compounds, or those which could be easily derivatised to become 
volatile (a property necessary for their conversion into the gas phase) (Kicman et 
al., 2006). While many “sudden energy” techniques were proposed for the 
ionisation of small biomolecules (Fenn, 2002), including fast ion bombardment 
(Benninghoven et al., 1976), fast atom bombardment (Devienne and Roustan, 
1982), plasma desorption (Torgerson et al., 1974), pyrolysis mass spectrometry 
(Meuzelaar et al., 1973), and laser desorption (Posthumus et al., 1978), it was 
not until the realisation that if non-volatile solutes were dissolved in volatile 
solvents, and highly charged droplets of these solutions produced, that the 
evaporation of the solvent would leave intact gaseous ions, that the ionisation of 
labile molecules was thought possible (Griffiths, 2008, Hillenkamp and Karas, 
2000, Fenn et al., 1989). Indeed, it was not until 1988 with the description of 
two soft ionization techniques, ESI and MALDI, that MS was seen to enter the 
biological arena (Falk et al., 2006).  
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1.5.1.1 Matrix Assisted Laser Desorption/Ionisation 
The development of MALDI can be traced back to an experiment conducted by 
Hillenkamp and Karas into the spatial distribution of Calcium ions (Ca2+) in heart 
muscle cells based on laser microprobe mass analysis (Griffiths, 2008, Karas et 
al., 1985). Hillenkamp noted that background signals made the spectrum hard to 
decipher, and that this background noise appeared to form a general pattern. It 
was later suggested that these signals may be fragment ions originating from the 
organic matrix, leading Karas and Hillenkamp to study the desorption of small 
organic molecules, and eventually proteins (Griffiths, 2008, Karas et al., 1985).  
 
The breakthrough which enabled the ionisation of large biomolecules, however, 
which involved the analyte, dissolved in glycerol, being combined with cobalt 
particles, was first described by Koichi Tanaka in 1987 (Tanaka et al., 1988), for 
which he shared the Nobel Prize in Chemistry in 2002. 
 
In terms of an Ultraflex II MALDI based analysis, the target protein mix is 
dissolved in a suitable solvent and mixed with an excess amount of matrix 
(generally α-cyano-4-hydroxycinaminic acid (HCCA) for peptides of less than 5 
kilodaltons (kDa) and 3,5-dimethoxy-4-hydroxy-cinnamic acid for larger peptides 
and proteins). The sample is spotted to an instrument specific steel MALDI plate, 
air dried, and bombarded by a photon beam from a smartbeam laser at a 
wavelength of 355 nanometers (nm) (Chait and Kent, 1992, Kicman et al., 2006). 
Upon entering the gas phase a voltage is applied between a grid or ring 
electrode and the inlet orifice of the MS, accelerating the ions into the mass 
analyser, as is shown on Figure 1-3.  
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Figure 1-3: The route through which analyte molecules are ionised during 
MALDI. Shown above is a diagrammatic representation of how an analyte 
molecule is ionised during MALDI. A laser shot is fired at the spotted analyte 
sample, ionising any matrix molecules in its path. Subsequently an ionised matrix 
molecule can transfer a proton to the analyte molecule, enabling its 
acceleration into the ToF tube. 
 
The advantages of MALDI include its large working mass range (capable of 
ionising molecules of between 100 Da and 300 kDa), enabling the rapid ionisation 
of both peptides and intact proteins. Furthermore, in terms of data 
interpretation, the predominance of singly charged ions lends itself to a 
relatively straightforward data interpretation (Hillenkamp and Karas, 2000). 
 
MALDI based ionisation is generally coupled with ToF based MS, due to the large 
working mass range of the ToF detector, and the fact that the pulsed nature of 
MALDI ionisation yields spatially distinct packets of ions suited for ToF based 
detection (Brown and Lennon, 1995a). 
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1.5.1.2 Electrospray Ionisation 
The development of ESI can be traced back to Dole and his co-workers, who in 
the late 1960s, successfully introduced a polystyrene polymer into the gas phase 
as a charged species (Dole et al., 1968). Unlike MALDI based ionisation where the 
exact mechanism of proton transfer has yet to be described, ESI based ionisation 
is seen as being simplistic in nature. The protein species to be analysed, 
dissolved in a polar solvent, are sprayed from the tip of a highly charged needle 
(3–4 kilovolts (kV)) towards the inlet of the MS (Fenn et al., 1989, Kicman et al., 
2006, Falk et al., 2006). These highly charged droplets are subjected to a warm 
flow of nitrogen, vaporising the solvent, and in doing so increasing the repulsive 
forces encountered between the ions on the surface of the shrinking droplet. 
Eventually these repulsive forces exceed the surface tension of the solvent (the 
Rayleigh limit), ripping the droplet apart (Coulombic explosion), a process which 
is repeated until the intact ions are desorbed into the gas phase (Fenn et al., 
1989, Jonsson, 2001), as shown on Figure 1-4. 
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Figure 1-4: The route through which an analyte molecule is ionised during ESI.  
Upon the analyte molecules being eluted from the LC they are carried to the ESI 
needle before being sprayed towards the orifice of the MS through applying a 
voltage between the needle and the orifice. As the solvent droplets move 
towards the orifice they are dried due to the warm flow of a sheath gas 
(generally nitrogen). As the droplets shrink the surface charge grows, leading to 
a coulombic explosion, splitting the solvent droplet into several smaller 
droplets, a process which repeats until only the intact analyte ions remain. 
 
Despite the presence of multiply charged ion species adding to the complexity of 
the data to be analysed (first requiring the charge state of each ion to be 
determined), these multiply charged species are one of the big advantage of ESI. 
In carrying multiple ions, the m/z of the target biomolecule is lowered, enabling 
its detection, and thus analysis, on a greater range of mass spectrometers 
(Bakhtiar and Tse, 2000). Furthermore, as the target biomolecule leaves the ESI 
needle in the liquid phase, RP-LC can be coupled directly to a mass 
spectrometer, without the need for manual sample manipulation and plate 
loading, as would be the case with LC-MALDI. 
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Due to the constant beam of ions created during ESI, this ion source can be 
coupled with the vast majority of modern mass spectrometers, including 
quadrupoles, orbitraps and fourier transform-ion cyclotron resonance (FT-ICR) 
based mass spectrometers. Indeed ESI can even be coupled with a ToF based 
mass analyser, though this particular setup will require the installation of an ion 
pusher electrode, pulsing well defined ion packets into the ToF tube (Kicman et 
al., 2006, Loboda and Chernushevich, 2009). 
 
1.5.2 Mass spectrometers 
Single stage mass spectrometers can be seen to perform two distinct tasks; to 
filter or separate the ions which enter the instrument, and to determine the m/z 
of those ions which are permitted to the detector. Indeed, while the 
development of ESI and MALDI in the late 1980s enabled the ionisation of large 
biomolecules, the data which could be obtained based upon the existing range of 
single stage mass spectrometers was limited (El-Aneed et al., 2009). It was thus 
the demand for peptide and protein sequence data, and the ability to identify 
PTM sites which led to the development of a new range of mass analyzers and 
complex multistage instruments, designed to tackle the challenges of the 
proteome (Domon and Aebersold, 2006). 
 
Described over the following few pages are some of the most common types of 
mass analysers and modern instrument setups.  
 
1.5.2.1 Time-of-Flight Mass Spectrometry 
Upon the target biomolecule being ionised in ToF based MS (most commonly 
through the application of MALDI); a high voltage is applied between either a 
grid or ring electrode and the inlet of the ToF tube, accelerating the ion plume 
towards the detector. As each ion is accelerated with the same force, the same 
kinetic energy will be imparted. Each ion should therefore move towards the 
detector at a different velocity based on its m/z (Merchant and Weinberger, 
2000, Khalsa-Moyers and McDonald, 2006). In practice, however, the ionisation 
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and immediate acceleration of the ion packet into the ToF tube can lead to each 
ion possessing one of a range of kinetic energies, broadening the final peak 
detected and reducing the resolution achieved (El-Aneed et al., 2009). In an 
attempt to correct for this inconsistency, two improvements have been 
introduced to modern ToF based mass spectrometers. The first, termed delayed 
extraction, causes the sample to be ionised under only a weak electrical field 
(Vestal et al., 1995). Under the influence of this weak field, each ion moves 
slowly towards the ToF tube, based on its initial velocity, later being subjected 
to high voltage based acceleration. In delaying the high energy acceleration step 
by approximately 100 nanoseconds (ns), the lower velocity ions are affected 
more by the acceleration than those ions present at a higher velocity, enabling 
the lower velocity ions to “catch up” (Vestal et al., 1995). The second 
improvement introduced to ToF based mass spectrometers has been the 
application of an electrostatic ion mirror, or reflectron, which acts to change 
the flight path of the ions towards an offset detector (El-Aneed et al., 2009, 
Mamyrin et al., 1973). In addition to increasing the flight path of the ions, 
yielding an increase in resolution (Clauser et al., 1999), the reflectron is also 
penetrated further by higher kinetic energy ions than low, helping to better 
focus the ions based on their m/z. 
 
ToF based mass analysers have several advantages over quadrupole based mass 
analysers. Firstly, as a result of the ToF based mass spectrometer separating the 
ions rather than filtering, each ion introduced into the MS will reach the 
detector. Furthermore, ToF based mass analysers have a higher resolution, 
accuracy and mass range than quadrupoles. By way of an example, when a ToF 
based mass detector is coupled with a MALDI source, the upper mass range will 
be limited to approximately 300 kDa (Hillenkamp and Karas, 1990). When the 
same ToF based mass spectrometer is coupled with an ESI source however, the 
upper mass limit can extend into the MDa (mega Daltons) (El-Aneed et al., 
2009). 
 
In addition to simply determining the accurate mass of an ion, MALDI-ToF based 
instrumentation can also be used to probe the structure of a biomolecule based 
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on one of several techniques. One such technique, termed post-source decay 
(Purcell and Gorman, 2001), fragments the target ions in one of two ways after 
the ions have been subjected to high voltage acceleration (Suckau et al., 2003). 
Fragmentation is achieved, firstly, through colliding the analyte ions with the 
ionised matrix while the ions are being “ripped” from the ion plume into the ToF 
tube, in addition to which, while transversing the ToF tube, vibrationally excited 
metastable ions can decay, yielding a-, b- and y- ions (Kaufmann et al., 1994). 
 
The names of these various fragment ions denotes the position at which the 
peptide backbone is fragmented, based upon Roepstorff–Fohlmann–Biemann 
nomenclature (Roepstorff and Fohlman, 1984). In brief, the terms an, bn and yn 
indicate both the distance at which the fragmentation occurred from the N-
terminal (a/b/y), and the number of incorporated amino acids (n). While the 
terms zn, yn and xn are used to indicate both the distance the fragmentation 
occurred from the C-terminal, and the number of incorporated amino acid 
residues (Steen and Mann, 2004). 
 
An alternative MALDI-ToF based fragmentation method can also be sought in in-
source decay (Brown and Lennon, 1995b), which differs from post-source decay 
in that the fragmentation occurs prior to the application of the high voltage 
acceleration. In in-source decay, a combination of laser induced fragmentation 
and rapid metastable decay result in the production of both c- and z-ions 
(Köcher et al., 2004). 
 
Finally, tandem ToF based instruments (ToF/ToF) are also capable of performing 
collision induced dissociation (CID) (Medzihradszky et al., 1999), fragmenting the 
analyte across the peptide bond so as to yield both b- and y-ions, immonium 
fragment ions and internal d- and w-fragment ions (Domon and Aebersold, 2006). 
Unlike both post-source decay and in-source decay, CID involves accelerating the 
isolated ions and colliding them with inert gas molecules (generally nitrogen) 
(Shukla and Futrell, 2000). 
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In terms of modern hybrid ToF based instrument setups, both ToF/ToF and Q-q-
ToF instruments exist (El-Aneed et al., 2009, Domon and Aebersold, 2006). 
Through combining two ToF based instruments, the first ToF tube can be applied 
solely to the separation of the ion plume, while a Bradbury–Nielsen velocity 
filter is placed between the two ToF stages, so as to permit only a single ion of 
interest into the second ToF tube. The second ToF tube can then be utilised to 
perform both CID, and to separate the product ions generated, thereby providing 
true MS/MS capability. In terms of applications, ToF/ToF based instruments are 
used regularly in quantitative proteomics, based upon the application of LC-
MALDI, in addition to being utilised in 2DGE based proteomics. As has previously 
been discussed (Section 1.4), the possession of MS/MS fragmentation data can 
offer a vast improvement in the precision in the identity assigned to a protein, 
compared to a PMF (Khalsa-Moyers and McDonald, 2006, Mann and Wilm, 1994). 
 
ToF based MS/MS may also be achieved through the use of ESI. In a typical Q-ToF 
based instrument, the first quadrupole will be tasked with filtering the ion 
beam, permitting only a target m/z to the second quadrupole. At this stage the 
second quadrupole can be operated as a collision cell, fragmenting the target 
ions and directing the product ions into the ToF based mass analyser (El-Aneed 
et al., 2009). In addition to utilising ESI based ionisation, and thus having an 
increased mass range when compared to a standard MALDI-ToF, Q-ToF based 
instruments also benefit from the high resolving power of the ToF mass analyser, 
making them ideal for the study of PTMs (Domon and Aebersold, 2006). 
 
1.5.2.2 Quadrupole Mass Spectrometry 
The quadrupole based mass analyzer was first described by Wolfgang in 1953 (El-
Aneed et al., 2009, Paul, 1990) and consists of two sets of linked parallel 
circular metal rods, through which a cycled direct-current (DC) voltage is 
applied. Further to the imparted DC voltage, an oscillating radio-frequency (RF) 
is also applied to each rod; the combination of which enables the manipulation 
of the ion beam in such a way as to either stabilise or destabilise certain m/z’s 
passing through the quadrupole, as is shown on Figure 1-5. Indeed, by increasing 
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the DC voltage applied to the quadrupole, the transmission window can be 
shrunk so as to permit only a specific m/z range to reach the detector 
(operationally termed Q) (Domon and Aebersold, 2006). It is therefore possible 
to utilise a quadrupole to either scan through a specified mass range, or to 
permit only a specific m/z to constantly reach the detector (Khalsa-Moyers and 
McDonald, 2006). The opposite can also be achieved, however, decreasing the 
DC voltage applied to the quadrupole (operationally termed RF only) results in a 
much wider beam of ions being permitted to reach the detector (Henchman and 
Steel, 1998). By introduction of a stream of inert gas to a RF only quadrupole, 
the instrument can be operated as a CID based collision cell (operationally 
termed q). Finally, the quadrupole may also function as a linear ion trap (LIT) 
(Khalsa-Moyers and McDonald, 2006). Through applying a static DC current to 
each end of the four rods, the stream of ions can be trapped in the quadrupole’s 
oscillating RF field. Slowly increasing the DC voltage of the quadrupole gradually 
releases the ions based on their m/z (Hager, 2002).  
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Figure 1-5: A diagram depicting the workings of a quadrupole based MS.  The 
above diagram depicts the workings of a quadrupole based MS, where the ion 
beam travels through a skimmer and between four metal rods imparted with 
both an RF frequency and an oscillating DC voltage. Through modifying both the 
DC and RF parameters it is possible to permit only a single m/z range to the 
detector, to scan through a range of m/z’s or to stabilise all ions entering the 
MS. Those ions which do not resonate at a frequency similar to that of the 
quadrupole will be destabilised, striking one of the rods, and in doing so 
becoming neutralised.  
 
While single stage quadrupole based MS are relatively cheap, small, robust and 
easy to use, they have limited applications in the field of proteomics (El-Aneed 
et al., 2009). Quadrupole based mass spectrometers are therefore often found in 
tandem, with the most common instrument setups being the triple quadrupole 
based MS (Q-q-LIT), and the Q-q-ToF based MS (Domon and Aebersold, 2006).  
 
In performing a general MS/MS based analysis on a triple quadrupole MS, the first 
two quadrupole mass filters operate in much the same way as they would in a Q-
ToF based instrument, where the first quadrupole is used to filter the ion beam, 
while the second acts as a collision cell. While the final MS stage of the Q-ToF 
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based MS involves each Q2 fragment ion being separated within the ToF tube 
based on its m/z, enabling a high resolution analysis, the final mass filter in a 
triple quadrupole based instrument can be set to either trap and detect each 
fragment ion at a low resolution, or to permit only a single ion of interest to the 
detector. Indeed, it is this versatility, and the variety of scan modes offered by 
triple quadrupole mass spectrometers which has resulted in them being one of 
the most abundant MS in the world (Wang and Stout, 2007). 
 
One such scan mode, termed selected reaction monitoring, or multiple reaction 
monitoring (MRM) when analysing more than one transition, utilises both 
quadrupoles one and three as mass filters, permitting only a pre-defined parent 
ion (Q1) and pre-defined product ion (Q3) to react the detector, while 
quadrupole two is utilised as a collision cell. Through utilising this configuration 
it is possible to perform a highly selective analysis on a target analyte, or 
analytes, mapping both retention time (assuming LC is utilised) and the signal 
intensity detected over the duration of a run (Lange et al., 2008). As this MS 
acquisition method filters all but those ions which share both a similar parent 
and product ion m/z, the MRM spectrum contains very little noise, this type of 
analysis is therefore ideal for the detection of low concentration biomarkers, 
present within complex samples, as is commonly required in proteomics. 
 
1.5.2.3 Fourier Transform-ion Cyclotron Resonance Mass 
Spectrometry 
FT-ICR was first conducted by Comisarow and Marshall in 1974 (Comisarow and 
Marshall, 1974), who in taking inspiration from the recent description of fourier 
transform-nuclear magnetic resonance, applied the same fast fourier transform 
calculation to ion cyclotron resonance spectrometry, and in doing so reducing 
the time taken to complete an analysis by several orders of magnitude. 
 
An FT-ICR functions by trapping an ion packet in a Penning trap, formed by six 
metal plates in a box configuration, placed within a super-conducting magnet 
under a high vacuum, as is shown on Figure 1-6. In addition to the strong 
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magnetic field acting to stabilise the ion packet in two of three dimensions, two 
opposing metal plates running perpendicular to the IRC cell (termed trapping 
plates) are activated upon the ion packet entering the cell, forming an 
electrostatic field which traps the ions in the remaining dimension (Steen and 
Mann, 2004).  
 
 
Figure 1-6: The components contained within an FT-ICR MS.  Depicted above 
are the basic components contained within an FT-IRC based MS, including two 
trapping plates (marked in blue), preventing the ion packet from escaping the 
IRC cell, two excitation plates (marked in orange), capable of amplifying the 
ions oscillation path, and two detector plates (marked in green), capable of 
detecting the ions m/z based on a change in the alternating current.  
 
The technique by which the m/z of the ions is measured in FT-ICR differs from 
that of both ToF based mass spectrometers and quadrupole based instruments, 
in that, the mass is determined indirectly as a measure of the frequency at 
which the ions oscillate in proximity to the two opposing detection plates within 
a magnetic field (Khalsa-Moyers and McDonald, 2006). In order for a detection to 
be made, the ions must thus be cycled within the IRC cell. This is achieved 
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through two distinct actions; firstly, when the ion packet is being impelled into 
the ICR cell, through the application of a weak DC voltage, the ions are 
subjected to a rapid DC pulse, imparting an initial gyrating motion. Secondly, 
the radius at which the ions are oscillating is amplified through the application 
of an RF voltage, applied to the two remaining opposing metal plates (termed RF 
plates). As the ions move both towards and away from the pair of detection 
plates, the m/z is measured in the form of an alternating current. When plotted, 
this current constitutes a sine wave, with the amplitude being proportional to 
the number of ions detected and the wavelength equal to the frequency at 
which ions are oscillating. Finally the data is deconvoluted through the 
application of the fast fourier transform, so as to yield a mass spectrum. 
 
FT-ICR has been coupled with both MALDI (Cornett et al., 2008) and ESI (Irungu 
et al., 2008), and can be found in tandem with both a single LIT, or indeed with 
triple quadrupole mass filters, enabling both ultra-high resolution and high mass 
accuracy MS/MS and MSn scanning (Domon and Aebersold, 2006). Both top-down 
and bottom-up based proteomics have been conducted through the FT-ICR 
(Dodds et al., 2007). It should be noted, however, that as the ions are trapped 
within the ICR cell at a low voltage, the kinetic energy of the ions must be kept 
to a minimum. This has led to the description of several new fragmentation 
techniques; including ECD (Sleno and Volmer, 2004), infrared multiphoton 
dissociation (IRMPD) (Little et al., 1994), sustained off-resonance irradiation 
collision-induced dissociation (SORI-CID) (Herrmann et al., 2005), and a 
combination of the latter, combination of infrared and collisional activation 
(Dodds et al., 2007). 
 
Of these new fragmentation techniques both IRMPD and SORI-CID are considered 
“gentle” ion activation techniques, yielding fragment ions from the application 
of low-energy processes (Dodds et al., 2007). In regard to SORI-CID, the ions 
oscillating within the IRC cell are excited by the application of an “off-
resonance” RF pulse, decelerating the ions prior to re-acceleration in the 
presence of a low-mass collision gas (Herrmann et al., 2005). IRMPD, meanwhile, 
involves the firing an infrared laser pulse into the IRC cell, slowly increasing the 
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energy of the ions until a bond is broken (Little et al., 1994). Both SORI-CID and 
IRMPD, however, have been found to fragment the biomolecules only at the 
sites, which require the lowest amount of energy. This has not therefore proven 
particularly useful for the fragmentation of singly protonated tryptic peptides, 
such as those obtained during MALDI. Both SORI-CID and IRMPD have therefore 
been combined to yield more informative fragmentation spectra than could be 
achieved using either IRMPD or SORI-CID alone (Dodds et al., 2007). 
 
Standing as an alternative to both IRMPD and SORI-CID, each of which involve the 
excitation of an ion up until the point of fragmentation, ECD involves colliding 
an ionised biomolecule (which must possess multiple positive charges) with an 
electron, neutralising a single positive charge, and in doing so extensively 
cleaving the backbone of the biomolecule (Sleno and Volmer, 2004). In practice 
ECD is achieved by heating a metallic filament within the IRC cell so as to 
produce free electrons, which prior to collision, will oscillate in a direction 
opposite to those ions possessing a positive charge (Khalsa-Moyers and McDonald, 
2006). As the target ion is stripped of a positive charge through ECD, it is 
applicable only to multiply charged ESI based ions. 
 
Due to the fact that FT-ICR instruments acquire each spectrum as a frequency, 
and that a frequency may be measured with extreme accuracy, FT-ICR 
instruments offer a resolution of greater than 100,000 (the m/z value divided by 
the peak width at the half the peak height) (Steen and Mann, 2004). FT-ICR 
instruments are, however, expensive and bulky (requiring a large 
superconducting magnet and liquid helium and nitrogen storage), and thus have 
so far been limited to expert-only laboratories (Khalsa-Moyers and McDonald, 
2006). 
 
1.5.2.4 Orbitrap Mass Spectrometry 
The orbitrap has been hailed as the first truly novel mass spectrometer to be 
introduced in over 25 years (Domon and Aebersold, 2006), with the term orbitrap 
describing how an ion rotates around an electrode with a harmonic oscillation 
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pattern indicative of its m/z (Makarov, 2000). The way in which a mass spectrum 
is generated on the orbitrap is similar to that of the FT-ICR MS, in that, upon a 
change in current being detected, the recorded data is subjected to a FFT so as 
to produce the final mass spectrum. As a result of this broadband method of ion 
detection, and the application of a fast fourier transform, the orbitrap boasts a 
resolution and mass accuracy similar to that of the FT-ICR (Makarov, 2000), 
without the burden of an expensive superconducting magnet. 
 
The orbitrap itself consists of a split barrel-like outer electrode and a spindle-
like centre axial electrode, each of which are held at constant DC voltage so as 
to form an electrostatic ion trap, as is shown on Figure 1-7. As the DC voltage 
within the trap is constant and no ion excitation applied, the ions are instead 
introduced to the trap at a position offset from the equator of the barrel, with 
each ion eventually falling into a radial oscillation with a frequency proportional 
to its m/z (Makarov and Scigelova, 2004). 
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Figure 1-7: The components contained within a hybrid quadrupole / Orbitrap 
MS. Depicted above are the main components utilised within a hybrid 
quadrupole orbitrap instrument, including two quadrupoles, enabling the 
scanning, trapping or fragmentation of the ion beam, a C-trap, acting as an LIT 
and an orbitrap based detector, measuring the m/z of each ion based on its 
oscillation path. 
 
Both MALDI (Luo et al., 2010), and ESI ion sources (Hu et al., 2005) have been 
applied to orbitrap based mass spectrometry, and the orbitrap is generally 
utilised in tandem with several quadrupole based mass filters. In addition to 
each quadrupole enabling a specific m/z to be scanned, trapped or stabilised, 
each distinct instrument stage also enables the atmospheric pressure to be 
further reduced (Makarov and Scigelova, 2004).  
 
The final component of many orbitrap instrument setups, prior to the orbitrap 
itself, is a unique curved LIT, termed a “C-trap”. By trapping the ion beam 
before it enters the detector, the ions can be introduced into the orbitrap in a 
pulsed fashion, similar to that required for both ToF and FT-ICR based mass 
spectrometry. In addition to trapping the ion stream, the C-trap can also be 
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utilised as a collision cell, where-upon raising the RF voltage of the quadrupole, 
can be seen to result in the “triple quadrupole-like” fragmentation of the 
trapped ions (Olsen et al., 2007). 
 
1.6 Protein Quantitation 
Up until the last decade, the field of proteomics was largely seen as a 
qualitative discipline, with a typical proteomic experiment consisting of a tissue 
or culture of interest being digested, assessed, and a list of proteins generated, 
without any interest having being paid to their abundance or cellular distribution 
(Baak et al., 2005). Indeed, this was in stark contrast to the field of genomics, 
which at the time had widely adopted quantitative strategies for the analysis of 
gene expression through the use of both microarrays and quantitative 
polymerase chain reaction (PCR) (qPCR) (Schulze and Usadel, 2010, Regnier and 
Julka, 2006). As has previously been discussed, however, the level of mRNA 
detected during such an analysis does not necessarily reflect the number of 
proteins within a cell, which, ultimately are the workhorses, driving the 
enzymatic reactions required to sustain life. 
 
Based upon the success of both qualitative proteomics and quantitative 
genomics, the proteomics community soon began to realise that similar 
comparative protein based analyses could be achieved (Regnier and Julka, 
2006), enabling the comparison of disturbed and undisturbed proteomes, cells 
grown in different media, diseased cells compared with healthy, and indeed the 
tracking of a disease’s progression.  
 
Having the capacity to visualise over 10,000 distinct protein spots, equating to 
over 1000 unique proteins, 2DGE was applied quite early on in the field of 
comparative proteomics (Schulze and Usadel, 2010, O’Farrell, 1975). Problems, 
however, were encountered due to both inter-gel variability, and the chemistry 
through which a variety of protein stains and dyes bind each biomolecule, 
preventing both inter- and intra-gel spot quantitation (Marouga et al., 2005). 
High-confidence 2DGE based comparative proteomics was thus delayed until 
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1997, when DIGE was first described. This features two differentially labelled 
samples being combined and co-analysed via 2DGE (M. Unlu et al., 1997). 
  
While comparative proteomics was also eventually conducted via LC-MS, its 
application was delayed due to the variable ionisation efficiency detected for a 
range of biomolecules, in addition to which varying sample components and 
hardware performance at the time of use can limit the reproducibility of this 
technique (Schulze and Usadel, 2010). So as to better explain, when a protein is 
proteolytically digested, an equal number of each proteolytic peptide should be 
liberated, the signal intensity achieved for each peptide during an MS scan can, 
however, still vary by several orders of magnitude, assuming each peptide is 
detected (Steen and Mann, 2004). This variation results from several 
independent factors, including the accessibility of the digest site to the 
protease, the solubility of the peptide (having been dried post-extraction) and 
the efficiency with which each peptide ionises within the MS source. It was thus 
realised that the only way in which a quantitative proteomic comparison could 
be made via MS would be if one of the samples were to be labelled with a stable 
isotope (13C, 15N, 2H or 18O), and both samples co-analysed via LC-MS (Vaudel et 
al., 2010). Under such conditions each biomolecule should elute from the LC at 
the same time, both molecules should ionise under the same conditions, and 
each peptide should thus be directly comparable based on a slightly differing 
m/z (Schulze and Usadel, 2010). 
 
Discussed over the following few pages are some of the most commonly used 
quantitative proteomic techniques, based on both 2DGE and LC-MS. 
 
1.6.1 Difference gel Electrophoresis 
Due to the varying conditions under which a poly-acrylamide gel is cast, the 
slightly varying components within each sample, and the way in which each 
sample traverses the 2D gel, 2DGE has been documented to contain a great deal 
of variation, making it unsuitable for use in comparative proteomics. In an effort 
to overcome these problems, Minden and co-workers in 1997 devised a technique 
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termed DIGE, which features the use of two molecular weight and pI-matched 
fluorescent cyanine dyes (Cy3, and Cy5), each covalently labelling approximately 
3% of the Lys residues within a given sample (minimal labelling). Upon 
completion of labelling, each sample is combined and co-separated on a single 
2D SDS-PAGE gel, with the samples being compared through the application of 
fluorescent imaging, with a sensitivity equal to that of silver staining (~1 ng) (M. 
Unlu et al., 1997), as depicted on Figure 1-8. A third cyanine dye (Cy2) can also 
be employed to label an additional pooled sample, so as to act as an internal 
standard, accounting for any variation in labelling efficiency (Lilley and 
Friedman, 2004).  
 
 
Figure 1-8: The workflow through which two proteomes can be compared 
based on DIGE.  Depicted above is the workflow used in a DIGE based proteomic 
analysis, including the growth, preparation and labelling of the two samples 
(with Cy3 and Cy5), their mixing, and separation based on 2DGE. Upon the 
samples being separated each is then compared based on a differing excitation 
and emission wavelength, enabling the protein expression patterns to be 
assessed. 
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Despite minimal labelling being applied to this technique with the best of 
intentions, those being to label only one Lys residue per protein (preventing 
multiple gel spots per protein), both to reduce the volume of dye required per 
analysis and to prevent sample solubility being compromised, the minimal 
labelling strategy actually became the greatest failing of this technique (Wu et 
al., 2006, M. Unlu et al., 1997). While a slight alteration in protein mobility 
within the second dimension has indeed been detected in labelled samples, the 
minimal labelling strategy labels only a small percentage of the total protein 
content. This becomes a particular problem when a protein identification is 
required for a specific protein spot as the location of the majority of the protein 
and the visualised protein spot do not match up (termed dual spot migration) 
(Tonge et al., 2001). 
 
In an attempt to improve upon the minimal labelling strategy, a variation of 
DIGE was described by Shaw and co-workers in 2003 which aimed to completely 
label a less prevalent amino acid, Cys, which accounts for just 2.47% of amino 
acids across eight random proteins (in comparison to the 10.1% accounted for by 
Lys) (Shaw et al., 2003). In addition to preventing dual spot migration, the 
improved fluorophores used in this reaction have been documented so as to offer 
the technique a 100- to 200-fold increase in sensitivity.  
 
Several disadvantages have been noted, however, in the application of 
saturation DIGE. Firstly, the electrophoretic mobility of the labelled proteins 
does appear to be significantly reduced. This was one of the main reasons the 
minimal labelling strategy was initially employed (Kondo and Hirohashi, 2007). It 
should also be noted that any given spot on a 2D gel can contain more than one 
protein, making quantification difficult (Zhu et al., 2010). Finally, it has been 
noted that approximately 5% of the proteins within the human proteome do not 
contain a Cys residue, further restricting the number of proteins to which 2DGE 
can be applied. 
 
53 
 
1.6.2 Stable Isotope Labelling by Amino Acids in Cell Culture 
As was discussed in Section 1.6., co-eluting sample components and instrument 
performance at the time of use can affect the reproducibility of the ion intensity 
achieved for any given biomolecule accessed via MS. Indeed the only way in 
which a biomolecule can be accurately compared between samples or 
instruments based upon the use of MS is through the introduction of one of a 
number of stable isotopes, including 13C, 15N, 2H or 18O. Several technical 
limitations do exist with the utilisation of these isotopes within comparative 
proteomics, including the difficulty in substituting atoms within a protein (13C 
and 15N). While hydrogen can be readily substituted by deuterium, this reaction 
has been noted to cause a small, but significant shift in retention time during 
RP-LC based separation (Bantscheff et al., 2007).  
 
In an attempt to overcome these problems both Lahm and Langen (Lahm and 
Langen, 2000), and Chait and co-workers (Oda et al., 1999), utilised 15N-
substituted media in the growth of a range of autotrophic microorganisms so as 
to assess any proteomic changes occurring during different states of growth. 
While the application of this technique appears to have been successful, the 
degree of 15N incorporated was not necessarily complete. Additionally, as each 
peptide contained a varying number of nitrogen atoms, the subsequent mass 
shift was often hard to predict (Ong et al., 2002). Lastly, while the production of 
the 15N media for autotrophic organisms proved costly, its application in higher 
organisms would certainly prove even more expensive, restricting the use of this 
technique (Ong et al., 2002). 
 
In an attempt to avoid the pitfalls of 15N labelling, Ong and co-workers in 2002 
described a comparative proteomic technique termed stable isotope labelling by 
amino acids in cell culture (SILAC), which utilised a growth media containing two 
13C labelled essential amino acids (Arg and Lys) so as to introduce a small mass 
shift between each protein suitable for detection on a MS (Ong et al., 2002), as 
is depicted on Figure 1-9. By selecting to label both Lys and Arg, and assuming 
the use of trypsin, each proteolytic peptide should in theory be labelled only 
once, ensuring a constant mass shift and enabling a rapid analysis (Vaudel et al., 
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2010). Indeed, one of the big advantages of SILAC is that each sample is 
combined at the cellular level, prior to the application of any biochemical 
processing or the variability of MS. In theory this should help to ensure that any 
sample losses encountered should affect both samples equally (Unwin and 
Whetton, 2007).  
 
 
Figure 1-9: The stages involved in a SILAC based proteomic analysis.  Depicted 
above are the stages involved in a SILAC based proteomic comparison of two 
samples. While one sample is grown on a control (light) media, the second 
sample is grown on a media containing both 13C labelled Arg and Lys (heavy). 
Upon cell lysis the samples are combined, digested, separated via LC and 
analysed via MS. Due to the small MW difference between the two samples, 
introduced by the labelled amino acids, the two peptides can be differentiated 
based on their parent ion m/z, and a quantitative comparison made. 
 
In practice, however, SILAC has been shown to require some 6-8 passages in 
modified media to achieve a labelling efficiency of just 90% (Ong et al., 2002). 
Furthermore, it has been noted that an excess of Arg within the labelled media 
can lead to the production of labelled Pro, a process which further complicates 
the data analysis (Schulze and Usadel, 2010). Finally, only a limited number of 
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cell lines are suited to growth on dialyzed serum, limiting the application of 
SILAC (Fenselau, 2007). 
 
1.6.3 18O Incorporation 
Chemical-based labelling techniques can also be applied to quantitative 
proteomics, achieving the same mass shifts associated with cells grown on heavy 
media but in a much shorter time frame and at a fraction of the cost. One such 
technique was described by Yao and co-workers in 2001 and involves the tryptic 
digestion of a protein sample in the presence of either H2O or H218O. As the 
cleavage of a protein is a form of hydrolysis, then peptides/proteins digested in 
the H218O will gain a 4 Da increase in mass (a 2 Da increase per 18O, two of which 
are incorporated), while those digested in the presence of H2O will not, enabling 
their differentiation and relative quantification via MS (Yao et al., 2001), as is 
shown on Figure 1-10. 
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Figure 1-10: The principle behind 18O labelling and comparative protein 
quantitation.  Depicted above is the workflow utilised during an 18O/16O 
comparative protein quantitative analysis, including the growth of both 
organisms on a normal media, their digestion in the presence of either H216O or 
H218O, their mixing and their analysis via LC-MS. Because of the 4 Da mass shifts 
introduced to each peptide, the molecules can be differentiated on the mass 
spectrum and quantified. 
 
There are many advantages conferred by the use of 18O labelling in comparison 
to a media based quantitative method, including the fast reaction time, the 
simplicity of the technique and its low cost. Perhaps one of the biggest 
advantages is that, in theory, the technique works equally as well in a complex 
pre-fractionated protein sample as it would with a single purified protein, giving 
it a much greater appeal in the field of proteomics (Vaudel et al., 2010). 
  
Many disadvantages have however been reported in the application of 18O 
labelling; the most worrying of which are the description of both incomplete 
labelling, and the occurrence of back exchange (reintroducing 16O back into a 
previously labelled sample). Furthermore, as 18O labelling yields only a 4 Da 
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mass increase, peak separation can be incomplete (Makarov and Scigelova, 
2004).  
 
While the 18O labelling reaction is relatively efficient, when a protein is 
digested, one 16O atom is released into the digestion buffer for every two 18O 
atoms incorporated, which over time can build up in the digestion buffer 
reducing the efficiency of the reaction. Upon the completion of labelling, the 
presence of either residual enzyme activity in water, or acid/base-catalysis can 
cause the bound 18O to be replaced by an 16O molecule, thereby complicating 
data analysis through the introduction of overlapping (+2 Da) peaks (Schnölzer et 
al., 1996). 
 
1.6.4 Isotope-Coded Affinity Tags 
A second chemical-based labelling technique designed for the relative 
quantification of peptides, which yields an increase in mass (between samples) 
greater than that obtained through the use of 18O labelling, was first described 
by Gygi and co-workers in 1999, termed isotope-coded affinity tags (ICAT) (Gygi 
et al., 1999). In brief, this technique features the differential labelling of two 
protein samples (with either a heavy or light ICAT tag), their co-digestion, avidin 
based affinity purification, separation and analysis based upon LC-MS/MS (Patton 
et al., 2002).  
 
The ICAT tags employed during this technique can be seen to be composed of 
three specific regions; a thiol specific (Cys binding) reactive group, a polyether 
linker region (containing either eight deuterium (heavy) or hydrogen (light) 
atoms), and a biotin affinity tag (enabling avidin based affinity chromatography) 
(Gygi et al., 1999).  
 
This technique offers several advantages over the use of 18O labelling, the first 
of which is the 8 Da mass difference imparted between the two labelled 
samples, double that obtained through the use of 18O labelling (Gygi et al., 1999, 
Yao et al., 2001). This is particularly important during proteomics as it better 
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enables the differentiation and quantification of multiply charged peptide 
species, the peaks from which may otherwise become overlapped. Furthermore, 
as affinity chromatography is utilised during the implementation of ICAT, the 
final sample should contain approximately 10-fold fewer peptides than it may 
otherwise have (Ong et al., 2002, Patton et al., 2002), increasing the precision 
of the quantification through increasing the protein sequence coverages 
achieved (by ensuring that only those peptides which are labelled will be 
selected for MS/MS). 
 
There are however several disadvantages to the utilisation of ICAT over 18O 
labelling, for example, not every protein contains a Cys residue. Indeed it has 
been documented that more than 5% of human proteins do not contain a Cys 
residue, a figure which increases when peptides are considered (Karlin et al., 
1991). In addition, as the heavy ICAT tag contains deuterium, the RPLC based 
retention time differs slightly between the heavy and light labelled peptides, 
introducing a potential source of error as a result of non-uniform peptide 
ionisation (varying retention times may result in different co-eluting sample 
components, each competing for ionisation) (Zhang et al., 2001, Patton et al., 
2002). Finally, the ICAT tags have been reported to interfere with the 
fragmentation spectra, complicating data interpretation (Haynes and Yates III, 
2000, Patton et al., 2002).  
 
Recently an attempt has been made to improve upon the first generation of ICAT 
tags, firstly through making the biotin moiety acid-labile, thereby reducing the 
size of the ICAT tag post-purification (with the aim of reducing MS/MS 
interference). Furthermore, 13C may be utilised instead of deuterium, which 
should enable peptide co-elute, enabling a more accurate relative quantitation 
(Yi et al., 2005).  
 
1.6.5 Tandem Mass Tags 
While SILAC, ICAT and 18O labelling, among countless other techniques, rely upon 
a peak area comparison being made between the parent ions of both a labelled 
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and an unlabelled peptide, it is worth considering that this form of analysis can 
in some cases become a hindrance. As was discussed in Section 1.3.2, the 
proteome of an organism at any given point in time will contain a vast number of 
proteins, which when subjected to a bottom-up based proteomic analysis, such 
as SILAC or 18O labelling, will yield an overwhelming number of proteolytic 
peptides. It is then worth considering that during a comparative proteomic 
analysis that at least two proteomes will be assessed, and therefore two parent 
ions will be present for each peptide, not to mention those which may result 
from the presence of PTMs and indeed the presence of isotopic peaks. It is 
therefore understandable that when it comes to analysing the data gathered 
during a so-called MS1 experiment, that peaks can become merged, preventing 
an accurate peak area from being obtained (Vaudel et al., 2010). 
 
In an attempt to overcome these problems, while further reducing the number 
of peptides present in a comparative proteomic analysis, a technique was 
described by Thompson and co-workers in 2003, termed tandem mass tags (TMT) 
(Thompson et al., 2003), which, in brief, features the harvesting, purification 
and digestion of two individual samples, at which point, each is differentially 
labelled with one of two isobaric tags. Each sample can then be pooled and 
analysed via LC-MS/MS, utilising an IDA scan, so as to fragment only those MS 
peaks which match a list of pre-defined selection criteria (Thompson et al., 
2003). As the TMT technique features the use of isobaric tags, only a single MS 
peak should be present for each peptide. A relative quantification is performed 
based upon the MS/MS spectra obtained, comparing the peak areas detected for 
each reporter ion (Ross et al., 2004). 
 
The duplex TMT tags utilised in this reaction can be seen to be composed of 
three distinct regions; a reporter group (with a mass of either 126.1 or 127.1 
Da), a reactive group (so as to enable the tag to be bound to a primary amine 
(both on the N-terminal of each peptide in addition to the side-chain of each Lys 
residue)), and a balancer group (increasing the mass of each tag to a total of 225 
Da) (Thompson et al., 2003, Byers et al., 2009), as is shown on Figure 1-11. More 
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recently TMT has been extended to enable the relative quantification of up to 
six biological samples (Dayon et al., 2008). 
 
 
Figure 1-11: The theory behind a duplex TMT based quantitative proteomic 
analysis.  Depicted above are the steps involved in a duplex TMT based 
quantitative proteomic analysis, including the growth of multiple samples, their 
labelling, and their detection via LC-MS. The duplex TMT tags feature a reporter 
group (with a mass of either 126.1 or 127.1 Da) and a balance group (with a mass 
of either 97.9 or 98.9 Da), which when bound to the amine group of a Lys or N-
terminal of a peptide, results in an overall mass increase of 225 Da for each tag. 
 
Following the description of duplex TMT in 2003, a second isobaric tag based 
quantitative technique was described by Ross and co-workers in 2004, termed 
isobaric tags for relative and absolute quantitation (iTRAQ), capable of 
comparing up to four biological samples. More recently this technique has also 
been extended to enable the labelling and comparison of up to eight unique 
biological samples; however it has been suggested that the peptide 
identification rate may be lower when using the eight-plex technique over the 
four-plex (Pichler et al., 2010). 
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Like TMT, each of the four iTRAQ tags are composed of three distinct regions; a 
reporter group (with a varying mass of between 114.1 and 117.1 Da), a reactive 
group (so as to enable the tag to be bound to a primary amine (both on the N-
terminal of each peptide in addition to the side-chain of each Lys residue)), and 
a varying balancer group (increasing the mass of each tag to a total of 144.1 Da) 
(Ross et al., 2004), as is shown on Figure 1-12. 
 
 
Figure 1-12: The theory behind an iTRAQ based quantitative proteomic 
analysis.  Depicted above are the steps involved in an iTRAQ based quantitative 
proteomic analysis, including the growth of multiple samples, their labelling, 
and their detection via LC-MS. The iTRAQ tags feature a reporter group (with a 
mass ranging from 114-117 Da) and a balance group (with a mass ranging from 
28-31 Da), which when bound to the amine group of a Lys or N-terminal of a 
peptide results in an overall mass increase of 144.1 Da for each tag. 
 
Both TMT and iTRAQ have many advantages over the use of other quantitative 
proteomic techniques, including their ability to reduce the complexity of 
multiplexed MS spectra, even those resulting from up to eight unique biological 
samples (iTRAQ).  
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While the utilisation of MS/MS enables the co-identification of each peptide 
(based upon the peptide fragmentation spectrum (discussed in Section 1.4)), the 
application of these isobaric techniques has several drawbacks. Firstly, a 
requirement of TMT/iTRAQ is that an MS/MS scan must be performed on each 
peptide if a quantitation is to be achieved. This can be particularly problematic 
depending on both the resolution of the HPLC based separation and the cycle 
time of the MS utilised. As an example, if a short, single dimension LC gradient is 
utilised in combination with a long cycle time mass spectrometer (which will 
depend on the age of the instrument and mass range being scanned), then many 
peptides may be rapidly eluted from the column and only a limited number of 
MS/MS scans performed. Furthermore, as both iTRAQ and TMT tags are applied 
to peptides, then it is possible for inconsistencies during cell lysis, fractionation 
and sample labelling to effect the precision of this technique (Unwin et al., 
2006). Finally, in the instance in which multiple peptides with similar m/z ratios 
co-elute, and thus are all subjected to MS/MS, chimeric spectra (overlapping 
MS/MS spectra which can complicate peptide identification) can present, 
summing reporter ion signals from multiple peptides, and thus yeilding incorrect 
quantitation data (Houel et al., 2010). 
 
1.6.6 Label-Free Quantification 
Serving as an alternative to both cell-culture based labelling and chemical 
labelling techniques, several label-free quantitative strategies have also recently 
been developed with the goal of achieving a faster (requiring no additional 
sample processing), cleaner and simpler quantification (Zhu et al., 2010).  
 
While an accurate MS-based comparative quantification between samples, 
instruments, and indeed laboratories is reliant on the use of stable isotopic 
labelling and the co-separation and analysis of each biomolecule (as was 
discussed in Section 1.6) (Schulze and Usadel, 2010), it is also true that these 
techniques can increase both the time and the complexity of sample 
preparation. They also require the use of high cost reagents and can risk reduced 
quantitative accuracy through incomplete labelling. Furthermore, aside from 
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iTRAQ, few quantitative techniques enable the direct comparison of more than 
two samples, something which is not a limiting factor during label-free analyses 
(Zhu et al., 2010). 
 
Label-free quantitation can be conducted in one of two ways, the first of which 
is based on the premise that the observed MS signal intensity correlates well 
with the quantity of ion injected (S. Pan et al., 2009). This technique is 
therefore based on the comparison of a peptide’s peak area between samples. 
This technique does however have several drawbacks, including the fact that the 
ion intensity of a peptide can vary between samples due both to the gradual 
deterioration of the nano-spray ESI needle and the reduced binding capacity of 
the LC column. Likewise, where a shift in the LC retention time has occurred, 
varying co-eluting peaks, and thus competition during ionisation, can lead to a 
change in the intensity of the ion (Zhu et al., 2010). These variations were 
foreseen and can be corrected for through the use of one of several suitable 
software packages (Shaw et al., 2003). 
 
In comparison to the quantitative accuracies of both 15N and SILAC, each of 
which regularly achieve coefficient of variation (CoV) values of less than 10%; 
and iTRAQ, which is described as being of a “medium” quantitative accuracy, 
with CoV values regularly between 10 and 30%, label-free quantification, based 
on the comparison of peptide ion intensities between samples is also described 
as being of a “medium” accuracy with CoV values regularly between 10 and 30% 
(Shaw et al., 2003). In brief, the CoV can be calculated by dividing the standard 
deviation by the mean. This is particularly useful in quantitation as it is a 
dimensionless measure of variation, comparable between techniques, 
laboratories and indeed data sets. 
 
The second label-free approach, termed spectral counting, is based on the 
premise that when the amount of a protein entering the MS increases, so too 
should the sequence coverage, and therefore the number of proteolytic peptides 
identified. The amount of protein within a sample is thus quantified through 
comparing the number of MS/MS spectra identified for each protein, offering an 
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advantage over the measurement of peak area alone, which is suited only to the 
comparison of a single peptide between samples (Zhu et al., 2010). Indeed, this 
form of label-free quantitation has also been applied to absolute quantitation 
using a technique termed protein abundance index, which can be calculated by 
dividing the total number of peptides identified from a protein by the number of 
peptides which can theoretically be identified (Schulze and Usadel, 2010, 
Ishihama et al., 2005).  
 
In applying spectral counting to the quantification of two ideal samples (samples 
which possess less than twofold variation in abundance and which contain at 
least four peptide peaks per protein), this label-free technique has been shown 
to display an accuracy greater than 95% (Schulze and Usadel, 2010). In contrast, 
when the same technique is applied to the quantification of lower abundance 
proteins, spectral counting has been found to provide only a “poor” level of 
quantitative accuracy, as a result of the reduced number of spectra available 
(Old et al., 2005), and will generally yield CoVs greater than 30% (Kondo and 
Hirohashi, 2007). 
 
1.6.7 Labelled Internal Standard Based Quantification 
While each of the previously discussed quantitative techniques has advantages 
and disadvantages when applied to a specific biological system, each can provide 
only a relative level of quantitation for peptides, between two or more samples. 
While useful for assessing the varying concentration at which a protein is 
expressed between a range of cellular states (generally expressed as a ratio), 
further interpretation of this data is difficult (Brownridge et al., 2011). There is 
growing demand for the absolute quantification of proteins within biological 
systems, where the exact number of protein molecules per cell is quantified, 
enabling both the quantification of samples where no reference material exists 
and the tracking of a disease’s progression (Drews, 2000, Brownridge et al., 
2011). 
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The idea of absolutely quantifying a molecule is not a new concept, indeed the 
absolute quantification of drug molecules has been performed since 1932, based 
upon isotope dilution analysis; with a more recent adaption utilising stable 
isotopes, in a technique termed stable-isotope dilution (Fassett, 1995). In brief, 
as the stable isotope has an identical structure to the analyte, it should behave 
in an identical manner when subjected to LC-MS/MS. The stable isotope should 
therefore co-elute with the analyte, and as such, be subjected to same matrix 
based ion suppression or enhancement, thereby enabling the peak areas of the 
two molecules to be directly compared. 
 
1.6.7.1 Protein Standard Absolute Quantification 
The production of isotopically labelled full-length proteins to act as standards 
for absolute quantification was first described by Brun and co-workers in 2007 
and termed protein standard absolute quantification (PSAQ) (Brun et al., 2007). 
PSAQ consists of a protein analogue being synthesised in the presence of 
uniformly labelled Lys and Arg residues (13C and 15N), which when cleaved with 
trypsin, will yield proteolytic peptides each containing one labelled amino acid 
residue. These peptides can then be compared with their non-labelled 
counterparts, and assuming the amount of the PSAQ-labelled protein added is 
known, an absolute concentration can be determined for each target protein 
(Brun et al., 2007), as is shown on Figure 1-13. 
 
The main advantage of PSAQ, over AQUA (described in Section 1.6.7.2) and 
quantitative concatamer (QconCAT) (described in Section 1.6.7.3), is the fact 
that an intact protein standard is utilised as an internal standard, and thus both 
the protein target and the internal standard should separate and digest under 
identical conditions, accounting for any potential sample loss. 
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Figure 1-13: The techniques through which PSAQ, AQUA and QconCAT enable 
an absolute quantitative proteomic analysis.  While PSAQ enables an absolute 
quantification to be performed based on the digestion of the target protein with 
a labelled intact protein standard, AQUA enables a quantification to be 
performed based upon the quantification of a single proteotypic target peptide. 
While QconCAT is performed in much the same way as AQUA, it enables the 
quantification of multiple proteins per sample through the construction, and 
subsequent co-digestion, of an artificial protein. 
 
While very little data has been published detailing the application of PSAQ in a 
biological system, sensitivity levels down to 44 femtomoles (fmol) (1.2 ng of 
protein in 100 microlitres (µL) of sample) have been described in human urine 
(Brun et al., 2007), while a more recent publication from the same group has 
detailed the technique to yield CoV values of between 0.6 and 30.7%, with non-
proteotypic peptides (the term proteotypic is discussed further in Section 
1.6.7.1.1) containing greater levels of variation (Jaquinod et al., 2012).  
 
PSAQ is, however, a time consuming and complicated technique, requiring the 
continued synthesis of a standard isotope-labelled protein via cell culture in 
labelled media, its purification, and finally its quantification by amino acid 
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analysis (AAA) (this point also applies to QconCAT however, while AQUA peptides 
are pre-quantified, enabling immediate use), prior to the protein being mixed 
with the target cell lysate and processed (Brun et al., 2007). Furthermore, this 
technique assumes that both the synthetic and target proteins will yield the 
same PTMs, as is required for the biomolecules to be separated and analysed 
under identical conditions (Brownridge et al., 2011). 
 
1.6.7.1.1 Proteotypic and Quantotypic Peptides 
In the field of quantitative proteomics, the terms proteotypic and quantotypic 
are used to indicate that the sequence of a peptide is ideal, and therefore the 
quantitation achieved for that cleaved peptide should be representative of the 
quantity of the parent protein present before digestion.  
 
On the topic of proteotypic peptides, Craig et al. state that proteotypic peptides 
should be compatible with all common proteomic sample handling steps, 
including enzymatic digestion, gel extraction, RP-LC and ionisation (Craig et al., 
2005). Bislev et al. further define the term proteotypic, stating that proteotypic 
peptides should have a length of between 7-20 amino acids and should be unique 
within their target proteome (with a sequence which can be mapped to single 
genomic location). Furthermore, Bislev et al. state that proteotypic peptides 
should not contain amino acid residues which are prone to modification 
(including Cys, Met, Try, Ser and N-terminal Gln residues), should not contain N-
terminal acidic residues (assuming the peptide is cleaved at a basic residue) and 
should not be cleaved from a sequence susceptible to missed cleavages (sites 
which are flanked by additional cleavage sites) (Bislev et al., 2012). 
 
1.6.7.2 AQUA Based Peptide Quantification 
During a bottom-up PSAQ based quantitative analysis of a protein, only a few 
proteotypic peptides will ultimately be quantified, so as to avoid any erroneous 
data which may be obtained from the quantitation of peptides not suited to 
spiked digest based analyses, such as those peptides which are susceptible to 
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missed cleavages (PSAQ should, however, still correct for these sequence flaws 
during quantitation). A quicker and cheaper approach may therefore be to 
produce synthetic labelled copies of those peptides which are eventually 
quantified, and to spike those into the sample during the proteolytic digest. This 
technique, termed AQUA, was first described by Gerber and co-workers in 2003 
(Gerber et al., 2003b) and is based upon the premise that for every protein 
molecule digested, a single copy of each proteolytic peptide will be generated, 
thus, through quantifying even a single peptide it should be possible to 
determine the amount of parent molecule present. AQUA peptides are now 
commercially available from both Sigma and Thermo, increasing their 
availability and application in the wider scientific community. 
 
During a typical AQUA experiment, a known amount of AQUA peptide (a 
synthetic internal standard peptide containing a uniformly 13C and 15N labelled 
amino acid residue) will be combined with the targeted protein, generally after 
1DGE based separation, but before the protease has been added to the gel 
pieces (Kirkpatrick et al., 2005a). In adding the AQUA peptide solution to the 
dehydrated gel pieces, the AQUA peptide is absorbed into the gel, ensuring an 
equal extraction efficiency for both the target and synthetic peptides post-
digestion (Gerber et al., 2003b). Following the completion of the proteolytic 
digest, the peptide extracts are pooled and dried, re-suspended in a polar 
solution, separated based upon RP-LC and quantified through the application of 
MRM based MS (first performing a relative quantification between the synthetic 
and target peptides, then through knowing the exact amount of internal 
standard added to the sample, calculating the absolute amount of target peptide 
within the sample analysed) (Kirkpatrick et al., 2005b).   
 
This technique has several advantages over the use of PSAQ, the most 
compelling of which is the fact that AQUA uses a labelled peptide instead of a 
full-length labelled protein. As peptides can be rapidly synthesised based upon 
solid-phase peptide synthesis (SPPS), this technique is both more rapid, and 
cheaper than PSAQ, therefore it is perhaps more applicable to large scale 
sample analysis (Brownridge et al., 2011). Furthermore, as AQUA peptides can 
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be synthesised so as to containing a range of PTMs, it thus enables the 
quantification of both modified and unmodified protein species (V. Mayya et al., 
2006).  
 
There are, however, several disadvantages to selecting AQUA over PSAQ, the 
most prominent of which is the assumption that during an AQUA based 
quantitation, the digest efficiency of the targeted protein will be complete 
(discussed further in Section 2.1), while PSAQ is capable of correcting for any 
inefficiency. In addition, another advantage of PSAQ is the fact that the intact 
labelled protein is added to the sample at an early stage, and thus can correct 
for any sample loss encountered during separation (Brun et al., 2007). During the 
storage of the AQUA peptide, and indeed during sample preparation, peptide 
loss through binding can also pose a problem, where it has been documented 
that up to 90% of the peptide may be lost over a period of 24 hours through the 
adsorption of the peptide to the sample vial (Zhang et al., 2010).  
 
1.6.7.3 QconCAT based Peptide Quantification 
A third stable isotope based quantitative technique also exists, offering an 
alternative to both AQUA and PSAQ, designed for the quantification of multiple 
(up to 100) peptides within a proteome. This technique, termed QconCAT was 
first described by Beynon and co-workers in 2005 (Beynon et al., 2005) and 
involves the synthesis of a stable isotopically labelled, artificial protein, 
composed of multiple peptide sequences for the absolute quantification of 
multiple proteins within a biological system. To produce this artificial protein, a 
de novo gene is designed in silico and synthesised commercially, the amplified 
vector is transfected into Escherichia coli and the protein expressed. Upon the 
protein having been purified, and quantified via AAA, a quantity of the artificial 
protein is added to the target proteome and co-digested, separated based on 
RP-LC and quantified through the application of MRM based mass spectrometry 
(first performing a relative quantification between the synthetic and target 
peptide peak areas, then, through knowing the amount of internal standard 
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added to the sample, calculating the absolute amount of target peptide, and 
thus parent protein, within the sample) (Beynon et al., 2005). 
 
QconCAT has several advantages over the application of AQUA. Firstly, the 
QconCAT derived peptides (Qpeptides) are the product of a proteolytic digest, 
removing much of the bias associated with incomplete digestion. Furthermore if 
more than ten proteins are to be quantified (Beynon et al., 2005), then it is 
more economical to utilise QconCAT rather than synthesise and purify multiple 
AQUA peptides. QconCAT also has an advantage over PSAQ in terms of the time 
required to prepare multiple standards, where upon designing the QconCAT 
gene, only one protein is to be expressed. 
 
QconCAT does however have several disadvantages over the application of PSAQ. 
Firstly, while QconCAT does involve a co-digestion step, accounting for much of 
the variation associated with incomplete digestion, the protease employed will 
bind to several amino acids both up and downstream of the cleavage site, and 
thus the digestion of both the target and artificial proteins may proceed with 
different digest efficiencies (Brownridge and Beynon, 2011, Beynon et al., 2005). 
Furthermore, for each protease utilised, a separate QconCAT may be required, 
increasing the cost and complexity of the method. Finally, as the Qpeptides are 
expressed through the use of cell culture, rather than chemical synthesised, 
they cannot be imparted with the same range of PTMs as an AQUA based 
analysis. 
 
1.7 Protein Isoforms 
When analysing the human genome it was noted that only 1.1% of the 
deoxyribonucleic acid (DNA) sequenced accounted for protein coding exons, 
while 24% was found to consist of intronic sequence and some 75% consisted of 
intergenic DNA, with no known function in the coding of either RNA or protein. 
This was particularly surprising as it indicated humans to have only two to three 
times as many genes as lower organisms such as the mustard plant or fruit fly, 
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indicating that functional complexity, rather than absolute gene number, was 
key in the complexity of the human proteome (Baak et al., 2005). 
 
RNA splicing has been documented to be ubiquitous in eukaryotes, enabling the 
production of a variety of related but distinct protein isoforms through the 
differential incorporation of a range of exons in the mature mRNA (Andreadis et 
al., 1987). It has been predicted that up to 75% of the 20,000 to 30,000 genes 
within the human genome may be subject to some form of alternative splicing 
(Johnson et al., 2003), yielding an average of two or three transcripts per gene 
(M. Nakao et al., 2005). Furthermore, it has since been estimated that up to 95% 
of human multi-exon genes may be subject to alternative splicing, making 
alternative splicing the rule, not the exception (Pan et al., 2008a). It should, 
however, be noted that while some of these sequences yield novel protein 
isoforms, many mRNAs, even if detectable at the transcriptional level, do not 
encode a functional protein (Leoni et al., 2011, Tress et al., 2007).  
 
In brief, transcribed RNA consists of both exons and introns, with the exons 
containing the translated protein coding sequence and the introns containing 
both regions of regulatory importance and intergenic sequence. Upon the 
removal of the introns, the exons can be ligated in different combinations, 
giving rise to various protein isoforms.  
 
These introns can be identified through locating the conserved 3’ and 5’ intronic 
splice sites, where the 5’ splice site is marked by conserved sequence 
MAG|GTRAGT (where M represents either an A or a C and R represents either an 
A or a G), and the 3’ splice site is marked by conserved sequence CAG|G. In 
addition, each intron should contain a splicing branch point, usually marked by a 
single adenosine residue, some 18-40 bases downstream of the 5’ intronic splice 
site (Reed, 1989).  
 
Where an alternative protein product is produced, the modified sequence of the 
polypeptide chain can affect the intra- and extracellular location of the protein, 
its regulation, and its efficiency in binding a specific substrate (Gunning, 2001). 
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Indeed alternative splicing can also result in the truncation of a protein, 
synthesising a protein isoform which may contain a binding domain but not a 
catalytic domain, resulting in a protein isoform with a function differing to that 
of the wild-type (Rauch et al., 2011).  
 
In addition to the application of alternative splicing in increasing the complexity 
of the proteome, alternative splicing has also been linked to defective mRNA 
splicing in diseased cells. When the synthesis of a protein isoform is linked to a 
disease such as cancer, the most common cause of alternative splicing is a 
mutation of the intronic splice site, usually leading to the exclusion of the 
adjacent exon, and in more than half of all cases a truncation (Venables, 2004). 
 
1.7.1 Quantifying Protein Isoforms 
A major challenge facing the field of proteomics is the highly variable 
concentration at which a range of proteins can be expressed, where often it is 
those proteins which are present at a low copy number which are the most 
biologically interesting, yet can be masked by higher abundance proteins  
(Anderson and Anderson, 2002, Klose, 1975, O’Farrell, 1975).  
 
The analysis of protein isoforms is therefore particularly challenging due both to 
the high degree of sequence homology shared by many of these isoforms, and 
their low copy numbers. While these proteins differ structurally, this variation 
may have only a limited effect on the pI and MW of the final protein product, 
making their differentiation based upon the use of 2DGE next to impossible (S. 
P. Gygi et al., 2000, Galeva and Altermann, 2002).  
 
In regards to the application of top-down based proteomics for the detection of 
protein isoforms, long acquisition times are required to generate the MS/MS 
spectra necessary to determine the structure of a protein, based upon the use of 
ECD. Off-line HPLC based separative techniques are therefore frequently 
employed in top-down based proteomics, so as to provide the levels of protein 
separation required. Furthermore, due to the range of ion species (charge 
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states) which may be generated from an intact protein, sensitivity has also 
proven to be an issue during the application of top-down based proteomics. This 
technique, therefore, is not best suited for the analysis of protein isoforms 
within complex cell lysates. 
 
Furthermore, when a bottom-up based proteomic technique is applied to the 
analysis of a protein isoform, the protein inference problem may be 
encountered. In brief, when a protein is proteolytically digested, the resulting 
peptides may have sequences identical to those of peptides cleaved from 
multiple proteins, leading to ambiguities in the determination of the proteins 
identity (Nesvizhskii and Aebersold, 2005). If a protein isoform is to be identified 
based upon the application of bottom-up based proteomics, therefore, only 
those peptides which have a sequence unique within the target proteome should 
be targeted. If the resolution of the HPLC based separation is not adequate, 
however, the isoform specific peptides of interest may co-elute with other 
proteolytic peptides. When this occurs, and assuming each of the peptides meets 
the IDA selection criteria, the most intense ions will be selected for MS/MS. As 
such, the isoform specific peptide may become masked from detection based. 
 
Based upon the targeting of only those proteolytic peptides which are unique to 
an isoform within the host proteome, an absolute quantification may also be 
performed. As AQUA, QconCAT and PSAQ are all capable of yielding labelled 
proteolytic peptides, the peak areas of both the labelled and un-labelled 
peptides may be compared, prior to the absolute amount of target protein being 
determined. Furthermore, as only two peptides from the complex digested cell 
lysate are of interest to the analyst, MRM based scanning may be utilised to 
reduce the complexity of the MS data obtained, while increasing the sensitivity 
of the MS towards those analytes which are targeted.  
 
Several labelled peptide based quantitative analyses of protein isoforms have 
previously been described, including the quantification of three of five known 
sucrose synthase isoforms in the root nodules of Medicago truncatula, a 
technique designed to improve upon an existing western-blot based semi-
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quantitative technique (Wienkoop et al., 2008). Likewise, a technique was 
designed to quantify several members of the Cytochrome P450 superfamily in 
human liver microsomes, enabling the specific quantification of isoforms CYP3A4 
and CYP3A5, and the quantification of the entire CYP3A family, but not isoform 
CYP3A43 (Wang et al., 2008b). 
 
1.8 Conclusion 
While gel electrophoresis was first utilised for the separation of proteins back in 
1959 (Kwietny et al., 1959), its use in comparative proteomics was delayed until 
the description of DIGE in 1997 (M. Unlu et al., 1997). Likewise, while mass 
spectrometry was first described in the late 1800s (Griffiths, 2008), it was not 
possible to ionise large intact biomolecules until the late 1980s (Falk et al., 
2006), at which point a whole range of new hybrid instruments had to be 
developed to enable the analysis of the proteome (El-Aneed et al., 2009). The 
field of proteomics can thus been seen as a relatively new area of scientific 
research, which having been applied to the qualitative analysis of many proteins 
in a range of biological systems, is now becoming increasingly quantitative (Baak 
et al., 2005). 
 
While new quantitative proteomic techniques are still regularly being described, 
the field of comparative proteomics has recently been likened to a minefield 
(Vaudel et al., 2010), with every advantage offered by one technique being 
offset by several disadvantages over another. Some of the most desirable traits 
in quantitative proteomics are thus the ability to multiplex (iTRAQ/TMT), which 
is offset by reagent costs and the inaccuracy of processing each sample 
separately. Additionally, the desire to combine samples early in sample 
preparation (15N or SILAC), is offset by the cost of the labelled media, and the 
fact that only a limited number of cell lines are suitable for growth on dialyzed 
serum. 
 
When an absolute quantification is to be performed, as appose to a relative 
quantitation (such as that performed by each of those techniques previously 
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mentioned), very few techniques exist. While AQUA offers a relatively cheap and 
sensitive technique for the analysis of a single peptide, the precision of the data 
achieved may be compromised by the efficiency of the proteolytic digest. In 
comparison, while both QconCAT and PSAQ can correct for any inefficiency 
encountered during proteolytic digestion, each requires the synthesis of a 
labelled protein, and subsequently its quantification prior to use, which may be 
both expensive and time consuming, perhaps not applicable to large scale 
sample analysis. 
 
Finally, when a protein isoform is to be quantified, the high sequence homology 
means that a proteolytic peptide must be selected which is unique within the 
host proteome. As relatively few sample components are targeted during such an 
analysis, MRM based scanning may be utilised, reducing the complexity of the MS 
data obtained, while increasing the sensitivity of the MS towards the targeted 
analyte.  
 
1.9 Aims 
While several stable isotopic labelling based techniques have been reported 
which are capable of quantifying multiple protein isoforms, to the author’s 
knowledge no technique has yet been described which enables the absolute 
quantification of every individual isoform within a particular family of protein 
isoforms. Indeed, this may be of particular interest in assessing how the ratio of 
a group of protein isoforms varies between a range of tissues or in a diseased 
state. 
 
Furthermore, while many publications detail the sequential and physicochemical 
properties desirable in a proteotypic peptide, none have explored the strategies 
which may be employed to enable the selection of a suitable AQUA peptide for 
the quantification of multiple protein isoforms, where the high sequence 
homology of these isoforms can drastically limit the number of peptides 
available for selection. The use of several proteases per analysis and different 
enzyme based proteolytic double digests may be required, in addition to the 
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selection of peptides which contain reactive amino acids, so as to enable the 
selection of a single peptide.  
 
In the light of this, the author aims to develop a range of techniques, which may 
be utilised for the selection of proteolytic peptides suitable for the absolute 
quantification of multiple protein isoforms. Indeed, in doing so, the author aims 
to explore the suitability of a range of proteases and peptides containing 
reactive amino acids so as to determine what measurable effects these non-ideal 
components have on the quantitative accuracy of the technique. 
 
Ultimately, when fully established and optimised, this type of analysis should 
enable the wider scientific community to: (i) Identify which isoforms of a 
particular protein family are expressed within a given tissue (through detecting 
isoform specific target peptides). (ii) Accurately quantify each isoform detected 
(through detecting both the isoform specific target and synthetic AQUA peptide), 
and (iii) Detect changes in the expression ratio of these isoforms under different 
physiological conditions. 
 
In order to achieve these ultimate technical aims, which are beyond the scope of 
a PhD project, the author intends to: (i) Identify several families which consist 
of multiple protein isoforms and screen each with the aim of identifying suitable 
AQUA peptides for the absolute quantification of each protein isoform. (ii) 
Characterise each AQUA peptide and intrinsic target peptide so as to develop a 
suitable triple-quadrupole based MRM acquisition method for the identification 
of each peptide within a single LC-MS run. (iii) Express suitable amounts of each 
protein isoform, enabling the proteolytic digests to be optimised using a range of 
commercially available proteases. (iv) Assess the accuracy and reproducibility of 
the AQUA technique using both a suitable number of replicates, and (v) Test 
these optimised AQUA based quantitative techniques on both non-
immunoprecipitated transfected protein species and endogenously expressed 
samples. 
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2 AQUA Peptide Selection 
2.1 General AQUA Peptide Selection Criteria 
When selecting an AQUA peptide for the quantification of a target protein, there 
are several physical, chemical and sequence specific factors which must be 
considered. For example, based upon both manufacturing constraints, and the 
requirement for a peptide which is suited to an analysis based upon LC-MS/MS, 
the peptide must; (i) Be between 6 and 15 amino acids in length; (ii) Contain a 
residue suitable for stable isotopic labelling (either Ala, Arg, Ile, Leu, Lys, Phe, 
Pro or Val), and; (iii) Be water soluble, being neither too hydrophilic (ideally 
being composed of at least 10% hydrophobic residues (including Ile, Leu, Val, 
Phe, Trp and Met) nor hydrophobic (ideally being composed of less than 50% 
hydrophobic residues) (Brun et al., 2009, Brun et al., 2007, Kettenbach et al., 
2011, Kirkpatrick et al., 2005a, Pratt et al., 2006, Pan et al., 2008b).  
 
In addition to the above list of requirements, Kirkpatrick et al. make several 
further recommendations, stating that a candidate peptide should be selected 
which; (i) Resolves well via high pressure LC (HPLC); (ii) Ionises well via ESI, and; 
(iii) Is devoid of any chemically reactive residues, with the term chemically 
reactive covering Trp, Met and Cys (each of which oxidises easily), in addition to 
the more sequence specific examples of having an Asp residue flanking a Gly or 
where a peptide possesses an N-terminal Gln or Asn residue (due to the 
Fluorenylmethyloxycarbonyl (Fmoc) based chemistry used during peptide 
synthesis (Gerber et al., 2007)) (Kaufmann et al., 1994, Pan et al., 2008b). 
 
In addition, Kettenbach et al. suggested that two or three peptides should be 
selected per protein, and that peptides generated through the cleavage of the 
target protein at sites susceptible to missed cleavages should be avoided 
(Kettenbach et al., 2011). This can be further broken down into two groups of 
digest site: (i) Those where the cleavage site is flanked by “ragged ends” (a 
cleavage site which is pre- or proceeded to either the C- or N-terminal by a 
similar cleavage site), and; (ii) Those where the digest site is flanked by an 
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amino acid carrying an opposite charge (such as a tryptic digest site (Arg or Lys) 
being flanked to either the C- or N-terminal by an Asp or Glu residue).  
 
To better explain the problem with flanking oppositely charged residues, when 
an acidic residue is located next to a basic residue, a salt bridge can form 
between the β-carboxyl group on the acidic residue and the ε-amino group on 
the basic residue. This is particularly problematic when trypsin is utilised, as 
trypsin binds to either Arg or Lys, cleaving via the formation of a salt bridge with 
Asp 189 (Siepen et al., 2006). Further to the above, flanking basic residues are 
even more problematic when trypsin is utilised. Proteases have been shown to 
recognise not only a single amino acid, but to bind to approximately three 
residues both up and downstream of the digest site (Zabłotna et al., 2004, 
Brownridge and Beynon, 2011). Indeed, where two basic residues are located 
within close proximity, only one will be cleaved, while the other cleavage is 
missed, which when performing an AQUA based quantification would be 
disastrous (Brownridge and Beynon, 2011).  
 
In addition to the advice offered by Kirkpatrick et al., Gerber et al. suggests 
that AQUA peptides should be selected based upon the results obtained from 
previous LC-MS experiments, reasoning that any data obtained from a previous 
analysis will show which peptides present with a high signal intensity, and as 
such, which peptides separate well via HPLC and ionise well via ESI (Gerber et 
al., 2007).  
 
2.2 AQUA Peptide Selection for the Quantification of a Protein 
Isoform  
When screening the proteolytic digest products of a protein with the aim of 
identifying a proteotypic peptide suitable for an AQUA based quantitative 
analysis, the number of candidate peptides is often limited (Brownridge et al., 
2011). Furthermore, if a PTM on a specific amino acid is to be quantified, just a 
single peptide per protease may be selected (Gerber et al., 2003b). Indeed this 
can also be the case when highly homologous protein isoforms are considered, 
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which may differ by as little as a single amino acid, or have identical sequences, 
but contain a truncation, making the selection of C-terminal peptides the only 
viable solution.  
 
A technique to increase the range of peptides available for selection, and thus 
increasing the chances of a suitable AQUA peptide being identified, may 
therefore be to review the proteolytic digest products of several proteases. In 
some cases, however, even when multiple proteases are utilised, it may not be 
possible to identify a peptide which fully conforms to the AQUA peptide 
selection criteria. In these situations it may be necessary to select a peptide 
which is not considered proteotypic, including those which contain chemically 
reactive amino acid residues, or those which are flanked by non-ideal residues 
(oppositely charged).  
 
2.2.1 Protease Selection 
In bottom-up based proteomics, trypsin is by far the most widely used and 
documented proteolytic enzyme (Olsen et al., 2004). This is a result of both the 
wide availability of this high quality sequencing grade enzyme, and its digest 
specificity, cleaving after Arg and Lys residues, except when proceeded by Pro. 
Furthermore, the sites at which trypsin cleaves account for approximately 10% of 
the residues identified within an average mix of proteins (Tsuji et al., 2010), 
yielding tryptic peptides which are rarely larger than 10 to 15 amino acids in 
length, with masses of between 1 and 3 kDa. Additionally these peptides 
generally exist in a doubly or triply charged state during LC-MS, and thus are 
suitable for detection on a range of mass spectrometers (Brownridge and 
Beynon, 2011).  
 
There may be cases, however, where trypsin will not yield a suitable proteotypic 
peptide. In these cases, an alternative protease must be utilised. While many 
exist, which is utilised will depend on which enzyme yields a suitable 
proteotypic peptide, and which is the most applicable to a quantitative LC-MS 
based analysis.  
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On the topic of protease selection, Kettenbach et al. suggests that 
chymotrypsin, Glu-C or Lys-C may be utilised (Kettenbach et al., 2011). While in 
theory chymotrypsin cleaves at Tyr, Trp, and Phe, general amide bond cleavage 
has also been documented at a slower rate. If indeed this is the case, then these 
non-specific cleavages may lead to missed cleavages at the intended digest site, 
making chymotrypsin unsuitable for AQUA based absolute quantification.  
 
In comparison, both Lys-C and Arg-C have been documented to cleave 
specifically at the C-terminal of either Lys or Arg, respectively. Due to the lower 
frequency at which both of these enzymes cleave, however, (with both Arg and 
Lys each accounting for only 5% of the residues identified within a random 
protein mix (Tsuji et al., 2010)), larger proteolytic peptides have been reported. 
These sometimes with m/z ratios unsuitable for detection on modern triple 
quadrupole based mass spectrometers (Kelleher et al., 1999).  
 
Another protease suggested by Kettenbach et al. is Glu-C, which, like trypsin, 
cleaves at two amino acid residues, Asp and Glu, both of which are present at a 
high frequency within an average mix of proteins (Tsuji et al., 2010). It should 
be noted, however, that the digest specificity of Glu-C is dependent on the 
buffer in which the digest is conducted, with Asp based cleavages occurring at a 
3,000 fold lower rate than Glu based cleavages, when conducted in a phosphate 
based buffer, while Glu-C is thought to cleave exclusively at Glu in an 
ammonium bicarbonate (AMBIC) based buffer (Houmard and Drapeau, 1972). 
When applying Glu-C to the absolute quantitation of a target protein, it is thus 
best to avoid Asp cleaved proteolytic peptides entirely, due to the low digest 
efficiency of Glu-C at Asp. Furthermore, as Glu-C cleaves specifically after acidic 
residues, the C-terminal of Glu-C cleaved proteolytic peptides is generally 
devoid of a C-terminal charge. This is of particular importance during ESI based 
mass spectrometry as it may limit the detectable fragmentation spectra 
exclusively to B-ions (as the only charge will be present on the peptides N-
terminal), reducing the charge state of the peptide. Where a peptide’s charge 
state is reduced, the m/z ratio will increase, affecting the ability of some mass 
spectrometers to detect the peptide.  
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In conclusion, while several proteases may serve as an alternative to trypsin, in 
cases where a suitable tryptic peptide cannot be identified, each has several 
disadvantages over the use of trypsin. Indeed the specificity, digest frequency 
and C-terminal charge imparted by trypsin makes it ideal for proteomics, 
justifying its widespread usage. 
 
2.2.2 Proteolytic Digest Optimisation  
Despite how important the process of complete proteolytic digestion is to the 
field of quantitative proteomics, no standardised in-solution or in-gel based 
digest techniques have as yet been described. Indeed most modern in-gel based 
proteolytic digests still follow the same basic workflows first documented by 
Shevchenko et al. back in 1996, over a decade before the description of absolute 
quantification based proteomics (Shevchenko et al., 1996).  
 
One of the factors most commonly optimised to achieve a complete proteolytic 
digestion is the enzyme:substrate ratio at which a proteolytic digest is 
performed. This generally ranges from 1:10 to 1:100 (enzyme:substrate, 
weight:weight (w/w)), as per the manufacturer’s instructions (Havliš and 
Shevchenko, 2004, Porter et al., Norrgran et al., 2009). Proteolytic double 
digests have also been documented, adding an equal volume of the protease 
after eight hours and digesting for a further ten hours (Mayya et al., 2006).  
 
In-solution proteolytic digests have also been performed in buffers containing a 
high levels of organic solvent, where the organic solvent is thought to expose the 
hydrophobic core of the protein, aiding in complete digestion (Hervey et al., 
2007). Digests containing levels of organic solvent as high as 80% (v/v) have been 
reported, apparently yielding faster digestions and higher sequence coverages 
(Wall et al., 2011). Conflicting reports, however, have suggested that proteolytic 
activity is reduced above 50% (v/v) organic solvent (Khmelnitsky et al., 1991), 
and that protein precipitation can occur in solutions containing 80% organic 
solvent (v/v) (Polson et al., 2003). A recent publication aiming to address the 
phenomenon, concluded that while an increase in sequence coverage may 
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present, the overall efficiency of the digest is greatly reduced (Wall et al., 
2011).  
 
An alternative strategy, based upon the same premise, employs the use of 
chaotropic agents to denature the hydrophobic core of the protein, and as such 
to increase the efficiency of the proteolytic digest. These agents surpass organic 
solvents in that they are suitable for use with mass spectrometry and have no 
effect on the activity of the protease (GORDON and JENCKS, 1963). Of these 
chaotropic agents, the most commonly documented is urea, capable of 
denaturing the hydrogen bonds within a protein. However, when urea is heated 
it has been reported to yield isocyanic acid, carbamylating free amines within 
the target protein, and thus blocking Lys based cleavages (Rajagopalan et al., 
1961).  
 
A more recent technique utilised to increase the digest efficiency of a protein 
has been in the application of acid labile surfactants (ALS) (Norrgran et al., 
2009). While ALS were originally employed as a replacement for SDS during in-
solution digests, it was noted that they considerably increased the efficiency of 
the digest (Siepen et al., 2006). While ALS are not directly compatible with mass 
spectrometry, they are easily degraded through acidification, a process which is 
already performed during in-gel digestion as a method to increase the extraction 
efficiency of the proteolytic peptides from the gel pieces. A recent investigation 
into the use of various digest additives found ALS to yield the highest average 
increase in digest efficiency, with other experimental parameters yielding little 
further benefit (Yu et al., 2003, Brownridge and Beynon, 2011).  
 
An interesting technique through which the digest efficiency of a protein can be 
assessed was recently described by Norrgran et al. who utilised several 
proteotypic (optimal peptides for use in quantification) AQUA peptides (as 
discussed in Section 1.6.7.2) to monitor the increasing quantities of multiple 
proteolytic peptides cleaved from ricin over the course of a digest. This 
technique was applied to digests performed in the presence of ALS, in the 
presence or 20% MeCN in AMBIC (v/v), in AMBIC alone, and in AMBIC with the 
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ricin having previously been reduced and alkylated. The results from this study 
suggested that the ALS based technique yielded peptide levels between 36 and 
73% higher than each of the other techniques (Norrgran et al., 2009). 
 
2.2.3 Reactive Amino Acid-Containing AQUA Peptides 
As this project involves the quantification of protein isoforms, which may be 
highly homologus, it may be necessary to develop methods to cope with the use 
of those peptides which contain reactive amino acids, so as to enable the 
selection of an AQUA peptide suitable for an absolute quantification. 
 
Within the field of proteomics, Cys residues are commonly alkylated through the 
use of iodoacetamide (IAA), so as to prevent protein folding though disulfide 
bond formation or oxidation during sample preparation. Both Kirkpatrick et al. 
and Kettenback et al. recommend that Cys residues within AQUA peptides are 
reduced with dithiothreitol (DTT) and alkylated with IAA, so as to block the 
sulfhydryl groups (Kettenbach et al., 2011, Kirkpatrick et al., 2005a). Through 
the use of IAA, it should therefore be possible to utilise Cys containing AQUA 
peptides and enable a greater range of proteolytic peptides to be selected. 
 
Unlike the relatively simple process of alkylating a Cys residue, no single solution 
exists for the complete modification of Met. Should complete oxidation be 
attempted then it is important other oxidation-prone residues are considered, 
including Cys, Trp, Tyr and His (Kim et al., 2001). If a complete reduction were 
attempted then it is conceivable that re-oxidation may occur during downstream 
processing. Finally, while it is possible to alkylate Met through the use of 
Iodoacetic acid, the reaction is reversible under reduction conditions (Goverman 
and Pierce, 1981, Kleanthous and Coggins, 1990). 
 
While several reagents have been reported as being capable of oxidising Met, 
including dimethyl sulfoxide (DMSO), tert-Butyl hydroperoxide, sodium 
periodate, sodium perborate, hydrogen peroxide, chloramine T, tribromocresol 
and N-chlorosuccinimide, few are suitable for the complete oxidation of Met 
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alone. For example, the final three chemicals listed were all found to oxidise 
small amounts of Cys, His and Tyr, in addition to Met (Keck, 1995), while Try 
based cleavage has been reported with the latter (Fujii et al., 1978). Of the 
remaining mild oxidative agents, hydrogen peroxide has been identified as being 
non-Met specific (Keck, 1995), yielded small amounts of stable Met sulphone 
(Fujii et al., 1978), while tert-Butyl hydroperoxide has been found to modify 
only a limited number of exposed Met residues within an intact protein (Keck, 
1995).  
 
DMSO has also been reported as being capable of oxidising Met, yielding 
complete modification of free Met in less than three hours. Furthermore, the 
author also explains how though the use of dimethyl sulfide (DMS) it is possible 
to completely reduce the oxidised Met in under four minutes with no observable 
side reactions (Shechter, 1984). 
 
Despite the promising results documented for DMSO, the oxidative chemical of 
choice is sodium periodate. In addition to both Kettenbach et al. and Kirkpatrick 
et al. recommending its use for oxidising Met containing AQUA peptides 
(Kettenbach et al., 2011, Kirkpatrick et al., 2005a), Fujii et al. found sodium 
periodate to completely oxidise Met in under seven hours, with negligible levels 
of sulphone (Fujii et al., 1978), while Yamasaki et al. reported nearly 
quantitative formation of Met sulfoxide when treating free Met with equimolar 
amounts of sodium periodate (Yamasaki et al., 1982). An alternative to sodium 
periodate may also exist in sodium perborate, which it is detailed can achieve 
the same results as sodium periodate but over much longer periods of time (Fujii 
et al., 1978). 
 
While both Cys and Met containing AQUA peptides may therefore be utilised, the 
majority of the AQUA peptide selection criteria (detailed in Section 2.1) must be 
strictly adhered to (Brun et al., 2009, Kettenbach et al., 2011, Kirkpatrick et al., 
2005a, Pratt et al., 2006). By way of an example, if a peptide is selected which 
is above the 15 amino acid limit, difficulties can occur during SPPS. Likewise, if 
a peptide is selected which is below six amino acids in length, problems may be 
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encountered in the retention of the peptide on the C18 column. Indeed, while 
Trp, like Cys and Met, can be easily oxidised during sample preparation, no 
single solution as yet exists so as to enable the use of Trp containing peptides.  
 
2.3 The AQUA Peptide Selection Process  
The AQUA peptide selection process employed during this study can broken down 
into three specific stages: (i) The generation and initial screening of the 
candidate peptides (during which a theoretical digestion of the target protein is 
performed with a range of proteases and each candidate peptide screened); (ii) 
The alignment of each candidate peptide against the host proteome (through the 
use of a protein basic local alignment search tool (BLASTP)), and; (iii) Screening 
each remaining candidate peptide for sequence flaws, through comparing it to 
the AQUA peptide selection criteria (Figure 2-1). 
 
 
Figure 2-1: The three stages of selection employed when choosing an AQUA 
peptide. Described are the three specific stages of peptide selection employed 
during the selection of an AQUA peptide, including the theoretical digestion of 
the target protein sequence and the screening of each candidate peptide against 
the AQUA peptide selection criteria, the BLASTP based alignment of each 
remaining candidate peptide against the host proteome, and the comparison of 
each remaining candidate peptide, so as to determine which is the most 
applicable for an LC-MS based quantitative analysis. 
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2.3.1 Initial Candidate Peptide Screening 
Following the theoretical digestion of the sequence unique to the target protein 
with a range of proteases, each candidate peptide was screened, so as to 
determine its length (with a length of between 6–15 amino acids being 
mandatory), to ensure it contained an amino acid residue suitable for stable 
isotopic labelling (either Ala, Arg, Ile, Leu, Lys, Phe, Pro or Val), and so as to 
determine the percentage of the candidate peptides sequence which was 
composed of hydrophobic amino acid residues (with a value of greater than 10%, 
but less than 50% being optimal). Those candidate peptides which fell outside 
these selection criteria were eliminated, while those peptides which conformed 
where subjected to a BLASTP based alignment. 
 
2.3.2 BLASTP Based Alignment 
So as to determine if the sequence of each candidate peptide was unique within 
its host proteome, each peptide was subjected to a BLASTP based alignment. 
Those peptides which were found to originate from several protein species were 
eliminated, while those candidate peptides which were found to have a unique 
sequence were screened for sequence flaws, through comparing each to the 
AQUA peptide selection criteria. 
 
In setting up the BLASTP based search the “Non-redundant protein sequences 
(nr)” database was selected and the specific organism search restricted to 
“Homo sapiens (taxid:9606)”, finally the search algorithm was retained at its 
default setting “blastp (protein-protein BLAST)”, as shown on Figure 2-2. 
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Figure 2-2: The NCBI BLASTP search settings utilised when aligning candidate 
proteolytic peptides against the Homo sapiens proteome.  So as to test if a 
candidate AQUA peptide was unique to the Homo sapiens proteome, the NCBI 
BLASTP based search tool was utilised, screening the non-redundant database, 
with the search restricted to Homo sapiens (taxid:9606) and the BLASTP search 
algorithm selected. 
 
By way of an example, Figures 2-3 and 2-4 show the Blast output data resulting 
from a unique peptide and a non-unique peptide respectively. 
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Figure 2-3: An example of an NCBI BLASTP based alignment; a technique 
performed so as to identify which peptides are unique within their target 
proteome.  An NCBI BLASTP based alignment of A-Raf WT tryptic peptide 
IGTGSFGTVFR. Circled in green are the search results obtained from the BLASTP 
based alignment. From the alignment, five positive matches were identified; 
these were quickly screened by identifying which proteins displayed a 100% 
“query coverage”. Those proteins which are circled in blue achieved a 100% 
query coverage, while those proteins which are marked in red had a sequence 
coverage of less than 100%. Those candidate peptides which achieved a 100% 
sequence coverage from only their parent protein were marked as unique within 
the Homo sapiens proteome. 
 
 
Figure 2-4: An example of an NCBI BLASTP based alignment where the peptide 
is not unique to a single protein.  An NCBI BLASTP based alignment of A-Raf WT 
tryptic peptide WHGDVAVK. The brief search results shown on this image detail 
the top 15 hits for this peptide, when aligned against the Homo sapiens 
proteome. Due to the large number of proteins identified with a 100% query 
coverage, this peptide was seen as not being unique, and thus was eliminated 
from the search.   
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2.3.3 Screening Each Remaining Candidate Peptide for Sequence 
Flaws 
Having eliminated any peptides which did not possess a sequence unique within 
the host proteome, each remaining candidate peptide was compared to the 
AQUA peptide selection criteria, as was detailed in Section 2.1, so as to 
determine which candidate peptide was most applicable to a quantitative LC-MS 
based analysis. 
 
2.4 Residue Selection for Stable Isotopic Labelling 
Upon a suitable AQUA peptide having been selected, one final factor must be 
considered prior to ordering, the position of the stable isotopically labelled 
amino acid residue, assuming that more than one suitable residue exists. 
 
Due to the varying ion fragmentation techniques utilised in each mass 
spectrometer, the fragmentation spectrum achieved for a peptide will differ 
between instruments. By way of an example, on a QToF based instrument, such 
as a QSTAR Pulsar, a range of Y-ions would be expected, with relatively few low 
series B-ions. In comparison, triple quadrupole based instruments, such as the 
API 2000, yield a range of both Y- and B-ions, with further internal 
fragmentations possible, thus presenting with a more complex MS/MS spectrum 
(Sherwood et al., 2009, Paizs and Suhai, 2005).  
 
So as to enable the stable isotopically labelled fragment ions to be detected 
during MS/MS scans conducted on both QToF and triple quadrupole based 
instruments, labelled residues in close proximity to the N-terminal were 
preferentially selected, so as to enable the labelled residue to be detected in 
both low B- and high Y-ions. 
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3 Methods 
3.1 Cell Culture and Protein Production 
Each of the A-Raf plasmids used during this study were donated by Dr. Jens 
Rauch, a post doctorate researcher based at Systems Biology Ireland, University 
College Dublin (previously of the Beatson Institute of Cancer Research, 
University of Glasgow). Each of the A-Raf plasmids features a human 
complementary DNA (cDNA) A-Raf insert, pcDNA3.1(+) vector and an N-terminal 
start codon/FLAG tag “ATGGATTACAAGGATGACGACGATAAG” which results in 
the additional N-terminal peptide sequence “MDYKDDDDK”. 
 
Each of the PDE4B plasmids (PDE4B1, 2 and 3) used during this study were 
donated by Dr. George Baillie, a reader based at the Institute of Cardiovascular 
and Medical Sciences, University of Glasgow. Each plasmid contains a human 
PDE4B cDNA insert within a pEE7 vector (Celltech, UK). 
 
3.1.1 Plasmid Amplification 
A vial of Subcloning Efficiency DH5α cells (Invitrogen, USA) was transformed with 
1 ng of plasmid, as per the manufacturer’s instructions. A single colony was 
picked from the agar plate, cultured and the amplified plasmid extracted via 
Midiprep (Promega, USA), as per the manufacturer’s instructions. The amplified 
plasmid was eluted from the Midiprep cartridge in 600 µL of nuclease-free water 
and further purified via ethanol precipitation, reconstituting in 400 µL of 
nuclease-free water.  
 
3.1.2 Genejuice Based Transfection of HEK293 
The HEK293 cells used during this study were donated by Dr. Sarah Cumming, a 
research assistant based at the Institute of Molecular, Cell and Systems Biology, 
University of Glasgow. 
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A total of 1.7 x 107 HEK293 cells were plated to a 150 mm tissue culture dish and 
incubated for 24 hours at 37 degrees Celsius (oC), 5% (v/v) carbon dioxide (CO2). 
The plated cells were transfected with Genejuice, as per the manufacturer’s 
instructions, and incubated for a further 72 hours at 37 oC, 5% (v/v) CO2. Cell 
lysis was performed on ice, replacing the spent media with 1 mL of lysis buffer. 
Following a 45 minute period of cell lysis, the solution was centrifuged at 12,000 
rpm for 10 minutes, so as to pellet any cellular debris, while retaining the 
soluble proteome.  
 
3.1.3 Anti-FLAG Based Immunoprecipitation 
Anti-FLAG M2 agarose beads (Sigma-Aldrich, Germany) were added to the lysed 
cell solution and the FLAG-tagged transfected protein enriched, as per the 
manufacturer’s instructions. The agarose beads were washed in cell lysis buffer 
three times and the enriched transfected protein eluted in protein loading 
buffer, vortexing for 30 seconds and incubating at 99 oC for 15 minutes. 
 
3.1.4 Gel Electrophoresis 
The enriched protein was loaded to a 4-12% Bis-Tris Gel (Invitrogen, USA) and 
electrophoresed in an X-cell mini electrophoresis system (Invitrogen, USA) at 50 
volts (V) for 15 minutes, increasing to 150 V for 50 minutes. 
 
3.1.5 Coomassie Blue Staining 
The electrophoresed 4-12% Bis-Tris Gel was washed three times in water for five 
minutes before being stained in Coomassie Blue staining solution for 30 minutes. 
Furthermore, the gel was washed in water twice, each for a period of 60 
minutes. An image of the stained gel was captured on a G:Box (Syngene, India), 
running GeneSnap version 7.08. 
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3.1.6 Western Blotting  
The electrophoresed 4-12% Bis-Tris Gel was incubated in NuPAGE Transfer Buffer 
(Invitrogen, USA), containing 20% (v/v) MeOH, for 15 minutes before being 
transferred to an XCell II blotting module (Invitrogen, USA) and electrophoresed 
at 30 V for a period of 60 minutes, so as to transfer the protein to an Immobilon-
P Membrane (Millipore, USA). Post-electrophoresis, the PVDF membrane was 
washed for five minutes in Tris-buffered saline with 0.05% Tween (v/v) (TBST), 
three times, before being incubated in Western Blocking Reagent (Roche, 
Switzerland), as per the manufacturer’s instructions. The blocked membrane 
was again washed for five minutes in TBST, three times, and incubated for a 
further 60 minutes in primary antibody solution, containing 1:1000 anti-FLAG 
HRP conjugate antibody (Sigma-Aldrich, Germany) and 0.5% (v/v) Western 
Blocking Reagent in TBST. The blocked PVDF membrane was washed for five 
minutes in TBST, three times, and the gel imaged on a G:Box, running GeneSnap 
version 7.08, with BM Chemiluminescence solution (Roche, Switzerland).  
 
3.2 Recombinant DNA Techniques 
3.2.1 Agarose Gel Electrophoresis Based DNA Purification 
DNA purification was performed on a 1.5% (w/v) agarose gel, containing SYBR 
Green (Sigma-Aldrich, Germany), in a Mini Horizontal gel electrophoresis unit 
(Sigma-Aldrich, Germany) and submerged in TBE Buffer. The gel was 
electrophoresed at 90 V for 35 minutes and imaged on a G:Box, running 
GeneSnap version 7.08. 
 
3.2.2 Agarose Gel Based DNA Extraction 
The DNA gel band of interest was excised and the DNA was extracted via a 
QIAquick gel extraction kit (Qiagen, Netherlands), as per the manufacturer’s 
instructions. The concentration of DNA was determined through the use of a 
Nanodrop 1000 Spectrophotometer (Thermo Fisher, USA), as per the 
manufacturer’s instructions. 
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3.2.3 T4 DNA Ligation 
DNA ligation was performed with T4 DNA Ligase, as per the manufacturer’s 
instructions. 
 
3.2.4 Miniprep Plasmid Screening 
Upon a new plasmid having been developed and Subcloning Efficiency DH5α cells 
transformed, as detailed previously, 20 colonies per agar plate were picked, 
cultured and the amplified plasmid extracted via Miniprep (Promega, USA), as 
per the manufacturer’s instructions. The purified plasmid was restriction 
digested with an appropriate enzyme, purified via agarose gel based 
electrophoresis and imaged on a G:Box, so as to screen the colonies for the 
presence of a plasmid containing an insert of the correct size and in the 
intended orientation. 
 
3.2.5 Plasmid Sequencing and Alignment 
Plasmids to be sequenced were sent to DNA Sequencing & Services (Dundee, 
U.K.) and the resulting data files exported from Applied Biosystems Sequence 
Scanner Software, version 1.0, to Microsoft Notepad. Each sequence was stored 
in a FASTA file format and saved as a text file. The FASTA files were opened 
with Clustal X, version 2.1, and the sequence data aligned. 
 
3.3 AQUA Peptide Characterisation 
3.3.1 AQUA Peptide Re-Suspension 
AQUA peptides TV*VTVR and GL*NQDCCVVYR (*denoting the uniform stable 
isotopic amino acid residues (13C, 15N)) were ordered from Thermo Fisher and 
arrived suspended in 2% (v/v) MeCN at 5 picomole (pmol)/µL. Each remaining 
AQUA peptide was ordered from Sigma and arrived lyophilised in 1 nanomole 
(nmol) vials. Each vial was reconstituted in 200 µL of 2% (v/v) MeCN and re-
suspended via sonicating for 30 seconds and vortexing for a further 30 seconds. 
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3.3.2 AQUA Peptide Alkylation 
Immediately prior to use, each AQUA peptide was dried and re-suspended in 500 
mM AMBIC, reducing in 45 mM DTT at 60 oC for 30 minutes and alkylating in 100 
mM IAA added, incubating in darkness at room temperature for 30 minutes. 
 
3.3.3 Zip Tip Based Sample Cleanup 
The alkylated AQUA peptides were purified via Zip Tip, as per the 
manufacturer’s instructions, and eluted in 50% (v/v) MeCN, 0.1% (v/v) 
Trifluoroacetic acid (TFA). The purified peptides were subsequently dried, re-
suspended in 2% (v/v) MeCN and characterised on a range of mass 
spectrometers. 
 
3.3.4 Determining the Limit of Detection 
Three solutions (100 fmol, 10 fmol and 100 attomole (amol)) were prepared for 
each AQUA peptide, through diluting the 5 pmol/µL stocks in 2% (v/v) MeCN. 
These solutions were used to prepare eight AQUA peptide sample dilutions (5 
pmol, 1 pmol, 200 fmol, 50 fmol, 10 fmol, 2 fmol, 500 amol and 100 amol), each 
of which was diluted to 20 µL in 2% (v/v) MeCN, dried, re-suspended in AMBIC, 
reduced and alkylated.  
 
The alkylated peptides were Zip Tip purified and re-suspended in 20 µL of 2% 
(v/v) MeCN, 0.1% (v/v) FA. The limit of detection (LoD) for each peptide was 
determined through LC-MS/MS. 
 
3.4 Single Shot Based Peptide Analysis 
3.4.1 Peptide Preparation for MALDI-ToF 
The purified alkylated AQUA peptides were spotted onto either a 192 well 4700 
MALDI plate or a 384 well Ultraflex II MALDI plate and supplemented with HCCA 
matrix. 
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3.4.2 Data Capture on a 4700 MALDI-ToF Based MS 
The 192 well MALDI plate containing the peptide samples was loaded to an 
Applied Biosystems 4700 Proteomics Analyzer MALDI-TOF-TOF-MS (AB SCIEX, 
USA), equipped with an Nd:YAG laser (355 nm) running in linear mode. The 4700 
was run in positive ion mode with an acceleration voltage of +15 kV. The MS was 
set to detect ions of between 400 m/z and 2,000 m/z and final MS spectra was 
generated through summing 500 shots, each with an acquisition time of 0.5 ns. 
To better assess the samples distribution on the MALDI plate, MS data were 
gathered while manually moving the MALDI plate. Data analysis was performed 
on DataExplorer version 4.0. 
 
3.4.3 Data Capture on an Ultraflex II MALDI ToF Based MS 
The 384 well MALDI plate containing the peptide samples was loaded to a 
Bruker-Daltonics Ultraflex II TOF/TOF mass spectrometer (Bruker, USA) equipped 
with a nitrogen laser (337 nm). The Ultraflex II was calibrated before each batch 
against the monoisotopic [M+H]+ peaks of the PepMix II calibration standard 
(Bruker, USA). The Ultraflex II MS was run in positive ion reflector mode, with an 
acceleration voltage of +25 kV and a delayed extraction time of 150 ns. The MS 
was set to detect ions of between 400 m/z and 2,000 m/z and a final MS spectra 
generated through summing 500 laser shots, each fired with a repetition rate of 
50 Hertz (Hz). The laser power of the Ultraflex II was manually adjusted for each 
sample spot, setting it to a point just above the minimum power required for the 
detection of a recognisable spectrum. To better assess the samples distribution 
on the MALDI plate, MS data were gathered while manually moving the MALDI 
plate. Data analysis was performed on FlexImaging, version 2.0. 
 
3.4.4 Direct Injection on an API 2000 MS 
A borosilicate emitter was loaded with the alkylated peptide, re-suspended in 
50% MeCN (v/v), 0.1 % TFA (v/v), and the emitter fitted to an API 2000 ESI triple 
quadrupole mass spectrometer (AB SCIEX, USA). MS scanning was performed in 
positive ion enhanced MS (EMS) mode with a voltage potential of 900 V applied 
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between the emitter and the inlet orifice. The MS was set to detect ions of 
between 400 and 2,000 m/z, in profile mode, with a scan time of one second 
and the final MS spectrum obtained through summing the MS data collected over 
a five minute period. The source temperature was set to 150 °C. 
 
Upon the parent ion peak of interest having been identified in enhanced MS 
(EMS) mode, the API 2000 was switched to enhanced product ion (EPI) mode and 
the MS set to fragment the parent ion. The MS was set to detect product ions of 
between 50 and 1,000 m/z, with a scan time of one second. The collision energy 
was initially set to 5 electron volts (eV) and increased in steps of 5 until no 
fragment peaks could be detected above 400 m/z or until the maximum collision 
energy of 60 eV was reached. An EPI spectrum was obtained at each collision 
energy setting for a period of two minutes and data analysis was performed on 
Analyst, version 4.2. 
 
3.4.5 Direct Injection on a QSTAR Pulsar MS 
Direct sample injection performed on the QSTAR Pulsar MS (AB SCIEX, USA) 
utilised the same settings as those detailed for the API 2000 MS. MS scanning was 
performed, however, in “Q1 MS” mode, while product ion analysis was 
performed in product ion mode.  
 
3.4.6 Direct Injection on a QTrap 5500 MS 
Direct infusion was performed on a 5500 QTrap LC/MS/MS System (AB SCIEX, 
USA) equipped with a DuoSpray source, featuring both turboionspray and 
Atmospheric-pressure chemical ionization (APCI) apertures. The syringe pump 
flow rate was set at 20 µL/minute (min) through the turboionspray source and an 
ESI voltage of 6 kV applied between the source and MS orifice. All other settings 
were retained as detailed for the API 2000 MS. Data analysis was performed on 
Analyst, version 1.5.1. 
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3.4.7 Direct Injection on a TripleToF 5600 MS 
Direct infusion was performed on a TripleTOF 5600 MS (AB SCIEX, USA) under the 
same conditions as those detailed for the 5500 QTrap, utilising the QToF scan 
types detailed for the QSTAR Pulsar. Data analysis was performed on Analyst TF, 
version 1.5.1. 
 
3.5 LC-MS Based Peptide Analysis 
3.5.1 In-Gel Digest Preparation 
The Coomassie staining gel band of interest was excised, retaining 2 millimetre 
(mm) to each side of the gel lane and cutting at a fixed length of 10 mm, prior 
to dicing the excised gel band into 1 mm cubes. The gel pieces were washed in 
100 mM AMBIC for 30 minutes, partial dehydrated the gel pieces through diluting 
to a ratio of 1:1 (v/v) in MeCN, and completely dehydrating in MeCN. The gel 
pieces were re-hydrated in 100 mM AMBIC, prior to reducing in 45 mM DTT, 
incubating at 60 oC for 30 minutes, and alkylating via the addition of 100 mM 
IAA, incubating in darkness for 30 minutes. Excess IAA was removed through 
partially dehydrating the gel pieces by diluting to a ratio of 1:1 (v/v) in MeCN, 
and the complete dehydrating the gel pieces in MeCN. 
 
3.5.2 In-Gel Digestion 
The protein within the gel pieces was digested with one of several proteases, as 
per the manufacturer’s instructions. Upon completion of the digest, the digest 
buffer was diluted to a ratio of 1:1 (v/v) with MeCN. The gel pieces were 
incubated twice in 1% (v/v) FA for a period of 20 minutes before dehydrating the 
gel pieces, three times, in MeCN. All supernatants were pooled and dried. 
 
3.5.3 Spiked Digestion 
The reduced and alkylated gel pieces were re-suspended in 0.1% RapiGest SF 
(w/v) and incubated at 37 oC for ten minutes, prior to drying. Five picomoles of 
each AQUA peptide were transferred to one of two microcentrifuge tubes, those 
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which contained Cys, and those without. The Cys containing peptides were 
dried, re-suspended in 500 mM AMBIC, reduced with DTT and alkylated with IAA, 
before being transferred to the dried gel pieces, while those devoid of Cys were 
transferred directly. The in-gel digestion and extraction steps proceeded as 
described previously. Upon completion of the final in-gel extraction step, the 
pooled extract was diluted in 0.5% (v/v) TFA and the solution incubated at 37 oC 
for 45 minutes. The solution was centrifuged at 13,000 rpm for ten minutes and 
the supernatant decanted to a sterile microcentrifuge tube and dried to 
completion.  
 
3.5.4 HPLC on an Ultimate 3000 
The in-gel digest was re-suspended in 2% MeCN (v/v), 0.1% FA (v/v) and loaded 
onto an Ultimate 3000 HPLC autosampler (Dionex, The Netherlands), maintained 
at 4 oC. The HPLC was equipped with a µ-Precolumn Cartridge (300 µm × 5 mm, 
5 µm particle size) and a C18 capillary column (75 µm × 15 cm, 3 µm particle 
size), both packed with PepMAP 100 C18 stationary phase (Dionex, The 
Netherlands), maintained at 30 oC via an Ultimate 3000 column oven (Dionex, 
The Netherlands). A 20 µL sample loop was fitted to the autosampler and the 
sample injected via the user defined injection mode, controlled through the 
Chromeleon HPLC software package.  
 
The HPLC micropump flow rate was maintained at 0.3 µL/min, 2% (v/v) Buffer B 
(90% MeCN (v/v), 0.1% FA (v/v), and the loading pump maintained at 20 µL/min, 
100% (v/v) Buffer A (2% MeCN (v/v), 0.1% FA (v/v). A 60 minute gradient was 
programmed on the HPLC, increasing the ratio of Buffer B from 2-40% (v/v) 
Buffer B over 30 minutes, the column was washed for 10 minutes at 90% (v/v) 
Buffer B, and returned to 2% Buffer B for 20 minutes. The MS trigger was set to 
activate after 0.1 minutes.   
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3.5.5 LC-MS on an API 2000 MS 
The API 2000 was equipped with a NanoSpray II ESI ion source, fitted with a 
PicoTip emitter. A voltage of 2.2 kV was applied between the ESI needle and the 
inlet orifice. The MS was set to detect ions of between 400 and 1,500 m/z with 
both the Q1 and Q3 transmission windows set to low resolution. The source 
temperature was set to 150 °C and a rolling collision energy was utilised. A 60 
minute IDA scan was performed in positive ion mode, scanning in the MS 
spectrum and selecting the four most abundant peaks for MS/MS, assuming the 
IDA selection criteria were met (the ions were between 400 – 1,500 m/z, with a 
charge state of between +1 and +4). Ions were excluded from IDA selection after 
two MS/MS spectra had been acquired for the parent ion. 
 
Protein identification was performed though submitting the MS/MS data to an 
internal Mascot server, version 1.9 (Matrix Science, UK), aligning the scan data 
against the NCBInr (latest version at the time of processing) protein sequence 
database. Peptide tolerance was set to ±1.2 Da and the MS/MS tolerance was set 
to ±0.6 Da. The search was set to allow for one missed cleavage and for the 
variable modification of Met (oxidation), while the modification of Cys was set 
to fixed (carbamidomethylation).  
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4 The Absolute Quantification of Four A-Raf Isoforms 
4.1 Introduction 
Oncogene rapidly accelerated fibrosarcoma (Raf) was first cloned and 
characterised from a mouse with lymphoma and lung adenocarcinoma by Ulf 
Rapp back in 1983. Rapp identified the cause of the carcinoma to be an acutely 
transforming murine sarcoma virus (3611-MSV), which was later re-named viral 
Raf (v-Raf) (Baccarini, 2005, Rapp et al., 1983). Following on from this Sutrave 
and co-workers later isolated a second gene (v-mill), this time within an avian 
retrovirus (Mill Hill no. 2 (MH2)) from a spontaneous ovarian tumour within a 
chicken, which shared an 80% sequence homology with the nucleotide sequence 
of v-Raf, and a 94% sequence homology with the predicted amino acid sequence 
of v-Raf (Jansen et al., 1984, Moelling et al., 1984, Sutrave et al., 1984). Jansen 
later went on to confirm that both these strains of retrovirus (3611-MSV and 
MH2) contained orthologous protein sequence, while Moelling and Rapp showed 
v-Raf/v-Mill to be the first identified oncoproteins with both Ser and Thr kinase 
activity (Jansen et al., 1984, Moelling et al., 1984).  
 
A total of three human Raf kinase genes have since been identified (A-Raf, B-Raf 
and Raf-1), each displaying a unique cellular expression pattern, regulatory 
mechanisms, and potency when functioning within the context of the mitogen 
activated protein kinase (MAPK) pathway (Wojnowski et al., 2000). Despite these 
differences, each member of the Raf family shares the same general structure 
(Figure 4-1), with several highly conserved domains, including conserved region 
one ((CR1), which contains the Rat sarcoma (Ras)-binding domain (RBD), 
required for Raf to bind with Ras and for membrane recruitment, and the Cys-
rich domain (CRD), which functions as a secondary Ras-binding site, yet is 
important for Raf auto-inhibition), conserved region two ((CR2) which is rich in 
Ser and Thr residues, important for the inhibitory phosphorylation of Raf) and 
conserved region three ((CR3) which consists of the kinase domain, but which 
contains an activation segment whose phosphorylation is crucial for kinase 
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activity), each of which is separated by a region of more variable sequence 
(Wellbrock et al., 2004a, Matallanas et al., 2011).  
 
 
Figure 4-1: The structural organisation of Raf, showing the regions of 
conserved sequence.  Depicted above is the structure of a typical full-length 
Raf protein, including CR1, which contains both the RBD and the CRD, CR2, 
which is rich in Ser and Thr residues, and CR3, which consists of the kinase 
domain, but which also contains the kinase activation segment, important for 
the activation of Raf. 
 
The MAPK cascade, in which each of the Raf family members are involved, is a 
complex signal transduction network, controlling a range of cellular processes 
including cell growth, differentiation, proliferation and apoptosis (Kolch, 2000). 
These signalling events are triggered when extracellular growth factors, such as 
epidermal growth factor (EGF) (Grandis and Sok, 2004), or platelet-derived 
growth factor (PDGF) (Morrison et al., 1989), bind their corresponding membrane 
bound Tyr kinase receptors (EGFR and PDGFR, respectively). Cytoplasmic 
signalling proteins such as Src (sarcoma) are then recruited to the cellular 
membrane and bound to the receptor via the phosphotyrosine binding domain. 
This binding results in the phosphorylation of Src which in turn creates a binding 
site for the Src homology 2 domain of protein Grb2 (Cohen et al., 1995, Pawson 
and Nash, 2000, Schlessinger, 2000). Src binding the mitogen receptor also 
results in the recruitment of protein SOS to the plasma membrane, causing 
protein G (Ras) to release its bound guanosine-5'-triphosphate (GDP) and uptake 
a more abundant guanosine-5'-triphosphate (GTP) molecule, thereby taking its 
activated configuration (Schlessinger and Bar-Sagi, 1994, Kolch, 2000).  
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Figure 4-2: The activation and subsequent signalling cascade of the MAPK 
pathway.  A depiction of a mitogen, in this case EGF, activating the MAPK 
pathway through the stimulation of EGFR. This cascade results in the activation 
of a variety of transcription factors depending on the initial extracellular 
stimulus and which MAPKKK is activated. 
 
The activation of Ras thus begins the main kinase cascade of the MAPK pathway, 
with the binding of Raf (MAPKKK) (Hallberg et al., 1994, Leevers et al., 1994, 
Stokoe et al., 1994), phosphorylation of MEK1/2 (MAPKK) and subsequent 
phosphorylation of extracellular signal-regulated kinase (ERK) (MAPK) (Gardner 
et al., 1994, Marais and Marshall, 1996, Yan and Templeton, 1994). Finally the 
phosphorylated ERK can be translocated throughout the cell, where it can 
activate various transcription factors, resulting in a unique gene expression 
pattern depending on the specific stimulus the cascade was activated in 
response to (Kolch, 2000, Schlessinger and Bar-Sagi, 1994) (Figure 4-2). 
 
While each of the Raf kinase species has its own specific regulatory mechanisms, 
which will be discussed later, it has been noted that each species is capable of 
binding 14–3–3 proteins (Kolch, 2000), which are believed to be responsible for 
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stabilising Raf in each of its conformational states; including the inactive, 
partially active and fully active. All three Raf family members are also reported 
as being capable of binding lipids, which is thought to play a role in the 
translocation (membrane recruitment) and/or regulation of Raf kinase activity 
(Daub et al., 1998, Ghosh et al., 1996, Kuroda et al., 1996).  
 
While each of the Raf kinases are expressed within human tissue, the expression 
of A-Raf and B-Raf was initially thought to vary between tissues, while Raf-1 was 
thought to be expressed ubiquitously, providing a basal level of Raf activity in all 
human cells (Wojnowski et al., 2000, Storm et al., 1990). More recently however 
A-Raf has also been shown to be expressed ubiquitously (Storm et al., 1990), and 
while the tissue specific expression pattern of B-Raf still appears restricted, it 
has been shown to be the most powerful activator of the MAPK pathway (Araujo 
et al., 2012), suggesting each isoform may fulfil a specific function in cellular 
signalling. 
 
4.1.1 Raf-1 
Raf-1 was initially thought to be the only member of the Raf family to be 
ubiquitously expressed, with similar levels of transcripts identified in most 
human tissue types. This initially led scientists to believe that the function of 
Raf-1 may be to provide a basal level of Raf kinase activity within all cells 
(Storm et al., 1990). Further to this, Raf-1 was found to be regulated by a 
housekeeping type promoter, further supporting the view that A-Raf and B-Raf 
may have played more specific roles in specialised tissues (Hagemann and Rapp, 
1999). More recently Huser et al. (Huser et al., 2001) and Mikula et al. (Mikula 
et al., 2001) explored the function of Raf-1 in fibroblast cells isolated from Raf-1 
−/− knockout mice, identifying Raf-1 deficient mice to suffer widespread 
apoptosis and to die in utero. While no alteration in ERK activation were 
detected (as B-Raf can fully compensate for the loss of Raf-1 in MAPK signalling), 
the loss of Raf-1 did increase the susceptibility of the cells toward apoptosis, as 
Raf-1 is required for the suppression of both proapoptotic mammalian sterile 20-
like kinase (MST2) and apoptosis signal-regulating kinase 1 (ASK-1) (Hurst et al., 
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1996, Mikula et al., 2001). In brief, MST kinases are cleaved by caspases during 
cell apoptosis, releasing a constitutively active MST kinase domain which 
translocates to the nucleus and phosphorylates histone 2B, eventually inducing 
DNA fragmentation (Romano et al., 2010). ASK-1 meanwhile is activated in 
response to various types of stress, and in its constitutively active form can 
phosphorylate both c-Jun N-terminus kinase (JNK) and p38. RAF2 and TRAF6 are 
subsequently recruited to the ASK1 signalosome where they promote ASK1-
dependent cell death and inflammatory cytokine production (Soga et al., 2012). 
 
An alternatively spliced Raf-1 isoform has recently been reported. This isoform 
differs from the wild type in that it lacks exon three, located within the Raf-like 
Ras-binding domain. Any functional consequences which result from this 
variation remain as yet unknown (He et al., 2009). 
 
4.1.2 B-Raf 
B-Raf was first identified by Marx et al. due to its transduction into the genome 
of an acute mitogenic retrovirus species (IC10), capable of transforming chicken 
embryonic neuroretina cells in primary culture (Marx et al., 1988). 
Simultaneously its human ortholog was also identified in NIH 3T3 cells, 
transfected with DNA from Ewing sarcoma (Ikawa et al., 1988). 
 
Until recently B-Raf was thought to play a niche roll in cellular signalling (Storm 
et al., 1990, Wojnowski et al., 2000), due in part to its somewhat restricted 
expression pattern (mainly localised to within the central nervous system 
(Barnier et al., 1995, Storm et al., 1990)), at least in comparison to Raf-1. In the 
last decade however it has been reported that immunoprecipitated (IP) B-Raf 
has a much stronger affinity for MEK than that of Raf-1, suggesting that it may 
yet play a major role in MAPK signalling (Huser et al., 2001). This increase in 
kinase activity is thought to result from the activation of B-Raf requiring fewer 
phosphorylation events than either Raf-1 or A-Raf (Wellbrock et al., 2004b). An 
in vivo experiment exploring this variation in Raf-MEK binding affinity led to the 
preparation of several knockout mice, including B-Raf -/-, A-Raf -/- and A-Raf -
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/Y (where A-Raf is located on the X chromosome). The fibroblast cells isolated 
from the B-Raf -/- knockout mice were found to yield approximately a 30% 
decreased in ERK phosphorylation when compared to wild-type cell lines 
(Pritchard et al., 2004, Wojnowski et al., 2000). This is in contrast to A-Raf -/- 
and -/Y fibroblast experiments, where no significant changes in phosphorylation 
were recorded (Huser et al., 2001, Mercer et al., 2002, Mikula et al., 2001). Due 
to this high kinase activity, B-Raf is highly regulated within its inactive state. 
Inactivated B-Raf is maintained in an auto inhibitory conformation with the 
carboxy-terminus (C-terminus) kinase domain and the N-terminus regulatory 
region being involved in an intramolecular interaction (Terai and Matsuda, 
2005). In addition, B-Raf is phosphorylated at both Ser 365 (located within the 
CR2 domain) and Ser 429 residues, further down regulating the kinase activity of 
the B-Raf. 
 
In the case of B-Raf activation, the auto inhibitory conformation is released upon 
B-Raf binding a GTPase (Ras in the case of the MAPK pathway), ultimately 
resulting in the phosphorylation of residues Thr 599 and Ser 602 within the 
active site (Mason et al., 1999, Peyssonnaux and Eychène, 2001, Wan et al., 
2004, Zhang and Guan, 2000). Despite this regulation, B-Raf is still seen as being 
the least regulated of the Raf kinases. Perhaps this is why B-Raf is so commonly 
mutated to a constitutively active state in human carcinoma (Abraham et al., 
2000).  
 
The most common mutation leading to the activation of B-Raf in human cancer 
results from a point mutation within the highly conserved Glycine-rich loop, a 
component of the activation segment located within the kinase domain. This 
substitution is detectable in approximately 70% of primary melanomas (Davies et 
al., 2002), in 10% of colorectal cancers (Di Nicolantonio et al., 2008), and in 30–
70% of papillary thyroid carcinoma (Kimura et al., 2003), and involves Val 600 
being replaced with a Glu; a change which is thought to contribute to 
tumorigenesis by markedly increasing the basal kinase activity of B-Raf and 
stimulating constitutive ERK phosphorylation (Prahallad et al., 2012). 
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An additional route of B-Raf tumorigenesis was recently identified in a human 
thyroid papillary carcinoma (Ciampi and Nikiforov, 2005). This route of 
activation involved the proteins N-terminus (responsible for the regulation of the 
kinase domain) being truncated and the kinase domain fused to staphylococcal 
nuclease and tudor domain containing 1 (SND1) (Dillon et al., 2011), leading to 
the constitutive activation of B-Raf (Ikawa et al., 1988, Marx et al., 1988). 
 
In the case of B-Raf isoforms, several reports suggest that complex alternative 
splicing is indeed undertaken, adding an additional level of regulation to the 
kinase. These isoforms have been shown to arise from the alternative splicing of 
exons 8b and 9b, which are unique to B-Raf and located between conserved 
regions two (cysteine rich domain) and three (kinase active site). This 
alternative splicing has been shown to yield at least ten tissue specific B-Raf 
isoforms (Barnier et al., 1995, Hingorani et al., 2003). While the mechanism 
regulating the alternative splicing of B-Raf remains unclear, a function has been 
proposed for these structural abnormalities; modifications resulting from the 
alternative splicing of exon 9b have been shown to increase both MEK kinase 
activity and the transformation efficiency of B-Raf. However, isoforms which 
result from the alternative splicing of exon 8b have been shown to have the 
opposite effect (Hmitou et al., 2007). A proposal has also been made as to the 
route through which the kinase activity of B-Raf is altered by these splice 
isoforms. It is believed that the presence of these exons modulate the ability of 
the protein’s N-terminus to interact with the C-terminus kinase domain, a 
mechanism otherwise used to inactivate B-Raf (Hmitou et al., 2007). 
 
4.1.3 A-Raf 
The function of A-Raf has been misinterpreted since its accidental discovery 
back in 1987 (Ishikawa et al., 1987). A-Raf was firstly thought to be tissue 
specific, a result of both the ubiquitous expression of Raf-1 and the variable 
levels of A-Raf expression within different tissue types (Storm et al., 1990, 
Wojnowski et al., 2000). Furthermore, being a member of the Raf family it was 
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assumed that A-Raf would exhibit some form of MEK kinase activity, while in fact 
any kinase activity exhibited by A-Raf is hard to detect (Huser et al., 2001). 
 
While A-Raf expression is ubiquitous, the concentrations expressed within a 
range of cells are indeed highly variable. The highest concentrations of A-Raf 
have been identified in urogenital tissues (kidney, testis, epididymus and ovary) 
while the lowest concentrations have been identified in neuronal tissue (Storm 
et al., 1990). The protein expression pattern exhibited by A-Raf suggests that it 
may be in-part regulated by steroid hormone receptors, which are also 
expressed at high levels in steroid hormone-responsive urogenital tissues (Lee et 
al., 1996). 
 
In comparison to the sequences of both Raf-1 and B-Raf, several single residue 
N-terminus substitutions have been identified in A-Raf. It is thought that these 
substitutions may be partially responsible for the limited kinase activity of the 
isoform, with Tyr 296 in particular playing a central role (Baljuls et al., 2007). 
This low kinase activity suggests that A-Raf may fulfil an alternative function 
within the cell (Huser et al., 2001), a hypothesis which is supported by A-Raf -/- 
knockout experiments, where the removal of A-Raf was found to have no 
significant effect on the levels of phosphorylated MEK (Pritchard et al., 2004, 
Wojnowski et al., 2000). Furthermore, the ERK based feedback phosphorylation 
of A-Raf (Thr-253/Ser-257/Ser-259) appears to positively regulate A-RAF activity 
(Baljuls et al., 2008), suggesting a possible role in post signalling protein 
recovery (Nekhoroshkova et al., 2009). 
 
Recent publications regarding A-Raf suggest the existence of several isoform 
species (Rauch et al., 2011). This research suggests that high levels of 
heterogeneous nuclear ribonucleoprotein H (hnRNP H) (known to alternatively 
splice c-src, bcl-x, plp/dm20, Drosophila nanos, HIV-1 splicing substrates and 
rodent tropomyosin) are required for the expression of full length A-Raf (hereby 
referred to as A-Raf wild type. (A-Raf WT)), whereas no effects have been 
documented on the expression of either full-length Raf-1 or B-Raf (Rauch et al., 
2010). When hnRNP H is expressed at a low level, or indeed in the absence of 
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hnRNP H, an alternatively spliced 171 amino acid isoform can be detected 
(Rauch et al., 2011), this new isoform, termed A-Raf Short, is discussed further 
in Section 4.1.3.2. 
 
4.1.3.1 A-Raf WT 
Further to the mouse embryonic fibroblast knockout experiments described in 
Section 4.1.3, Pritchard et al. designed a second set of knockout experiments so 
as to determine the function of A-Raf WT (Pritchard et al., 1996). From this 
work both A-Raf -/- and A-Raf -/Y knockout mice appeared to die between 7 and 
21 days after birth. Further analysis revealed these mice to display colon 
organogenesis abnormalities and neurologic defects which resulted in abnormal 
movement and proprioception. In review Rauch et al. commented that the 
pathological phenotypes observed in these A-Raf deficient mice seemed to 
suggest an increase in apoptosis, which may be due to a lack of control over the 
MST2 pathway (Rauch et al., 2010). Rauch et al. subsequently performed a small 
interfering RNA (siRNA)–mediated knockdown of either hnRNP H or A-Raf WT, 
each of which lead to MST2-dependent cell apoptosis. Further to the conclusion 
drawn from the A-Raf knockout experiments, this siRNA experiment helped to 
cement the important role that hnRNP H plays in the splicing of A-Raf WT (Rauch 
et al., 2010). This research suggests that A-Raf WT is necessary for the 
inactivation of MST2, and thus the prevention of apoptosis (Figure 4-3).  
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Figure 4-3: The cellular function and interaction of hnRNP H, A-Raf WT and A-
Raf Short.  In the presence of high levels of hnRNP H A-Raf WT is generated, 
binding to both MST2, thereby preventing apoptosis, and G-protein Ras, 
potentially regulating the MAPK pathway. In the presence of low levels of hnRNP 
H, or indeed in the absence of hnRNP H, A-Raf Short is generated, binding to 
active Ras, and exerting a dominant negative effect on the MAPK pathway yet 
having no influence on MST2, which if activated will signal cell apoptosis. 
 
4.1.3.2 A-Raf Short 
It was recently discovered that high concentrations of hnRNP H are required for 
the expression of A-Raf WT. In cells where hnRNP H levels are low, or indeed 
depleted, as is the case in most cell types, a new short A-Raf isoform is 
expressed (Rauch et al., 2011). This new isoform, termed A-Raf Short, has a MW 
of approximately 16 kDa and consists of some 171 amino acid residues.  The 
structure of this new protein lacks approximately 2/3 of the A-Raf WT C-
terminus, including CR3 (the Raf kinase domain) and CR2 while retaining the 
majority of CR1, including the Ras-binding domain, located on the N-terminus of 
Raf (Rauch et al., 2011). The generation of this alternative A-Raf Short mRNA 
results from the inclusion of introns two and four while correctly splicing out 
110 
 
introns one and three. The termination of mRNA translation in A-Raf Short 
results from the inclusion of intron four, where nucleotide 716 begins the 
generation of a premature stop codon (Rauch et al., 2011). In a recent 
publication detailing the expression of A-Raf short (Rauch et al., 2011), Rauch et 
al. comment that “intron inclusion is a rare event in alternative splicing and, in 
combination with preterminal stop codons, these transcripts are commonly 
prone to nonsense-mediated decay”. However both Northern and Western 
blotting against A-Raf Short showed both the mRNA and truncated isoform were 
detectable in cultured cells, in addition to human tissues (Rauch et al., 2011). As 
was the case with the A-Raf WT, tissue specific expression patterns were 
identified for A-Raf Short, with the placenta, kidney, pancreas, lung, and spleen 
exhibiting high levels of expression, while skeletal muscles, heart, liver, and 
colon contained only low levels of expression (Rauch et al., 2011). 
 
Due to the structure of A-Raf Short, it has been suggested that this isoform may 
play an opposing role to that of A-Raf WT in cell signalling. Firstly, due to the 
presence of CR1, including the Ras binding domain, this isoform has the ability 
to compete with A-Raf WT, and Raf’s in general, for activated Ras, and indeed 
displays a similar binding affinity to that of the wild type. This functionality was 
confirmed by Rauch et al. who found that A-Raf Short behaved as a dominant 
negative mutant, suppressing both Ras signalling and ERK activation. Secondly, 
due to the truncated C-terminus, A-Raf Short lacks the ability to prevent MST2 
associated proapoptotic signalling (Rauch et al., 2011).  
 
Further research into the biological significance of A-Raf Short by Rauch et al. 
found that head and neck carcinomas and colon carcinomas which over 
expressed hnRNP H were also those which expressed lower levels of A-Raf Short. 
Indeed the expression of A-Raf WT could enable uninhibited MAPK signalling, a 
possible pathophysiologic mechanism used by tumours to evade apoptosis (Rauch 
et al., 2011). 
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4.1.3.3 DA-Raf-1 and DA-Raf-2 
During a recent study by Yokoyama et al. into the molecular mechanisms 
through which G-protein M-Ras functions within the cell, the existence of two 
additional A-Raf isoforms were uncovered. The first of these isoforms, termed 
Deleted A-Raf 1 (DA-Raf-1), constituted a 186 amino acid protein resulting from 
the alternative splicing of the A-Raf gene, where intron six had been retained, 
giving rise to a premature stop codon starting at the second nucleotide of the 
intron (Yokoyama et al., 2007). DA-Raf-1 was found to contain the entire 
sequence from CR1, including the Ras-binding domain and Cys-rich domain, but 
lacked conserved regions 2 and 3, containing the Ser and Thr rich domain and 
the Raf kinase domain respectively (Wellbrock et al., 2004b, Yokoyama et al., 
2007). 
 
The function of DA-Raf-1 was found to be similar to that of A-Raf Short, binding 
activated Ras and acting as a dominant negative antagonist to the 
phosphorylation of ERK through the MAPK pathway. As a result DA-Raf-1 is 
thought to positively regulate myogenic differentiation by inducing cell cycle 
arrest, muscle-specific protein expression, and myotube formation (Yokoyama et 
al., 2007). 
 
The second isoform identified during the study was Deleted A-Raf 2 (DA-Raf-2), 
constituting a 153 amino acid protein, also resulting from the alternative splicing 
of the A-Raf gene. In this case intron five was retained, giving rise to a 
premature stop codon starting at the second nucleotide of the intron (Yokoyama 
et al., 2007).  
 
Besides confirming the ubiquitous expression of the DA-Raf species in a variety 
of mouse tissues, including the brain and heart, very little additional information 
was published by Yokoyama et al. (Yokoyama et al., 2007). Instead a subsequent 
publication by Nekhoroshkova et al. further addressed the function of these DA-
Raf isoforms. In this study the authors suggest that A-Raf WT and DA-Raf-2 are 
specifically localised to the recycling endosome and that DA-Raf-2 did not 
necessarily function as an inhibitor of mitogenic signalling (Nekhoroshkova et al., 
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2009). Instead Nekhoroshkova et al. proposed a new model of functionality for 
the entire A-Raf family (Figure 4-4), where Ras activates both Raf-1 and B-Raf, 
which in turn are responsible for the activation of the MAPK pathway. It is only 
then; upon the phosphorylation of ERK, that A-Raf WT is activated, interacting 
with ADP ribosylation Factor six GTPase (ARF6), possibly through EFA6, 
ultimately resulting in the recycling of endosome bound receptors 
(Nekhoroshkova et al., 2009). 
 
 
Figure 4-4: The cellular functions and signalling events associated with A-Raf 
WT and DA-Raf-2, as described by Nekhoroshkova et al.  Following the 
activation of the MAPK pathway (not fully depicted), A-Raf WT is activated via 
ERK based feedback phosphorylation. Activated A-Raf binds G-protein Ras where 
it activates ARF-6 GTPase, possibly through interacting with EFA6. In the 
presence of a high concentration of DA-Raf-2, A-Raf WT is prevented from 
binding Ras and thus ARF-6 activation is blocked (Nekhoroshkova et al., 2009). 
 
Regarding the function of the additional A-Raf isoforms, Nekhoroshkova et al. 
further suggest that DA-Raf-2 may act as a dominant negative antagonist to A-
Raf WT, much as was previously suggested for both A-Raf Short and DA-Raf-1 in 
the MAPK pathway (Nekhoroshkova et al., 2009, Rauch et al., 2011, Yokoyama et 
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al., 2007). In support of the model proposed by Nekhoroshkova et al., A-Raf, 
ARF6 and EFA6 were all found to be expressed at high levels within the Purkinje 
cells of the mouse cerebellum, while DA-RAF-2 was found to be expressed at a 
high level throughout the brain. Nekhoroshkova et al. viewed this pattern of A-
Raf expression to be of critical importance for rapid endocytosis and synaptic 
vesicle recycling within the brain, as required for the physiological functioning 
of neurons (Nekhoroshkova et al., 2009). 
 
So as to confirm the expression of these new DA-Raf isoforms within human 
tissue, Rauch et al. recently probed a total of 89 specimens collected from head 
and neck and colon biopsies, identifying the transcripts in only one of the 
samples. In conclusion the author commented that this profile of A-Raf 
expression fitted our current understanding of alternative splicing; where in 
general, only two of a given number of potential isoforms will be expressed 
within a tissue at the same time (Rauch et al., 2011, Wang et al., 2008a).  
 
4.1.4 A-Raf Literature Overview 
While the existence of A-Raf WT was first documented some 25 years ago 
(Ishikawa et al., 1987), the true function of this kinase in molecular signalling is 
only beginning to be realised, differentiating it from the standard MAPKKK role 
filled by the other members of the Raf family (Wellbrock et al., 2004b). 
 
Further to that of A-Raf WT, it has only been within the last few years that three 
A-Raf isoforms have been reported. These isoforms, while differing in sequence, 
all retain CR1, containing the Ras-binding domain and Cys-rich domain, yet lack 
both conserved regions two and three, which enable phosphorylation based 
regulation and Raf kinase activity respectively. Due to the structural qualities of 
these isoforms many researchers have concluded that they may act as dominant 
negative regulator of the MAPK pathway through acting as an antagonist to Raf 
(Nekhoroshkova et al., 2009, Yokoyama et al., 2007). As yet there are very few 
publications exploring the expression and function of these A-Raf isoforms, and 
those which do at times appear contradictory. For example, Yokoyama et al. 
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was the first to publish the sequences of both DA-Raf-1 and 2, stating that these 
isoforms may be involved in the regulation of Ras within the MAPK pathway 
(Yokoyama et al., 2007). Nekhoroshkova et al. later published a paper on the 
same isoforms, suggesting that DA-Raf-2 may instead be involved in the 
regulation of receptor recycling within endosomes (Nekhoroshkova et al., 2009). 
Both of these studies were however conducted within different cell lines, and 
indeed in different species, which may account for much of the functional 
variation observed. 
 
Most recently, Rauch et al. published a paper on the existence of A-Raf Short, 
showing this isoform to be involved in the regulation of Ras and the MAPK 
pathway, while in addition tested 89 tissue samples for DA-Raf 1 and 2, finding 
only one sample which expressed the isoforms (Rauch et al., 2011). As way of an 
explanation Rauch et al. noted that intronic sequence retention within mRNA 
was rare and when considered in combination with the detected premature stop 
codons, it was likely that these transcripts would suffer nonsense-mediated 
decay (Rauch et al., 2011). 
 
Our understanding of A-Raf and its splice isoforms is, therefore, still in its 
infancy. It may yet be many years until the true function of these proteins are 
uncovered. 
 
4.2 Project Aims 
Despite there being very few peer reviewed publications confirming the 
structures and functions of each of these A-Raf isoforms, they make excellent 
candidates for this project, in which it is hoped the absolute amount of each A-
Raf isoform within a sample can be calculated, based on the use of unique AQUA 
peptides. 
 
Ultimately, when fully established and optimised, this type of analysis should 
enable researchers to: (i) Identify which A-Raf isoforms are expressed within a 
tissue (through detecting isoform specific target peptides). (ii) Accurately 
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quantify each A-Raf isoform detected (through detecting both the isoform 
specific target and synthetic AQUA peptide), and (iii) Detect changes in 
expression ratio of the A-Raf isoforms under different physiological conditions. 
 
In order to achieve these ultimate technical aims, which are beyond the scope of 
a PhD project, a more specific set of project aims were devised. As such, during 
this project I aim to: (i) Screen each of the previously detailed A-Raf isoform 
sequences, identifying and selecting suitable AQUA peptides for the absolute 
quantification of each protein. (ii) Characterise each AQUA peptide/intrinsic 
target peptide and develop a suitable triple-quadrupole based MRM acquisition 
method for the identification of each peptide within a single LC-MS run. (iii) 
Express suitable amounts of each A-Raf isoform, enabling the proteolytic 
digestions to be optimised using a range of commercially available proteases. 
(iv) Assess the accuracy and reproducibility of the AQUA technique through the 
use of a suitable number of digest replicates, and (v) Test the optimised 
analytical technique on both non-immunoprecipitated exogenously and 
endogenously expressed A-Raf WT. 
 
4.3 Methods Specific to A-Raf 
4.3.1 Proteolytic Digest Optimisation 
Lyophilised BSA was re-suspended in either 500 mM AMBIC, or 500 mM AMBIC 
with 0.1% (w/v) RapiGest SF surfactant. The BSA was reduced and alkylated with 
DTT and IAA, prior to the IAA being quenched through the addition of Cys. The 
alkylated BSA was digested with one of three proteases, trypsin, Glu-C or Lys-C, 
at an enzyme:substrate ratio of 1:10, 1:20, 1:50, 1:100 or 1:200 (w/w), as per 
the manufacturer’s instructions. Following digestion, the solutions were vacuum 
centrifuged to completion and re-suspended in 2% MeCN, 0.1% FA (v/v). Each 
digest was separated on an Ultimate 3000 HPLC and analysed on an API 2000 MS. 
The MS/MS data was submitted to MASCOT and the percentage sequence 
coverage recorded. 
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4.3.2 Met Oxidation and Reduction 
4.3.2.1 DMSO Based Met Oxidation  
Myoglobin, Lysozyme and Lactoglobulin were re-suspended in 500 mM AMBIC, 
reduced with DTT and alkylated with IAA, prior to quenching with 100 mM Cys. 
The alkylated proteins were digested via the addition of 1:20 (enzyme:sustrate 
(w/w)) trypsin, as per the manufacturer’s instructions. The digested peptide 
solution was dried, prior to re-suspension in 500 mM Hydrochloric acid (HCl), 100 
mM DMSO and oxidised as described by Shechter (Shechter, 1984). The oxidised 
peptides were spotted to a 192 well MALDI plate and analysed on an AB SCIEX 
4700 MALDI-ToF MS. 
 
4.3.2.2 DMS Based Met Sulfoxide Reduction  
The DMS based reduction proceeded as described for the DMSO based oxidation, 
however, the reduction was performed in 100 mM HCl, 300 mM of DMS, as 
described by Shechter (Shechter, 1984). 
 
4.3.2.3 Sodium Periodate Based Met Oxidation 
AQUA peptide VPTV*CVDMSTNRQQ was reduced with DTT and alkylated with IAA, 
prior to being combined with 125 pmol of sodium periodate in 10 mM 2-(N-
morpholino)ethanesulfonic acid (Mes), pH 6.0. The oxidation proceeded as 
described by Wolschner et al. (Wolschner et al., 2009). The oxidised peptides 
were Zip Tip purified, spotted to a 384 well MALDI plate and analysed via 
Ultraflex II MALDI-ToF MS. 
 
4.3.2.4 β-mercaptoethanol Based Met Sulfoxide Reduction  
Alkylated, oxidised AQUA peptide VPTV*CVDMSTNRQQ, prepared as described in 
Section 4.3.2.3, was dried and re-suspended in 1%, 10% or 20% (v/v) β-
mercaptoethanol, incubating at 99 oC for 60 minutes. The sample was vacuum 
centrifuged to completion, re-suspended in 0.1% (v/v) TFA and Zip Tip purified, 
spotting to a 384 well MALDI plate and analysing on an Ultraflex II MS. 
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4.3.3 MALDI Based Analysis of AQUA Peptide VPTV*CVDMSTNRQQ 
4.3.3.1 Characterisation of AQUA Peptide VPTV*CVDMSTNRQQ 
Lyophilised AQUA peptide VPTV*CVDMSTNRQQ was re-suspended in either 20 µL 
of DMSO or 20 µL of 10% FA (v/v), sonicated for 30 seconds and vortexed for a 
further 30 seconds, so as to ensure the complete re-suspension. Each was 
subsequently diluted to 200 µL in 0.1% FA (v/v). Peptide VPTV*CVDMSTNRQQ was 
vacuum centrifuged, re-suspended in 500 mM AMBIC, reduced with DTT and 
alkylated with IAA, prior to Zip Tip purification and analysis on an Ultraflex II 
MS. 
 
4.3.3.2 AnchorChip Based Sample Concentration 
AQUA peptide VPTV*CVDMSTNRQQ, reconstituted in either 20 µL of 10% DMSO 
(v/v), diluted to 200 µL in 0.1% FA (v/v), or 20 µL of 10% FA (v/v) diluted to 200 
µL in 0.1% FA (v/v), was spotted to a PAC II MALDI plate and washed in situ in 10 
mM ammonium phosphate, as per the manufacturer’s instructions, prior to 
analysis on an Ultraflex II MS. 
 
4.3.3.3 LC-MALDI Based AQUA Quantitation 
DA-Raf-2 transfected HEK293 IP was loaded to an SDS-PAGE gel and separated, 
stained, excised, reduced and alkylated. The protein bands were digested with 
either trypsin or Lys-C, as per the manufacturer’s instructions, in the presence 
of each DA-Raf-2 AQUA peptide. The digested peptide products were extracted 
and vacuum centrifuging to completion, re-suspended in 10% (v/v) β-
mercaptoethanol, in 100 mM AMBIC, and incubating at 99 oC for 60 minutes. 
 
The reduced DA-Raf-2 peptides were injected onto an Ultimate 3000 HPLC and 
spotted to a 384 well Ultraflex II MALDI plate via a Dionex Probot MALDI Spotter. 
The Probot spotter was controlled with the Dionex µCarrier software package, 
spotting to each MALDI well for a period of five minutes, so as to yield a total of 
12 MALDI spots per sample. The 0.3 µL/min HPLC flow rate was supplemented 
with a 0.3 µL/min flow of HCCA matrix solution from the Probot, giving a total 
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plated droplet size of 3 µL. The 384 well MALDI plate was analysed on an 
Ultraflex II MS, summing a total of 500 laser shots and comparing the peak 
heights for isotopic peaks M, M+1, M+2 and M+3. 
 
4.3.4 A-Raf TNT Based Protein Production 
A-Raf WT and A-Raf Short protein stocks were synthesised using a Quick Coupled 
Transcription/Translation kit, as per the manufacturer’s instructions. The spent 
TNT solution was immunoprecipitated, separated via SDS-PAGE and western 
blotted, so as to enable the yield of the TNT reaction to be assessed. 
 
4.3.5 A-Raf Short Plasmid Manipulation 
4.3.5.1 A-Raf Short Primer Design for SOE PCR 
The 3’ splice site, 5’ splice site and branch point (located 18-40 nucleotides 
upstream of the 3’ splice site (Rogozin et al., 2005)) were identified for intron 
two of the A-Raf Short cDNA plasmid insert, each of the three were then 
screened so as to identify a suitable site directed mutagenesis point, identifying 
a location where; (i) A single base pair could be changed and yet the triplet code 
of the exon would be maintained intact (retaining the exact protein sequence of 
A-Raf Short); (ii) A single base pair could be changed, and in doing so modifying 
the consensus sequence for the splice site (preventing it from being spliced); (iii) 
The base is located within 1 kb of a unique restriction digest site (enabling the 
final splice overlap extension (SOE) product to be accurately replicated, cleaved 
and purified) (Vallejo et al., 2008), and (iv) The creation of a site directed 
mutagenesis probe would adhere to the general rules of PCR primer selection. 
Further to the above rules for selecting a suitable site directed mutagenesis site, 
the final primer must also adhere to the general rules for PCR primer design, as 
detailed by Dieffenbach et al. (Dieffenbach et al., 1993), with the exception of 
primer length, which in the case of SOE PCR, must be long enough to allow for 
sufficient annealing to either side of the point mutation (between 18 and 24 
bases (Vallejo et al., 2008)). 
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4.3.5.2 SOE PCR Overlap Production 
The SOE PCR performed in this study, as is shown on Figure 4-5, was adapted 
from the protocol detailed by Heckman and Pease (Heckman and Pease, 2007). 
 
 
Figure 4-5: The steps involved in the SOE PCR based site directed mutagenesis 
of A-Raf Short.  As to conduct the first step of SOE PCR, two reactions are run, 
the first of which features the use of both T7 and ARAFMUTSAR primers, while 
the second features the use of both BGH reverse and ARAFMUTSAF primers, 
thereby creating two small PCR products which cross the mutagenic target site. 
The amplified PCR products are purified and combined, serving as templates for 
the second stage of SOE PCR, which when combined with T7 and BGH reverse 
primers, extended only the mutated sequences. 
 
Two 32 cycle PCR reactions were performed on an Eppendorf Mastercycler, the 
first of which contained both the T7 and ARAFMUTSAR (GCCATCCCGGACAGT 
CACTTGTGTGTATGTGCAGATGTAGG) primers, while the second contained both 
BGHrev and ARAFMUTSAF (CCTACATCTGCACATACACACAAGTGACTGTCCGGG 
ATGGC) primers. The components added to each reaction and the PCR program 
settings are detailed in Tables 4-1 and 4-2 respectively. 
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Table 4-1: The reaction products required for the first PCR stage of SOE PCR.  
The components required for the production of the overlapping SOE PCR 
fragments; the first ranging from the T7 promoter to the end of the 
ARAFMUTSAR primer, while the second ranges from the start of the ARAFMUTSAF 
primer to the BGHrev promoter. The component volumes listed in this table are 
those which are required per reaction. A control reaction was also run where the 
PCR template was replaced by water.  
Reagent: Volume per Tube (µL) Final Concentration 
10x Pfu Polymerase Buffer 5 1x 
2 mmol/µL Deoxyribonucleotide triphosphate (dNTP) Mix 5 0.2 mmol/µL 
100 pmol/µL ARAFMUTSAR/ARAFMUTSAF Primer 0.5 50 pmol/µL 
100 pmol/µL T7/BGHrev Primer 0.5 50 pmol/µL 
300 ng/µL A-Raf Short Plasmid 0.3 100 ng 
3.5 U/µL Pfu Polymerase 1 3.5 U 
Nuclease-free Water 37.7 - 
Total 50 - 
 
Table 4-2: The PCR program parameters for the first stage of SOE PCR.  The 
PCR cycle details used during the first stage of SOE PCR. As Pfu polymerase was 
utilised, an extension temperature of 72 oC was selected. Meanwhile an 
annealing temperature of 50 oC was selected, so as to enable the binding of the 
primers which contained a mismatch.  
Cycle Number Denature Anneal Extend 
1 95 oC for 3 minutes - - 
2 – 31 95 oC for 1 minute 50 oC for 1 minute 72 oC for 2 minutes 
32 - - 72 oC for 10 minutes 
 
The completed PCR reaction mixes were supplemented with DNA Gel Loading 
Buffer, subjected to agarose gel based purification, and extracted with a 
QIAquick spin column. 
 
4.3.5.3 SOE PCR Overlap Extension 
The purified PCR products from the T7/ARAFMUTSAR and BGHrev/ARAFMUTSAF 
reactions were combined at equal quantities (w/w) and heated to 65 oC for 10 
minutes. The water bath was switched off and the temperature slowly returned 
to that of the room, so as to aid with the annealing of the complementary 
sequence around the modified base. 
 
The second SOE PCR extension reaction was prepared as is detailed in Table 4-3 
and run using the same PCR program as was detailed in Table 4-2. 
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Table 4-3: The reaction products required for the second PCR stage of SOE 
PCR.  The components required for the extension of the overlapping SOE PCR 
fragments. The volumes listed on this table are those required per reaction. A 
control reaction was also run where the PCR template was replaced by water. 
Reagent: Volume per Tube (µL) Final Concentration 
10x Pfu Polymerase Buffer 5 1x 
2 mmol/µL dNTP Mix 5 0.2 mmol/µL 
100 ng/µL Purified PCR Mix 2 200 ng 
100 pmol/µL T7 Primer 0.5 50 pmol/µL 
100 pmol/µL BGHrev Primer 0.5 50 pmol/µL 
3.5 U/µL Pfu Polymerase 1 3.5 U 
Nuclease-free Water 36 - 
Total 50 - 
 
4.3.5.4 Restriction Digest of the Final PCR Product 
The final PCR reaction mix (which should be identical to the insert from A-Raf 
Short with the exception of the G→A substitution) was double restriction 
digested with BamHI and NheI, as per the manufacturer’s instructions. Likewise, 
pcDNA3.1(+) was  double restriction digested with BamHI and NheI, as per the 
manufacturer’s instructions. The restriction digested fragments were separated 
via agarose gel based electrophoresis, visualised, excised, purified and 
quantified. The insert and vector were ligated with T4 DNA Ligase, as per the 
manufacturer’s instructions, and transformed into library efficiency DH5α cells. 
The transformed cells were plated and approximately 20 colonies per plate 
screened for the presence of the modified plasmid. In brief, each colony was 
cultured and the amplified plasmid extracted via Miniprep. The purified plasmid 
was double restriction digested with BamHI and NheI, with the aim of identifying 
an insert with a length of approximately 555 bp. Where a suitable plasmid was 
identified, it was sent for sequencing, as to confirm the presence of the single 
base mutation. 
 
4.3.6 Non-Immunoprecipitated Exogenously Expressed A-Raf WT 
1.7x107 HEK293 cells were plated to a 150 mm tissue culture dish and 
transfected with the FLAG-tagged A-Raf WT plasmid, through the application of 
Genejuice transfection reagent, as per the manufacturer’s instructions. After 72 
hours the spent media was drained and the cells lysed through the addition of 
cell lysis buffer. The lysed cells were centrifuged at 12,000 rpm for 10 minutes 
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and the supernatant diluted in Protein Loading Buffer, incubating at 99oC for 15 
minutes. 
 
The exogenously expressed A-Raf WT cell lysate was loaded to an SDS-PAGE gel 
and electrophoresed, stained and the A-Raf WT gel band excised, reduced with 
DTT and alkylated with IAA, prior to digestion with trypsin in the presence of 
each of the A-Raf WT AQUA peptides. The proteolytic peptides were extracted, 
vacuum centrifuged and re-suspended in 2% MeCN, 0.1% FA (v/v), injecting onto 
an Ultimate 3000 and analysing via a QTrap 5500, running the A-Raf MRM 
acquisition method previously devised. 
 
4.3.7 Endogenously Expressed A-Raf WT 
Endogenous A-Raf WT expression was assessed in HEK293 cells incubated for 96 
hours, without the application of transfection. 
 
4.4 Results and Discussion 
4.4.1 AQUA Peptide Selection 
When searching for an AQUA peptide suitable for the quantification of a protein 
isoform, regions of sequence unique to that isoform must first be identified. 
These regions of sequence are theoretically digested, so as to yield a number of 
candidate peptides. Each of these candidate peptides is screened, so as to 
determine its length, if it contains an amino acid residue suitable for stable 
isotopic labelling, and to assess the percentage of hydrophobic residues from 
which the peptides sequence is composed. Each candidate peptide which is 
deemed initially suitable is aligned against the host proteome, using the BLASTP 
search tool, to determine if its sequence is unique within the host proteome, 
and finally each peptide is compared to the AQUA peptide selection criteria, so 
as to determine if it is suitable for an LC-MS based quantitative analysis. 
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Due to the repetitive nature of the AQUA peptide selection process, only the 
selection of an AQUA peptide suitable for the quantification of A-Raf WT will be 
detailed, in addition to which, each AQUA peptide selected will be listed. 
 
4.4.1.1 Sequence Unique to Each A-Raf Isoform 
The areas of sequence unique to each A-Raf protein isoform are shown on Figure 
4-6. Of the A-Raf isoforms, A-Raf WT was found to be the least homologous A-Raf 
isoform, containing some 421 residues of unique sequence.  
 
 
Figure 4-6: An alignment of each of the four A-Raf isoforms, highlighting the 
regions of sequence unique to each.  An alignment of each of the four A-Raf 
isoforms, based on Clustal X. Highlighted in yellow, green and blue are the 
regions of sequence unique to A-Raf Short, DA-Raf-1 and A-Raf WT respectively. 
In being unique these areas are the first targeted in the search for suitable AQUA 
peptides. 
 
From Figure 4-6 it was also clear that A-Raf Short has a reasonable amount of 
unique sequence, totalling some 69 unique residues, of which some 54 result 
from the inclusion of intron two, while the remaining 15 residues resulted from 
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the inclusion of intron four, prior to termination. DA-Raf-1 meanwhile has only 
one residue of unique sequence, resulting from the inclusion of intron six, while 
DA-Raf-2, which results from the inclusion of intron five, appears to be 
completely homologous to A-Raf WT. 
 
4.4.1.2 AQUA Peptide Selection for the Quantification of A-Raf WT 
Of the four known A-Raf protein isoforms, A-Raf WT contained the most unique 
sequence, and as such selecting an AQUA peptide suitable for the quantification 
of A-Raf WT should prove the least problematic. 
 
The first step in the search for a suitable AQUA peptide was thus to take the 
sequence unique to A-Raf WT (Figure 4-6) and to perform a trypsin based 
theoretical digest, screening each peptide so as to determine its length and 
amino acid composition (in relation to the number of hydrophobic residues), 
while searching for the presence of an amino acid suitable for stable isotopic 
labelling. For a peptide to be deemed suitable it should thus: be between 6 and 
15 amino acids in length, be composed of between 10 and 50% hydrophobic 
residues, and contain at least one residue suitable for stable isotopic labelling. 
Any peptide which did not meet these criteria was eliminated from the search. 
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Table 4-4: A theoretical digestion performed on the sequence unique to A-Raf 
WT.  A theoretical digestion performed on the sequence unique to A-Raf WT, 
based upon the use of trypsin. Peptides which resulted from this theoretical 
digestion were subsequently screened, and only those with a length of between 
6-15 amino acids, which were composed of between 10 and 50% hydrophobic 
residues and which contained an amino acid suitable for stable isotopic labelling 
were deemed initially suitable. 
Tryptic Peptide Fragment: 
Length 
(AA) 
Hydrophobic 
Residues (%) 
Contains AQUA 
Suitable AA 
Initially 
Suitable 
R-QHEAPSNRPLNELLTPQGPSPR-T 22 14% TRUE No 
R-TQHCDPEHFPFPAPANAPLQR-I 21 14% TRUE No 
R-IR-S 2 50% TRUE No 
R-STSTPNVHMVSTTAPMDSNLIQLTGQSFSTDAAGSR-G 36 22% TRUE No 
R-GGSDGTPR-G 8 0% TRUE No 
R-GSPSPASVSSGR-K 12 8% TRUE No 
R-K-S 1 0% TRUE No 
K-SPHSK-S 5 0% TRUE No 
K-SPAEQR-E 6 0% TRUE No 
R-ER-K 2 0% TRUE No 
R-K-S 1 0% TRUE No 
K-SLADDK-K 6 17% TRUE Yes 
K-K-K 1 0% TRUE No 
K-K-V 1 0% TRUE No 
K-VKNLGYR-D 7 29% TRUE Yes 
R-DSGYYWEVPPSEVQLLK-R 17 29% TRUE No 
K-R-I 1 0% TRUE No 
R-IGTGSFGTVFR-G 11 36% TRUE Yes 
R-GR-W 2 0% TRUE No 
R-WHGDVAVK-V 8 38% TRUE Yes 
K-VLK-V 3 67% TRUE No 
K-VSQPTAEQAQAFK-N 13 15% TRUE Yes 
K-NEMQVLR-K 7 43% TRUE Yes 
R-K-T 1 0% TRUE No 
K-TRHVNILLFMGFMTRPGFAIITQWCEGSSLYHHLHVADTR-F 40 38% TRUE No 
R-FDMVQLIDVAR-Q 11 55% TRUE No 
R-QTAQGMDYLHAK-N 12 17% TRUE Yes 
K-NIIHR-D 5 40% TRUE No 
R-DLK-S 3 33% TRUE No 
K-SNNIFLHEGLTVK-I 13 38% TRUE Yes 
K-IGDFGLATVK-T 10 40% TRUE Yes 
K-TR-W 2 0% TRUE No 
R-WSGAQPLEQPSGSVLWMAAEVIR-M 23 35% TRUE No 
R-MQDPNPYSFQSDVYAYGVVLYELMTGSLPYSHIGCR-D 36 28% TRUE No 
R-DQIIFMVGR-G 9 56% TRUE No 
R-GYLSPDLSK-I 9 22% TRUE Yes 
K-ISSNCPK-A 7 14% TRUE Yes 
K-AMR-R 3 33% TRUE No 
R-R-L 1 0% TRUE No 
R-LLSDCLK-F 7 43% TRUE Yes 
K-FQR-E 3 33% TRUE No 
R-EERPLFPQILATIELLQR-S 18 39% TRUE No 
R-SLPK-I 4 25% TRUE No 
K-IER-S 3 33% TRUE No 
R-SASEPSLHR-T 9 11% TRUE Yes 
R-TQADELPACLLSAAR-L 15 20% TRUE Yes 
R-LVP 3 67% TRUE No 
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From Table 4-4 it is clear that even when large regions of unique sequence are 
theoretically digested with trypsin, the majority of the candidate peptides 
identified are still unsuitable. Indeed, from the 47 peptides identified during this 
theoretical digest, only 14 were seen as being initially suitable; less than 30%.  
 
Each remaining candidate peptide was subjected to an NCBI BLASTP based 
alignment, identifying which of the 14 remaining peptides were unique to A-Raf 
WT within the Homo sapiens proteome. Where a peptide was identified as 
originating exclusively from the target protein, it was deemed unique. Otherwise 
the peptide was eliminated from the search.  
 
Table 4-5: An NCBI BLASTP based alignment of each A-Raf WT candidate 
peptide against the Homo sapiens proteome.  The results obtained from an 
NCBI BLASTP based alignment of 14 A-Raf WT candidate peptides against the 
Homo sapiens proteome. Peptides found to originate only from A-Raf WT within 
the Homo sapiens proteome were labelled as unique. 
Tryptic Peptide Fragment: Unique 
K-SLADDK-K No 
K-VKNLGYR-D Yes 
R-IGTGSFGTVFR-G Yes 
R-WHGDVAVK-V No 
K-VSQPTAEQAQAFK-N Yes 
K-NEMQVLR-K Yes 
R-QTAQGMDYLHAK-N No 
K-SNNIFLHEGLTVK-I No 
K-IGDFGLATVK-T No 
R-GYLSPDLSK-I No 
K-ISSNCPK-A Yes 
R-LLSDCLK-F No 
R-SASEPSLHR-T No 
R-TQADELPACLLSAAR-L Yes 
 
Following the completion of the NCBI BLASTP based alignment, only six of the 
initial 47 candidate peptides identified in Table 4-4 were found to be unique to 
A-Raf WT within the Homo sapiens proteome (Table 4-5), less than 13%. 
 
The next step in the identification of an optimal A-Raf WT candidate peptide 
was to further analyse each of the six remaining candidate peptides, through 
comparing each to the AQUA peptide selection criteria, so as to identify any 
sequence flaws which may affect the efficiency of the proteolytic digest. Shown 
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in Table 4-6 are the results obtained from the screening of each of the candidate 
peptides. 
 
Table 4-6: Further screening of the A-Raf WT candidate peptides against the 
AQUA peptide selection criteria.  A more thorough analysis of each A-Raf WT 
candidate peptide, identifying which of the six remaining peptides complied 
with each of the AQUA peptide selection criteria.  
Tryptic Peptide Fragment: Comments on Peptide Suitability: 
K-VKNLGYR-D C-terminus of peptide succeeded by Asp. 
KR-IGTGSFGTVFR-G N-terminus of peptide preceded by Lys. 
K-VSQPTAEQAQAFK-N Suitable AQUA peptide. 
K-NEMQVLR-K C-terminus of peptide succeeded by Lys. 
K-ISSNCPK-A Suitable AQUA peptide. 
R-TQADELPACLLSAAR-L Suitable AQUA peptide. 
 
From Table 4-6 it is clear that only three of the six remaining candidate peptides 
were somewhat suitable. Of the three peptides which were rejected, two were 
eliminated due to the presence of flanking basic residues, while the third was 
eliminated due to the presence of a flanking acidic residue. 
 
The final step in the selection a suitable AQUA peptide was thus to compare 
each of the three remaining candidate peptides, so as to determine which was 
most suited to an LC-MS based analysis, assessing both length and sequence, the 
results from which are shown below. 
  
Peptide VSQPTAEQAQAFK: 
Peptide VSQPTAEQAQAFK was cleaved with trypsin, and thus a minimum of two 
charges per peptide would be expected. Furthermore, the initial 
characterisation of this peptide (Table 4-4) suggests it to be composed of just 
15% hydrophobic residues, therefore no problems were foreseen with the use of 
this peptide during LC-MS/MS.    
 
Peptide ISSNCPK: 
Upon reviewing the sequence of peptide ISSNCPK, two consecutive Ser residues 
were detected, which in the presence of a low pH solution, can undergo 
dehydration. This reaction converts the Ser residues to dehydroalanine, and in 
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doing so yielding multiple MS peaks per peptide. As such, this peptide was 
eliminated from the search. 
 
Peptide TQADELPACLLSAAR: 
On reviewing the sequence of peptide TQADELPACLLSAAR, it was found to be 
composed of 15 amino acid residues, which while permitted, increases the 
chance of this peptide presenting with multiple charged states. So as to better 
explain the problem, when a peptide may exist in one of a number of charged 
states, the amount of peptide detected for any specific MS parent ion peak 
would be reduced, therefore increasing the amount of sample required for the 
LoD to be reached. As such this peptide was eliminated from the search. 
 
In conclusion, of the three candidate peptides, only one was deemed suitable for 
an AQUA based quantification, peptide VSQPTAEQAQAFK. This peptide was found 
to be of a reasonable length, while lacking any obvious sequence flaws and was 
found to conform to all of the AQUA peptide selection criteria.  
 
A-Raf WT serves also as an example of the problems associated with selecting a 
proteotypic peptide for the quantification of a protein isoform. From a 58 kDa 
protein, unique sequence totalling 421 amino acids was identified, from which, 
only 47 candidate peptides were identified, only one of which was found to be 
ideal. 
 
4.4.1.3 A-Raf AQUA Peptide Selection Overview 
Through the use of the AQUA peptide selection workflow, as was detailed in 
Chapter 2, it has been possible to select a single AQUA peptide for the 
quantification of all but one A-Raf isoform, A-Raf Short, which instead was 
quantified through the use of two AQUA peptides, each of which is listed on 
Table 4-7, and shown on Figure 4-7. 
 
 
129 
 
Table 4-7: The AQUA peptides selected for the quantification of each of the 
A-Raf isoforms.  Each of the AQUA peptides selected for the quantification of 
each of the four A-Raf isoforms. 
Peptide Protease Present in: Comments: 
VSQPTAEQAQAFK Trypsin A-Raf WT Located within CR3, and thus unique to A-Raf WT 
TVVTVR Trypsin A-Raf WT, DA-Raf-1 & DA-Raf-2 
Selected for the quantification of A-Raf Short, through 
subtracting the quantitation value obtained for this peptide 
from that obtained for peptide GLNQDCCVVYR 
GLNQDCCVVYR Trypsin All four A-Raf isoforms Selected for the quantification of all four A-Raf isoforms.  
LLTPQGPR Glu-C DA-Raf-1 The C-terminus peptide of DA-Raf-1 
VPTVCVDMSTNRQQ Lys-C DA-Raf-2 The C-terminus peptide of DA-Raf-2 
 
 
Figure 4-7: Each of the AQUA peptides selected for the quantification of the 
four A-Raf isoforms.  A Clustal X alignment of each of the four A-Raf isoforms. 
Highlighted in yellow is peptide TVVTVR, present in A-Raf-WT, DA-Raf-1 and DA-
Raf-2. Highlighted in green is peptide GLNQDCCVVYR, present in each of the four 
A-Raf isoforms. Highlighted in blue is peptide LLTPQGPR, present only in DA-Raf-
1. Highlighted in red is peptide VPTVCVDMSTNRQQ, present only in DA-Raf-2. 
Finally, highlighted in purple is peptide VSQPTAEQAQAFK, present only in A-Raf 
WT. 
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4.4.2 AQUA Peptide Optimisation 
4.4.2.1 The Oxidation and Reduction of Met 
4.4.2.1.1 The Modification of Met Within Three Intact Proteins 
So as to assess the efficiency with which DMSO and DMS oxidise and reduce Met, 
respectively; Lactoglobulin, Lysozyme and Myoglobin were reduced, alkylated 
and digested with trypsin, prior to being oxidised with DMSO, or reduced with 
DMS, and analysed via MALDI-ToF. Due to the repetitive nature of this 
experiment, only those results obtained for Myoglobin are detailed. 
 
 
Figure 4-8: The Met containing tryptic peptides identified in Myoglobin.  A 
theoretical tryptic digestion was performed on Myoglobin, so as to identify any 
Met containing peptides, following which the mass to charge ratios for both the 
oxidised and reduced species were calculated. 
 
From Figure 4-8 it is clear that just two Met containing peptides were identified 
during the tryptic digestion of Myoglobin, and while both peptides were 
detected via MS, only peptide HPGDFGADAQGAMTK appears to have been 
affected by either the DMS based reduction or the DMSO based oxidation (Figure 
4-9). 
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Figure 4-9: The DMS and DMSO based reduction and oxidation of Met 
containing Myoglobin peptide HPGDFGADAQGAMTK.  Following the trypic 
digestion of Myoglobin, peptide HPGDFGADAQGAMTK was oxidised with DMSO 
and reduced with DMS, prior to analysis based upon MALDI-ToF. Peptide 
HPGDFGADAQGAMTK is shown in an unmodified state (top spectra), following 
DMSO based oxidation (middle spectra) and after DMS based reduction (bottom 
spectra). 
 
From Figure 4-9 it is clear that peptide HPGDFGADAQGAMTK, in an unmodified 
state, is almost completely reduced. While this is good for gauging the efficiency 
with which DMSO oxidises this peptide, it makes assessing the DMS based 
reduction impossible. When oxidised with DMSO, peptide HPGDFGADAQGAMTK 
presented with a +16 Da peak, approximately 70% the height of reduced peak 
1,503 m/z, therefore, while the oxidation of peptide HPGDFGADAQGAMTK was 
at least partially successful, it is far from being complete. 
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Upon the completion of the DMS and DMSO based reduction and oxidation of 
Met, it was clear that both of these reactions were not as efficient as is required 
for a successful AQUA analysis, and as such were abandoned. When unmodified 
Met containing peptides presented in a partial oxidised state, the DMS and DMSO 
based reactions were reasonably efficient. In comparison, in those situations 
where the unmodified peptide was almost completely reduced, the efficiency of 
the DMSO based oxidation was poor. This would suggest that the reactions may 
only proceed in situations where the Met is susceptible to modification, perhaps 
somewhat influenced by the sequence of the surrounding amino acid residues. 
 
4.4.2.1.2 Met Modification within AQUA Peptide VPTV*CVDMSTNRQQ 
Met containing AQUA peptide VPTV*CVDMSTNRQQ was treated with DTT and IAA 
prior to the addition of sodium periodate, so as to completely oxidise the Met. 
Upon the completion of this reaction, a complete reduction was attempted, 
based on the use of β-mercaptoethanol. 
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Figure 4-10: The Sodium Periodate based oxidation and β-mercaptoethanol 
based reduction of AQUA peptide VPTV*CVDMSTNRQQ.  A screenshot of 
multiple spectra obtained from an Ultraflex II MS, in which the complete sodium 
periodate based oxidation and β-mercaptoethanol based reduction of AQUA 
peptide VPTV*CVDMSTNRQQ were attempted. The reduction of the Met sulfoxide 
back to Met was performed under three conditions, in 1%, 10% and 20% (v/v) β-
mercaptoethanol. All intended modifications are detailed in comparison to the 
singly charged, reduced parent ion peak, 1,578.7 m/z. 
 
From Figure 4-10 it is evident that the Met within AQUA peptide 
VPTV*CVDMSTNRQQ is almost completely reduced. When reacted with DTT and 
IAA, the parent ion peak (1,578.7 m/z) is replaced by two new peaks, the first 
with a mass shift of +57 Da, suggestive of IAA based alkylation, while the second 
has a mass shift of just +9 Da, explained by Kruger et al. to result from IAA 
based non-specific alkylation of Met. In situations where Met alkylation occurs, 
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two 57 Da modifications are incorporated, however, during ionisation, in-source 
fragmentation occurs, causing a loss of 105 Da (Kruger et al., 2005). It is 
therefore recommended that all future alkylation based reactions should be 
proceeded by an additional DTT reduction step, reducing any alkylated Met, so 
as to yield a single +57 Da MS peak (Kleanthous and Coggins, 1990). 
  
The alkylated peptide was subsequently oxidised with sodium periodate, while 
the literature suggested a single +16 Da (+73 Da from unmodified) peak should 
present, instead approximately nine peaks were detected, each at a different 
intensity. While it is conceivable that oxidation based damage may have 
degraded various elements within the peptide, it has proven possible to reduce 
each of these peaks back to a single +57 Da parent ion. Instead, as was the case 
during alkylation, these peaks may result from the sodium periodate causing 
several reversible side reactions, each of which is fragmented during ionisation. 
 
When a β-mercaptoethanol based reduction of the oxidised peptide was 
attempted, 1% (v/v) β-mercaptoethanol proved somewhat inefficient. When the 
level of β-mercaptoethanol was increased to 10% (v/v), however, almost all of 
the Met sulfoxide was reduced to Met. Increasing the level of β-mercaptoethanol 
further, to 20% (v/v), the same results were seen as those obtained in 10% (v/v) 
β-mercaptoethanol, but the reduced Met peak presented at a lower intensity. 
The loss of peak intensity at 20% (v/v) β-mercaptoethanol may result from the 
high levels of β-mercaptoethanol affecting the ability of the peptide to bind the 
Zip Tip resin, resulting in peptide loss prior to MALDI spotting. Similarly if Zip Tip 
purification was failing to remove the β-mercaptoethanol, then matrix 
crystallisation and ionisation may be affected. 
 
While the ability of sodium periodate to oxidise Met was clearly greater than 
that of the acidified DMSO, complete modification though oxidation was still 
seen to be the least attractive option. Through selecting the correct oxidative 
chemical, it was thought that undesirable side reactions could be avoided, yet 
non-specific oxidation persisted. Instead complete reduction in 10% (v/v) β-
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mercaptoethanol, immediately prior to LC-MS, may offer this experiment the 
greatest chance of success. 
 
4.4.2.2 Proteolytic Digest Optimisation 
When an AQUA based quantitative analysis is conducted, the digest efficiency is 
of critical importance. So as to identify the reaction conditions under which the 
maximum digest efficiency could be achieved for each utilised protease (trypsin, 
Glu-C and Lys-C), BSA was digested with each proteases at a range of 
enzyme:substrate ratios ((w/w) from 1:10 to 1:200), with or without the 
addition of RapiGest SF ALS, the results of which are shown on Table 4-8. 
 
Table 4-8: The optimisation of trypsin, Lys-C and Glu-C based digestions of 
BSA.  The results obtained when the digest efficiencies of trypsin, Lys-C and Glu-
C were assessed through the digestion of BSA at a range of enzyme:substrate 
ratios, with and without the addition of 0.1% (w/v) RapiGest SF surfactant. The 
results shown detail the percentage sequence coverages achieved. 
  
Protease Concentration 
(Enzyme:Protein, (w/w)) 
 Surfactant Protease 1:10 1:20 1:50 1:100 1:200 Average 
- trypsin 17% 10% 14% 15% 13% 14% 
0.10% trypsin 14% 16% 11% 14% 14% 14% 
- Glu-C 19% 15% 15% 11% 13% 15% 
0.10% Glu-C 33% 40% 30% 34% 27% 33% 
- Lys-C 4% 5% 6% 4% 7% 5% 
0.10% Lys-C 15% 16% 11% 8% 6% 11% 
Average 17% 17% 15% 14% 13% 
  
It should first be noted that the sequence coverages detailed on Table 4-8, while 
low, do not necessarily indicate the digest efficiencies of the proteases to be 
particularly low. These numbers instead indicate the portion of the BSA 
peptideome which was available for detection on an API 2000 MS. Ideally this 
would include all peptides between 8 and 25 residues in length (Brownridge and 
Beynon, 2011), which yield a m/z of between 400 and 1,500, with a single to 
quadruple charge state, which are suitable for retention on a C18 column, and 
elute within the 60 minute RP-LC gradient.  Further to these limitations, the API 
2000 has a long cycle time and a relatively high LoD, when compared to modern 
MS instruments; as a result, only the most abundant peptides were detected.  
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Each set of protease digests were also run at different times, with slightly 
different instrument setups, and as such the sequence coverages achieved 
between proteases cannot be compared. Indeed, as an alternative strategy, the 
number of peptides detected during each analysis may also have been 
compared. The aim of this experiment was, however, simply to assess if the 
RapiGest SF ALS surfactant had a positive impact on protein digest efficiency, as 
would be indicated through an increase in the BSA sequence coverage, and thus 
the exact method utilised was not critical. In addition, the BSA digest 
efficiencies achieved at a range of enzyme:substrate ratios (w/w) were also 
assessed. 
 
While the addition of the ALS surfactant yielded very little improvement in the 
sequence coverage achieved for BSA digested with trypsin, it appears to have 
made a substantial difference to the sequence coverages achieved for the BSA 
digested with either Glu-C or Lys-C (Table 4-8). In regard to detecting the 
optimum enzyme:substrate ratio (w/w), the results achieved for both the trypsin 
and Glu-C based digestions, without the addition of ALS, would suggest the 
highest sequence coverages were achieved with an enzyme:substrate ratio of 
1:10. These results, however, conflict with those obtained through the digestion 
of BSA in the presence of ALS, for which an enzyme:substrate ratio of 1:20 
yielded the highest sequence coverages. This conflicting data may be traced to 
several factors; firstly, in the absence of the ALS, more protease may have been 
required to obtain a higher sequence coverage. Alternatively, the initial high 
sequence coverages achieved (Trypsin and Glu-C 1:10 enzyme:substrate ratio) 
may have resulted from the optimised ESI spray and the presence of a new 
picotip emitter at the beginning of the batch, temporarily boosting the 
performance of the API 2000. 
 
From this brief experiment it was concluded that an enzyme:substrate ratio of 
at least 1:20 (w/w), should be achieved during each proteolytic digest, and that 
RapiGest SF should be utilised. 
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4.4.3 MRM Acquisition Method Design 
When utilising a triple quadrupole based MS, MRM scanning can be employed, 
thereby increasing the sensitivity of the MS towards the specific target ions, 
while reducing the background noise detected. Indeed this type of acquisition 
method is ideal for use during an AQUA based quantitation where only a limited 
number of target peptides are to be detected. MRM based acquisition methods 
do, however, require a great deal of manual optimisation, including the 
selection of a dwell time low enough to achieve several data points per eluting 
peak, yet high enough so as provide a reasonable sensitivity (Keshishian et al., 
2007), while requiring the selection of suitable fragment ions which are 
reasonably abundant and indeed the optimisation of the collision energy for each 
fragment ion (Kettenbach et al., 2011).  
 
4.4.3.1 MRM Selection and Optimisation 
So as to identify both the exact Q1 mass of each AQUA peptide, and to enable 
the selection of three Q3 fragment ion peaks per peptide, each AQUA peptide 
was reduced, alkylated, Zip Tip purified and loaded onto a Proxeon offline 
Borosilicate emitter and infused on an API 2000 MS. In brief, the m/z ratio of the 
parent ion was detected through the use of an EMS scan, collecting ions between 
300-1000 m/z over one second. So as to obtain a higher quality spectrum, the MS 
data collected over five minutes was summed, prior to analysis. Upon the MS 
parent ion having been detected, the API 2000 scan mode was switched to EPI, 
collecting ions between 100-1500 m/z over one second. Again the EPI data was 
summed for a total of five minutes, prior to analysis. 
 
In this chapter, only the characterisation of peptide VSQP*TAEQAQAFK will be 
detailed, a peptide which most commonly fragments at a single amino acid 
(Pro), and as such is one of the more difficult peptides for which to identify 
multiple fragment ions.  
 
138 
 
 
Figure 4-11: Both the MS and MS/MS spectra obtained for AQUA peptide 
VSQP*TAEQAQAFK on an API 2000.  (Left), The MS spectrum obtained for AQUA 
peptide VSQP*TAEQAQAFK during a direct injection, showing a single doubly 
charged peak at 706.6 m/z, which was subsequently selected as the Q1 mass of 
interest for all future A-Raf MRM  based analyses. (Right) The product ion 
spectra obtained from the fragmentation of peak 706.6 m/z, with a collision 
energy of 25 eV. Marked in red are the three Q3 fragments manually selected for 
use in the A-Raf MRM acquisition method. 
 
Figure 4-11 shows the intense doubly charged peak detected for peptide 
VSQP*TAEQAQAFK at 706.6 m/z. As no signal was detected for the singly or triply 
charged peptide species (data not displayed), peak 706.6 m/z was selected as 
the Q1 target and therefore subjected to EPI based fragmentation.  
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Figure 4-12: The predicted fragmentation spectrum for both synthetic and 
endogenous peptide VSQPTAEQAQAFK.  A predicted fragmentation spectrum 
for the synthetic (right) and endogenous (left) versions of peptide 
VSQP*TAEQAQAFK, as obtained from Protein Prospector: MS-Product, enabling a 
more rapid identification of suitable Q3 fragment ions. 
 
When Q1 ion 706.6 m/z was subjected to an EPI based scan, several intense 
fragment ions were detected. One of the most abundant peaks identified was 
1,096.6 m/z, which in comparison to a predicted fragmentation spectrum 
(Protein Prospector MS-Product, Figure 4-12) was identified as being the Y10 ion. 
As this peptide contained a Pro residue, the most likely residue for a 
fragmentation to occur, few other intense Y or B-ion peaks were detected. 
Further analysis however identified both the Y6 and B6 ions, which presented at 
692.4 m/z and 590.3 m/z, respectively, both of which were selected as suitable 
Q3 ions. 
 
The optimum collision energy for each fragment ion was determined through 
increasing the Q2 collision energy from 5 eV, in multiples of five, from a 
minimum of five to a maximum of 60. 
 
While selecting the most intense fragment ion for an MRM based acquisition 
method may seem sensible, thereby lowering the amount of peptide required 
per detection, Kettenbach et al. suggests that preference should be given to 
those fragments with a m/z ratio higher than their parent ion. As internal 
fragmentation ions are generally detected in the lower spectrum (below 400 
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m/z). Selecting a fragment with a higher m/z should therefore ensure less noise 
is detected for the transition (Kettenbach et al., 2011). Furthermore, ion trap 
instruments such as the API 2000 are less efficient at trapping ions with m/z’s 
below approximately 1/3 of the parent ion m/z, therefore selecting low MW 
fragment ions is best avoided (Hopfgartner et al., 2004). 
 
Upon selecting a total of three complete MRM transitions per peptide, the 
corresponding target peptide values were calculated based on the MW of the 
AQUA peptide minus the additional weight of the 13C and 15N labelling. An equal 
dwell time was selected for each A-Raf MRM transition, resulting in a total scan 
time of two seconds per cycle. This approach enabled the collection of 15 data 
points per transition, assuming an LC-MS peak width of 30 seconds. 
 
Shown on Table 4-9 is the complete A-Raf MRM acquisition method, detailing the 
transitions selected for each target and synthetic peptide, with the exception of 
Met containing AQUA peptide VPTV*CVDMSTNRQQ.  
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Table 4-9: The MRM transitions selected for the detection of each A-Raf 
target/AQUA peptide.  The MRM based acquisition method developed for the 
detection of each of the four A-Raf isoforms; including the Q1 and Q3 MRM 
transitions, the Q2 optimised collision energy and the dwell time selected for 
each transition (in milliseconds (ms)). 
Peptide (Q1) Fragment (Q3) Q1 m/z Q3 m/z Dwell Time (ms) Collision Energy (eV) 
TV*VTVR B2 340.7 207.1 75 5 
TV*VTVR Y3 340.7 375.2 75 15 
TV*VTVR Y4 340.7 474.3 75 10 
TVVTVR B2 337.7 201.1 75 5 
TVVTVR Y3 337.7 375.2 75 15 
TVVTVR Y4 337.7 474.3 75 10 
VSQP*TAEQAQAFK Y10 705.9 1096.6 75 25 
VSQP*TAEQAQAFK Y6 705.9 692.4 75 30 
VSQP*TAEQAQAFK B6 705.9 590.3 75 25 
VSQPTAEQAQAFK Y10 702.9 1090.6 75 25 
VSQPTAEQAQAFK Y6 702.9 692.4 75 30 
VSQPTAEQAQAFK B6 702.9 584.3 75 25 
GL*NQDCCVVYR B3 695.8 292.2 75 30 
GL*NQDCCVVYR Y2 695.8 338.2 75 30 
GL*NQDCCVVYR Y3 695.8 437.3 75 30 
GLNQDCCVVYR B3 692.3 285.2 75 30 
GLNQDCCVVYR Y2 692.3 338.2 75 30 
GLNQDCCVVYR Y3 692.3 437.3 75 30 
LLTP*QGPR Y7 444.3 774.4 75 15 
LLTP*QGPR Y6 444.3 661.4 75 15 
LLTP*QGPR Y5 444.3 560.3 75 25 
LLTPQGPR Y7 441.3 768.4 75 15 
LLTPQGPR Y6 441.3 655.4 75 15 
LLTPQGPR Y5 441.3 554.3 75 25 
 
4.4.3.2 Detection of AQUA Peptide VPTV*CVDMSTNRQQ 
When 5 pmol of AQUA peptide VPTV*CVDMSTNRQQ was analysed on an API 2000 
MS, no MS peak was detected. So as to test if this was a fault with the MS, a 
second sample was prepared and injected onto a QSTAR Pulsar MS, which also 
failed to detect the peptide. Both machines were later injected with a range of 
other AQUA peptides, each of which was detected at a reasonable intensity 
(data not shown).  
 
So as to test if the AQUA vials were empty, or if the peptide had failed to re-
suspend, two unopened vials of AQUA peptide VPTVCVDMSTNRQQ were 
reconstituted in either 20 µL of 10% DMSO (v/v), or 20 µL of 10% FA (v/v), each 
of which was then further diluted to 200 µL in 0.1% FA (v/v), and analysed on an 
Ultraflex II MS. 
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Figure 4-13: A MALDI-ToF based characterisation of AQUA peptide 
VPTVCVDMSTNRQQ, based upon the use of both MS and MS/MS.  (Left) The MS 
spectrum obtained from the ionisation of AQUA peptide VPTVCVDMSTNRQQ on an 
Ultraflex II MALDI-ToF MS. Through summing 500 shots it was possible to detect a 
singly charged peak at 1,640.8 m/z. (Right) The MS/MS spectrum obtained from 
the fragmentation of singly charged peak 1,640.8 m/z, marked in red is the 
fragment ion transition selected. 
 
Though a singly charged parent ion peak was detected in both solutions, with a 
mass to charge ratio of 1,640.8 m/z, the ion intensity was low, achieving only 
1,000 counts per 500 summed pulses (Figure 4-13). While not directly 
comparable, AQUA peptides VSQP*TAEQAQAFK and LLTP*QGPR, analysed at a 
similar concentration levels and under similar conditions, achieved ion 
intensities of 5x104 and 3.5x105, respectively. 
 
As peptide VPTV*CVDMSTNRQQ could be detected based upon MALDI ToF, an LC-
MALDI based method was developed for the quantification of this particular 
peptide, separating the target sample via SDS-PAGE, reducing, alkylating, 
digesting in the presence of each of the AQUA peptides, further reducing the 
Met residue in 10% 2-Mercaptoethanol (v/v), injecting onto an Ultimate 3000 
HPLC, and spotting the eluting solution to a 384 well MALDI plate via a Dionex 
Probot MALDI Spotter, prior to sample analysis on an Ultraflex II MS.  
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4.4.3.2.1 AnchorChip Based Sample Concentration  
In an attempt to increase the MS and MS/MS peak intensities obtained for AQUA 
peptide VPTV*CVDMSTNRQQ, an AnchorChip PAC II 384 well MALDI plate was 
tested, which is claimed to offer an increase in sensitivity of 10 and 100-fold 
over conventional ground steel MALDI plates. The PAC II MALDI plate offers this 
increase in sensitivity though the application of 800 nm hydrophilic “Anchors” 
set in a hydrophobic surround. When the sample is spotted to the PAC II MALDI 
plate, the combination of hydrophilic and hydrophobic surfaces concentrates the 
drying sample. Furthermore, the HCCA matrix is pre-applied to the PAC II MALDI 
plate, ensuring ideal analyte crystallisation conditions, while reducing sample 
preparation time. In situ sample purification may also be performed, eliminating 
Zip Tip based sample loss. 
 
AQUA peptide VPTV*CVDMSTNRQQ, reconstituted in either 20 µL of 10% DMSO 
(v/v), diluted to 200 µL in 0.1% FA (v/v), or 20 µL of 10% FA (v/v) diluted to 200 
µL in 0.1% FA (v/v), was spotted to a PAC II MALDI plate and washed in situ in 10 
mM ammonium phosphate. The DMSO containing peptide sample, however, 
failed to crystallise, instead remaining on the MALDI plate as a dense brown 
droplet, as is shown on Figure 4-14. The DMSO containing peptide sample was 
therefore not subjected to MALDI-ToF based analysis. 
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Figure 4-14: AQUA peptide VPTV*CVDMSTNRQQ spotted to an AnchorChip PAC 
II MALDI plate.  AQUA peptide VPTV*CVDMSTNRQQ was spotted to an AnchorChip 
PAC II MALDI plate, reconstituted in either 20 µL of 10% DMSO (v/v), diluted to 
200 µL in 0.1% FA (v/v), or 20 µL of 10% FA (v/v) diluted to 200 µL in 0.1% FA 
(v/v). While peptide VPTV*CVDMSTNRQQ reconstituted in 10% FA (v/v), diluted 
to 200 µL in 0.1% FA (v/v) crystallised on the PAC II MALDI plate, the DMSO 
containing samples failed to crystallise. 
 
When the FA containing peptide sample spot was subjected to MALDI-ToF based 
analysis, relatively intense HCCA matrix peaks were detected at 832 m/z and 
892 m/z (Smirnov et al., 2004), however, the VPTV*CVDMSTNRQQ parent ion 
peak (1,640.8 m/z) could not be detected (Figure 4-15). As the only difference 
between this analysis and those run previously was the use of the PAC II MALDI 
plate, then the application of this plate and in situ washing must have been 
responsible for the loss of the parent ion peak.  
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Figure 4-15: An MS spectrum of AQUA peptide VPTV*CVDMSTNRQQ, detected 
on an Ultraflex III MS.  The spectrum obtained when detecting AQUA peptide 
VPTV*CVDMSTNRQQ, re-suspended in 10% (v/v) FA, diluted to 200 µL in 0.1% 
(v/v) FA, on an Ultraflex II MS featuring an AnchorChip PAC II MALDI plate. AQUA 
peptide VPTV*CVDMSTNRQQ MS peak 1,640.8 m/z was not detected. 
 
As the PAC II MALDI plate is intended for use in proteomics, the components 
contained within this peptide sample should not affect the retention of the 
peptide VPTV*CVDMSTNRQQ. Indeed the only chemical the manufacturer 
cautions the use of is MeCN, which was not present in this sample. As such the 
use of the PAC II MALDI plate was abandoned and a conventional ground steel 
MALDI plate utilised.  
 
4.4.3.3 MALDI Based Characterisation of AQUA Peptide 
VPTV*CVDMSTNRQQ 
AQUA peptide VPTV*CVDMSTNRQQ was reduced, alkylated, Zip Tip purified and 
spotted to a 384 well MALDI plate prior to analysis on an Ultraflex II MS.  
 
As a singly charged peak was previously detected for peptide 
VPTV*CVDMSTNRQQ, at 1,640.8 m/z, the mass spectrometer was switched to 
MS/MS mode and CID performed at 6 x 10-6 Torr of Argon. During the MS/MS scan 
a single peak was found to dominate the spectrum at 864.1 m/z, which in 
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comparison to a predicted peptide fragmentation pattern (Protein Prospector: 
Ms-Product), was identified as being the Y7 ion (Figure 4-16). 
 
 
Figure 4-16: The predicted fragmentation pattern of both endogenous and 
synthetic VPTVCVDMSTNRQQ, as predicted by Protein Prospector: MS-
Product.  The predicted fragmentation pattern of peptide VPTVCVDMSTNRQQ, 
showing (left) the endogenous peptide and (right) synthetic AQUA peptide 
fragment pattern. 
 
While it was possible to detect both MS and MS/MS peaks for AQUA peptide 
VPTV*CVDMSTNRQQ, both were detected with low signal intensities, even when 
relatively high amounts of sample were analysed (5 pmol). As many endogenous 
proteins are expressed at femtomolar to atomolar levels within cell lysates 
(Seibert et al., 2005, He and Chiu, 2003), this MS/MS detection method may 
struggle to detect anything cruder than an enriched IP. The requirement for 
MS/MS fragmentation was thus abandoned for peptide VPTV*CVDMSTNRQQ, 
instead comparing only the parent ion peak heights. 
 
4.4.3.4 MRM Linear Response and LoD on an API 2000 
A total of eight dilutions of each AQUA peptide were prepared at amounts 
ranging from 5 pmol to 100 amol, each of which were reduced and alkylated 
prior to being injected onto an Ultimate 3000 LC and analysed on an API 2000 
MS, using the A-Raf MRM method previously devised. 
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Contained within the AB SCIEX Analyst 4.2 software bundle is an MRM 
quantitation algorithm capable of automatically detecting and integrating a peak 
area for each MRM transition, based on a peak elution time defined by the user. 
While this may seem useful, in reality this automation can be quite problematic. 
For example, if the defined peak elution time is off by a matter of seconds, an 
alternative peak will be selected within the specified time frame, yielding an 
incorrect quantification. Furthermore, when the peak area is automatically 
integrated, the baseline alignment is often incorrect, comparing the peak area 
of half the synthetic peak to the entire endogenous peak, based upon the 
selection of sub-optimal noise percentage and peak grouping settings. Finally, if 
even a single ion is detected within the peak elution window, this peak will 
automatically be selected as the target transition, and as a result, data will 
always be obtained for an MRM transition, even when no target peak was 
present. 
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Figure 4-17: The signal response and LoD automatically/incorrectly assigned 
to AQUA peptide TV*VTVR.  The peak areas/signal response obtained when 
three TV*VTVR transitions were automatically integrated with the IntelliQuan 
quantitation algorithm, present in Analyst 4.2, at eight different quantities, 
ranging from 5 pmol to 100 amol, on an API 2000 MS. The data are presented in a 
logarithm format, plotting the amount of peptide injected against the peak area 
detected. A linear trend line was fitted to each transition, showing the R2 values 
for each equation. In this case the automatic integration has been performed 
incorrectly, as background noise has continued to be integrated, even when no 
analyte peak is present. 
 
Figure 4-17 shows the results obtained when eight dilutions of AQUA peptide 
TV*VTVR were automatically integrated through Analyst 4.2. The peak areas 
obtain can be seen to level out when only a small amount of peptide was 
injected, leading to an intercept greater than zero, whereas under a linear 
response, with an intercept of zero, the peptide should simply fail to be 
detected. This was due to a minimum peak height not being specified in Analyst, 
and thus any noise detected within the specified peak elution timeframe was 
quantified. It is, therefore, important that manual peak integration is performed 
after each experiment (Figure 4-18), as was recommended by Keshishian et al. 
(Keshishian et al., 2007). 
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Figure 4-18: How target 
and synthetic peaks 
should be manually 
integrated for each MRM 
transition.  Each MRM 
peak should be manually 
integrated, so as to 
ensure an accurate LoD is 
assigned. In this case A-
Raf AQUA peptide 
GL*NQDCCVVYR, 
transition Y3 is shown, 
being identified at: A. 5 
pmol, B. 1 pmol, and C. 
200 fmol on a 5500 Qtrap 
MS. As the transition was 
not identified at 200 
fmol, then the limit of 
detection for A-Raf AQUA 
peptide GL*NQDCCVVYR 
should be recorded as 1 
pmol. 
 
 
 
150 
 
 
Figure 4-19: The signal response and LoD manually/correctly assigned to A-Raf 
AQUA peptide TV*VTVR.  The peak areas/signal response obtained when three 
TV*VTVR transitions were manually integrated with the IntelliQuan quantitation 
algorithm, present in Analyst 4.2, at eight different sample quantities, ranging 
from 5 pmol to 100 amol, on an API 2000 MS. The data are presented in a 
logarithm format, plotting the amount of peptide added, against the peak area 
achieved. A linear trend line was fitted to each transition, showing the R2 values 
for each equation. In this case only five of the eight data points were plotted, as 
no analyte peak was detected for the remaining three. 
 
Through removing the 2 fmol, 500 amol and 100 amol data points, the R2 values 
for each remaining linear alignment were seen to increase (Figure 4-19). Despite 
the data for both tables being integrated differently, the same conclusions can 
be drawn. A strong linear relationship was detected for the calibration line, 
down to 50 fmol, after which, the 10 fmol data point was less strongly 
correlated. This is due to the lower signal to noise ratio (SNR) obtained when 
only a small quantity of sample is injected, where obtaining an accurate peak 
area can prove difficult, as small peak integration errors can have a larger effect 
on the final quantity. As a linear response was confirmed for each A-Raf AQUA 
MRM transition, the LoD for each peptide was determined to be the lowest 
quantity at which each of the three Q3 transitions could be detected. For 
peptide TV*VTVR the LoD was thus set at 10 fmol, for GL*NQDCCVVYR the LoD 
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was set at 5 pmol, for LLTP*QGPR the LoD was set at 200 fmol and for 
VSQP*TAEQAQAFK the LoD was set at 1 pmol, assuming detection is performed 
on an API 2000 MS (Table 4-10).  
 
In situations where a non-linear response is detected, this may offer an 
indication of the peptide binding the sample vial, a process which will has a 
greater effect at lower peptide quantities. 
 
Table 4-10: The LoD’s achieved for each of the A-Raf MRM transitions on an 
API 2000.  The peak areas obtained when eight different quantities of each A-
Raf AQUA peptide, ranging from 5 pmol to 100 amol, were injected. Detailed are 
the peak areas, where the detected counts per second (cps) values were 
summed over the width of the peak. 
Peptide Fragment 5 pmol 1 pmol 200 fmol 50 fmol 
TV*VTVR B2 7.96E+05 1.52E+05 3.92E+04 8.37E+03 
TV*VTVR Y3 3.42E+05 6.71E+04 1.64E+04 3.96E+03 
TV*VTVR Y4 1.01E+06 1.88E+05 4.55E+04 9.95E+03 
GL*NQDCCVVYR B3 7.61E+02 0.00E+00 0.00E+00 0.00E+00 
GL*NQDCCVVYR Y2 6.33E+03 0.00E+00 0.00E+00 0.00E+00 
GL*NQDCCVVYR Y3 3.80E+03 1.20E+02 0.00E+00 0.00E+00 
LLTP*QGPR Y7 1.48E+04 1.64E+03 6.01E+02 0.00E+00 
LLTP*QGPR Y6 1.47E+05 1.84E+04 4.20E+03 0.00E+00 
LLTP*QGPR Y5 2.11E+05 2.86E+04 6.58E+03 0.00E+00 
VSQP*TAEQAQAFK Y10 5.15E+04 1.42E+04 2.36E+03 7.61E+02 
VSQP*TAEQAQAFK Y6 1.11E+04 2.88E+03 4.40E+02 0.00E+00 
VSQP*TAEQAQAFK B6 3.92E+03 1.60E+03 0.00E+00 0.00E+00 
Peptide Fragment 10 fmol 2 fmol 500 amol 100 amol 
TV*VTVR B2 2.72E+03 0.00E+00 0.00E+00 0.00E+00 
TV*VTVR Y3 8.01E+02 0.00E+00 0.00E+00 0.00E+00 
TV*VTVR Y4 2.76E+03 0.00E+00 0.00E+00 0.00E+00 
GL*NQDCCVVYR B3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
GL*NQDCCVVYR Y2 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
GL*NQDCCVVYR Y3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
LLTP*QGPR Y7 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
LLTP*QGPR Y6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
LLTP*QGPR Y5 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
VSQP*TAEQAQAFK Y10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
VSQP*TAEQAQAFK Y6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
VSQP*TAEQAQAFK B6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
 
During a review of the precision and accuracy of MRM based analyses, Addona et 
al. recommended that a LoD is selected at which the faintest of peptide peaks 
can be detected. Addona et al. does however recommend that quantifications 
are performed at the lower limit of quantification (LLOQ), rather than the LoD, 
a value approximately three times greater than the LoD (Addona et al., 2009). 
Based on the MRM data obtained, the lowest level at which each A-Raf isoform 
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can be quantified is 5 pmol, as set by the LoD for peptide GL*NQDCCVVYR. In 
regard to the LLOQ, a LoD of 5 pmol is already relatively high, and as such the 
LoD was retained as the single limiting factor. 
4.4.3.5 LoD on a QTrap 4000 
When access to a more sensitive triple quadrupole based mass spectrometer 
became available (QTrap 4000), the LoD for peptide GL*NQDCCVVYR was again 
tested, injecting the same amount of peptide (Table 4-11). 
 
Table 4-11: The LoD achieved for AQUA peptide GL*NQDCCVVYR on a QTrap 
4000 MS.  Eight different quantities of alkylated AQUA peptide GL*NQDCCVVYR 
were injected onto an Ultimate 3000 HPLC, and the peak area detected on a 
QTrap 4000, using the previously devised A-Raf MRM based acquisition method. 
Both the peak height and area are measured in cps. 
Fragment Amount Analyte Peak Area (cps) Analyte Peak Height (cps) Analyte SNR 
B3 1.5 pmol 2.85E+06 1.58E+05 6.72E+04 
Y2 1.5 pmol 1.23E+07 6.77E+05 3.06E+05 
Y3 1.5 pmol 9.53E+06 4.98E+05 3.39E+05 
B3 300 fmol 6.84E+04 3.74E+03 3.04E+03 
Y2 300 fmol 2.80E+05 1.65E+04 1.52E+04 
Y3 300 fmol 2.03E+05 1.04E+04 8.72E+03 
B3 60 fmol 1.47E+04 8.36E+02 1.08E+03 
Y2 60 fmol 6.38E+04 3.57E+03 2.57E+03 
Y3 60 fmol 5.21E+04 2.83E+03 1.47E+03 
B3 15 fmol 2.68E+03 1.05E+02 1.12E+02 
Y2 15 fmol 4.54E+03 2.25E+02 1.96E+02 
Y3 15 fmol 3.24E+03 1.99E+02 7.19E+01 
B3 3 fmol 0.00E+00 0.00E+00 0.00E+00 
Y2 3 fmol 0.00E+00 0.00E+00 0.00E+00 
Y3 3 fmol 0.00E+00 0.00E+00 0.00E+00 
B3 600 amol 0.00E+00 0.00E+00 0.00E+00 
Y2 600 amol 0.00E+00 0.00E+00 0.00E+00 
Y3 600 amol 0.00E+00 0.00E+00 0.00E+00 
B3 150 amol 0.00E+00 0.00E+00 0.00E+00 
Y2 150 amol 0.00E+00 0.00E+00 0.00E+00 
Y3 150 amol 0.00E+00 0.00E+00 0.00E+00 
B3 30 amol 0.00E+00 0.00E+00 0.00E+00 
Y2 30 amol 0.00E+00 0.00E+00 0.00E+00 
Y3 30 amol 0.00E+00 0.00E+00 0.00E+00 
 
In terms of instrument specification, the API 2000 is detailed as having a 2,400 
Da/sec quadrupole scan time, and an MRM LoD for Reserpine of 50 picograms 
(pg), with a SNR of less than 800. This equates to a LoD for Reserpine of 
approximately 82 fmol under ideal conditions. In comparison, the QTrap 4000 is 
detailed as having a 24,000 Da/sec quadrupole scan time and an MRM LoD for 
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Reserpine of 200 femtogram (fg), with a SNR of less than 1,200 and a CoV of less 
than 5%. This equates to a LoD for Reserpine of 330 amol under ideal conditions, 
250 fold lower than on the API 2000. 
 
From Table 4-11 it is clear that there is a substantial difference in the LoD 
achieved for AQUA peptide GL*NQDCCVVYR on the API 2000 and QTrap 4000. 
While the LoD was originally set to 5 pmol on the API 2000, the smallest quantity 
of peptide which could be injected and all three GL*NQDCCVVYR transitions 
detected, the LoD for the QTrap 4000 was set to 15 fmol, over a 300 fold 
difference, and indeed similar to the LoD changes stated in the instruments 
specifications. This instrument was, however, not available for use on a regular 
basis, and as such method development continued on the API 2000. 
 
4.4.3.6 LoD on a QTrap 5500 
Following the reduced LoD achieved for peptide GL*NQDCCVVYR on the QTrap 
4000 instrument, a QTrap 5500 instrument was tested under the same 
conditions, injecting the same amount of peptide.  
 
The QTrap 5500 is specified as to have a quadrupole scan speed of up to 20,000 
Da/sec and an MRM LoD for Reserpine of 50 fg, with a SNR of less than 2,000, 
and a CoV of less than 5%. The LoD of Reserpine was thus calculated at 
approximately 80 amol under ideal conditions, four fold lower than on the QTrap 
4000 instrument, and 1000 fold lower than on the API 2000 MS. If this increase in 
sensitivity were to translate directly to the LoD achieved for AQUA peptide 
GL*NQDCCVVYR, then the LoD for this A-Raf peptide should fall to just 5 fmol. 
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Table 4-12: The LoD achieved for AQUA peptide GL*NQDCCVVYR on a QTrap 
5500 MS.  Eight different quantities of alkylated AQUA peptide GL*NQDCCVVYR 
were injected onto an Ultimate 3000 HPLC and detected on a QTrap 5500, using 
the previously devised A-Raf MRM based acquisition method. Both the peak 
height and area are measured in cps. 
Fragment Amount Analyte Peak Area (cps) Analyte Peak Height (cps) Analyte SNR 
B3 5 pmol 1.02E+07 1.15E+06 4.65E+03 
Y2 5 pmol 5.39E+07 5.50E+06 4.21E+05 
Y3 5 pmol 4.14E+07 4.41E+06 1.24E+05 
B3 1 pmol 1.21E+05 1.68E+04 5.96E+01 
Y2 1 pmol 5.95E+05 7.37E+04 4.86E+03 
Y3 1 pmol 4.52E+05 5.59E+04 1.51E+03 
B3 200 fmol 0.00E+00 0.00E+00 N/A 
Y2 200 fmol 2.01E+05 2.10E+04 1.57E+03 
Y3 200 fmol 1.28E+05 1.35E+04 3.79E+02 
B3 50 fmol 0.00E+00 0.00E+00 N/A 
Y2 50 fmol 2.00E+04 2.28E+03 1.62E+02 
Y3 50 fmol 1.22E+04 1.72E+03 4.59E+01 
B3 10 fmol 0.00E+00 0.00E+00 N/A 
Y2 10 fmol 0.00E+00 0.00E+00 N/A 
Y3 10 fmol 5.96E+03 6.47E+02 1.76E+01 
B3 2 fmol 0.00E+00 0.00E+00 N/A 
Y2 2 fmol 0.00E+00 0.00E+00 N/A 
Y3 2 fmol 0.00E+00 0.00E+00 N/A 
B3 500 amol 0.00E+00 0.00E+00 N/A 
Y2 500 amol 0.00E+00 0.00E+00 N/A 
Y3 500 amol 0.00E+00 0.00E+00 N/A 
B3 100 amol 0.00E+00 0.00E+00 N/A 
Y2 100 amol 0.00E+00 0.00E+00 N/A 
Y3 100 amol 0.00E+00 0.00E+00 N/A 
 
From Table 4-12 it is clear that the improvement in LoD which was detected on 
the QTrap 4000 did not directly translate to an improvement in LoD on the 
QTrap 5500, which instead yielded a LoD for peptide GL*NQDCCVVYR of 1 pmol. 
This increased LoD was, however, most likely due to sub-optimal acquisition 
method settings, originally designed for use on the API 2000, an older instrument 
with a significantly different hardware setup. If the declustering potential, 
collision cell exit potential, ESI voltage and gas flow settings were further 
optimised on the QTrap 5500, then an increase in sensitivity over the QTrap 4000 
may have been achieved. Access to the QTrap 5500 however was limited and 
thus acquisition method re-optimisation was kept to a minimum during this 
study. 
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4.4.3.7 LoD for AQUA peptide VPTV*CVDMSTNRQQ 
A total of eight dilutions of AQUA peptide VPTV*CVDMSTNRQQ were prepared at 
levels ranging from 5 pmol to 100 amol, each sample was reduced and alkylated, 
reducing the sample a second time, so as to reverse non-specific Met alkylation. 
The peptide was further reduced in 10% 2-Mercaptoethanol (v/v), so as to 
completely reduce the Met residue, prior to the sample being spotted onto a 388 
well MALDI plate, and the sample analysed on an Ultraflex II MS. 
 
 
Figure 4-20: The signal response 
obtained for AQUA peptide 
VPTV*CVDMSTNRQQ on an 
Ultraflex II MS, when eight 
different quantities were 
injected.  Eight dilutions of 
peptide VPTV*CVDMSTNRQQ, 
ranging from 5 pmol to 100 amol, 
were ionised on an Ultraflex II 
MS, the spectra shown detail the 
intensities achieved (summed 
counts) plotted against the m/z. 
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From Figure 4-20 it is clear that only when 5 pmol of peptide VPTV*CVDMSTNRQQ 
was ionised, was a strong MS signal response elicited. Peak 1,641 m/z was 
detected with a signal intensity of 6,600 counts, summed over the 500 laser 
shots fired, and while a signal response was obtained from 1 pmol of 
VPTV*CVDMSTNRQQ, the signal intensity reached only 11 counts. The LoD for 
peptide VPTV*CVDMSTNRQQ was thus set to 1 pmol, which while presenting with 
a weak signal response, was still the limit at which a detection was possible. Due 
to the lack of data points below 5 pmol of peptide VPTV*CVDMSTNRQQ, a linear 
signal response could not be confirmed. 
 
4.4.4 A-Raf Protein Production 
While an AQUA peptide was selected for the quantification of each of the four A-
Raf isoforms, each AQUA peptide was characterised, and a single MRM based MS 
acquisition method developed, a stock solution was required for each A-Raf 
protein isoform, so as to enable the analysis of both the proteolytic digest 
efficiency of the spiked digest technique, and the suitability of the MRM based 
acquisition method for the detection and quantification of each of the four A-Raf 
isoforms, within increasingly complex samples. In terms of the quantity of 
protein required, the A-Raf peptide with the highest LoD was AQUA peptide 
GL*NQDCCVVYR, which requires some 5 pmol of each isoform, so as to enable a 
single quantification to be performed. Furthermore, as each quantitation utilises 
in-gel spiked digestion, then a maximum gel loading volume of 25 µL applied. 
Thus, for an MS sample to be viable, the quantity of protein within the sample 
must be between 250 fmol/µL, assuming 20 µL of sample and 5 µL of protein 
loading buffer, and 200 fmol/µL, assuming the sample is pre-suspended in 
protein loading buffer. While no endogenous concentration data exists for A-Raf, 
it is clear that a sufficient amount of sample may not be achievable based upon 
endogenous expression alone. Instead a simple transient transfection was 
utilised, capable of yielding intracellular protein concentrations as high as 50 
mg/L (Durocher et al., 2002).  
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4.4.4.1 TnT Based Protein Production 
As a way of obtaining protein expression levels similar to that of transient 
transfection, in a solution containing only a limited number of protein species, a 
TNT Quick Coupled Transcription/Translation reaction was performed. This kit, 
it is claimed, is capable of producing significantly more protein (2 to 6-fold) in a 
60 to 90 minute reaction, than a standard in vitro rabbit reticulocyte lysate 
reaction using RNA templates (Hurst et al., 1996). A TNT based reaction was thus 
performed for both A-Raf WT and A-Raf Short, the target proteins 
immunoprecipitated against anti-FLAG, and each isoform sample analysed via 
SDS-PAGE, first staining the gel with Coomassie, then verifying the expression 
through the use of a western blot (Figures 4-21 and 4-22). 
 
 
Figure 4-21: A 1D-SDS-PAGE based separation of TNT transfected A-Raf WT 
and A-Raf Short.  A-Raf WT and Short plasmids were subjected to a TNT based 
transfection, the spent reaction mix was immunoprecipitated against anti-FLAG 
agarose beads and the immunoprecipitate run on a 1D-SDS-PAGE gel. Shown on 
the above image is a gel loaded with 2 µL of each TNT spent reaction mix, 25 µL 
of each IP and 25µL of each IP supernatant, each visualised through the use of 
Coomassie Blue protein stain. 
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Figure 4-22: A western blot of TNT transfected FLAG-tagged A-Raf WT and A-
Raf Short.  A-Raf WT and A-Raf Short plasmids were subjected to a TNT based 
transfection, the spent reaction mix was immunoprecipitated through the use of 
anti-FLAG agarose beads and the immunoprecipitate run on a 1D-SDS-PAGE gel, 
prior to being transferred to a PVDF membrane. Shown on this image is a 
western blot containing 2 µL of each TNT spent reaction mix, 25 µL of each IP 
and 25µL of each IP supernatant, each of which were visualised through the use 
of an anti-FLAG HRP conjugate antibody and BM HRP Chemiluminescence 
reagent. 
 
From Figure 4-21 it is clear that there were still a high number of proteins 
present within the spent TNT reaction mix, with no particularly bright bands 
indicating the presence of the transfected target. The IP supernatant gel lanes 
also yield the same protein expression patterns as the spent reaction mix, with 
no Coomassie stained bands obviously extracted. Furthermore, when the IP gel 
lanes were assessed, no differences could be detected between the A-Raf WT 
and A-Raf Short lanes, with only the anti-FLAG Ig heavy and light antibody chains 
detected at a high abundance. This would indicate that either the amount of 
protein produced was lower than the LoD for Coomassie Blue (50-100 ng 
(Shevchenko et al., 1996)), even upon IP based enrichment, or that the 
transfections had failed. 
 
Western blotting, however, did confirm the expression of the A-Raf target 
proteins, yielding protein bands with a MW of approximately 58 kDa (the average 
MW for A-Raf WT & FLAG tag) and 19 kDa (the average MW for A-Raf Short & 
FLAG tag) (Figure 4-22). Furthermore, as the intensity of the 
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immunoprecipitated protein bands were several times brighter than those of the 
TNT reaction mix, it can be assumed that the IP was successful, indeed no 
excess protein was detected in the IP supernatant, suggesting the volume of 
anti-FLAG beads added to be sufficient. 
 
In conclusion, while it was possible to produce limited amounts of the A-Raf WT 
and A-Raf Short with the TNT reaction kit, the final protein concentrations were 
so low that the protein bands could not be visualised through Coomassie staining 
alone. If a LoD of 100 ng for Coomassie is assumed, then a maximum quantity of 
1.4 pmol can be estimated for A-Raf WT, and 5 pmol estimated for A-Raf Short. 
While this may seem reasonable, this is per reaction, providing enough solution 
to run a single replicate. As such, when several isoforms and replicates are 
considered, the reagent costs and labour are increased significantly. 
 
4.4.4.2 HEK293 Based Protein Production 
Due to the low expression levels achieved during the TNT reactions, HEK293 
based transfections were performed, the protein immunoprecipitated using anti-
FLAG, separated via SDS-PAGE and visualised through both Coomassie Blue and 
western blotting.  
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Figure 4-23: A 1D-SDS-PAGE based separation of HEK293 transfected A-Raf WT 
and A-Raf Short.  A-Raf WT and Short plasmids were transfected into HEK293 
through the use of Genejuice transfection reagent. The transfected cells were 
lysed after 72 hours and the transfected protein immunoprecipitated through 
the use of anti-FLAG M2 agarose beads. A 1D-SDS-PAGE gel was subsequently 
loaded with 25 µL of IP, 25 µL of the IP supernatant and 25 µL of the TNT IP, 
which acted as an A-Raf positive control. The protein bands were visualised with 
Coomassie Blue protein stain. Circled in red are the two transfected A-Raf 
proteins. 
 
From Figure 4-23 we can see that both A-Raf WT and A-Raf Short were expressed 
at levels suitable for detection through the use of Coomassie Blue, and thus both 
were expressed at a level of at least 50 ng/ 25 µL (approximately 860 fmol/ 25 
µL for A-Raf WT, and 3 pmol/ 25 µL for A-Raf Short). While this is still below the 
level required for an accurate detection on an API 2000, it does offer a massive 
improvement over that achieved with the TNT kit.  
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Figure 4-24: A western blot of HEK293 transfected A-Raf WT and A-Raf Short.  
A-Raf WT and A-Raf Short plasmids were transfected into HEK293 through the 
use of Genejuice transfection reagent. The HEK293 cells were lysed after 72 
hours, and the transfected protein immunoprecipitated with anti-FLAG M2 
agarose beads. A 1D-SDS-PAGE gel was loaded with 25 µL of the IP, 25 µL of the 
IP supernatant and 25 µL of the TNT IP, which acted as an A-Raf positive control. 
The separated protein was transferred to a PVDF membrane, and the transfected 
protein bound to an anti-FLAG HRP conjugate antibody. The complex was 
visualised with BM Chemiluminescence reagent. 
 
Figure 4-24 provides confirmation that the protein bands visualised on the 
Coomassie Blue stained gel were indeed the FLAG tagged transfected protein 
targets, expressed at much higher quantity than those achieved with the TNT 
kit. Also worth noting is the level at which A-Raf Short has been expressed, 
which is so high that photobleaching has occurred. Photobleaching will occur 
when all of the HRP substrate has been consumed from the core of the protein 
band, thus providing no further illumination. Furthermore, the MW of the A-Raf 
Short protein band appears to have shifted. While it was previously detected at 
19 kDa (Figure 4-22), it now has a MW of approximately 15 kDa (Figure 4-24).  
 
As the isoform appeared to have been expressed correctly during the TNT based 
transfection, it can be assumed that the HEK293 based transfection is 
responsible, perhaps as a result of incorrect splicing. If the sequence from intron 
two is being incorrectly spliced, then a MW difference of approximately 4.6 kDa 
would be expected, while if it were intron four which was being spliced, then a 
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MW difference of just 1.6 kDa would be expected. Furthermore, if intron four 
was being spliced out, then the premature stop codon would be missed, 
producing a much longer isoform, further suggesting intron two. 
 
In conclusion, while there appears to have been an issue with the expression of 
A-Raf Short, the levels of protein achieved during the HEK293 based 
transfections were of a suitable level, and far exceed those achieved during the 
TNT based reactions. Furthermore, the volumes of IP produced mean that many 
SDS-PAGE replicates can be run per transfection. 
 
4.4.4.3 A-Raf Short Incorrect Splicing 
4.4.4.3.1 Evidence Supporting Incorrect Splicing 
To further investigate the possible incorrect splicing of A-Raf Short, the A-Raf 
Short transfected HEK293 IP was loaded to, and separated on, an SDS-PAGE gel, 
the appropriate band excised, and in-gel digested with trypsin. The peptide 
solution was injected onto an Ultimate 3000 LC and analysed on an API 2000 MS, 
running the previously devised A-Raf MRM acquisition method. 
 
As peptide TVVTVR crossed the splice site of intron two, it was hoped that 
through assessing the A-Raf Short IP peptideome for the presence of this 
sequence, that its detection would indicate that intron two was being 
incorrectly spliced. Based on the MW difference detected during the A-Raf Short 
transfections (Figures 4-22 and 4-24), which accounts for almost 25% of the 
proteins total MW, this was the only logical variation in sequence. 
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Figure 4-25: An MRM based detection of incorrectly spliced A-Raf Short, 
obtained from a HEK293 based transfection.  The spectrum obtained from an 
MRM based detection of incorrectly spliced A-Raf Short, obtained from a HEK293 
based transfection and analysed on an API 2000 MS, using the previously devised 
A-Raf MRM acquisition method. Shown on the top window is an XIC spectrum 
detailing the time at which peptide TVVTVR was detected. Shown on the bottom 
MRM spectrum meanwhile are the two TVVTVR Q3 fragment ions (B2 and Y4), 
thereby confirming the detection of peptide TVVTVR.  
 
Figure 4-25 indicates that the main protein product produced during the HEK293 
transfection of A-Raf Short was indeed missing the sequence from intron two, as 
is indicated by the presence of intron two crossing peptide TVVTVR. These MRM 
transitions were of a high intensity, discounting the detection of noise and 
spectral artefacts, and as two of the three TVVTVR MRM transitions were 
detected, the presence of peak TVVTVR was confirmed. 
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4.4.4.3.2 Modifying the Splice Site of Intron Two via Site Directed 
Mutagenesis 
As the HEK293 based transfections were found to yield adequate levels of A-Raf 
protein expression, it was decided that the A-Raf Short plasmid should be 
modified in such a way so as to prevent the incorrect splicing of intron two. The 
full details of site directed mutagenesis, via splice overlap extension PCR (SOE), 
have previously been described by Ho et al. (Ho et al., 1989), in brief however, 
a splice site was selected where a single base pair could be modified, 
maintaining the sequence of A-Raf Short, but disrupting the splice sites 
bordering intron two, preventing the intron from being removed. 
 
The A-Raf Short plasmid was sequenced with CMV and T7 forward primers, 
located upstream of the initiation of transcription, and the BGH reverse primer, 
located downstream of the termination of transcription. The sequence data 
obtained for each primer was aligned using Clustal X and screened for the 
presence of the 3’ and 5’ splice sites and the internal branch point. While the 3’ 
and 5’ splice sites were easily identified, with the introns 5’ beginning GT, of 
conserved sequence MAG|GTRAGT (where M represents either an A or a C and R 
representing either an A or a G), and the introns 3’ ending AG, of conserved 
sequence CAG|G (Reed, 1989), the branch point was harder to identify. While 
the branch point is usually marked by a single adenosine residue, located some 
18-40 bases downstream of the 5’ DNA splice site, several adenosine residues 
were identified, any of which may have been acting as the branch point and as 
such a branch point based mutation was rejected. Of the two remaining 
mutation sites, the 5’ splice site was also found to be unsuitable. If either the G 
or T from consensus sequence GT were modified, to prevent splicing, then this 
would ultimately lead to a change in the proteins sequence, replacing the Val 
with one of several other residues. The modification of the 3’ splice site 
appeared more promising however, where changing the G from consensus 
sequence AG retained the Gln residue, while preventing splicing (Crick, 1968). 
 
So as to enable site directed mutagenesis to be performed on the last base of 
intron two, 40 mer complementary oligonucleotides were created, where base G 
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was replaced with an A, while providing ample sequence to either side of the 
mutation point, so as to enable annealing (Figure 4-26). 
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                     T7 promoter                     NhelI 
>CMV For CTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGCC 
>BGH Rev CTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGCC 
        Initiation of transcription 
 
>CMV For GCCACCATGGATTACAAGGATGACGACGATAAGGAGCCACCACGGGGCCCCCCTGCCAAT 
>T7  ----------------AGGATGACGACGATAAGGAGCCACCACGGGGCCCCCCTGCCAAT 
>BGH Rev GCCACCATGGATTACAAGGATGACGACGATAAGGAGCCACCACGGGGCCCCCCTGCCAAT 
>Protein             M  D  Y  K  D  D  D  D M/K E  P  P  R  G  P  P  A  N     
 
>CMV For GGGGCCGAGCCATCCCGGGCAGTGGGCACCGTCAAAGTATACCTGCCCAACAAGCAACGC 
>T7  GGGGCCGAGCCATCCCGGGCAGTGGGCACCGTCAAAGTATACCTGCCCAACAAGCAACGC 
>BGH Rev GGGGCCGAGCCATCCCGGGCAGTGGGCACCGTCAAAGTATACCTGCCCAACAAGCAACGC 
>Protein       G  A  E  P  S  R  A  V  G  T  V  K  V  Y  L  P  N  K  Q  R   
        Border or exon 2/intron 2 
>CMV For ACGGTGGTGAGTCATGGAAGCGAAATGGCAGGGGCTGTGGATGGACCCAGTTGTAACTCT 
>T7  ACGGTGGTGAGTCATGGAAGCGAAATGGCAGGGGCTGTGGATGGACCCAGTTGTAACTCT 
>BGH Rev ACGGTGGTGAGTCATGGAAGCGAAATGGCAGGGGCTGTGGATGGACCCAGTTGTAACTCT 
>Protein       T  V  V  S  H  G  S  E  M  A  G  A  V  D  G  P  S  C  N  S   
 
>CMV For GGGATCAAAAGGGTGACAACGGTTGGGGGAGGCCTTTGCAGAAGGATGGGAACATCAGCT 
>T7  GGGATCAAAAGGGTGACAACGGTTGGGGGAGGCCTTTGCAGAAGGATGGGAACATCAGCT 
>BGH Rev GGGATCAAAAGGGTGACAACGGTTGGGGGAGGCCTTTGCAGAAGGATGGGAACATCAGCT 
>Protein       G  I  K  R  V  T  T  V  G  G  G  L  C  R  R  M  G  T  S  A   
                       Border of intron 2/exon 3 
>ARAFMUTSAF                          CCTACATCTGCACATACACACAAGTGACTGTCCGG 
>CMV For GCGCTTCTGTTGGGCATTGAGGACCCCTACATCTGCACATACACACAGGTGACTGTCCGG 
>T7  GCGCTTCTGTTGGGCATTGAGGACCCCTACATCTGCACATACACACAGGTGACTGTCCGG 
>BGH Rev GCGCTTCTGTTGGGCATTGAGGACCCCTACATCTGCACATACACACAGGTGACTGTCCGG 
>Protein       A  L  L  L  G  I  E  D  P  Y  I  C  T  Y  T  Q  V  T  V  R   
 
>ARAFMUTSAF GATGGC 
>CMV For GATGGCATGAGTGTCTACGACTCTCTAGACAAGGCCCTGAAGGTGCGGGGTCTAAATCAG 
>T7  GATGGCATGAGTGTCTACGACTCTCTAGACAAGGCCCTGAAGGTGCGGGGTCTAAATCAG 
>BGH Rev GATGGCATGAGTGTCTACGACTCTCTAGACAAGGCCCTGAAGGTGCGGGGTCTAAATCAG 
>Protein       D  G  M  S  V  Y  D  S  L  D  K  A  L  K  V  R  G  L  N  Q   
 
>CMV For GACTGCTGTGTGGTCTACCGACTCATCAAGGGACGAAAGACGGTCACTGCCTGGGACACA 
>T7  GACTGCTGTGTGGTCTACCGACTCATCAAGGGACGAAAGACGGTCACTGCCTGGGACACA 
>BGH Rev GACTGCTGTGTGGTCTACCGACTCATCAAGGGACGAAAGACGGTCACTGCCTGGGACACA 
>Protein       D  C  C  V  V  Y  R  L  I  K  G  R  K  T  V  T  A  W  D  T   
 
>CMV For GCCATTGCTCCCCTGGATGGCGAGGAGCTCATTGTCGAGGTCCTTGAAGATGTCCCGCTG 
>T7  GCCATTGCTCCCCTGGATGGCGAGGAGCTCATTGTCGAGGTCCTTGAAGATGTCCCGCTG 
>BGH Rev GCCATTGCTCCCCTGGATGGCGAGGAGCTCATTGTCGAGGTCCTTGAAGATGTCCCGCTG 
>Protein       A  I  A  P  L  D  G  E  E  L  I  V  E  V  L  E  D  V  P  L   
                 Border of exon 4/intron 4  
>CMV For ACCATGCACAATTTTGTGAGTGCAGGGTGGACGGTGGGGGTGGACCATGGTTGGGGGTGT 
>T7  ACCATGCACAATTTTGTGAGTGCAGGGTGGACGGTGGGGGTGGACCATGGTTGGGGGTGT 
>BGH Rev ACCATGCACAATTTTGTGAGTGCAGGGTGGACGGTGGGGGTGGACCATGGTTGGGGGTGT 
>Protein       T  M  H  N  F  V  S  A  G  W  T  V  G  V  D  H  G  W  G  C   
        BamHI 
>CMV For CCTTAGGGATCCACTAGTCCAGTGTGGTGGAATTCTGCAGATATCCAGCACAGTGGCGGC 
>T7  CCTTAGGGATCCACTAGTCCAGTGTGGTGGAATTCTGCAGATATCCAGCACAGTGGCGGC 
>BGH Rev CCTTAGGGATCCACTAGTCCAGTGTGGTGGAATTCTGCAGATATCCAGCAC--------- 
>Protein       P  * 
                                       BGH Reverse promoter 
>CMV For CGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTT 
>T7  CGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTT 
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Figure 4-26: The 40 mer oligonucleotide selected for the site directed 
mutagenesis of A-Raf Short.  A Clustal X based alignment of the A-Raf Short 
coding sequence from the A-Raf Short plasmid, showing the intronic sequence 
unique to A-Raf Short (highlighted in blue) and the sequence common to all A-
Raf isoforms (highlighted in green). This alignment was constructed from the 
sequence obtained when the A-Raf Short plasmid was sequenced with T7 and 
CMV forward promoters and BGH reverse promoter (highlighted in red). Based 
upon this genetic map, a 40 mer site directed mutagenesis primer (highlighted in 
purple) was designed to change a single base pair within the A-Raf Short plasmid 
sequence (highlighted in brown), and in doing so preventing intron two from 
being spliced out. Also shown on the alignment are the restriction digest sites 
(highlighted in yellow) used to cleave the SOE PCR strands, and the consensus 
protein sequence for A-Raf Short. 
 
Having performed site directed mutagenesis on A-Raf Short, through SOE based 
PCR, the mutated double stranded DNA insert was restriction digested with NhelI 
(upstream) and BamHI (downstream), prior to agarose gel based purification. 
The digested insert was ligated into pcDNA3.1(+) with T4 DNA ligase, where the 
vector had been pre-digested with the same two restriction enzymes. The 
ligated plasmid was cloned into library efficiency DH5a cells and plated on agar. 
Subsequently each colony was picked and amplified, prior to a miniprep based 
plasmid purification. The amplified DNA was restriction digested with NhelI and 
BamHI, separated via agarose gel based electrophoresis, and screened for the 
presence of a suitably sized plasmid insert (555 bp). 
 
Where a colony was identified as containing a mutated insert, some 500 ng of 
plasmid was sent for sequencing, so as to ensure that only the intended base was 
modified, the results from which are shown on Figure 4-27. 
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Figure 4-27: The genetic sequence obtained from the A-Raf Short plasmid, 
both before and after site directed mutagenesis.  An alignment performed on 
the sequence obtained from the A-Raf Short plasmid both before and after site 
directed mutagenesis, based upon the use of CMV forward. Highlighted in Yellow 
is the T7 forward sequence, while in red is the upstream Nhel1 restriction digest 
site. Finally, in green is the 40 mer site directed mutagenesis oligonucleotide, 
with the single modified nucleotide highlighted in red. 
 
4.4.4.3.3 Confirming the Retention of Intron Two 
Both the mutated and non-mutated A-Raf Short plasmids were amplified via 
Midiprep and transfected into HEK293 with Genejuice transfection reagent. The 
A-Raf Short proteins were immunoprecipitated, separated via SDS-PAGE, and 
visualised via western blot. 
 
 
Figure 4-28: A western blot showing the MW difference between HEK293 
transfected A-Raf short, before and after the completion of site directed 
mutagenesis.  Shown on this WB are the protein bands obtained from 
transfected A-Raf Short, before and after site directed mutagenesis. The protein 
bands shown here were visualised through the use of an anti-FLAG HRP 
conjugate antibody and BM Chemiluminescence reagent. 
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From Figure 4-28 we can see that the MW of the mutated A-Raf Short protein 
increased, in comparison to that produced by the non-mutated plasmid. As to 
further prove the success of this experiment, a spiked digest was performed on 
A-Raf Short, identifying the expression of peptide GLNQDCCVVYR alone. 
 
4.4.5 Spiked Digest Based Quantitative Analyses 
In interfacing the separative capacity of SDS-PAGE with the analytical 
competence of mass spectrometry, the extraction of large polypeptides and 
proteins has proven problematic. The method of choice for protein recovery has 
instead been to perform a proteolytic digestion within the gel, eluting the 
peptide fragments for a bottom-up based MS analysis (Cohen and Chait, 1997). 
Problems have however been described during peptide extraction, with only 70–
80% of the total proteolytic peptides generally being recovered. Furthermore 
post-recovery sample handling has been known to further reduce the amount of 
peptide by 10% to 15%, assuming minimal handling, and up to 50% with vacuum 
centrifugation based techniques (Speicher et al., 2000). 
 
While sample losses are inevitable, AQUA aims to minimise the effect of these 
losses on the precision of the quantitation through adding the peptide standards 
directly to the dehydrated gel pieces, before the protease has been applied. In 
doing so, the synthetic peptides should be fully absorbed into the gel pieces and 
thus will be subject to the same extraction bias as the target peptides. 
Furthermore, any sample loss encountered during downstream processing should 
affect both peptides equally (Gerber et al., 2003a).  
 
4.4.5.1 Single Isoform Based Spiked Digests 
So as to assess the efficiency with which each of the target peptides were 
digested (through comparing peak area ratios for each target peptide/protease, 
each of which should be present at an equal ratio), to identify any problems 
resulting from the re-suspension and modification of each AQUA peptide (which 
would result in a specific peptide presenting with a different peak area ratio), 
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and to test the AQUA based absolute quantification workflow; 25 µL of each A-
Raf IP (obtained from HEK293 immunoprecipitates) was loaded onto an SDS-PAGE 
gel and electrophoresed. The A-Raf isoform gel bands were excised and in-gel 
digested in the presence of each AQUA peptide. Following peptide extraction the 
samples were loaded onto an Ultimate 3000 LC and analysed on an API 2000 MS, 
running the A-Raf MRM acquisition method previously devised. 
 
If we consider that each transfected plate contains some 1.1x108 HEK293 cells, 
and that six plates were transfected per isoform, then a total of 6.6x108 cells 
were lysed, and the transfected protein immunoprecipitated. If we then 
consider that the anti-FLAG beads were re-suspended in 360 µL of protein 
loading buffer, then the 25 µL of IP loaded to each SDS-PAGE gel well should 
contain the transfected, immunoprecipitated contents of approximately 4.6x107 
HEP293 cells. 
 
4.4.5.1.1 A-Raf WT Single Isoform Spiked Digest 
Figure 4-29 shows the extracted ion chromatogram (XIC) obtained from the 
spiked digestion based analysis of A-Raf WT via LC-MS on an API 2000. From the 
spectrum four main peaks can be seen to elute, the first of which was peptide 
TVVTVR, eluting after approximately 17 minutes with a high signal intensity. The 
second peptide to elute was GLNQDCCVVYR, after approximately 21 minutes, 
presenting with a low signal intensity, almost entirely masked by the elution of 
peptide LLTP*QGPR, which also elutes after 21 minutes. Finally peptide 
VSQP*TAEQAQAFK eluted after 22 minutes, again almost entirely masked by the 
high signal intensity of peptide LLTP*QGPR. 
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Figure 4-29: An XIC obtained from the spiked digestion of A-Raf WT on an API 
2000.  Through digesting 25 µL of immunoprecipitated A-Raf WT with trypsin, in 
the presence of 5 pmol of TV*VTVR, GL*NQDCCVVYR, VSQP*TAEQAQAFK and 
LLTP*QGPR, a spiked digest solution was obtained which was injected onto an 
Ultimate 3000 and analysed on an API 2000 MS. 
 
It is also worth noting the shape of the eluting peaks, each of which suffers from 
tailing. This would indicate that the peptides were being retained based upon 
several modes of retention. To better explain, while RP-LC retains and separates 
molecules based upon their hydrophobic interactions with the stationary phase 
(C18), residual polar interactions between the peptides and the silanol groups on 
the PepMap silica based particles may also have been occurring. 
 
The quantification data for the nine A-Raf WT replicates was manually 
integrated with Analyst 4.2, both the average quantity of peptide detected 
(averaging three MRM transitions per peptide) and a CoV value were calculated 
for each peptide (Table 4-13). 
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Table 4-13: The quantity and variation data obtained from the spiked 
digestion of 25 µL of immunoprecipitated A-Raf WT on an API 2000.  Through 
comparing the peak areas for both the synthetic and endogenous A-Raf peptides, 
three sets of quantities were obtained per peptide, per replicate. These values 
were averaged, so as to obtain a single quantity per peptide per replicate, and a 
CoV determined for this value. Further to the above, an overall average was 
calculated for each value. 
 
TVVTVR – Present in all but A-
Raf Short 
VSQPTAEQAQAFK – Unique to 
A-Raf WT 
GLNQDCCVVYR – Present in all 
isoforms 
Replicate 
Average per 
Replicate (pmol/µL) CoV 
Average per 
Replicate (pmol/µL) CoV 
Average per 
Replicate (pmol/µL) CoV 
1 0.65 2.97% 1.06 34.25% 1.38 15.44% 
2 0.67 1.65% 0.97 30.72% 1.14 18.48% 
3 0.66 7.36% 1.13 55.99% 0.99 16.02% 
4 0.69 2.31% 0.95 24.13% 1.27 16.73% 
5 0.64 7.46% 0.86 20.59% 1.19 16.89% 
6 0.72 3.45% 1.06 31.78% 1.39 29.60% 
7 0.66 0.71% 1.08 15.79% 1.24 18.37% 
8 0.71 0.81% 1.21 17.20% 0.83 14.20% 
9 0.71 11.02% 1.28 8.47% 1.33 12.24% 
Average 0.68 5.62% 1.07 27.39% 1.2 21.69% 
 
While the amount of TVVTVR appears to remain constant throughout the run 
(Table 4-13 & Figure 4-30), with a averaged CoV of just 5.62%, the amount of 
peptides GLNQDCCVVYR and VSQPTAEQAQAFK detected per sample appear more 
variable, with averaged CoVs of 21.69% and 27.39%, respectively. This variation 
may have been due to the estimated amount of A-Raf WT within the 25 µL of 
HEK293 IP being between 600 fmol (based upon the quantification data obtained 
for peptide TVVTVR) and 1.2 pmol (based upon the quantification data obtained 
for peptide GLNQDCCVVYR), below the 5 pmol LoD assigned to peptide 
GLNQDCCVVYR, and just achieving the 1 pmol LoD assigned to peptide 
VSQPTAEQAQAFK. 
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Figure 4-30: The quantities of each A-Raf WT target peptide detected during 
the spiked digestion of A-Raf WT transfected HEK293 IP on an API 2000.  The 
amount of each A-Raf WT target peptide detected during the spiked digestion of 
25 µL of A-Raf WT transfected HEK293 IP is shown. In brief, this single quantity, 
per peptide, was calculated through comparing the peak areas for three MRM 
transitions per peptide, per replicate, and the values averaged. A CoV value was 
determined for this averaged value. This bar chart helps to visualise the 
variation detected between each peptide and replicate.  
 
An analysis of variance (ANOVA) based statistical analysis was performed on this 
data, so as to assess if the means of the quantitations achieved for each peptide 
were equal, assuming a normal distribution. Therefore, during this test, the null 
hypothesis (H0) stated that the means of these groups were equal. This analysis 
was performed based upon an alpha level of 0.05 (95% confidence level), giving a 
critical F-value (the variance between groups/the overall variance) of 3.4, which 
if exceeded, would require the H0 to be rejected. As is shown on Table 4-14, an 
F-value of 37.5 was achieved, therefore the H0 was rejected, indicating the 
mean quantification values achieved for these peptides to be significantly 
different. 
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Table 4-14: An ANOVA based statistical analysis performed on the data 
obtained from the spiked digest of A-Raf WT transfected HEK293 IP.  The 
quantification data obtained during the spiked digestion of 25 µL of A-Raf WT 
transfected HEK293 IP was subjected to ANOVA. During this statistical analysis, 
the data obtained for each targeted A-Raf WT peptide, and each digest replicate 
were tested, so as to assess if the means obtained for each peptide were equal. 
Highlighted in yellow is the F-value, which if above 37.5, would indicate the 
data to be significantly different, in 95% of cases. 
Groups Count Sum Average Variance F-value 
TVVTVR 9 6.110681 0.678965 0.000783 37.45343 
VSQPTAEQAQAFK 9 9.607307 1.067479 0.017092 
 GLNQDCCVVYR 9 10.76608 1.196231 0.0344 
  
In conclusion, the data obtained from the spiked digestion of 25 µL of A-Raf WT 
transfected HEK293 IP was found to be inaccurate, containing significant levels 
of variation between peptides. This may have resulted from two of the three A-
Raf WT peptides being below their LoDs within the IP. 
 
4.4.5.1.2 A-Raf Short Single Isoform Spiked Digest  
Twenty five microlitres of A-Raf Short transfected HEK293 IP was digested with 
trypsin in the presence of each of the A-Raf AQUA peptides. Three transitions 
were compared, per peptide, and the data averaged. A total of nine replicates 
were run, the data from which is shown on Table 4-15. 
 
Table 4-15: The quantity and variation data obtained from the spiked 
digestion of 25 µL of immunoprecipitated A-Raf Short on an API 2000.  
Through comparing the peak areas for both the synthetic and endogenous A-Raf 
peptides, three sets of quantities were obtained per peptide, per replicate. 
These values were averaged, so as to obtain a single quantity per peptide per 
replicate, and a CoV determined for this value. Further to the above, an overall 
average was calculated for each value. 
 
GLNQDCCVVYR – Present in all isoforms 
Replicate Average per Replicate (pmol/µL) CoV 
1 3.47 16.22% 
2 3.84 14.42% 
3 4.03 6.98% 
4 3.09 15.21% 
5 4.54 2.89% 
6 3.40 4.06% 
7 3.42 11.78% 
8 3.36 12.28% 
9 5.25 7.23% 
Average 3.82 19.42% 
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As only one target peptide was present in A-Raf Short (peptide GLNQDCCVVYR), 
a comparison could not be made between peptide quantitation values. From 
Table 4-15, it is clear that the estimated amount of peptide GLNQDCVVYR 
detected in the 25 µL of A-Raf Short transfected HEK293 IP was variable between 
samples, despite the level of A-Raf Short being above the LoD. This would 
suggest that the variation detected for peptide GLNQDCCVVYR during the spiked 
digestion of A-Raf WT transfected HEK293 IP may not merely have been due to 
the low protein expression levels (Figure 4-31), but perhaps was due to the way 
in which alkylated peptide GLNQDCCVVYR was prepared.  
 
 
Figure 4-31: The quantity of peptide TVVTVR, detected during the spiked 
digestion of A-Raf Short transfected HEK293 IP on an API 2000.  The amount 
of peptide TVVTVR detected during the spiked digestion of 25 µL of A-Raf Short 
transfected HEK293 IP is shown. In brief, this single quantity was calculated 
through comparing the peak areas for three MRM transitions per replicate, and 
the values averaged. A CoV value was determined for this averaged value. This 
bar chart helps to visualise the variation detected between each peptide and 
replicate.  
 
4.4.5.1.3 DA-Raf-1 Single Isoform Spiked Digest 
The quantification of DA-Raf-1 required the digestion of this truncated A-Raf 
isoform with either trypsin or Glu-C, separately, presenting an opportunity for 
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the digest efficiencies of these proteases to be compared. The data obtained 
from each of the digests is shown on Table 4-16. 
 
Table 4-16: The quantity and variation data obtained from the spiked 
digestion of 25 µL of immunoprecipitated DA-Raf-1 on an API 2000.  Through 
comparing the peak areas for both the synthetic and endogenous A-Raf peptides, 
three sets of quantities were obtained per peptide, per replicate. These values 
were averaged, so as to obtain a single quantity per peptide per replicate, and a 
CoV determined for this value. Further to the above, an overall average was 
calculated for each value. 
 
LLTPQGPR – Unique to DA-Raf-
1 
TVVTVR – Present in all but A-
Raf Short GLNQDCCVVYR – Present in all isoforms 
Replicate 
Average per 
Replicate (pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
1 41.26 5.27% 31.56 2.51% 34.02 5.17% 
2 39.75 2.26% 27.48 7.20% 28.04 1.38% 
3 44.34 3.24% 28.06 0.09% 29.6 1.81% 
4 42.28 3.76% 33.54 5.37% 38.1 3.24% 
5 39.49 1.44% 33.29 7.98% 36.58 2.19% 
6 43.73 4.08% 39.04 6.03% 42.05 1.95% 
7 40.22 6.29% 36.49 1.72% 25.4 5.80% 
8 45.82 2.96% 31.35 3.34% 36.65 5.34% 
9 41.55 11.84% 36.09 0.29% 33.71 8.30% 
Average 42.05 6.72% 32.99 11.82% 33.79 15.48% 
 
From Table 4-16, and indeed Figure 4-32, it is clear that the amount of DA-Raf-1 
detected per 25 µL of DA-Raf-1 transfected HEK293 IP was higher than that 
estimated for either A-Raf WT or A-Raf Short. Peptide TVVTVR, which was 
previously found to yield the most reproducible data, estimated there to be 
32.99 pmol of DA-Raf-1 per 25 µL of IP. These high expression levels may have 
been due to the smaller MW of this isoform, yielding higher levels of protein 
expression within the 72 hours, or that more copies of this smaller protein can 
be maintained within the cell before becoming toxic. 
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Figure 4-32: The quantities of each DA-Raf-1 target peptide detected during 
the spiked digestion of DA-Raf-1 transfected HEK293 IP on an API 2000.  The 
amount of each DA-Raf-1 target peptide detected during the spiked digestion of 
25 µL of DA-Raf-1 transfected HEK293 IP is shown. In brief, this single quantity, 
per peptide, was calculated through comparing the peak areas for three MRM 
transitions per peptide, per replicate, and the values averaged. A CoV value was 
determined for this averaged value. This bar chart helps to visualise the 
variation detected between each peptide and replicate.  
 
An ANOVA based statistical analysis was performed on this data, so as to assess if 
the means of the quantitations achieved for each peptide were equal, assuming 
a normal distribution. Therefore, during this test, the H0 stated that the means 
of these groups were equal. This analysis was performed based upon an alpha 
level of 0.05, giving a critical F-value of 3.4, which if exceeded, would require 
the H0 to be rejected. As is shown on Table 4-17, an F-value of 14.3 was 
achieved, therefore the H0 was rejected, indicating the mean quantification 
values achieved for these peptides to be significantly different.  
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Table 4-17: An ANOVA based statistical analysis performed on the data 
obtained from the spiked digest of DA-Raf-1 transfected HEK293 IP.  The 
quantification data obtained during the spiked digestion of 25 µL of DA-Raf-1 
transfected HEK293 IP was subjected to ANOVA. During this statistical analysis, 
the data obtained for each targeted DA-Raf-1 peptide, and each digest replicate 
were tested, so as to assess if the means obtained for each peptide were equal. 
Highlighted in yellow is the F-value, which if above 3.4, would indicate the data 
to be significantly different, in 95% of cases. 
Groups Replicates Sum Average Variance F-value 
LLTPQGPR 9 378.4426 42.04918 4.806482 14.27344 
TVVTVR 9 296.8988 32.98876 14.78117 
 GLNQDCCVVYR 9 304.1512 33.79458 27.98013 
  
From viewing the averaged quantitation values presented on Table 4-16, the 
data obtained for peptides TVVTVR and GLNQDCCVVYR appeared more closely 
grouped than those obtained for peptide LLTPQGPR. As the level of peptide 
LLTPQGPR was higher than the level of peptide TVVTVR, then this difference 
may have resulted from the incomplete re-suspension of AQUA peptide in 2% 
MeCN (v/v) (Figure 4-32). 
 
So as to confirm there was no variation detected between the means of peptides 
GLNQDCCVVYR and TVVTVR, assuming a normal distribution, a two-tailed (two-
tailed as either an increase, or a decrease in mean would be considered 
variation) T-test was performed (Table 4-18). During this test, a H0, that the 
means of these groups were equal, was stated. This analysis was performed 
based upon an alpha level of 0.05, giving a critical P-value of 2.3, which if 
exceeded, would require the H0 to be rejected. As is shown on Table 4-18, a P-
value of 0.64 was achieved, therefore the H0 was accepted, indicating the mean 
quantification values achieved for these peptides was equal.  
 
Table 4-18: A T-test based statistical analysis performed on the data obtained 
from the spiked digest of DA-Raf-1 transfected HEK293 IP.  A comparison of 
the quantitation values obtained for peptides TVVTVR and GLNQDCCVVYR, so as 
to determine if the means of each set of data were significantly different. 
Highlighted in yellow is the two-tailed P-value, which if above 2.3, would 
suggest that there was significant variation between the groups in 95% of cases.  
  TVVTVR GLNQDCCVVYR 
Mean 32.98875937 33.79457691 
Variance 14.7811722 27.98012665 
Replicates 9 9 
P-value 0.642086961 
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In conclusion, when 25 µL of DA-Raf-1 transfected HEK293 IP was digested with 
trypsin, no variation was detected between the quantitation values obtained for 
peptides TVVTVR and GLNQDCCVVYR, based upon a two-tailed t-test. However, 
when a Glu-C based spiked digest was performed and the quantification values 
compared for both the trypsin and Glu-C cleaved peptides via ANOVA, significant 
variation was detected.  
 
Large CoV values were also obtained between each replicate, which may have 
resulted from small variations in pipetting volume made during the loading of 
the SDS-PAGE gel or indeed the accuracy of the gel band excision pre-digestion. 
While these small variations would not usually have a noticeable effect on the 
data obtained, the high expression level at which the DA-Raf-1 was detected 
within the transfected HEK293 IP may have exacerbated this problem. Indeed, 
the signal response of the internal standards (IS) on the API 2000 (data not 
shown) appeared constant between injections, further suggesting the cause of 
the variation to originate before the internal standard was added. 
 
4.4.5.1.4 DA-Raf-2 Single Isoform Spiked Digest 
While DA-Raf-2 contains three AQUA peptides, GLNQDCCVVYR, TVVTVR and 
VPTVCVDMSTNRQQ, peptide VPTVCVDMSTNRQQ failed to be detected via ESI-MS, 
instead requiring a MALDI-ToF based analysis. When running this set of spiked 
digest based analyses, no MALDI MS was available for use, resulting in a 
comparison only being made between peptides TVVTVR and GLNQDCCVVYR. 
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Table 4-19: The quantity and variation data obtained from the spiked 
digestion of 25 µL of immunoprecipitated DA-Raf-2 on an API 2000.  Through 
comparing the peak areas for both the synthetic and endogenous A-Raf peptides, 
three sets of quantities were obtained per peptide, per replicate. These values 
were averaged, so as to obtain a single quantity per peptide per replicate, and a 
CoV determined for this value. Further to the above, an overall average was 
calculated for each value. 
 
TVVTVR – Present in all but A-Raf Short GLNQDCCVVYR – Present in all isoforms 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1 11.39 7.46% 7.27 9.57% 
2 10.86 2.23% 8.25 2.71% 
3 11.27 6.21% 6.80 3.85% 
4 11.60 7.57% 13.91 4.56% 
5 11.04 1.29% 6.50 3.42% 
6 11.52 5.73% 13.29 8.49% 
7 12.14 1.04% 12.96 5.56% 
8 11.57 1.57% 12.85 10.54% 
9 11.42 5.36% 6.93 1.65% 
Average 11.42 4.77% 9.86 32.38% 
 
From Table 4-19, and Figure 4-33, peptide TVVTVR again appears to yield the 
most reproducible data, estimating there to be to 11.42 pmol of DA-Raf-2 per 25 
µL of DA-Raf-2 transfected HEK293 IP, with a CoV of 4.77%. When the quantity of 
DA-Raf-2 is assessed through the use of peptide GLNQDCCVVYR, however, 25 µL 
of transfected IP is estimated to contain between 6.5 and 13.91 pmol of DA-Raf-
2, with an average CoV of 32.38%.  
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Figure 4-33: The quantities of each DA-Raf-2 target peptide detected during 
the spiked digestion of DA-Raf-2 transfected HEK293 IP on an API 2000.  The 
amount of each DA-Raf-2 target peptide detected during the spiked digestion of 
25 µL of DA-Raf-2 transfected HEK293 IP is shown. In brief, this single quantity, 
per peptide, was calculated through comparing the peak areas for three MRM 
transitions per peptide, per replicate, and the values averaged. A CoV value was 
determined for this averaged value. This bar chart helps to visualise the 
variation detected between each peptide and replicate.  
 
So as to assess if there was any variation between the means of peptides 
GLNQDCCVVYR and TVVTVR, assuming a normal distribution, a two-tailed T-test 
was performed. During this test, a H0, that the means of these groups were 
equal, was stated. This analysis was performed based upon an alpha level of 
0.05, giving a critical P-value of 2.3, which if exceeded, would require the H0 to 
be rejected. As is shown on Table 4-20, a P-value of 0.16 was achieved, 
therefore the H0 was accepted, indicating the mean quantification values 
achieved for these peptides was equal.  
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Table 4-20: A T-test based statistical analysis performed on the data obtained 
from the spiked digest of DA-Raf-2.  A T-test based statistical analysis assessing 
the quantitation data obtained for peptides TVVTVR and GLNQDCCVVYR. This 
test was performed so as to assess if each data set contained an equal level of 
variation. Highlighted in yellow is the two-tailed P value, where a figure above 
2.3 would suggest there to be significant variation between the two groups in 
95% of cases.  
  TVVTVR GLNQDCCVVYR 
Mean 11.42455233 9.861816048 
Variance 0.132878544 10.65610144 
Observations 9 9 
P-value 0.160234094 
  
During the analysis of the DA-Raf-2 transfected HEK293 IP, the level of DA-Raf-2 
expressed was above the LoD for peptide GLNQDCCVVYR, and thus an accurate 
quantification should be possible. The high CoV values detected during the 
quantification of peptide GLNQDCCVVYR, however, may indicate the alkylation 
of both the target protein (when the amount of GLNQDCCVVYR detected was 
lower than the amount of TVVTVR) and the IS (when the amount of 
GLNQDCCVVYR detected was higher than the amount of TVVTVR) to be 
incomplete.  
 
4.4.5.1.5 Single Isoform Spiked Digest Overview 
Several problems were identified during the spiked digestion of each of the four 
A-Raf isoforms on an API 2000 MS. Firstly, the high quantitation value achieved 
for peptide LLTPQGPR during the spiked digestion of DA-Raf-1 indicated that 
there may be less peptide LLTP*QGPR within the sample than was expected. If 
this was the case, then it may be due to the incomplete re-suspension of this 
AQUA peptide in 2% MeCN (v/v). So as to test this theory, an unopened vial of 
AQUA peptide LLTPQGPR was re-suspended in 20 µL of 10% FA (v/v), diluting 
further to 200 µL in 0.1% FA (v/v) and the spiked digestions re-running.  
Secondly, peptide GLNQDCCVVYR presented with both high CoV and quantitation 
values, significantly different to those detected for other peptides quantified for 
each A-Raf isoform. So as to ensure peptide GLNQDCCVVYR was alkylated 
correctly, peptide GL*NQDCCVVYR was alkylated in-solution, and the peptide 
further reduced with DTT or quenched with excess Cys. The results from which 
are shown on Figure 4-34.   
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Figure 4-34: An investigation performed so as to determine the source of the 
variation detected during the spiked digestion of AQUA peptide 
GL*NQDCCVVYR.  An analysis performed on 5 pmol of AQUA peptide 
GL*NQDCCVVYR, in an unmodified state (where the peptide exists in a partially 
di-sulfide bonded state), when reduced with DTT (breaking the di-sulfide bonds), 
when reduced with DTT and alkylated with IAA, when reduced with DTT, 
alkylated with IAA and reduced again with DTT, and finally when reduced with 
DTT, alkylated with IAA and the IAA quenched with Cys. Circled in red are the 
various states in which AQUA peptide GL*NQDCCVVYR was identified. This data 
was collected on an Ultraflex II MS. 
 
From Figure 4-34 it appears that when peptide GL*NQDCCVVYR was treated with 
DTT and IAA that multiple alkylation peaks were detected. Similar results have 
previously been reported, including the alkylation of the amino-group on Lys 
(Galvani et al., 2001), it is therefore possible that in this situation the amino-
group on either the peptides N-terminus, or the C-terminal Arg residue may have 
been alkylated. These unintended alkylations could, however, be reversed or 
prevented through the addition of excess DTT or Cys, post-alkylation. This 
experiment helps to explain some of the variation detected during the spiked 
digest based analyses, and as a result all future in-gel and in-solution alkylation 
reactions will be quenched with one of the above reagents. 
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4.4.5.2 Optimisation of the Single Isoform Based Spiked Digests 
4.4.5.2.1 A-Raf WT Single Isoform Spiked Digest Optimisation 
As peptides GLNQDCCVVYR and VSQPTAEQAQAFK yielded highly variable CoV 
values during the previous A-Raf WT spiked digestion, perhaps due in part to the 
low level of A-Raf WT detected within the transfected HEK293 IP, a second 
transfected HEK293 IP was prepared, in this case re-suspending the washed anti-
FLAG beads in half the volume of protein loading buffer (180 µL). The 25 µL of IP 
loaded into each SDS-PAGE gel well, therefore, should contain the transfected, 
immunoprecipitated contents of approximately 9.2x107 HEP293 cells. This 
change, it was hoped, would double the amount of the A-Raf WT within the IP, 
from 600 fmol per 25 µL to approximately 1.2 pmol per 25 µL, enabling larger 
MRM peak areas to be obtained for peptides VSQPTAEQAQAFK and 
GLNQDCCVVYR. In addition to this change, a second DTT based reduction step 
was incorporated into the in-gel spiked digest based protocol, so as to ensure 
any undesirable alkylations were reversed, prior to LC-MS. 
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Table 4-21: The quantity and variation data obtained from the optimised 
spiked digestion of 25 µL of immunoprecipitated A-Raf WT on an API 2000.  
Through comparing the peak areas for both the synthetic and endogenous A-Raf 
peptides, three sets of quantities were obtained per peptide, per replicate. 
These values were averaged, so as to obtain a single quantity per peptide per 
replicate, and a CoV determined for this value. Further to the above, an overall 
average was calculated for each value. 
 
TVVTVR – Present in all but A-
Raf Short 
VSQPTAEQAQAFK – Unique to A-
Raf WT 
GLNQDCCVVYR – Present in all 
isoforms 
Replicate 
Average per 
Replicate (pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
1 1.24 16.04% 1.6 8.36% 2.2 13.50% 
2 1.44 17.62% 1.8 3.53% 2.56 9.60% 
3 1.01 13.00% 1.14 1.34% 2.31 5.58% 
Average 1.23 20.61% 1.53 18.90% 2.36 10.88% 
 
From reviewing Table 4-21 and Figure 4-35, it would appear that the amount of 
A-Raf WT detected within the transfected HEK293 IP increased from 600 fmol 
per 25 µL, to 1.23 pmol per 25 µL, as quantified with peptide TVVTVR, over 
three sample replicates, with a CoV of 20.6%. 
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Figure 4-35: The quantities of each A-Raf WT target peptide detected during 
the optimised spiked digestion of A-Raf WT transfected HEK293 IP on an API 
2000.  The amount of each A-Raf WT target peptide detected during the 
optimised spiked digestion of 25 µL of A-Raf WT transfected HEK293 IP is shown. 
In brief, this single quantity, per peptide, was calculated through comparing the 
peak areas for three MRM transitions per peptide, per replicate, and the values 
averaged. A CoV value was determined for this averaged value. This bar chart 
helps to visualise the variation detected between each peptide and replicate.  
 
An ANOVA based statistical analysis was performed on this data, so as to assess if 
the means of the quantitations achieved for each peptide were equal, assuming 
a normal distribution. Therefore, during this test, the H0 stated that the means 
of these groups were equal. This analysis was performed based upon an alpha 
level of 0.05, giving a critical F-value of 5.1, which if exceeded, would require 
the H0 to be rejected. As is shown on Table 4-22, an F-value of 15.9 was 
achieved, therefore the H0 was rejected, indicating the mean quantification 
values achieved for these peptides to be significantly different.  
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Table 4-22: An ANOVA based statistical analysis performed on the data 
obtained from the optimised spiked digest of A-Raf WT transfected HEK293 
IP.  The quantification data obtained during the optimised spiked digestion of 25 
µL of A-Raf WT transfected HEK293 IP was subjected to ANOVA. During this 
statistical analysis, the data obtained for each targeted A-Raf WT peptide, and 
each digest replicate were tested, so as to assess if the means obtained for each 
peptide were equal. Highlighted in yellow is the F-value, which if above 5.1, 
would indicate the data to be significantly different, in 95% of cases. 
Groups Count Sum Average Variance F-value 
 TVVTVR 3 3.69 1.23 0.0463 15.86367 
 VSQPTAEQAQAFK 3 4.54 1.513333 0.114533 
  GLNQDCCVVYR 3 7.07 2.356667 0.034033 
   
While significant variation was detected between the means of the three A-Raf 
WT peptides, quantified through the spiked digestion of 25 µL of A-Raf WT 
transfected HEK293 IP, the data obtained for peptides VSQPTAEQAQAFK and 
TVVTVR appeared more closely grouped (Table 4-21). So as to assess if there was 
any variation between the means of peptides TVVTVR and VSQPTAEQAQAFK, 
assuming a normal distribution, a two-tailed T-test was performed. During this 
test, a H0, that the means of these groups were equal, was stated. This analysis 
was performed based upon an alpha level of 0.05, giving a critical P-value of 
2.8, which if exceeded, would require the H0 to be rejected. As is shown on 
Table 4-23, a P-value of 0.28 was achieved, therefore the H0 was accepted, 
indicating the mean quantification values achieved for these peptides was equal.  
 
Table 4-23: A T-test based statistical analysis performed on the data obtained 
from the optimised spiked digestion of A-Raf WT.  A T-test based statistical 
analysis performed on the quantitation data obtained for peptides TVVTVR and 
VSQPTAEQAQAFK. This test was performed so as to assess if the data obtained 
for each of the peptide contained an equal level of variation. Highlighted in 
yellow is the two-tailed P-value, where a value above 2.8 would indicate that 
there was significant variation between the groups in 95% of cases.  
  TVVTVR VSQPTAEQAQAFK 
Mean 1.227833452 1.514465864 
Variance 0.045132721 0.113404655 
Replicates 3 3 
P-value 0.280471873 
  
As the CoV values obtained for peptide GLNQDCCVVYR remained low over the 
three replicates, and with three transitions per replicate, this would suggest 
that the in-gel digestion, recovery and LC-MS/MS methods were reproducible. 
Variation was detected between the quantitation values obtained for peptide 
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GLNQDCCVVYR and those obtained for peptides TVVTVR and VSQPTAEQAQAFK, 
however, which would indicate a problem with the quantification of this peptide 
(Figure 4-35). As the in-gel digest and in-solution AQUA preparation protocols 
were previously modified to ensure excess alkylation was not an issue (which 
eliminated quantification ratios which presented at a rate lower than expected), 
the only logical conclusion was that the in-solution processing of the AQUA 
peptide, prior to spiking the gel pieces, was responsible for the sample loss. 
 
Sample loss occurring during downstream processing has previously been 
documented, with vacuum centrifugation based protocols, such as this, causing 
losses of up to 50% (Speicher et al., 2000). The only solution would therefore be 
to order each of the Cys containing AQUA peptides pre-alkylated, requiring no 
further down-stream processing. While unmodified peptides were intentionally 
selected during this study to correct for any inefficiency encountered during the 
alkylation of Cys, this reaction has since been shown to be complete.  
 
4.4.5.2.2 DA-Raf-1 Single Isoform Spiked Digest Optimisation 
When a spiked digestion was first performed on the DA-Raf-1 transfected HEK293 
IP, 32.99 pmol of DA-Raf-1 was detected, per 25 µL of sample, with a CoV value 
of 11.82% (based upon the use of peptide TVVTVR). In comparison, when peptide 
LLTPQGPR was quantified, the amount of DA-Raf-1 within 25 µL of DA-Raf-1 
transfected HEK293 IP was calculated to be 42.05 pmol, with a CoV of 6.72%. 
Therefore, the incomplete re-suspension of AQUA peptide LLTPQGPR was 
suspected. So as to test this theory, an unopened vial of peptide LLTPQGPR was 
re-suspended in 20 µL of 10% FA (v/v), further diluting to 200 µL in 0.1% FA 
(v/v). The spiked digest was then re-run, loading 5 µL of the DA-Raf-1 
transfected HEK293 IP to each SDS-PAGE gel lane, equal to the transfected, 
immunoprecipitated contents of approximately 9x106 HEP293 cells. 
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Table 4-24: The quantity and variation data obtained from the spiked 
digestion of 5 µL of immunoprecipitated DA-Raf-1 on an API 2000.  Through 
comparing the peak areas for both the synthetic and endogenous A-Raf peptides, 
three sets of quantities were obtained per peptide, per replicate. These values 
were averaged, so as to obtain a single quantity per peptide per replicate, and a 
CoV determined for this value. Further to the above, an overall average was 
calculated for each value. 
 
LLTPQGPR – Unique to DA-Raf-1 
TVVTVR – Present in all but A-
Raf Short 
GLNQDCCVVYR – Present in all 
isoforms 
Replicate 
Average per Replicate 
(pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
1 7.54 9.65% 7.37 3.29% 5.46 35.67% 
2 7.81 16.41% 7.64 13.48% 4.69 9.64% 
Average 7.68 12.30% 7.51 9.12% 5.08 26.29% 
 
 
Figure 4-36: The quantities of each DA-Raf-1 target peptide detected during 
the optimised spiked digestion of DA-Raf-1 transfected HEK293 IP on an API 
2000.  The amount of each DA-Raf-1 target peptide detected during the 
optimised spiked digestion of 5 µL of DA-Raf-1 transfected HEK293 IP is shown. In 
brief, this single quantity, per peptide, was calculated through comparing the 
peak areas for three MRM transitions per peptide, per replicate, and the values 
averaged. A CoV value was determined for this averaged value. This bar chart 
helps to visualise the variation detected between each peptide and replicate.  
 
Through assessing Table 4-24 and Figure 4-36, the precision of the 
quantifications achieved through the use of peptide LLTPQGPR were seen to 
improve, at least in comparison to those achieved through the use of peptide 
TVVTVR. An ANOVA based statistical analysis was performed on this data, so as 
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to assess if the means of the quantitations achieved for each peptide were 
equal, assuming a normal distribution. Therefore, during this test, the H0 stated 
that the means of these groups were equal. This analysis was performed based 
upon an alpha level of 0.05, giving a critical F-value of 9.6, which if exceeded, 
would require the H0 to be rejected. As is shown on Table 4-25, an F-value of 
34.4 was achieved, therefore the H0 was rejected, indicating the mean 
quantification values achieved for these peptides to be significantly different.  
 
Table 4-25: An ANOVA based statistical analysis performed on the data 
obtained during the optimised spiked digest of DA-Raf-1 transfected HEK293 
IP.  The quantification data obtained during the optimised spiked digestion of 5 
µL of DA-Raf-1 transfected HEK293 IP was subjected to ANOVA. During this 
statistical analysis, the data obtained for each targeted A-Raf WT peptide, and 
each digest replicate were tested, so as to assess if the means obtained for each 
peptide were equal. Highlighted in yellow is the F-value, which if above 9.6, 
would indicate the data to be significantly different, in 95% of cases. 
Groups Count Sum Average Variance F-value 
LLTPQGPR 2 15.35 7.675 0.03645 34.36794 
TVVTVR 2 15.01 7.505 0.03645 
 GLNQDCCVVYR 2 10.15 5.075 0.29645   
 
While significant variation was detected between the quantification values 
obtained for each of the three DA-Raf-1 peptides, during the spiked digestion of 
the DA-Raf-1 transfected HEK293 IP, the averaged quantitation values obtained 
for peptides TVVTVR and LLTPQGPR appeared more closely grouped (Table 4-
24). So as to assess if there was any variation between the means of peptides 
TVVTVR and LLTPQGPR, assuming a normal distribution, a two-tailed T-test was 
performed. During this test, a H0, that the means of these groups were equal, 
was stated. This analysis was performed based upon an alpha level of 0.05, 
giving a critical P-value of 4.3, which if exceeded, would require the H0 to be 
rejected. As is shown on Table 4-26, a P-value of 0.5 was achieved, therefore 
the H0 was accepted, indicating the mean quantification values achieved for 
these peptides to be equal. This is particularly impressive as each of the 
peptides originated from a different SDS-PAGE gel, and indeed were both 
peptides were digested with different proteases. 
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Table 4-26: A T-test based statistical analysis performed on the data obtained 
from the optimised spiked digestion of DA-Raf-1.  A T-test based statistical 
analysis performed on the quantitation data obtained from peptides TVVTVR and 
LLTPQGPR. This statistical test was performed so as to determine if the variation 
between the data sets was equal. Highlighted in yellow is the two-tailed P value, 
where a figure above 4.3 would indicate there to be significant variation 
between the groups in 95% of cases.  
  LLTPQGPR TVVTVR 
Mean 7.67510408 7.505279247 
Variance 0.037150395 0.035091527 
Observations 2 2 
P-value 0.465849755 
  
As peptides TVVTVR and LLTPQGPR were found to have equal means, while 
significant variation was identified between the means of the three DA-Raf-1 
peptides, this would indicate peptide GLNQDCCVVYR to be the cause of the 
variation. As this experiment was conducted before the in-gel digest protocol 
was modified, then this variation most likely resulted from peptide 
GLNQDCCVVYR receiving excess alkylation. 
 
4.4.5.2.3 DA-Raf-2 QTrap 4000 and Ultraflex II Based Analysis 
When a spiked digestion was last performed on the DA-Raf-2 transfected HEK293 
IP, no MALDI-ToF MS was available for the quantification of Lys-C cleaved 
peptide VPTVCVDMSTNRQQ. When running this spiked digestion however, an 
Ultraflex II was available, enabling all three DA-Raf-2 peptides to be quantified. 
Furthermore, as 11.42 pmol of DA-Raf-2 was detected per 25 µL of IP (based 
upon the data obtained for peptide TVVTVR), the SDS-PAGE gel loading volume 
was reduced by 50% (to 12.5 µL), equal to the transfected, immunoprecipitated 
contents of approximately 2.3x107 HEP293 cells. 
 
Regarding the MALDI based data analysis; the peak heights for isotopic peaks M, 
M+1, M+2 and M+3 were assessed, the data averaged, and a CoV value calculated.  
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Table 4-27: The quantity and variation data obtained from the spiked 
digestion of 12.5 µL of immunoprecipitated DA-Raf-2 on a QTrap 4000.  
Through comparing the peak areas for both the synthetic and endogenous A-Raf 
peptides, three sets of quantities were obtained per peptide, per replicate. 
These values were averaged, so as to obtain a single quantity per peptide per 
replicate, and a CoV determined for this value. Further to the above, an overall 
average was calculated for each value. 
 
TVVTVR – Present in all but A-
Raf Short 
GLNQDCCVVYR – Present in all A-
Raf isoforms 
VPTVCVDMSTNRQQ – Unique to 
DA-Raf-2 
Replicate 
Average per Replicate 
(pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
Average per Replicate 
(pmol/µL) CoV 
1 6.67 2.07% 9.66 9.40% 10.75 14.47% 
2 6.97 3.26% 9.7 9.69% 16.69 6.88% 
3 6.14 4.49% 9.16 8.90% 14.91 5.06% 
4 6.18 3.11% 8.67 9.99% 17.39 7.48% 
5 5.78 4.61% 8.12 10.35% 18.57 7.98% 
Average 6.41 7.03% 9.17 10.69% 15.66 8.37% 
 
Table 4-27 and Figure 4-37 show the quantitation data obtained from the spiked 
digestion of 12.5 µL of DA-Raf-2 IP. Of the results obtained, peptide TVVTVR 
estimated there to be 6.41 pmol of DA-Raf-2 per 12.5 µL of DA-Raf-2 transfected 
HEK293 IP, with an averaged CoV of just 7.03%. 
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Figure 4-37: The quantities of each DA-Raf-2 target peptide detected during 
the spiked digestion of DA-Raf-2 transfected HEK293 IP on a QTrap 4000, and 
an Ultraflex II.  The amount of each DA-Raf-2 target peptide detected during 
the spiked digestion of 12.5 µL of DA-Raf-2 transfected HEK293 IP is shown. In 
brief, this single quantity, per peptide, was calculated through comparing the 
peak areas for three MRM transitions per peptide, per replicate, and the values 
averaged. A CoV value was determined for this averaged value. This bar chart 
helps to visualise the variation detected between each peptide and replicate.  
 
An ANOVA based statistical analysis was performed on this data, so as to assess if 
the means of the quantitations achieved for each peptide were equal, assuming 
a normal distribution. Therefore, during this test, the H0 stated that the means 
of these groups were equal. This analysis was performed based upon an alpha 
level of 0.05, giving a critical F-value of 3.9, which if exceeded, would require 
the H0 to be rejected. As is shown on Table 4-28, an F-value of 34.5 was 
achieved, therefore the H0 was rejected, indicating the mean quantification 
values achieved for these peptides to be significantly different.  
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Table 4-28: An ANOVA based statistical analysis performed on the data 
obtained during the optimised spiked digest of DA-Raf-2 transfected HEK293 
IP.  The quantification data obtained during the optimised spiked digestion of 5 
µL of DA-Raf-2 transfected HEK293 IP was subjected to ANOVA. During this 
statistical analysis, the data obtained for each targeted A-Raf WT peptide, and 
each digest replicate were tested, so as to assess if the means obtained for each 
peptide were equal. Highlighted in yellow is the F-value, which if above 3.9, 
would indicate the data to be significantly different, in 95% of cases. 
Groups Count Sum Average Variance F-value 
TVVTVR 5 31.74 6.348 0.22117 34.5119 
GLNQDCCVVYR 5 45.31 9.062 0.45382 
 VPTVCVDMSTNRQQ 5 78.31 15.662 9.29812   
 
In comparison to the amount of DA-Raf-2 detected in 12.5 µL of DA-Raf-2 
transfected HEK293 IP through the quantitation of peptide TVVTVR, peptide 
GLNQDCCVVYR estimated there to be 9.17 pmol of DA-Raf-2 per 12.5 µL of 
sample, a value approximately 25% higher. This phenomenon was previously 
been explained to result from the loss of IS during the alkylation of peptide 
GLNQDCCVVYR. In comparison to both peptides TVVTVR and GLNQDCCVVYR, 
however, peptide VPTVCVDMSTNRQQ predicted the amount of DA-Raf-2 per 12.5 
µL of sample to be even higher (15.66 pmol/ 12.5 µL with a CoV of only 8.37%). 
Therefore, there most likely was also a problem with the preparation of AQUA 
peptide VPTVCVDMSTNRQQ, rather than the incomplete digestion of DA-Raf-2 
with Lys-C. As peptide VPTVCVDMSTNRQQ was already re-suspended in 10% FA 
(v/v), and diluted to 200 µL in 0.1% FA (v/v), then there was no reason to 
suspect incomplete re-suspension. Instead, as with peptide GLNQDCCVVYR, 
AQUA peptide VPTVCVDMSTNRQQ may suffer from sample loss as a result of 
down-stream processing. Some redundancy does, however, exist in the 
quantification of the four A-Raf peptides, enabling the amount of DA-Raf-2 to be 
determined when each of the four A-Raf isoforms are quantified. 
 
4.4.5.3 Multiple Isoform Spiked Digest Based Analysis 
Having performed single isoform based spiked digestions to quantify the amount 
of A-Raf expressed in a range of transfected HEK293 cell IP, and having obtained 
statistically comparable quantification values for peptides TVVTVR, 
VSQPTAEQAQAFK and LLTPQGPR, it should be possible to combine known 
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amounts of each A-Raf isoform, and to re-quantify each, based upon the amount 
of each target peptide detected. 
 
Approximately 1 pmol of each A-Raf isoform (each based upon a quantification 
performed with peptide TVVTVR, with the exception of A-Raf Short, which was 
instead quantified with peptide GLNQDCCVVYR) was separated via SDS-PAGE, the 
target gel bands excised, reduced and alkylated before being transferred to a 
single vial and digested in the presence of 5 pmol of each AQUA peptide. The 
peptides were extracted and vacuum centrifuged, injecting onto an Ultimate 
3000 HPLC and analysing on a QTrap 5500 MS, running the MRM acquisition 
method previously devised.   
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Figure 4-38: The complex XIC obtained during the trypsin based spiked 
digestion of each of the four A-Raf isoforms, analysed on a QTrap 5500.  
Through digesting immunoprecipitated A-Raf WT, A-Raf Short, DA-Raf-1 and DA-
Raf-2 with trypsin, in the presence of 5 pmol of AQUA peptides TV*VTVR, 
GL*NQDCCVVYR, VSQP*TAEQAQAFK and LLTP*QGPR, a spiked digest solution was 
obtained which was injected onto an Ultimate 3000 HPLC and analysed on an 
QTrap 5500 MS. 
 
From Figure 4-38 it is clear that the XIC obtained from the trypsin based 
digestion of the four A-Raf isoforms is a lot more complex than that obtained for 
A-Raf WT on the API 2000 (Figure 4-29). This will, in part, be due to the 
increased number of isoforms being analysed, but also due to the increase in 
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sensitivity offered by the QTrap 5500 over the API 2000, detecting more ions 
with m/z ratios similar to those targeted by the MRM acquisition method within 
the sample. It is thus important that when each peptide is quantified, that the 
correct peak is selected (selecting a peak which is present in each MRM 
transition, three transitions per peptide, and is present in both the synthetic and 
target XICs). The data obtained from the mixed isoform based analyses are listed 
on Table 4-29 and presented on Figure 4-39. 
 
Table 4-29: The quantity and variation data obtained from the spiked 
digestion of 1 pmol of each of the four immunoprecipitated A-Raf isoforms on 
a QTrap 5500.  Through comparing the peak areas for both the synthetic and 
endogenous A-Raf peptides, three sets of quantities were obtained per peptide, 
per replicate. These values were averaged, so as to obtain a single quantity per 
peptide per replicate, and a CoV determined for this value. Further to the 
above, an overall average was calculated for each value. 
 
TVVTVR – Present in all but A-Raf Short GLNQDCCVVYR – Present in all A-Raf isoforms 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1 2.00 5.73% 2.42 7.71% 
2 1.93 1.77% 2.19 7.93% 
3 2.07 4.27% 2.52 2.97% 
Average 2.00 4.81% 2.37 8.26% 
 
LLTPQGPR – Unique to DA-Raf-1 VSQPTAEQAQAFK – Unique to A-Raf WT 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1 0.75 2.71% 0.33 18.21% 
2 0.69 4.48% 0.33 14.15% 
3 0.72 3.42% 0.44 2.03% 
Average 0.72 4.69% 0.37 18.40% 
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Figure 4-39: The quantities of each A-Raf target peptide detected during the 
spiked digestion of 1 pmol of each of the four A-Raf isoforms on a QTrap 
5500.  The amount of each A-Raf target peptide detected during the spiked 
digestion of 1 pmol of each of the four A-Raf isoforms. In brief, this single 
quantity, per peptide, was calculated through comparing the peak areas for 
three MRM transitions per synthetic or endogenous A-Raf peptide, per replicate, 
and the values averaged. A CoV value was determined for this value. This bar 
chart helps to visualise the variation detected between each peptide and 
replicate.  
 
In theory, as 1 pmol of each of the four A-Raf isoforms is digested, 4 pmol of 
peptide GLNQDCCVVYR would be expected (present in each of the four 
isoforms), 3 pmol of peptide TVVTVR would be expected (present in A-Raf WT, 
DA-Raf-1 and DA-Raf-2), 1 pmol of peptide LLTPQGPR would be expected 
(present only in DA-Raf-1) and 1 pmol of peptide VSQPTAEQAQAFK would be 
expected (present only in A-Raf WT). Instead, however, 2.37 pmol of peptide 
GLNQDCCVVYR was detected, with a CoV of 8.26%, 2 pmol of peptide TVVTVR 
was detected, with a CoV of 4.81%, 0.72 pmol of peptide LLTPQGPR was 
detected, with a CoV of 4.69%, and 0.37 pmol of peptide VSQPTAEQAQAFK was 
detected, with a CoV of 18.40% (Table 4-29). This peptide quantitation data was 
subsequently used to calculate the amount of each A-Raf isoform present within 
the sample. In brief, A-Raf Short was quantified through subtracting the amount 
of peptide TVVTVR detected, from the amount of peptide GLNQDCCVVYR 
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detected. Furthermore, DA-Raf-2 was quantified through subtracting the amount 
of peptide LLTPQGRP and VSQPTAEQAQAFK detected, from the amount of 
peptide TVVTVR detected (Table 4-30). 
 
Table 4-30: The amount of each A-Raf isoform detected during a mixed 
isoform based spiked digestion.  A set of spiked digests were performed, in 
which 1 pmol of each of the four A-Raf isoforms were digested. Through 
comparing the peak areas obtained for each peptide, a quantitation was 
attempted for each A-Raf isoform. 
Peptide Present in: Average quantity (pmol) 
GLNQDCCVVYR A-Raf WT, A-Raf Short, DA-Raf-1, DA-Raf-2 2.37 
TVVTVR A-Raf WT, DA-Raf-1, DA-Raf-2 2.00 
LLTPQGPR DA-Raf-1 0.72 
VSQPTAEQAQAFK A-Raf WT 0.37 
Isoform Calculating the quantity of each isoform: Quantity (pmol) 
A-Raf WT VSQPTAEQAQAFK 0.37 
A-Raf Short GLNQDCCVVYR - TVVTVR 0.38 
DA-Raf-1 LLTPQGPR 0.72 
DA-Raf-2 TVVTVR - VSQPTAEQAQAFK - LLTPQGPR 0.91 
 
The data presented in Table 4-30 suggests that each of the four A-Raf isoforms 
were present at a level below 1 pmol. There may be several reasons why the 
peptide and protein levels detected during this experiment differed from those 
expected. Firstly, the amount of A-Raf Short detected within the A-Raf Short 
transfected HEK293 IP was quantified through the use of peptide GLNQDCCVVYR, 
meaning the amount of A-Raf Short, and thus the amount of peptide 
GLNQDCCVVYR, added to the gel, may have been incorrect. Secondly, as A-Raf 
Short was again quantified during this experiment with peptide GLNQDCCVVYR, 
the quantity detected may also have been incorrect. 
 
In conclusion, the mixed isoform based spiked digestion may have been more 
successful if an accurate quantitation could have been achieved for peptides 
GLNQDCCVVYR and VPTVCVDMSTNRQQ. 
 
4.4.5.4 Non-Immunoprecipitated Exogenous HEK293 Spiked Digest 
While further optimisation may have improved the results obtained from the 
mixed isoform based spiked digestions, and indeed the single isoform based 
spiked digestions; a few final experiments were performed, so as to assess if it 
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was possible to detect the exogenous level of A-Raf WT within a transfected cell 
lysate, without the use of immunoprecipitation based sample enrichment. As the 
spiked digestions featured 1D-SDS-PAGE, LC based separation and MRM based 
acquisition, then in theory the majority of the non-target protein and peptide 
species within the cell lysate should be isolated from the point at which the 
target peptides elute. Should any non-target peptides co-elute with the target, 
it is likely they would have different Q1 and Q3 m/z ratios, and therefore should 
not be detected.  
 
A 150 mm dish of HEK293 cells was transfected with A-Raf WT, and lysed after 
72 hours. The cell lysate was centrifuged to remove any un-lysed cells and 
cellular debris and diluted to 1 mL with Protein Loading Buffer. Twenty five 
microlitres of cell lysate was loaded to an SDS-PAGE gel, separated, and digested 
with trypsin in the presence of each of the A-Raf AQUA peptides. The resulting 
solution was injected onto an Ultimate 3000 HPLC and detected via a QTrap 
5500 MS, using the MRM acquisition method previously devised. 
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Figure 4-40: The XIC obtained when 25 µL of transfected, un-enriched, A-Raf 
WT lysate was subjected to a spiked digest based analysis, detecting on a 
QTrap 5500, utilising either low or unit Q1 resolution MRM transition 
windows.  Twenty five µL of non-enriched, HEK 293 transfected A-Raf WT was 
analysed on a QTrap 5500 MS using the A-Raf MRM based MS acquisition method. 
The XIC spectra shown were performed with a Q1 resolution set to either low 
(top) or unit (bottom), utilising mass transmission windows of 1-1.4 atomic mass 
units (amu) and 0.6-0.8 amu, respectively, so as to reduce the number of non-
targeted peaks detected. 
 
From Figure 4-40, we can see that the XIC spectra obtained with a low resolution 
Q1 transition window (permitting ions within 1.2 ± 0.2 amu of the target m/z) 
was a lot more complex than the XICs obtained for either the QTrap 5500 based 
mixed isoform digests (Figure 4-38) or the API 2000 based A-Raf WT single 
isoform digests (Figure 4-29). In addition to the many non-target peaks 
detected, the spectra background was also found to contain excessive noise. 
This was most likely due to the absence of the IP enrichment step, adding the 
cell lysate directly to the SDS-PAGE gel, which resulted in more proteins being 
digested and thus more ions entering the mass spectrometer with similar Q1 and 
Q3 m/z ratios to those of the target peptides. 
 
While the use of low Q1 and Q3 transition windows were required for the 
detection of each of the A-Raf AQUA peptides on the low sensitivity API 2000 MS, 
ensuring that all target ions were permitted to the detector, a more restrictive 
transmission window could be selected for the high sensitivity QTrap 5500, so as 
to reduce excessive noise. 
 
The Q1 transmission window was thus changed from low resolution, permitting 
ions within 1.2 ± 0.2 amu of the target m/z, to unit resolution, permitting only 
ions within 0.7 ± 0.1 amu of the target m/z to the collision cell, while the Q3 
transmission window was retained with a low resolution transition window. At 
the expense of slightly reducing the sensitivity of the QTrap 5500, this change in 
the Q1 transmission window should filter out the majority of the noise being 
permitted to the collision cell, and in doing so reducing the noise entering Q3. 
Indeed Figure 4-40 appears to confirm that using unit resolution in Q3 has 
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removed a number of non-target peaks from the XIC, further reducing the 
background noise against which the target peaks are quantified. 
 
An additional route through which the background noise could be reduced would 
be to apply stable isotope standards with capture by anti-peptide antibodies 
(SISCAPA), post-proteolytic digestion. While the IP enriched A-Raf WT solution 
was separated via 1D-SDS-PAGE and only a segment of the gel excised (relating 
to the MW of the protein of interest), this gel band may still contain hundreds of 
proteins, in addition to the high amount of protease added to the gel. Therefore 
post-digestion many thousands of peptides may yet exist within the extracted 
sample, competing with the target peptides for ionisation, and possibly 
introducing interfering peaks to the MRM spectrum. So as to reduce the 
complexity of the extracted sample, SISCAPA utilises a 100 nanolitre (nL) 
nanoaffinity column, which contains immobilised antibodies specific to the 
target peptides, enabling any unbound peptides to be washed off the column 
and only those peptides of interest eluted (Anderson et al., 2004a). 
 
Table 4-31: The quantity and variation data obtained for each A-Raf WT target 
peptide, detected during the spiked digestion of an A-Raf WT transfected, 
un-enriched, HEK293 cell lysate.  Through comparing the peak areas for both 
the synthetic and endogenous A-Raf peptides, three sets of quantities were 
obtained per peptide, per replicate. These values were averaged, so as to obtain 
a single quantity per peptide per replicate, and a CoV determined for this value. 
Further to the above, an overall average was calculated for each value. 
 
TVVTVR – Present in all but A-
Raf Short 
VSQPTAEQAQAFK – Unique to A-
Raf WT 
GLNQDCCVVYR – Present in all 
A-Raf isoforms 
Replicate 
Average per 
Replicate (pmol/µL) CoV 
Average per 
Replicate (pmol/µL) CoV 
Average per 
Replicate (pmol/µL) CoV 
1 0.07 71.88% 6.12 149.01% 0.1 99.18% 
2 0.03 136.02% 0.91 67.71% 0.1 106.65% 
3 0.02 119.22% 6.02 134.43% 0.1 97.16% 
4 0.1 83.35% 5.28 94.63% 0.09 88.95% 
5 0.07 112.22% 8.44 145.54% 0.09 87.03% 
Average 0.06 98.27% 5.35 135.84% 0.1 81.70% 
 
From Table 4-31 it is clear that while high levels of peptide VSQPTAEQAQAFK 
were detected, 5.35 pmol of A-Raf WT per 25 µL of transfected HEK293 cell 
lysate, large CoV values were also achieved (135.84%). Large CoV values were 
also achieved for both peptides TVVTVR and GLNQDCCVVYR, achieving some 
98.27% and 81.70%, respectively. The quantitation values obtained for peptides 
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TVVTVR and GLNQDCCVVYR, however, were considerably lower, detecting just 
60 fmol of A-Raf WT per 25 µL of cell lysate, and 100 fmol of A-Raf WT per 25 µL 
of cell lysate, respectively. When the MRM transitions were reviewed, the cause 
of the erratic quantitation values was determined (Figure 4-41). While AQUA 
peptides TVVTVR and GLNQDCCVVYR were detected at a high intensity, AQUA 
peptide VSQPTAEQAQAFK was missing. As such, while 5 pmol of AQUA peptides 
TV*VTVR and GL*NQDCCVVYR was being compared to background noise, resulting 
in low quantitation values, background noise was being compared to background 
noise for VSQPTAEQAQAFK, resulting in a much higher quantitation value. 
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Figure 4-41: The MRM spectra obtained from both the synthetic and 
endogenous peaks detected during the analysis of 25 µL of A-Raf WT 
transfected, non-enriched HEK293 cell lysate.  The MRM peaks obtained for 
target and synthetic peptides VSQPTAEQAQAFK, GLNQDCCVVYR and TVVTVR 
following the injection of 25 µL of A-Raf WT transfected, un-enriched, HEK293 
cell lysate, on a QTrap 5500.  
  
In conclusion, no A-Raf WT was detected during the quantification of the A-Raf 
WT transfected HEK293 cell lysate, suggesting the level of A-Raf WT within the 
non-immunoprecipitated solution to be below the LoD for this isoform on a 
QTrap 5500. 
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If we consider that the previous A-Raf WT transfected HEK293 IP contained 1.2 
pmol of A-Raf WT per 25 µL of sample, and that approximately 360 µL of IP was 
produced from a total of six cell culture plates, then the total amount of 
transfected A-Raf WT protein, per plate, was 2.88 pmol. If the same quantity is 
assumed for this non-enriched sample, diluted to 1 mL in protein loading buffer, 
then the 25 µL added to the SDS-PAGE gel should contain approximately 72 fmol 
of the A-Raf WT. While this is below the LoD for peptide GLNQDCCVVYR on the 
QTrap 5500, a quantification should be possible on a QTrap 4000 MS. 
 
4.4.5.5 Endogenously Expressed A-Raf WT Spiked Digest 
Further to the detection of exogenously expressed A-Raf WT from a non-
immunoprecipitated cell lysate, the detection of endogenously expressed A-Raf 
WT was attempted from a HEK293 cell lysate. 
 
A 150 mm plate of HEK293 cells was incubated for 96 hours, lysed, diluted to 1 
mL in Protein Loading Buffer, and 25 µL loaded to an SDS-PAGE gel. A gel band, 
centred on a MW of 58 kDa, was excised from the gel and digested with trypsin, 
in the presence of each of the four A-Raf AQUA peptides. The tryptic peptides 
were extracted and vacuum centrifuged, re-suspended in 20 µL of Buffer A and 
injected onto an Ultimate 3000 HPLC, coupled to a QTrap 5500 MS. 
 
As was the case with the non-immunoprecipitated exogenously expressed cell 
lysate, no A-Raf WT was detected during this analysis (data not shown). 
 
4.5 Conclusion 
During this project it has been possible to develop a set of AQUA peptide 
selection criteria, and to apply these to the selection of AQUA peptides suitable 
for the quantification of each of the four A-Raf isoforms. In the case of A-Raf WT 
this was as simple as selecting a peptide located in the catalytic domain, unique 
to this isoform, while for DA-Rafs 1 and 2, non-ideal C-terminus peptides were 
the only solution. These non-ideal peptides contained Cys and Met residues, or 
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were cleaved with non-ideal proteases, each challenge enabled the author to 
test how detrimental these sequence flaws were to an AQUA based 
quantification. Finally, a subtraction based quantification was performed for A-
Raf Short, subtracting the estimated amount of a peptide present in A-Raf WT, 
DA-Raf-1 and DA-Raf-2 from that achieved for a peptide present in each of the 
four A-Raf isoforms. 
 
Through characterising and quantifying these AQUA peptides it was possible to 
detect each Q1 ion, and to select several Q3 transitions, per peptide, in doing so 
creating an A-Raf MRM acquisition method capable of detecting each targeted 
peptide within a complex sample. Protocols were also developed for the 
complete modification of Cys and Met, while proteolytic digest parameters were 
optimised, so as to maximise the peptide yield per proteolytic digestion.  
 
Upon development of the MS based analysis, the LoD was determined for each A-
Raf isoform on a range of triple quadrupole based mass spectrometers, and each 
A-Raf isoform expressed at a level suitable for spiked digest based quantitative 
analyses. 
 
Several problems were encountered during this project however. The first of 
which was the MS instrumentation available for use. As the LoD test showed, the 
API 2000 MS was 300 times less sensitive than the QTrap 4000 MS. Should a more 
sensitive instrument have been available, then the detection of each of the 
endogenously expressed A-Raf isoform should have been possible. Secondly, 
problems were encountered with AQUA peptide GL*NQDCCVVYR. While peptide 
GLNQDCCVVYR was intentionally ordered in a reduced state, so as to enable a 
comparable IAA based alkylation to be performed on both the target and 
synthetic peptides, this additional processing led to a 25% sample loss. 
 
While several problems were encountered during this project, slowing the 
development of this quantitative technique drastically, the theory behind this 
analysis remains sound, and indeed some promising results were obtained during 
the spiked digest based analyses. Through simply re-ordering the Cys containing 
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AQUA peptides pre-alkylated, utilising SISCAPA base peptide purification and 
performing the quantitative analyses on a sensitive triple quadrupole based MS, 
the detection of endogenous A-Raf within a HEK293 cell lysate should be 
possible. 
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5 Absolute Quantification of the PDE4B Group of Protein 
Isoforms 
5.1 Introduction 
5.1.1 cAMP and PKA Activation 
Adenine ribonucleotide, later named 3'-5'-cyclic adenosine monophosphate 
(cAMP), was first discovered in 1957 when Sutherland and Rall subjected dog 
liver fractions to homogenisation in the presence of adenosine-5'-triphosphate 
(ATP), Mg++ and epinephrine or glucagon (Sutherland and Rall, 1957). By way of 
an explanation the author suggested that the cAMP may be acting as a secondary 
messenger within the cell (Sutherland and Rall, 1958). 
 
Several discoveries have since been made in the field of intra-cellular signalling; 
one of which was the discovery that cAMP is generated through the conversion of 
cytoplasmic ATP by adenylyl cyclase (Gary M, 1988). In turn, it was discovered 
that distinct ligands were capable of elevating the production of cAMP, 
suggesting the existence of hormone specific receptors (such as for epinephrine 
or norepinephrine) (Orly and Schramm, 1976). Previously each hormone had 
been thought to bind adenylyl cyclase directly. It was also noted that GTP was 
required for the activation of adenylyl cyclase, leading to the development of a 
new signalling model in which an adenylyl cyclase-stimulatory GTP-binding 
protein (G-protein) was required for the production of cAMP (Dohlman et al., 
1991). This G-protein was first purified and cloned in 1987 by Gilman (Gilman, 
1987), who noted it to be composed of three distinct subunits, the α, β, and γ, 
each of which were present in a 1:1:1 ratio and named in order of decreasing 
mass.  
 
In the most recent model of cAMP production, the primary signalling molecule 
binds to activate its specific extracellular receptor, creating a receptor based 
binding site for protein G. By binding with the receptor, a conformational 
change occurs within the G-protein, causing the α subunit to exchange a bound 
GDP for a cytoplasmic GTP, and in doing so disassociating from both the β and γ 
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subunits (Patel et al., 2001). Having activated the G-protein, the free α subunit 
binds adenylyl cyclase, enabling the conversion of ATP to cAMP (Dohlman et al., 
1991), as is shown on Figure 5-1. 
 
 
Figure 5-1: The signalling cascade required for the production of intercellular 
cAMP.  This image depicts how an extracellular hormone can lead to the 
production of intercellular cAMP, which requires the extracellular hormone 
binding its specific receptor. This binding causing the α subunit of the G-protein 
to exchange a bound GDP molecule for a GTP, and in doing so disassociating 
from both the β and γ subunits. The α subunit of the activated G-protein can 
then bind the adenylyl cyclase, initiating the conversion of cytoplasmic ATP to 
cAMP. 
 
Upon uncovering the mechanism of cAMP generation, and unhappy with a theory 
in which cAMP dependent protein kinase A (PKA) was “swimming about, happily 
phosphorylating a variety of cellular constituents” (Beavo and Brunton, 2002), it 
was suggested that cAMP based signalling may be compartmentalised. Were this 
proven to be the case, then it was theorised that the hormone specific 
receptors, nine of which had been identified, would be located within close 
proximity to the final effector (TASKÉN and AANDAHL, 2004). This was later 
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confirmed through experimentation with prostaglandin E and the β-adrenergic 
receptor agonist isoprenaline, both of which resulted in equivalent elevation of 
cardiac cAMP levels, but only isoprenaline activated glycogen phosphorylase 
(Beavo and Brunton, 2002).  
 
Upon the production of cAMP, PKA is the classical cAMP effector protein, 
responsible for transmitting the secondary signal (Houslay and Adams, 2003). 
PKA exists within the cell as a tetramer, composed of two regulatory (R) 
subunits, held together by N-terminal dimerisation domains, each of which is 
independently bound to a catalytic (C) subunit (Francis et al., 2011). Several R 
and C subunit isoforms have been identified, with some four genes encoding 
subunit R (RI-α, RI-β, RII-α and RII-β), and three encoding subunit C (C-α, C-β 
and C-γ). Due to the range of possible isozymes, PKA can be classified as either a 
Type I or Type II enzyme; based on which R subunit it contains. Type I enzymes 
(RI) are predominantly located within the cytoplasm, while Type II enzymes (RII) 
have been identified on the cell membrane and organelles (Kim et al., 2007). 
This range of PKA isoforms helps to further increase the substrate specificity of 
the kinase (Francis et al., 2011). 
 
The final method by which the specificity of PKA is increased is via binding to an 
A-kinase anchoring protein (AKAP), a scaffolding protein which maintains PKA 
within close proximity to its final substrate pool (Edwards and Scott, 2000). Type 
II PKA tetramers are bound strongly to AKAPs, with a nM affinity. In contrast, 
Type I PKA tetramers only display µM levels of affinity towards the ligand, and 
have not as yet been shown to bind AKAP in vitro (Beavo and Brunton, 2002, 
Houslay and Adams, 2003, Kim et al., 2007). 
 
In terms of PKA activation, each tetramer binds four cAMP molecules (two cAMP 
molecules per R subunit), causing the catalytic subunits to dissociate from the 
regulatory subunits. This conformational change activates the PKA, enabling 
phosphorylation, as is shown on Figure 5-2 (Kim et al., 2007, Lugnier, 2006).  
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Figure 5-2: The signalling cascade required for the activation of PKA and 
subsequent protein phosphorylation.  This image depicts how the production of 
cAMP, can activate AKAP-bound PKA, causing the catalytic subunits to dissociate 
from the regulatory, enabling protein phosphorylation to proceed. In brief, the 
extracellular hormone binds its specific receptor, causing the α subunit of the G-
protein to exchange a bound GDP molecule for a GTP, and in doing so 
disassociating from both the β and γ subunits. The α subunit of the activated G-
protein can then bind the adenylyl cyclase, initiating the conversion of 
cytoplasmic ATP to cAMP. Upon the release of cAMP into the cytoplasm it can 
bind an AKAP-bound PKA tetramer, causing the catalytic subunits (C) to 
dissociate from the regulatory (R), activating PKA and enabling it to 
phosphorylate protein substrates through the conversion of ATP to ADP. 
 
Once created, the only route through which cAMP can be degraded, and thus the 
signalling event terminated, is through the conversion of the cAMP to 5’-AMP by 
cAMP degrading phosphodiesterases (PDE) (Houslay and Adams, 2003). These PDE 
proteins are anchored throughout the cytosol and nuclear and plasma 
membranes, degrading cAMP in such a way so as to create an asymmetric 
gradient of cAMP localised within the vicinity of the final effector, as is shown 
on Figure 5-3. These cAMP gradients are “read” by AKAP-bound PKA molecules, 
213 
 
leading to gene expression and phenotypic changes which mark the completion 
of the signalling cascade (Houslay et al., 1998, Miles D, 2001). 
 
 
Figure 5-3: cAMP gradient compartmentalisation, based upon the expression 
of PDE.  Depicted above is the route through which cAMP is compartmentalised 
exclusively to the region of the final effector. Through the expression of PDE, 
and thus the degradation of cAMP, cAMP gradients can be established within the 
cell.  
 
By the late 1970s and early 1980s the possibility of stimulating or inhibiting 
these distinct PDE isoforms through the application of small organic molecules 
had been proposed (LEVIN and WEISS, 1976, Wells et al., 1981). This was of 
particular interest to the therapeutic drugs industry as PKA signalling and PDE 
catalysed signal degradation had been known to influence a wide range of 
pharmacological processes, including the production and action of 
proinflammatory mediators, ion channel functioning, muscle contraction, 
learning, cell differentiation, apoptosis, lipogenesis, glycogenolysis and 
gluconeogenesis (Perry and Higgs, 1998). By targeting the actions of these PDE 
enzymes it appeared possible to develop drugs for the treatment of heart 
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failure, depression, asthma, inflammation and erectile dysfunction (TORPHY, 
1998). Furthermore, as each PDE isozyme appeared to exhibit a unique tissue 
expression pattern, then these therapeutic agents should be organ and tissue 
specific (TORPHY, 1998). 
 
5.1.2 cAMP Specific Phosphodiesterases 
The first research to be carried out on a PDE was undertaken by Butcher and 
Sutherland in 1962, identifying a magnesium dependent phosphodiesterase 
capable of cAMP degradation (Butcher and Sutherland, 1962). Furthermore, the 
authors identified this specific PDE species to be inhibited by methyl xanthenes, 
and stimulated by imidazole (Butcher and Sutherland, 1962). Following this 
discovery, it was hypothesised that there may be a number of different isoforms 
(Boswell-Smith et al., 2006), which was confirmed in 1970 when Beavo at al. 
characterised three PDE isoforms from bovine and rat tissues based on anion-
exchange chromatography (BEAVO et al., 1970). These isozymes were calcium-
calmodulin (CaM)-PDE, cAMP-PDE and cGMP-PDE, each named in regard to their 
substrate specificity and sensitivity to CaM, and numbered based on the order in 
which they eluted from the LC column (Boswell-Smith et al., 2006). By 
performing similar PDE based separations on a range of tissues (BEAVO et al., 
1970, Wells et al., 1975, Butcher and Sutherland, 1962), and with the advent of 
the molecular age (Boswell-Smith et al., 2006), the number of PDE isoforms 
identified grew extensively. By 1995 this amounted to seven different gene 
families having been identified in mammalian tissues, with most families 
presenting several distinct genes and isoforms (Beavo, 1995, Boswell-Smith et 
al., 2006). This increasingly complex set of data and its associated naming 
convention led to several problems. For example, often when PDE isoforms 
eluted they didn’t display the biochemical characteristics with which they were 
associated. While this led to some confusion, it was found to be due to the 
varying complement of PDE isoforms present in each tissue and species 
(TORPHY, 1998). Further to this, it was also common for a PDE isozyme to be 
named based on its inhibitor, activator or the ligand to which it preferentially 
bound; some examples of which include: ROI-PDE (rolipram-inhibited PDE), CaM-
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PDE (calmodulin-activated PDE), cGS-PDE (cGMP-stimulated PDE), and cGB-PDE 
(cGMP-binding PDE) (Beavo, 1995, Lugnier, 2006). Therefore it was decided that 
an official PDE naming convention was required, a process which was initiated in 
1995 by Beavo (Beavo, 1995). Under this convention, the first two letters of a 
protein’s name indicated the species from which the gene was extracted, HS, for 
example, indicating a Homo sapiens origin. Further to this, the next three 
letters and one or two Arabic numerals indicated the gene family, and thus the 
elution order previously assigned to the protein, an example of which is PDE4 
(HSPDE4 thus far). The penultimate letter in this nomenclature related to the 
specific PDE gene, for example gene B within the PDE4 family (HSPDE4B thus 
far), while the final Arabic numeral indicated the specific PDE isoform, for 
example isoform splice pattern 1, giving a final designation of HSPDE4B1 (Beavo, 
1995, Lugnier, 2006). 
 
In regards to this project, all further PDE isoforms discussed are of a Homo 
sapiens origin, unless otherwise stated, and as such the naming convention will 
be shortened through the removal of the first two letters, indicative of species. 
 
5.1.3 The Physical Properties of the PDE Family  
As of 2011, a total of 11 mammalian PDE families had been described, giving rise 
to over 20 unique genes and some 50 protein isoforms (Jeon et al., 2005). Each 
of these isoforms has been sequenced, biochemically analysed and 
pharmacologically characterised. Furthermore, an NCBI gene reference for 
PDE12 (NCBI:201626) was created on the 9th October 2011, suggesting there may 
yet be many more unknown PDE families, genes and isoforms. 
 
Each of the 11 PDE families has been shown to share a basic common structure, 
which includes a catalytic domain, and one or more regulatory domains, located 
between the N-terminus and the catalytic domain (Lugnier, 2006). The PDE 
catalytic domain has been shown to consist of some 270 amino acids, 
homologous in nature and highly conserved throughout evolution (Lugnier, 2006, 
Zoraghi et al., 2004). Indeed, it is because of this distinct yet conserved 
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catalytic domain that each of the PDE isoforms are thought to have diverged 
from a common ancestor some 940 million years ago, before the separation of 
sponges and eumetozoans (Koyanagi et al., 1998). Research into the structure of 
the Homo sapiens PDE catalytic sub-units found only a 50% sequence identity 
across each family (David M, 1999). Similarly, research conducted in vertebrate 
and insect species found only a 30% sequence identity across each PDE family, 
but a 60–90% sequence identity when comparing any single PDE family between 
species (Graeme B, 1994). This shows just how important the conservation of 
each PDE family has been in evolution, while confirming just how great the 
differences are between each of the PDE species (Lugnier, 2006). 
 
Of particular interest to PDE based research are the structural sub-domains of 
the catalytic core, frequently targeted by therapeutic agents, so as to 
allosterically regulate targeted PDE isozymes (TORPHY, 1998). Over the last 
decade this research has unveiled three helical sub-domains, including an N-
terminal cyclin-folding region, a linker region, and a C-terminal helical bundle. 
Where these three regions interface, a deep hydrophobic pocket is formed. This 
pocket is composed of four sub-sites; including a metal-binding site (M site), a 
core pocket (Q pocket), a hydrophobic pocket (H pocket) and a lid region (L 
region) (Sung et al., 2003, Francis et al., 2000).  
 
In comparison to the highly conserved catalytic domain, each of the 11 PDE 
families have been shown to contain unique regulatory regions, including a 
calmodulin binding site, unique to PDE1, an allosteric cGMP binding site, present 
in PDE species PDE2, PDE5, PDE6, PDE10, and PDE11 (Zoraghi et al., 2004), a 
phosphatidic binding site, unique to PDE4, a PAS domain, unique to PDE8, 
autoinhibitory sequence, unique to PDE species PDE1 and PDE4, and a membrane 
association domain, present on PDE species PDE2, PDE3 and PDE4. Furthermore, 
each PDE family has been found to contain various unique phosphorylation sites 
and dimerization motifs  (Bolger, 1994). 
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5.1.4 PDE4  
PDE4, previously termed cAMP-PDE, is characterised by its specificity towards 
cAMP. It is also potently and specifically inhibited by rolipram (Francis et al., 
2000). PDE4 expression has been identified in the smooth muscle cells of the 
airway, within the brain and within the tissues of the cardiovascular system 
(Muller et al., 1996). Furthermore, PDE4 has been shown to be the predominant 
PDE species expressed within inflammatory cells, and has been implicated in 
inflammatory airway disease (Wang et al., 1999, Houslay et al., 1998).  
 
The PDE4 family of protein isoforms are the most widely characterised of the 
PDE families, though it was not until the advent of molecular cloning during the 
1990s that the extraordinary diversity of this family was revealed (Perry and 
Higgs, 1998). Four genetically distinct PDE4 genes have so far been identified, 
termed PDE4A–D, each spanning some 50 kb and containing at least 18 exons 
(Houslay and Adams, 2003). These genes are thought to give rise to at least 35 
different isoforms through the alternative splicing of each protein’s N-terminal 
(Boswell-Smith et al., 2006, Muller et al., 1996, Bolger, 1994). 
 
In terms of structure, each PDE4 isozyme has been shown to contain the same 
three functional domains; the PDE catalytic domain, which accounts for between 
18 and 46% of the protein and is located close to the protein’s C-terminal (Jeon 
et al., 2005), and two regulatory sub-domains. The first of which, upstream 
conserved region one (UCR1), consisting of some 60 amino acids and located 
close to the proteins N-terminal, while the second, upstream conserved region 
two (UCR2), consists of some 80 amino acids and is located between the first 
regulatory domain and the catalytic core (Thompson, 1991, Bolger, 1994), as is 
depicted on Figure 5-4.  
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Figure 5-4: The sequence orientation of typical long, short and super-short 
PDE isoforms.  Depicted above are the typical structures of long, short and 
super-short PDE4 isoforms, detailing how long PDE4 isoforms contain both UCR’s 
1 and 2, whereas short PDE4 isoforms contain only UCR2. Finally super-short PDE 
isoforms contain only half of UCR2, while each of the PDE4 isoforms contains the 
conserved catalytic core. 
 
PDE4 isoforms found to contain both UCRs 1 and 2 have been termed long 
isoforms, whereas those found to contain only UCR2 have been termed short-
isoforms. Super-short PDE4 isoforms have also been documented, containing only 
a truncated version of UCR2 (Houslay et al., 1998). Of these conserved 
regulatory domains, it has been suggested that it is UCR1 which is the most 
heavily regulated, involving allosteric regulation, membrane targeting and 
catalytic inhibition. UCR2, meanwhile, is thought to be involved in the formation 
of PDE4 dimers (Graeme B, 1994), a theory which complements the work of 
Zoraghi et al., who suggests PDE to be dimeric, but concluded that the function 
of this dimerisation was, as yet, poorly understood (Zoraghi et al., 2004). 
 
Research by Oki et al. has shown long PDE4 isoforms to be stimulated by the PKA 
catalysed phosphorylation of Ser-54 within UCR1 of PDE4D3. This conformational 
change has been shown to increase the kinase activity of all long PDE isoforms by 
approximately 60%. This increase in kinase activity is thought to act as a short-
term feedback mechanism, helping to restore basal levels of cAMP within the 
cell following a signalling event (Oki et al., 2000). Richter and Conti have also 
demonstrated PKA catalysed phosphorylation to be dependent on long PDE 
isoform dimerisation. This dimeric state, it is thought, may help to stabilise the 
PDE4 isoforms in a high-affinity rolipram binding state (Richter and Conti, 2004). 
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In the early 1970s the characteristic PDE4 inhibitor rolipram was tested as a 
potential therapeutic agent (Scott et al., 1991). This research was conducted 
around the premise that elevated levels of cAMP may enhance noradrenergic 
neurotransmission within the central nervous system. Rolipram was thus seen as 
a potential treatment for depression, which, while proven effective, was shown 
to cause nausea and disturbance of the gastrointestinal tract long before any 
statistically significant therapeutic effect could be established (Scott et al., 
1991). These side effects were attributed to “off target” events, which 
characterise general PDE4 inhibitors which inhibit each of the 35 isoforms 
equally, due to their action on the highly conserved catalytic site. Further 
research into PDE4 inhibition found it to block cell trafficking, cell proliferation 
and to attenuate the production of inflammatory mediators, cytokines and 
reactive oxygen species (Souness et al., 2000), while suppressing the immune 
system (Boswell-Smith et al., 2006). 
 
One physical property of the PDE4 family which does lend itself toward further 
drug development is the distinct cellular and tissue specific distribution pattern 
displayed by each of the four PDE4 isoforms. Therefore, should one specific PDE 
isoform by targeted by a drug treatment, any side effects should be minimised. 
For example, PDE4B appears to be expressed in the heart, brain, skeletal 
muscle, and lung, but not in the placenta, liver, kidney, or pancreas (McLaughlin 
et al., 1993). PDE4C meanwhile appears to be expressed in neuronal tissues but 
not in immune or inflammatory cells (Engels et al., 1995, Engels et al., 1994), 
while PDE4D appears to be expressed in the blood fractions and skeletal muscles 
(Cheung et al., 2007). The exception in this case is PDE4A which appears to be 
expressed ubiquitously, though slightly higher levels of expression have been 
noted in monocytes, the skeletal muscles, the testis, and the pons (Bolger et al., 
1993, Obernolte et al., 1993, Livi et al., 1990).  
 
It should be noted that isoform specific PDE4 inhibitors which compete with 
cAMP for the active site have proven elusive due to the conserved nature of the 
PDE4 catalytic unit. Several PDE4 inhibitors have, however, entered clinical 
trials more recently, aiming to treat reactive airway diseases, autoimmune 
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diseases, B-cell malignancies, chronic lymphocytic leukemia and acute 
lymphoblastic leukemia (Smith et al., 2005). 
 
5.1.4.1 PDE4B 
The sequence which encodes the PDE4B family of protein isoforms is thought to 
be located on chromosome 1p31.2-32.1, spanning some 580 kb, and comprising 
at least 17 exons (Otowa et al., 2011). Alternative splicing of this gene has been 
shown to give rise to at least five protein isoforms (PDE4B1–5), each varying in 
length and regulation, as a result of a unique N-termini. The transcription of 
each of the five PDE4B isoforms is thought to be initiated through unique 
upstream promoters, each transcribing a unique 5’ exon before incorporating a 
shared catalytic C-terminal (Wallace et al., 2005). 
 
As was discussed previously, PDE4B appears to be expressed in the heart, brain, 
skeletal muscle, lung (McLaughlin et al., 1993) and blood fractions (Wallace et 
al., 2005). In terms of expression within the central nervous system, PDE4B has 
been detected in the amygdala, hypothalamus and frontal cortex (Cherry and 
Davis, 1999), regions which are thought to be key in the mediation of stress and 
anxiety (Charney and Deutch, 1996). While many members of the PDE4 family 
are expressed throughout the brain, including those areas associated with 
reward and affect (Iona et al., 1998, Cherry and Davis, 1999), the PDE4B family 
is thought to be of particular importance for the transduction of complex signals 
and brain integration (Menniti et al., 2006). Furthermore, PDE4 has been found 
to account for approximately 33% of the total cAMP hydrolytic activity within 
mouse heart (Leroy et al., 2011).  
 
Recent publications have further defined the role of PDE4B within the brain to 
include the regulation of anxiety and depression (Pandey et al., 2005), with 
PDE4 inhibitor rolipram exhibiting antidepressant (O’Donnell and Frith, 1999) 
and anxiolytic-like behaviours in animals (Silvestre et al., 1999). As a way of 
confirming this function Rutten et al. prepared PDE4B -/- knockout mice, 
commenting that the animals showed “enhanced basal postsynaptic responses to 
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stimulation and long-term depression” (Rutten et al., 2011). PDE4B has also 
been linked to multifunctional scaffolding protein Disrupted-in-Schizophrenia-1 
(DISC1), which is thought to be required for the parallel processing of signals 
from GSK-3 and PDE4. DISC1 is thought to play a role in the regulation of 
neurodevelopment, signal transduction and intracellular transport and exocytosis 
within the brain (Jaaro-Peled et al., 2010). Furthermore, DISC1 has been seen as 
a candidate susceptibility factor for psychiatric disorders such as schizophrenia, 
schizoaffective disorder, bipolar disorder and depression (Millar et al., 2005). 
Indeed post-mortem brain samples obtained from patients with schizophrenia 
and bipolar disorder have suggested that each of these conditions may be linked 
to the expression pattern of PDE4B, which appears to differ from that of healthy 
individuals (Fatemi et al., 2008, Kähler et al., 2010, Numata et al., 2009a). 
 
5.1.4.1.1 PDE4B1 
PDE4B1 is a long PDE isoform, incorporating both UCRs 1 and 2. PDE4B1 is 
thought to span some 736 amino acids (Bolger et al., 1993), and to present with 
a single SDS-PAGE gel band with a MW of approximately 104 kDa (Shepherd et 
al., 2003). Unlike the majority of the PDE4B family, PDE4B1 appears not to be 
expressed at a high concentration within human brain (Dwivedi, 2010). Instead 
PDE4B1 has been implicated in the transduction of cAMP based signalling within 
osteoblast cells; where glucocorticoid dexamethasone (DEX) based 
immunosuppressive treatments have been shown to reduce the levels of PDE4B1 
transcription. Following long-term treatment with DEX, the metabolic activity of 
these osteoblast cells appears modified and the life span of the cells reduced 
through inhibiting bone formation (Ahlström et al., 2005). 
 
5.1.4.1.2 PDE4B2 
PDE4B2 is a short-PDE isoform, and thus is regulated solely through UCR2 and 
cannot be phosphorylated by PKA. PDE4B2 is thought to span some 564 amino 
acids (Bolger et al., 1993), and to present with a single SDS-PAGE gel band with 
a MW of approximately 78 kDa (Shepherd et al., 2003). The Homo sapiens 
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consensus sequence for PDE4B2, appears to be of a length identical to, and to 
display 90% sequence identity with, its counterpart in Rattus norvegicus (Bolger, 
1994). 
 
Unlike PDE4B1, PDE4B2 has been shown to be expressed at a high concentration 
within the human brain (Dwivedi, 2010). However, PDE4B2 expression within the 
prefrontal cortex and hippocampus appears to be decreased in patients suffering 
from depression (Dwivedi, 2010) and schizophrenia (Fatemi et al., 2008). Several 
single nucleotide polymorphisms (SNPs) linked to schizophrenia have also been 
identified in the introns bracketing the PDE4B2 coding locus in Caucasian and 
African American populations (Fatemi et al., 2008), again proving this isoform to 
be of critical importance to mental health.  
 
PDE4B2 inhibition has also be seen as a potential treatment for diffuse large B-
cell lymphoma (DLBCL), where PDE4B2 has been identified as the predominant 
PDE4B isoform in normal B cells, which when unabated prevents cAMP induced 
apoptosis (Smith et al., 2005). 
 
5.1.4.1.3 PDE4B3 
PDE4B3, much like PDE4B1, is a long PDE isoform, incorporating both UCRs 1 and 
2. PDE4B3 is thought to span some 721 amino acids (Huston et al., 1997) and to 
yield a single SDS-PAGE gel band with a MW of approximately 103 kDa (Shepherd 
et al., 2003). Like PDE4B2, the consensus sequence for Homo sapiens PDE4B3 
appears to have a length identical to, and to display a 90% sequence identity 
with, its counterpart in Rattus norvegicus (Bolger, 1994). 
 
While PDE4B2 has been shown to be highly expressed within the human brain, 
PDE4B3 has been shown to be highly expressed within the brain, heart, lung and 
liver (Dwivedi, 2010). PDE4B3 expression has been shown to be decreased in 
patients suffering from bipolar disorder, but not from depression or 
schizophrenia, suggestion isoform specificity in mental illness (Fatemi et al., 
2008). PDE4B3 has also been shown to be of importance for hippocampal long-
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term potentiation (LTP) during learning, with PDE4B3 expression being up-
regulated just two hours after tetanisation, peaking after six and rapidly 
degrading after eight (Fatemi et al., 2008). 
 
5.1.4.1.4 PDE4B4 
Whether PDE4B4 is expressed in Homo sapiens is a hotly debated topic first 
addressed by Shepherd et al. in 2003. While Shepherd failed to identify PDE4B4 
in human tissues, a previously unpublished 659 amino acid long-PDE4B isoform 
was successfully identified in Rattus norvegicus. This new PDE4B isoform was 
found to express a unique 17 amino acid N-terminal, while incorporating the 
same regulatory and catalytic domains as are present in PDE4B1 and PDE4B3 
(Shepherd et al., 2003). Upon analysis, this novel PDE4B3 coding mRNA sequence 
in Rattus norvegicus was found to be expressed in multiple tissues, including the 
liver and brain. BAC screening of Mus musculus chromosome four meanwhile, 
identified a gene with a sequence identity of greater than 95% to that of the 
Rattus norvegicus PDE4B4 gene. Indeed, while several Homo sapiens BACs were 
also found to contain a similar sequence, every possible reading frame was found 
to contain tightly clustered stop codons. Shepherd et al. thus concluded that the 
gene coding for PDE4B4 in Homo sapiens amounted to a dead exon (or 
pseudogene), coding a protein of function in rodents, but not humans (Shepherd 
et al., 2003). Several authors however have reported the detection of PDE4B4 in 
Homo sapiens tissues (Farooqui et al., 2000, Takahashi et al., 1999), including 
Fatemi et al. who detected three long PDE4B isoforms (PDE4B1, PDE4B3, and 
PDE4B4) and one short-PDE4B isoform (PDE4B2) through western blotting (Fatemi 
et al., 2008), and Braun et al. who reported the detection of a distinct 85 kDa 
protein band in several human tissues when western blotting with two well 
characterized antibodies (Braun et al., 2007). 
 
In terms of function, Fatemi et al. observed a significant decrease in the levels 
of PDE4B4 transcription in patients suffering from schizophrenia (Fatemi et al., 
2008), while Shepherd et al. noted PDE4B4 expression to be restricted to the 
cytosol of transfected COS7 cells. This was seen as being particularly interesting 
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as each of the previously identified long PDE4B isoforms were all membrane 
associated. Shepherd et al. did acknowledge however that this change in 
localisation may be due to the COS7 cells not expressing the correct PDE 
anchoring protein (Shepherd et al., 2003). 
 
5.1.4.1.5 PDE4B5 
PDE4B5 is a super-short PDE4 isoform discovered by Cheung et al. in 2007. 
PDE4B5 is thought to span some 484 amino acids, and to include a unique 16 
amino acid N-terminal region and a truncated UCR2, while maintaining the same 
catalytic subunit present in each of the PDE4B isoforms (Cheung et al., 2007). 
High levels of PDE4B5 expression have been noted in brain (fetal brain, 
cerebellum, frontal lobe, pons, putamen, thalamus, and hippocampus), and 
weaker levels of expression have also been noted in the retina, spinal cord, 
pituitary, fetal kidney, jejunum, ileum, lung carcinoma A549 cells, testis, HeLa 
cells, and G361 melanoma cells. PDE4B5 has also been shown to be conserved in 
vertebrae, chicken, frog, zebrafish, and fugu; suggesting it may play a strong 
functional role. Furthermore, the N-terminal region unique to PDE4B5 was also 
identified in PDE4D6, suggesting this sequence to be both functional and highly 
conserved (Cheung et al., 2007).  
 
In regard to the function of PDE4B5, the uneven distribution pattern of this 
isoform within the cytosol suggests that PDE4B5 may play a role within the 
cytosolic vesicles and complexes (Cheung et al., 2007). 
 
5.1.5 PDE4B Literature Overview 
While the first PDE isoform was identified some 50 years ago (Butcher and 
Sutherland, 1962), it was not until the advent of molecular cloning during the 
1990s that the extraordinary diversity of PDE isoforms was revealed (Perry and 
Higgs, 1998). As of 2011 this has resulted in the description of some 11 
mammalian PDE families, giving rise to over 20 unique genes and at least 50 PDE 
isoforms (Jeon et al., 2005). While many PDE isoforms have been identified, and 
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their expression patterns mapped to a range of tissues, very little information 
exists about their specific function, aside from degrading cAMP. For example, 
PDE4B1 is not highly expressed within the brain, but has instead been linked to 
cell signalling within osteoblast cells (Ahlström et al., 2005).  
 
The focus of PDE based research appears aimed at entire PDE families or genes, 
with PDE4 having been characterised by its potent inhibition through therapeutic 
agent rolipram, and thus PDE4 has been implicated in depression (Scott et al., 
1991). Likewise PDE4B has been linked to multifunctional scaffolding protein 
DISC1, and as such has been implicated in both schizophrenia and bipolar 
disorder (Fatemi et al., 2008, Kähler et al., 2010, Numata et al., 2009a).  
 
In keeping with the functions assigned to PDE4 and PDE4B, PDE4B2 has been 
linked to depression and schizophrenia, and PDE4B3 linked to bipolar disorder 
(Fatemi et al., 2008, Dwivedi, 2010). It should be noted however that the 
function of these isoforms was determined based on the probing of tissues 
obtained from patients with mental disorders specifically, and so other cellular 
roles may exist. 
 
The existence of long-isoform PDE4B4 has proven controversial, with several 
authors having identified the isoform (Braun et al., 2007, Fatemi et al., 2008, 
Farooqui et al., 2000, Takahashi et al., 1999), despite all possible N-terminal 
reading frames being noted as to contain tightly clustered stop codons (Shepherd 
et al., 2003). Where PDE4B4 expression has been identified, the isoform has, like 
short-isoform PDE4B2, been implicated in schizophrenia (Fatemi et al., 2008), 
which is interesting as PDE4B4 appears to be localised exclusively to the 
cytoplasm, a location generally assigned to the short-PDE isoforms (Shepherd et 
al., 2003). 
 
Finally, PDE4B5 has only recently been identified, and as yet no specific function 
has been assigned to this super-short isoform. However, the uneven distribution 
pattern identified for PDE4B5 within the cytosol, suggesting the isoform may be 
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involved in signalling within the cytosolic vesicles or complexes (Cheung et al., 
2007). 
 
While the discovery of PDE4B5 as recently as 2007 showed that new PDE isoforms 
continue to be discovered, the registering of a new PDE family, PDE12, on 9th 
October 2011 suggests our knowledge of these protein families may yet be in its 
infancy.  
 
5.2 Project Aims 
Despite there being very few peer reviewed publications confirming the function 
and tissue specific distribution pattern of each of the five PDE4B isoforms, they 
should make excellent candidates for this project, enabling a range of human 
tissues to be probed, so as to identify: (i) Which PDE4B isoforms are expressed 
within a tissue, and indeed whether PDE4B4 is expressed at all (through 
detecting isoform specific target peptides). (ii) The concentration at which each 
PDE4B isoform is expressed (through detecting both the isoform specific target 
and synthetic AQUA peptide), and (iii) How the PDE4B isoform expression ratio 
varies under different physiological conditions (including in patients suffering 
from mental disorders). 
 
As the goals listed above are beyond the scope of a PhD project, a more 
achievable set of project aims were devised. As such, during this project I aim 
to: (i) Screen for each of the PDE4B isoforms, identifying and selecting suitable 
AQUA peptides for the absolute quantification of each PDE4B protein. (ii) 
Characterise each AQUA peptide/intrinsic target peptide so as to develop a 
suitable triple-quadrupole based MRM acquisition method for the identification 
of each peptide within a single LC-MS run. (iii) Express suitable amounts of each 
PDE4B isoform, enabling the proteolytic digestion of each isoform to be 
optimised using a range of commercially available proteases, and (iv) Assess the 
accuracy and reproducibility of the AQUA technique though quantifying each 
protein solution expressed with a suitable number of replicates. 
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5.3 PDE Specific Methods 
5.3.1 Proteolytic Digest Optimisation 
5.3.1.1 Arg-C Digest Optimisation 
Lyophilised BSA was re-suspended in 500 mM AMBIC, containing 0.1% RapiGest SF 
surfactant (w/v), reduced with DTT and alkylated with IAA, prior to the IAA 
being quenched with excess Cys. Following vacuum centrifugation, the BSA was 
re-suspended and digested with Arg-C at an enzyme:substrate ratio of 1:10, 
1:20, 1:50, 1:100 and 1:200 (w/w), as per the manufacturer’s instructions. Each 
digested BSA sample was vacuum centrifuged to completion and re-suspended in 
2% MeCN, 0.1% FA (v/v), prior to analysis on an API 2000 MS. The resulting data 
files were analysed via MASCOT. The percentage sequence coverage of BSA was 
recorded. 
 
5.3.1.2 Probing for Residual Glu-C Catalysed Asp Cleavage in AMBIC 
Lyophilised BSA was re-suspended in 500 mM AMBIC, containing 0.1% RapiGest SF 
surfactant (w/v), reduced with DTT and alkylated with IAA, prior to the IAA 
being quenched with excess Cys. Following vacuum centrifugation, the BSA was 
re-suspended in 25 mM AMBIC and digested with Glu-C at an enzyme:substrate 
ratio of 1:20 (w/w), as per the manufacturer’s instructions. The digest 
proceeded for between 10 and 20 hours, with a vial being removed every hour 
and the digest terminated through the addition of FA. Each digested BSA sample 
was vacuum centrifuged to completion and re-suspended in 2% MeCN, 0.1% FA 
(v/v), spotting each solution to a 384 well MALDI plate. PepMix II calibration 
standard and HCCA matrix was added to each MALDI spot, prior to analysis on an 
Ultraflex II MS.  
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5.3.2 PDE4B Plasmid Preparation 
5.3.2.1 Sequencing PDE4B in pEE7 
Homo sapiens PDE4B1, PDE4B2 or PDE4B3 coding cDNA in pEE7 was sequenced 
with HCMV and SV40 and the sequence data subjected to a standard NCBI 
nucleotide based BLAST search, so as to identify any significant regions of known 
sequence, in this case seeking an alignment with the Homo sapiens PDE4B gene 
set. Because of the size of both the PDE4B cDNA inserts (accounting for between 
1.8 and 2.2 kb), and the pEE7 vector (approximately 7 kb), however, the 
sequence of the entire plasmid could not be determined based upon the use of 
HCMV and SV40 alone. The pEE7 upstream regulatory domains were therefore 
sequenced with a custom 21 mer reverse primer “PDE4B_SEQ” 
(GTTCAGCATTCTTTTGAACTT). Upon receipt of this sequencing data, the 
sequences were again subjected to a standard NCBI nucleotide based BLAST 
search. 
 
With both the up and downstream pEE7 regulatory domains having been 
sequenced, the plasmid was screened with software package NEBcutter, version 
2.0, so as to identify suitable restriction digest sites applicable for the removal 
of the intact PDE4B inserts, yet ensuring that the enzymes presented in an order 
suitable for the forward ligation of the fragments into pcDNA3, enabling a higher 
copy number amplification of the plasmid. 
  
5.3.2.2 Transferring the PDE4B Inserts from pEE7 
PDE4B1 in pEE7, PDE4B3 in pEE7 and pcDNA3 were restriction digested with 
EcoRI, as per the manufacturer’s instructions. Likewise, PDE4B2 in pEE7 and 
pcDNA3.1(+) were restriction digested with BamHI and HindII, as per the 
manufacturer’s instructions. The restriction digest products were separated via 
agarose gel based electrophoresis, visualised with SYBR green, and excised based 
upon expected insert lengths of 2.3 kb for PDE4B1, 1.7 kb for PDE4B2, 2.2 kb for 
PDE4B3 and 5.4 kb for pcDNA3 and pcDNA3.1(+). The purified DNA fragments 
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were recovered via a QIAquick gel extraction kit and quantified on a Nanodrop 
1000 Spectrophotometer. 
 
Each PDE4B cDNA insert and complementary pcDNA vector were ligated with T4 
DNA Ligase, as per the manufacturer’s instructions, and transformed into library 
efficiency DH5α cells, as per the manufacturer’s instructions. The transformed 
cells were plated and approximately 20 colonies per plate screened for the 
presence of the modified plasmids. In brief, each viable colony was cultured and 
the amplified plasmid extracted via Miniprep, prior to restriction digestion with 
either EcoRI (for PDE4B1 and PDE4B3) or BamHI and HindIII (for PDE4B2). Each 
digested sample was separated via agarose gel based electrophoresis and 
visualised through the use of SYBR green, with the aim of identifying an 
appropriate restriction digest pattern, based on the previously detailed cDNA 
insert sizes. Where a plasmid appeared compliant it was sent for sequencing, so 
as to confirm the presence of the correct insert, and indeed that the insert was 
ligated in the correct orientation. 
 
5.3.2.3 FLAG-tag Insertion Into PDE4B Containing pcDNA3 or 
pcDNA3.1(+) 
PDE4B1 and PDE4B3 cDNA inserts in pcDNA3 were restriction digested with 
HindIII and BamHI, as per the manufacturer’s instructions. Likewise, PDE4B2 in 
pcDNA3.1(+) was restriction digested with NheI and HindIII, as per the 
manufacturer’s instructions. The restriction digested DNA was separated via 
agarose gel based electrophoresis and visualised with SYBR green. The gel bands 
of interest were excised and recovered via a QIAquick gel extraction kit, as per 
the manufacturer’s instructions, quantifying each sample with a Nanodrop 1000 
Spectrophotometer. 
 
Custom N-terminal FLAG-tag forward and reverse primers PDE1&3FLAGFor 
(AGCTTGGTACCTATGGATTACAAGGATGACGACGATAAGACG) and PDE1&3FLAGRev 
(GATCCGTCTTATCGTCGTCATCCTTGTAATCCATAGGTACCA) for long PDE4B 
isoforms PDE4B1 and PDE4B3, and custom N-terminal FLAG-tag forward and 
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reverse primers B2-PC3.1Forward (CTAGCGCGGCCGCATGGATTACAAGGATGAC 
GACGATAAGA) and B2-PC3.1Reverse (AGCTTCTTATCGTCGTCATCCTTGTAATCCA 
TGCGGCCGCG) for short-PDE4B isoform PDE4B2 were combined at an equal 
concentration (w/w) and heated to 65 oC for 10 minutes. The water bath was 
switched off and the temperature slowly equilibrated to that of the room, 
enabling the single stranded primers to anneal to form a double stranded insert, 
ready for ligation. 
 
The double stranded FLAG-tag inserts were combined with their complementary 
plasmid and ligated with T4 DNA Ligase, as per the manufacturer’s instructions. 
The ligated plasmids were transformed into library efficiency DH5α cells, as per 
the manufacturer’s instructions. The transformed cells were plated and 
approximately 20 colonies per plate screened for the presence of the modified 
plasmids. In brief, each colony was cultured and the amplified plasmid 
recovered via Miniprep. The plasmids were restriction digested with either KpnI 
(for PDE4B1 and PDE4B3) or NotI (for PDE4B2) and the restriction digest products 
separated via agarose gel based electrophoresis, visualising through the 
application of SYBR green. Where a plasmid appeared to contain a FLAG tagged 
insert, with a length greater than the unmodified PDE4B cDNA containing 
plasmid, it was sent for sequencing. 
 
5.4 Results and Discussion 
5.4.1 AQUA Peptide Selection 
5.4.1.1 Sequence Unique to Each PDE4B Isoform 
While the four A-Raf isoforms presented with a shared N-terminal, and each was 
differentiated by the intron at which the isoform terminated (each encountering 
a premature stop codon), each of the PDE4B isoforms were found to contain a 
shared C-terminal and were instead differentiated on a short run of unique N-
terminal sequence. In some ways, this made the quantification of the PDE4B 
isoforms more difficult, as the selection of unique C-terminal peptides was 
impossible. Instead, the quantification of PDE4B focused on the selection of 
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unique N-terminal proteolytic peptides, generated by a range of proteases. In 
those cases where a suitable peptide could not be identified, subtraction based 
quantification was again employed.  
 
Shown on Figure 5-5 is the sequence unique to each of the four PDE4B isoforms, 
the first of which, long-isoform PDE4B1, was found to contain 93 residues of 
unique sequence before the inclusion of shared domain UCR1. PDE4B2 
meanwhile, being a short-isoform, was found to contain only 39 residues of 
unique sequence before the inclusion of shared domain UCR2, while long-isoform 
PDE4B3 was found to contain 78 residues of unique sequence before the 
inclusion of shared domain UCR1.  
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Figure 5-5: A Clustal X based alignment of PDE4B1, PDE4B2, PDE4B3 and 
PDE4B5, highlighting the areas of sequence unique to each of the isoforms.  
Each of the PDE4B isoforms was aligned via Clustal X, with the exception of 
PDE4B4 which has no confirmed sequence. Highlighted in purple are the areas of 
sequence unique to PDE4B1, highlighted in green are the areas of sequence 
unique to PDE4B2, highlighted in yellow are the areas of sequence unique to 
PDE4B3 and highlighted in blue are the areas of sequence unique to PDE4B5. 
 
As no protein sequence has as yet been described for long-PDE4B isoform 
PDE4B4, it was excluded from this particular alignment. It was imperative, 
however, that the sequence of PDE4B4 was considered when peptides were 
selected for the quantification of multiple PDE4B isoforms.  
 
Finally, super-short isoform PDE4B5 was found to contain only 15 residues of 
unique sequence, before the inclusion of a truncated version of shared domain 
UCR2, making it the most difficult to quantify. 
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5.4.1.2 AQUA Peptides Selected for the Quantification of PDE4B 
Through the use of the AQUA peptide selection workflow, as was detailed in 
Chapter 2, five AQUA peptides have been selected for the quantification of each 
of the five PDE4B isoforms (Table 5-1). 
 
Table 5-1: The AQUA peptides selected for the quantification of each of the 
PDE4B isoforms.  Each of the AQUA peptides selected for the quantification of 
each of the four PDE4B isoforms. 
Peptide Protease Present in: Comments: 
DYFECSLSK Trypsin PDE4B1 Located within the unique C-terminal of PDE4B1. 
NSPCFFR Arg-C PDE4B3 Located within the unique C-terminal of PDE4B3. 
VNPQEESYQK Trypsin 
PDE4B1, PDE4B3 and 
PDE4B4 
Bridges the UCR2 N-terminal splice site, and therefore is present 
only in the long PDE4B isoforms. 
TIQTYRSVSE Glu-C 
PDE4B1, PDE4B2, 
PDE4B3 and PDE4B4 
Located within UCR2, and this is present in both long and short 
PDE4B isoforms. 
TDIDIATE Glu-C 
All five PDE4B 
isoforms 
Located in close proximity to the C-terminal of the PDE4B 
isoforms, and therefore is present in each of the PDE4B isoforms. 
 
Each of the peptides selected for the quantification of the five PDE4B isoforms is 
also shown on Figure 5-6. 
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Figure 5-6: The AQUA peptides selected for the quantification of each of the 
five PDE4B isoforms.  A Clustal X based alignment of the four known PDE4B 
consensus sequences. Highlighted in blue is peptide NSPCFFR, selected for the 
quantification of PDE4B3 exclusively, highlighted in purple is peptide 
DYFECSLSK, selected for the quantification of PDE4B1 exclusively, highlighted in 
red is peptide VNPQEESYQK, selected for the quantification of PDE4B1, PDE4B3 
and PDE4B4, highlighted in green is peptide TIQTYRSVSE, selected for the 
quantification of PDE4B1, PDE4B2, PDE4B3 and PDE4B4, and highlighted in brown 
is peptide TDIDIATE, selected for the quantification of each of the five PDE4B 
isoforms. 
 
5.4.2 AQUA Peptide Optimisation 
As each of the techniques developed for optimising both the target and synthetic 
peptides have previously been discussed, then the optimisation of each of the 
PDE4B peptides will not be discussed here. This includes the selection of suitable 
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Q1 and Q3 masses, collision energy optimisation, Cys alkylation, and the 
optimisation of tryptic, Glu-C and Lys-C catalysed digests. 
 
As Proteolytic enzyme Arg-C has not yet been optimised however, a BSA based 
digest optimisation was conducted for this protease. Furthermore, while Glu-C 
has been optimised, AQUA peptide TDIDIATE was found to be cleaved at Glu, yet 
was found to contain two Asp residues, and as such this digest was further 
assessed for any residual Asp based cleavage upon the depletion of Glu-X 
peptide bonds.  
  
5.4.2.1 Proteolytic Digest Optimisation 
When performing an AQUA based absolute quantification, the digest is of critical 
importance (Kirkpatrick et al., 2005a). Indeed, the only protease used within 
this research to have not been optimised is Arg-C, as it is required for the 
digestion of long-PDE4B isoform PDE4B3, and thus the production of target 
peptide NSPCFFR. 
 
As was performed with trypsin, Lys-C and Glu-C, 25 µg vials of BSA were digested 
at a range of enzyme:substrate ratios (w/w), ranging from 1:10 to 1:200, in the 
presence of 0.1% (w/v) RapiGest SF surfactant, as per the manufacturer’s 
instructions. From these digests (the data for which is not shown) proteolytic 
peptides were detected from only the 1:20 enzyme:substrate ratio (w/w) digest 
sample, which even then achieved a sequence coverage for BSA of only 5%. If we 
consider that trypsin cleaves at both Lys and Arg, each of which occur at a 
frequency of 5% within an average mix of proteins (Tsuji et al., 2010), and that 
tryptic peptides are rarely larger than 10 to 15 amino acids in length, with a 
mass of between 1,000 and 3,000 Da, then it is clear that a high sequence 
coverage is possible. In comparison, if we consider that Arg-C cleaves exclusively 
at Arg, which occurs at a frequency of only 5%, then the expected peptide 
length doubles to approximately 20 amino acids, with a mass of between 2,000 
and 6,000 Da, somewhat unsuitable for detection on modern triple quadrupole 
based mass spectrometers (Kelleher et al., 1999). By way of an example, when 
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BSA was theoretically digested with trypsin, some 47 peptides were identified, 
presenting with an average peptide length of 11.6 amino acids. When the same 
protein was digested with Arg-C however, only 21 peptides were identified, 
presenting with an average peptide length of 25 amino acids. 
 
In conclusion, perhaps it was poor experimental design which has limited this 
Arg-C catalysed digest optimisation, where Arg-C may be more suitable for 
specific cleavages or for use in combination with a second protease, rather than 
being the sole enzyme responsible for yielding peptides suitable for MS. This 
result does not however necessarily signify the elimination of either peptide 
NSPCFFR or the use of Arg-C, as low sequence coverages were also obtained 
during the digestion of BSA with trypsin, Lys-C and Glu-C, yet the spiked 
digestion of A-Raf in no way suggested either protease based digestion to be 
incomplete.  
 
5.4.2.2 Residual Glu-C Catalysed Cleavage at Asp 
As has previously been discussed, in the presence of a phosphate based buffer, 
Glu-C is thought to cleave specifically at Glu and Asp, with Asp based cleavage 
occurring at a 3000 fold lower rate. When the same digest is performed in AMBIC 
however, the digest is thought to be restricted exclusively to Glu (Houmard and 
Drapeau, 1972). As AQUA peptide TDI*DIATE, selected for the quantification of 
PDE4B isoform PDE4B5, was found to be cleaved to both the C and N-termini at 
Glu, but to contain two Asp residues, an experiment was devised to detect any 
residual Asp based cleavage. This focussed on the final few hours of a typical 18 
hour proteolytic digest, the point at which the majority of the Glu-X peptide 
bonds will have been depleted (based on the manufacturer’s recommended 
digest time). 
 
The first step in this experiment was thus to identify Glu-C cleaved BSA peptides 
which are digested at Glu, but which contain one or more Asp residues, the 
results of which are shown on Figure 5-7. 
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Figure 5-7: Proteolytic peptides obtained from BSA cleaved with Glu-C at Glu, 
but which contain Asp.  A theoretical Glu-C catalysed digestion was performed 
on BSA, identifying any peptides which were cleaved at Glu exclusively, but 
which contained Asp. Highlighted in yellow are those Glu-C cleaved peptides, 
while the residue marked in red is a Glu-C cleavage site between two such 
peptides. 
 
From Figure 5-7, we can see that some four Glu cleaved, Asp containing BSA 
peptides were identified. These digest solutions were spotted to a 384 well 
MALDI plate and ionised in an Ultraflex II MS. Analysis of the resulting MS data 
revealed that only one peptide was detected at a high intensity, peptide 
AKDAFLGSFLYE, while peptides DKGACLLPKIE and LTEFAKTCVADE were barely 
detectable above the spectrum background noise and no signal was detected for 
peptide DKDVCKNYQE. Therefore, the intensity of peptide AKDAFLGSFLYE alone 
was recorded at each of the ten digest time points, as to detect any residual Asp 
based cleavage.  
 
So as to increase the reliability of the results obtained, PepMix II MALDI 
calibration standard was added to each of the digest spots. By assessing any 
change in the ionisation response to these known calibrants, the intensity of 
peptide AKDAFLGSFLYE could be adjusted so as to account for any variation in 
analyte-matrix co-crystallisation. 
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Figure 5-8: The peak intensities obtained for three PepMix II calibration 
standards.  The peak intensities detected for three molecules from the PepMix II 
calibration standard, ionised on an Ultraflex II MS. 1 µL of the PepMix II 
calibration standard was added to each of the BSA digest MALDI spots, enabling 
any variations in signal intensity detected to be used to normalise the ion 
intensity detected for peptide AKDAFLGSFLYE. 
 
Figure 5-8 shows the ion intensity/MS response detected for the three small 
molecules from the PepMix II calibration standard, and while the ion intensity 
for peaks 1347 m/z and 1619 m/z appears stable over the time course, each 
achieving an R2 value of 0.01, peak 1046 m/z has presented with a slight 
increase in intensity over the course of the digest, achieving an R2 value of 0.39. 
While an actual change in quantity is not possible, this increase in intensity may 
instead be due to Angiotension II (peak 1046 m/z) being the smallest of the 
molecules detected, and as such may have been more prone to ion suppression 
and analyte-matrix co-crystallisation conditions. 
 
The data collected from these PepMix II molecules was averaged for each time 
point and this data set compared to an overall average value for the PepMix II 
batch. Any variations detected in the MS response to the PepMix II molecules was 
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used to adjust the ion intensity detected for peptide AKDAFLGSFLYE at each 
time point, as is shown on Figure 5-9. 
 
 
Figure 5-9: The ion intensity detected for Glu-C cleaved peptide 
AKDAFLGSFLYE.  The ion intensity detected for Glu-C cleaved BSA peptide 
AKDAFLGSFLYE, as digested over a ten hour time period (between 10 and 20 
hours). This peptide was selected due to its cleavage at Glu exclusively, while 
containing an Asp residue, enabling the detection of any residual Asp based 
cleavage. The ion intensity detected for peptide AKDAFLGSFLYE during this 
analysis was normalised based on the signal response detected for three PepMix 
II calibrants, so as to account for any variation in ionisation efficiency/analyte-
matrix co-crystallisation conditions. 
 
From Figure 5-9 it is clear that there is a slight increase in the amount of 
peptide AKDAFLGSFLYE detected over the course of the experiment, achieving 
an R2 value of 0.35. This would suggest that the Glu-C catalysed digestion of BSA 
has continued slowly, right up until the experiment was terminated. If any 
residual Asp based cleavage was present, then the quantity of peptide 
AKDAFLGSFLYE would have been expected to fall, however this appeared to not 
be the case. Indeed even if a small number of Asp bonds were cleaved upon the 
depletion of Glu catalysed digest sites during an in-gel digestion, this residual 
activity should affect both the target and synthetic peptides equally.  
240 
 
In conclusion; as no residual Asp based cleavage was detected during the Glu-C 
catalysed digestion of BSA, therefore the selection and use of peptides cleaved 
at Glu, but which contain Asp, would appear to be a suitable approach. 
 
5.4.3 MRM Based Acquisition 
5.4.3.1 MRM Method Development 
Having previously detailed the technique through which suitable Q1 and Q3 
masses were selected, the optimisation of the collision energy for each 
transition and the selection of a suitable dwell time for each of the MRM 
transitions, none of these techniques will be discussed here. Instead, shown on 
Table 5-2 is the complete MRM acquisition method designed for the detection of 
the five AQUA peptides, and thus capable of quantifying each of the four known 
PDE4B isoforms. 
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Table 5-2: The MRM transitions selected for the detection of each of the 
PDE4B peptides.  The acquisition method developed for the detection of each of 
the five PDE4B isoforms; detailing the Q1 and Q3 MRM transitions, the Q2 
optimised collision energies and the dwell times selected for each transition. 
Peptide Sequence (Q1) Fragment Ion (Q3) Q1 m/z Q3 m/z Dwell Time (ms) Collision Energy (eV) 
NSPCFFR B2 464.2 202.1 60 20 
NSPCFFR Y4 464.2 629.3 60 25 
NSPCFFR Y5 464.2 726.3 60 20 
NSP*CFFR B2 467.2 202.1 60 20 
NSP*CFFR Y4 467.2 629.3 60 25 
NSP*CFFR Y5 467.2 732.3 60 20 
TIQTYRSVSE Y2 592.3 235.1 60 25 
TIQTYRSVSE Y7 592.3 841.4 60 25 
TIQTYRSVSE Y8 592.3 969.5 60 20 
TIQTYR*SVSE Y2 597.3 235.1 60 25 
TIQTYR*SVSE Y7 597.3 851.4 60 25 
TIQTYR*SVSE Y8 597.3 979.5 60 20 
VNPQEESYQK Y4 611.3 525.3 60 35 
VNPQEESYQK Y6 611.3 783.4 60 30 
VNPQEESYQK Y8 611.3 1008.5 60 30 
VNP*QEESYQK Y4 614.3 525.3 60 35 
VNP*QEESYQK Y6 614.3 783.4 60 30 
VNP*QEESYQK Y8 614.3 1014.5 60 30 
TDIDIATE B5 877.4 558.3 60 30 
TDIDIATE B6 877.4 629.3 60 30 
TDIDIATE B7 877.4 730.4 60 30 
TDI*DIATE B5 884.4 565.3 60 30 
TDI*DIATE B6 884.4 636.3 60 30 
TDI*DIATE B7 884.4 737.4 60 30 
DYFECSLSK B2 574.8 279.1 60 20 
DYFECSLSK Y6 574.8 723.3 60 20 
DYFECSLSK Y7 574.8 870.4 60 20 
DYF*ECSLSK B2 579.8 279.1 60 20 
DYF*ECSLSK Y6 579.8 723.3 60 20 
DYF*ECSLSK Y7 579.8 880.4 60 20 
 
5.4.3.2 MRM Linear Response and LoD on an API 2000 
As was performed for each of the A-Raf peptides, each PDE4B AQUA peptide was 
injected onto an Ultimate 3000 HPLC and detected on an API 2000 MS using the 
previously devised PDE4B MRM acquisition method. Each peptide was injected at 
eight different quantities, ranging from 5 pmol to 100 amol, and analysed 
through Analyst software package, version 4.2. Each peak automatically selected 
by the quantitation software was reviewed manually, so as to avoid erroneous 
peak integration. The results from this experiment are shown on Table 5-3.  
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Table 5-3: The LoD’s achieved for each of the PDE4B MRM transitions, as 
detected on an API 2000.  The data obtained when eight different quantities of 
each AQUA peptide, ranging from 5 pmol to 100 amol, were injected. Shown are 
the peak areas detected, in counts per second (cps), summed over the width of 
the peak. As no peaks were detected below 50 fmol, the results from these 
experiments were omitted. 
Peptide Q3 Ion 5 pmol 1 pmol 200 fmol 50 fmol 
NSP*CFFR B2 2.72E+005 1.82E+004 8.41E+002 0.00E+000 
NSP*CFFR Y4 4.81E+004 3.27E+003 2.60E+002 0.00E+000 
NSP*CFFR Y5 1.10E+005 7.75E+003 4.20E+002 0.00E+000 
TIQTYR*SVSE Y2 1.35E+005 3.09E+004 9.68E+003 4.05E+002 
TIQTYR*SVSE Y7 2.79E+004 6.33E+003 1.80E+003 2.58E+002 
TIQTYR*SVSE Y8 4.45E+004 9.63E+003 3.24E+003 4.30E+002 
VNP*QEESYQK B5 3.77E+004 8.11E+003 1.00E+003 0.00E+000 
VNP*QEESYQK B6 3.01E+004 5.53E+003 1.40E+003 0.00E+000 
VNP*QEESYQK B7 1.15E+005 2.18E+004 4.27E+003 0.00E+000 
TDI*DIATE B2 7.18E+004 1.90E+004 3.78E+003 1.07E+003 
TDI*DIATE Y6 5.89E+004 1.62E+004 3.49E+003 7.71E+002 
TDI*DIATE Y7 2.32E+004 7.22E+003 1.49E+003 3.68E+002 
DYF*ECSLSK B2 1.16E+005 7.01E+003 1.45E+003 0.00E+000 
DYF*ECSLSK Y4 3.30E+004 1.15E+003 4.23E+002 0.00E+000 
DYF*ECSLSK Y5 4.41E+004 1.43E+003 5.85E+002 0.00E+000 
 
From Table 5-3 it is clear that there are varying LoDs for each of the PDE4B 
isoforms, for example, AQUA peptides TDI*DIATE and TIQTYR*SVSE could be 
detected on the API 2000 when 50 fmol of either peptide was injected. It should, 
therefore, be possible to quantify both short and super-short PDE4B isoforms, 
PDE4B2 and PDE4B5, in a sample containing 50 fmol or more of each protein and 
to achieve a linear MS response (Figure 5-10). As AQUA peptides NSP*CFFR, 
DYF*ECSLSK and VNP*QEESYQK were only detected when 200 fmol of peptide was 
injected, however, then the LoD for long-PDE4B isoforms PDE4B1, PDE4B3 and 
PDE4B4 on an API 2000 was set to 200 fmol.  
 
243 
 
 
Figure 5-10: The signal intensity and LoD achieved for PDE4B AQUA peptide 
TDI*DIATE.  The peak areas obtained during the analysis of three TDI*DIATE 
transitions, when injected at eight quantities, ranging from 5 pmol to 100 amol, 
on an API 2000 MS. This data is presented in a logarithm format, plotting the 
amount of peptide added against the summed signal intensity. Linear trend lines 
are included for each transition, showing the R2 values for each equation. 
 
5.4.3.3 LoD on a QTrap 5500 
As was the case when quantifying each of the A-Raf protein isoforms, when 
instrument time became available on a more powerful triple quadrupole based 
MS, the LoD for the lowest performing PDE4B AQUA peptide was re-analysed. 
The reason for this switch in instrument was to increase the sensitivity of the 
MRM based acquisition method, and in doing so, lowering the LoD for each of the 
PDE4B peptides, thereby reducing the quantity of sample required for an 
analysis to be performed.  
 
While previously the LoD for each of the long-PDE4B isoforms was found to be 
200 fmol, due to the low ionisation efficiencies detected for peptides NSP*CFFR, 
DYF*ECSLSK and VNP*QEESYQK, the lowest ion intensity was detected for PDE4B3 
peptide NSP*CFFR (Table 5-3). AQUA peptide NSP*CFFR was thus injected onto 
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an Ultimate 3000 HPLC and analysed on a QTrap 5500 at eight different 
quantities, the results of which are shown on Table 5-4. 
 
Table 5-4: The LoD’s achieved for each NSP*CFFR transition, as detected on a 
QTrap 5500 MS.  Eight quantities of alkylated AQUA peptide NSP*CFFR were 
injected on an Ultimate 3000 HPLC and detected on a QTrap 5500, using the 
previously devised PDE4B MRM based acquisition method. Both the peak height 
and peak area were measured and summed, with cps denoting counts per 
second. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From Table 5-4 it is clear that the LoD for PDE4B3 peptide NSP*CFFR on a QTrap 
5500 is 2 fmol, the lowest quantity at which all three peptide transitions could 
be detected above the background noise. As the LoD for peptide NSP*CFFR on an 
API 2000 was 200 fmol, this change in instrument has presented a 100 fold 
increase in sensitivity. While the manufacturer has documented the LoD for 
Reserpine to have increased 1000 fold from the API 2000 to the QTrap 5500, this 
increase in sensitivity failed to be achieved during the analysis of A-Raf peptide 
GL*NQDCCVVYR, which showed only a 5 fold increase. This low sensitivity may 
have in part been due to sub-optimal instrument parameters, where altering the 
Fragment Quantity Analyte Peak Area (cps) Analyte Peak Height (cps) Analyte SNR 
B2 5 pmol 7.84E+07 4.81E+06 2.11E+05 
Y4 5 pmol 5.66E+07 3.54E+06 3.07E+05 
Y5 5 pmol 1.10E+08 6.45E+06 5.54E+05 
B2 1 pmol 2.01E+06 1.35E+05 5.08E+03 
Y4 1 pmol 1.45E+06 9.94E+04 7.67E+03 
Y5 1 pmol 3.00E+06 1.95E+05 2.19E+04 
B2 200 fmol 3.83E+05 2.70E+04 9.48E+02 
Y4 200 fmol 2.74E+05 1.86E+04 1.35E+03 
Y5 200 fmol 5.82E+05 4.00E+04 4.08E+03 
B2 50 fmol 6.04E+04 4.01E+03 1.47E+02 
Y4 50 fmol 4.25E+04 2.81E+03 1.92E+02 
Y5 50 fmol 9.10E+04 6.93E+03 8.22E+02 
B2 10 fmol 2.71E+04 1.77E+03 6.01E+01 
Y4 10 fmol 2.24E+04 1.36E+03 8.13E+01 
Y5 10 fmol 4.19E+04 2.81E+03 2.63E+02 
B2 2 fmol 2.01E+03 2.44E+02 8.76E+00 
Y4 2 fmol 1.20E+03 2.33E+02 1.82E+01 
Y5 2 fmol 2.86E+03 2.86E+02 3.37E+01 
B2 500 amol 0.00E+00 0.00E+00 N/A 
Y4 500 amol 0.00E+00 0.00E+00 N/A 
Y5 500 amol 0.00E+00 0.00E+00 N/A 
B2 100 amol 0.00E+00 0.00E+00 N/A 
Y4 100 amol 0.00E+00 0.00E+00 N/A 
Y5 100 amol 0.00E+00 0.00E+00 N/A 
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declustering potential, collision cell exit potential and gas flow rates may have 
lowered the LoD. 
 
5.4.4 PDE4B Protein Production 
With a LoD similar to that of A-Raf, and an effective technique for protein 
production already developed, it was the author’s intention for the PDE4B 
plasmids to be transfected into HEK293 cells using Genejuice transfection 
reagent, expressed exogenously, and purified via IP. Unlike the A-Raf plasmids 
however, the PDE4B genes were supplied in a pEE7 vector designed by Celltech 
in 1989 (Stephens and Cockett, 1989). While the use of an alternative plasmid 
was in itself not a problem, no sequence information could be obtained as to the 
up and downstream regulatory domains of the pEE7 plasmid, preventing the 
PDE4B isoforms from being FLAG tagged. Furthermore, when the PDE4B plasmids 
were amplified and purified via Midiprep, the plasmid yields were on average 10 
fold lower than those obtained for A-Raf (data not shown). By way of an example 
of the scale of the problem, a typical A-Raf transfection batch would utilise six 
150 x 25 mm tissue culture plates and require a total of 120 ng of plasmid. As 
each 50 mL midiprep reaction yielded only 20 ng of plasmid on average, protein 
production on this scale became unviable. Instead it was decided that the PDE4B 
inserts should be transferred to pcDNA3, and each isoform supplemented with an 
N-terminal FLAG tag so as to enable purification. In order to achieve this aim, 
the pEE7 based PDE4B plasmids were first partially sequenced to identify 
suitable up and downstream restriction digest sites, the inserts ligated into 
pcDNA3, and suitable N-terminal FLAG tags designed for each species. In brief, a 
FLAG tag consists of an artificial 8-amino acid peptide sequence, which in theory 
does not occur in nature and thus an anti-flag antibody based IP should be 
specific to the FLAG tagged target protein. Furthermore, as the FLAG tag is 
designed to be hydrophilic, it should be located on the surface of the protein, 
ensuring the sequence is available for anti-FLAG binding. 
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5.4.4.1 Sequencing PDE4B in a pEE7 Vector  
As the only source of literature to be identified detailing the construction of the 
pEE7 plasmid noted the presence of a HCMV promoter and an SV40 poly(A) 
(Stephens and Cockett, 1989), each of the PDE4B plasmids were sequenced with 
both of the above primers. While the HCMV promoter appeared to be present 
within the pEE7 plasmid (the sequence data obtained is not shown), the data in 
no way aligned with any published Homo sapiens PDE4B sequence, though many 
non-PDE4B alignments were achieved, suggesting the sequence may instead have 
originated from the pEE7 plasmid. When the SV40 sequence data was aligned via 
a nucleotide BLAST search, however, a stretch of shared PDE4B sequence was 
revealed, from the catalytic domain of the PDE4B isoforms, to just downstream 
of each insert, showing both EcoRI and BamHI restriction digest sites. 
 
Based on the sequence data obtained from the SV40 primer, a custom 21 mer 
reverse primer was created “GTTCAGCATTCTTTTGAACTT” (PDE4B_SEQ), capable 
of sequencing the UCRs and upstream regulatory domains of the pEE7 plasmid. In 
addition to confirming the sequence of each PDE4B isozyme, the sequence 
obtained through the use of PDE4B_SEQ primer revealed the PDE4B1 and PDE4B3 
inserts to be preceded by both EcoRI and HindIII restriction digest sites, while 
PDE4B2 was found to be preceded by HindIII. 
 
5.4.4.2 Transfer of the PDE4B Inserts to pcDNA3 and pcDNA3.1(+) 
In terms of the selection of suitable restriction enzymes for the transfer of the 
PDE4B inserts from pEE7 to pcDNA3, both long-PDE4B isozymes PDE4B1 and 
PDE4B3 were found to be preceded by both EcoRI and HindIII and proceeded by 
both EcoRI and BamHI. During the sequencing of the PDE4B1 and PDE4B3 UCRs 
with PDE4B_SEQ however, both isozymes were found to contain an additional 
BamHI restriction digest site, discounting the use of this restriction enzyme.  
 
With EcoRI thus selected as the 3’ restriction enzyme, both EcoRI and HindIII 
were identified as suitable 5’ restriction enzymes for the forward insertion of 
PDE4B1 and PDE4B3 into pcDNA3, though neither was completely ideal. In the 
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case of utilising EcoRI as both the 3 and 5’ restriction digest site, this risked the 
ligation of multiple inserts per plasmid or the insert being incorrectly 
orientated. While the use of HindIII as the 5’ digest site appeared more trivial, it 
was discovered that HindIII was the first restriction digest site after the pcDNA3 
T7 promoter, making the insertion of a FLAG-tag more complicated. As such, 
EcoRI was selected as the single restriction enzyme for the cleavage of both 
PDE4B1 and PDE4B3 from pEE7.    
 
In contrast, short-PDE4B isoform, PDE4B2, was found to be preceded by HindIII 
exclusively, making it the only choice, while being proceeded by both EcoRI and 
BamHI, each of which were suitable for the forward ligation of PDE4B2 into 
pcDNA3. Of these two enzymes, BamHI was finally selected as it yielded the 
shorter insert of the two.  
 
One problem which was encountered with the transfer of PDE4B2 to pcDNA3 
resulted from the use of non-optional 5’ restriction digest site HindIII, which as 
previously discussed, was found to immediately precede the T7 promoter in 
pcDNA3. As to prevent further problems arising during the insertion of a FLAG-
tag, PDE4B2 was instead ligated into pcDNA3.1(+), which featured several 
additional restriction digest sites upstream of HindIII. 
 
5.4.4.3 Incorporation of FLAG-tags into the PDE4B Plasmids 
Several components are required for the incorporation of a successful N-terminal 
FLAG tag, these include: (i) The identification of several restriction digest sites 
between the promoter of the vector and the start codon of the insert, and (ii) 
The incorporation of a double stranded insert which: (a) Contains restriction 
digest sites complementary to those used to cleave from the plasmid, featuring 
an overhang ready for ligation. (b) Contains an appropriate sequence for the 
expression of a FLAG-tag. (c) Contains an additional restriction digest site 
upstream of the FLAG-tag, ideally not present within the vector, for the purpose 
of screening colonies post cloning. (d) Contains a start codon, and (e) Maintains 
the correct reading frame through the incorporation of an appropriate number of 
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additional nucleotides, while ensuring the additional sequence does not 
inadvertently contain a stop codon, which would terminate translation. 
 
In the case of long-PDE4B isoforms PDE4B1 and PDE4B3, both of which were 
ligated into pcDNA3 with EcoRI, a shared double stranded insert was designed to 
replace a stretch of sequence cleaved from the pcDNA3 vector, stretching from 
the HindIII restriction digest site (immediately downstream of the T7 promoter) 
to the BamHI restriction digest site (immediately upstream of the EcoRI 
restriction digest site). The final sequences for these single stranded primers are 
“AGCTTGGTACCTATGGATTACAAGGATGACGACGATAAGACG” for PDE1&3FLAGFor, 
and “GATCCGTCTTATCGTCGTCATCCTTGTAATCCATAGGTACCA” for 
PDE1&3FLAGRev, the components of which are more fully explained on Figures 
5-11 and 5-12, for PDE4B isoforms PDE4B1 and PDE4B3, respectively. 
 
 
Figure 5-11: The design of the N-terminal FLAG-tag to be inserted into 
PDE4B1 in pcDNA3.  The components required for a successful FLAG-tag capable 
of spanning the gap between HindIII (marked in red) and BamHI (marked in 
purple) in pcDNA3, enabling the rapid purification of the PDE4B protein. 
Included within the FLAG-tag insert are a KpnI restriction digest site (marked in 
orange), an ATG (Met) start codon (marked in green), the sequence for the 
FLAG-tag (marked in blue) and some additional sequence intended to maintain 
the correct reading frame (retained in black). 
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Figure 5-12: The design of the N-terminal FLAG-tag to be inserted into 
PDE4B3 in pcDNA3.  The components required for a successful FLAG-tag capable 
of spanning the gap between HindIII (marked in red) and BamHI (marked in 
purple) in pcDNA3, enabling the rapid purification of the PDE4B protein. 
Included within the FLAG-tag insert are a KpnI restriction digest site (marked in 
orange), an ATG (Met) start codon (marked in green), the sequence for the 
FLAG-tag (marked in blue) and some additional sequence intended to maintain 
the correct reading frame (retained in black). 
 
In the case of short-PDE4B isozyme PDE4B2, ligated into pcDNA3.1(+) with both 
HindIII and BamHI, a double stranded insert was designed to replace a stretch of 
sequence spanning from the NheI restriction digest site (immediately 
downstream of the T7 promoter), to the HindIII restriction digest site (the 3’ site 
at which PDE4B2 was ligated). The final sequence for these single stranded 
inserts was “CTAGCGCGGCCGCATGGATTACAAGGATGACGACGATAAGA” for B2-
PC3.1Forward and “AGCTTCTTATCGTCGTCATCCTTGTAATCCATGCGGCCGCG” for 
B2-PC3.1Reverse, the structures of which are more fully explained on Figure 5-
13. 
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Figure 5-13: The design of the N-terminal FLAG-tag to be inserted into 
PDE4B2 in pcDNA3.1(+).  The components required for a successful FLAG-tag 
capable of spanning the gap between NheI (marked in orange) and HindIII 
(marked in red) in pcDNA3.1(+), enabling the rapid purification of the PDE4B 
protein. Included within the FLAG-tag insert are a NotI restriction digest site 
(marked in scarlet), an ATG (Met) start codon (marked in green), the sequence 
for the FLAG-tag (marked in blue) and some additional sequence intended to 
maintain the correct reading frame (retained in black). 
 
5.4.5 Spiked Digest Based Quantitative Analyses 
So as to assess the efficiency with which each of the target peptides were 
digested (through comparing peak area ratios for each target peptide/protease, 
each of which should be present at an equal ratio), to identify any problems 
resulting from the re-suspension and modification of each AQUA peptide (which 
would result in a specific peptide presenting with a different peak area ratio), 
and to test the AQUA based absolute quantification workflow; 25 µL of each 
PDE4B transfected HEK93 IP was loaded onto an SDS-PAGE gel and 
electrophoresed. The PDE4B isoform containing gel bands were excised and in-
gel digested in the presence of each AQUA peptide. Following peptide extraction 
the samples were loaded onto an Ultimate 3000 LC and analysed on a QTrap 
4000 MS, running the PDE4B MRM acquisition method previously detailed. 
 
If we consider that each transfected plate contains some 1.1x108 HEK293 cells, 
and that six plates were transfected per isoform, then a total of 6.6x108 cells 
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were lysed, and the transfected protein immunoprecipitated. If we then 
consider that the anti-FLAG beads were re-suspended in 360 µL of protein 
loading buffer, then the 25 µL of IP loaded to each SDS-PAGE gel well should 
contain the transfected, immunoprecipitated contents of approximately 4.6x107 
HEP293 cells. 
 
While only three of the five PDE4B plasmids were transfected (PDE4B1, PDE4B2 
and PDE4B3), together these three PDE4B isoforms contained each of the five 
PDE4B AQUA peptides, thus enabling each to be analysed. 
 
5.4.5.1 PDE4B1 Single Isoform Spiked Digest 
As was performed during the spiked digestion of A-Raf, 25 µL of PDE4B1 
transfected HEK293 IP was digested with either trypsin, or Glu-C, in the 
presence of each of the PDE4B AQUA peptides. Three transitions per peptide 
were analysed and the data averaged. A total of five digest replicates were 
performed and each replicate injected twice, the data from which is shown on 
Table 5-5. 
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Table 5-5: The quantity and variation data obtained from the spiked digestion 
of 25 µL of immunoprecipitated PDE4B1 on a QTrap 4000.  Through comparing 
the peak areas for both the synthetic and endogenous PDE4B peptides, three 
sets of quantities were obtained per peptide, per replicate. These values were 
averaged, so as to obtain a single quantity per peptide, per replicate, and a CoV 
determined for this value. Further to the above, an overall average was 
calculated for each value. 
 
TIQTYRSVSE – Present in all but PDE4B5 TDIDIATE – Present in all isoforms 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1-1 2.28 1.09% 1.62 6.62% 
1-2 2.25 6.03% 1.76 15.07% 
2-1 2.03 1.84% 2.83 27.81% 
2-2 1.99 2.71% 2.67 35.93% 
3-1 2.18 2.69% 2.29 23.37% 
3-2 2.21 2.52% 2.26 14.44% 
4-1 2.10 1.19% 2.22 27.05% 
4-2 2.10 0.02% 2.17 25.37% 
5-1 2.51 2.69% 2.56 1.27% 
5-2 2.51 2.80% 2.53 2.19% 
Average 2.21 8.36% 2.29 24.74% 
 
VNPQEESYQK – Present in PDE4B1, 3 and 4 DYFECSLSK – Unique to PDE4B1 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1-1 2.99 4.91% 3.63 3.25% 
1-2 3.03 4.76% 3.61 3.05% 
2-1 2.98 6.11% 3.51 2.93% 
2-2 2.98 5.63% 3.56 3.24% 
3-1 2.72 4.68% 3.20 2.48% 
3-2 2.74 5.99% 3.23 3.44% 
4-1 3.04 5.42% 3.41 2.56% 
4-2 3.03 5.36% 3.41 3.30% 
5-1 2.66 5.55% 3.35 2.41% 
5-2 2.71 6.17% 3.40 3.74% 
Average 2.89 6.94% 3.43 4.91% 
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Figure 5-14: The quantities of each PDE4B1 target peptide detected during 
the spiked digestion of PDE4B1 transfected HEK293 IP on a QTrap 4000.  The 
amount of each PDE4B1 target peptide detected during the spiked digestion of 
25 µL of PDE4B1 transfected HEK293 IP is shown. In brief, this single quantity, 
per peptide, was calculated through comparing the peak areas for three MRM 
transitions per peptide, per replicate, and the values averaged. A CoV value was 
determined for this averaged value. This bar chart helps to visualise the 
variation detected between both peptides and replicates. 
 
The data presented on Table 5-5 and Figure 5-14 is interesting as each peptide 
initially appears to be detected at a different level. Throughout the batch, 
however, the peptides cleaved with Glu-C (TIQTYRSVSE and TDIDIATE) appear to 
be detected at levels closer to those detected for tryptic peptide VNPQEESYQK. 
As each digest replicate was performed on the same PDE4B1 transfected IP and 
each digest conducted under the same conditions, this variation can only be 
attribute to either the HPLC column or the ESI needle, either of which may have 
required further equilibration so as to enable optimal peptide binding and 
elution, or for a more stable ESI spray. Figure 5-15 provides evidence of this 
increase in ion intensity over the course of the batch. 
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Figure 5-15: The increasing ion intensity detected over the course of an MRM 
based LC-MS/MS analysis of Glu-C cleaved PDE4B1.  The increase in ion 
intensity detected for AQUA peptide TIQTYRSVSE, fragment Y2, and AQUA 
peptide TDIDIATE, fragment B5, over the course of a batch of five Glu-C digested 
PDE4B1 transfected HEK293 IP replicates. 
 
As only a single spiked digest replicate was considered accurate, then an ANOVA 
based statistical analysis was not performed. From reviewing the data presented 
on Table 5-5 however, the quantity of peptide DYFECSLSK detected during the 
spiked digestion of 25 µL of PDE4B1 transfected HEK293 IP, was approximately 
40% higher than that obtained for each of the other peptides. As was the case 
with AQUA peptide GL*NQDCCVVYR, this variation may be due to the additional 
processing (in-solution alkylation and vacuum centrifugation) which this Cys 
containing AQUA peptide was subjected to, prior to in-gel digestion. 
 
5.4.5.2 PDE4B2 Single Isoform Spiked Digest 
Twenty-five micro litres of PDE4B2 transfected HEK293 cell IP was digested with 
Glu-C in the presence of each of the PDE4B AQUA peptides, three transitions per 
peptide were analysed, and the data averaged. A total of five digest replicates 
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were performed, injecting each replicate twice, the data from which is shown 
on Table 5-6. 
 
Table 5-6: The quantity and variation data obtained during the spiked 
digestion of 25 µL of immunoprecipitated PDE4B2 on a QTrap 4000.  Through 
comparing the peak areas for both the synthetic and endogenous PDE4B 
peptides, three sets of quantitation values were obtained, per peptide, per 
replicate. These values were averaged, so as to obtain a single quantity, per 
peptide, per replicate, and a CoV determined for this value. Further to the 
above, an overall average was calculated for each value. 
 
TIQTYRSVSE – Present in all but PDE4B5 TDIDIATE – Present in all isoforms 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1-1 0.38 4.88% 0.81 59.67% 
1-2 0.38 1.41% 0.78 60.39% 
2-1 0.42 2.85% 0.80 54.99% 
2-2 0.42 5.03% 0.84 59.27% 
3-1 0.35 2.65% 0.67 68.18% 
3-2 0.35 1.73% 0.72 67.58% 
4-1 0.34 1.93% 0.78 66.76% 
4-2 0.35 2.37% 0.67 61.74% 
5-1 0.35 5.84% 0.67 69.69% 
5-2 0.35 5.82% 0.66 59.34% 
Average 0.37 9.01% 0.74 52.90% 
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Figure 5-16: The quantities of each PDE4B2 target peptide detected during 
the spiked digestion of PDE4B2 transfected HEK293 IP on a QTrap 4000.  The 
amount of each PDE4B2 target peptide detected during the spiked digestion of 
25 µL of PDE4B2 transfected HEK293 IP is shown. In brief, this single quantity, 
per peptide, was calculated through comparing the peak areas for three MRM 
transitions per peptide, per replicate, and the values averaged. A CoV value was 
determined for this averaged value. This bar chart helps to visualise the 
variation detected between both each peptide and each replicate. 
 
As is shown on Table 5-6 and Figure 5-16, despite PDE4B2 being digested with 
only one protease, and containing just two peptides, the results obtained for 
this isozyme appeared more variable than those achieved during the analysis of 
PDE4B1 (Table 5-5). While peptide TIQTYRSVSE achieved an average CoV of less 
than 10%, peptide TDIDIATE achieved a CoV of 52.9%, warranting further 
investigation.  
 
So as to assess if there was any variation between the means of peptides 
TIQTYRSVSE and TDIDIATE, assuming a normal distribution, a two-tailed T-test 
was performed. During this test, a H0, that the means of these groups were 
equal, was stated. This analysis was performed based upon an alpha level of 
0.05, giving a critical P-value of 2.1, which if exceeded, would require the H0 to 
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be rejected. As is shown on Table 5-7, a P-value of 7x1012 was achieved, 
therefore the H0 was rejected, indicating that the mean quantification values 
achieved for these peptides was different.  
 
Table 5-7: A T-test based statistical analysis performed on the data obtained 
from the spiked digest of PDE4B2.  A T-test based statistical analysis assessing 
the quantitation data obtained for peptides TIQTYRSVSE and TDIDIATE. This test 
was performed so as to assess if each data set contained an equal level of 
variation. Highlighted in yellow is the two-tailed P value, where a figure above 
2.1 would suggest there to be significant variation between the two groups in 
95% of cases.  
  TIQTYRSVSE TDIDIATE 
Mean 0.369 0.74 
Variance 0.000898889 0.0048 
Observations 10 10 
P(T<=t) two-tail 7.11469E-12 
  
Upon further investigating the data obtained for peptide TDIDIATE, fragment B5 
was found to be present at a level more than three times higher than that 
achieved for peptide TIQTYRSVSE (Table 5-6). However, when TDIDIATE 
fragment B6 alone was analysed, the amount of peptide TDIDIATE detected in 
the sample was identical to the amount of peptide TIQTYRSVSE detected (Table 
5-8).  
 
Table 5-8: The amount of PDE4B2 detected, based upon the quantitation of 
for each TDIDIATE transition, during the spiked digestion of PDE4B2 
transfected HEK293 IP on a QTrap 4000.  The amount of peptide TDIDIATE 
detected within 25 µL of PDE4B2 transfected HEK293 IP, based upon a 
quantitation performed with each of the three TDIDIATE transitions. 
 
TDIDIATE transition (pmol/µL) 
Replicate B5 B6 B7 
1-1 1.34 0.39 0.70 
1-2 1.30 0.38 0.66 
2-1 1.27 0.40 0.73 
2-2 1.38 0.42 0.71 
3-1 1.18 0.33 0.49 
3-2 1.28 0.38 0.50 
4-1 1.36 0.39 0.57 
4-2 1.13 0.34 0.52 
5-1 1.20 0.29 0.53 
5-2 1.09 0.34 0.54 
Average 1.25 0.37 0.60 
 
When the MRM spectra obtained for fragment B5 were analysed, it was found 
that several highly intense co-eluting peaks were present. In addition, fragment 
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B5 was only the second most intense peak detected in the spectrum. It is 
therefore possible that beneath the target peak, there may also be a co-eluting 
matrix peak, which certainly would explain the higher than expected 
quantitation data obtained (Figure 5-17). 
 
 
Figure 5-17: The XIC spectra obtained for TDIDIATE transitions B5 and B6, 
during the spiked digestion of 25 µL of PDE4B2 transfected HEK293 IP.  The 
XIC spectra obtained for TDIDIATE transitions B5 (A) and B6 (B) during the analysis 
of 25 µL of PDE4B2 transfected HEK293 IP. Shown on spectrum A are the high 
intensity non-target peaks detected, eluting at a time similar to that of peptide 
TDIDIATE. While similar peaks were detected in spectrum B, these were of a 
lower intensity. 
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As the majority of the work conducted during this study was performed on a 
relatively insensitive API 2000, then both the Q1 and Q3 transmission windows 
were set to a low resolution, permitting ions within 1.2 ± 0.2 amu of the target 
m/z, to obtain the best possible limits of detection. This hardware profile, 
however, also permits more noise to reach the detector, including co-eluting 
peaks, which may interfere with an accurate quantification of the target and 
synthetic peptides. On transferring this acquisition method to a more sensitive 
MS, such as the QTrap 4000, it may be more prudent to select a more restrictive 
transmission window as to reduce excessive noise, such as that detected during 
the quantitative analysis of PDE4B2. 
 
5.4.5.3 PDE4B3 Single Isoform Spiked Digest 
Twenty-five micro litres of PDE4B3 transfected HEK293 cell IP was digested with 
either trypsin, Glu-C or Arg-C, in the presence of each of the PDE4B AQUA 
peptides. Three fragment ions were analysed per peptide, and the data 
averaged. A total of five digest replicates were performed and each replicate 
injected twice, the data from which is shown on Table 5-9. 
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Table 5-9: The quantity and variation data obtained during the spiked 
digestion of 25 µL of immunoprecipitated PDE4B3 on a QTrap 4000.  Through 
comparing the peak areas for both the synthetic and endogenous PDE4B 
peptides, three sets of quantities were obtained, per peptide, per replicate. 
These values were averaged, so as to obtain a single quantity, per peptide, per 
replicate, and a CoV determined for this value. Further to the above, an overall 
average was calculated for each value. 
 
TIQTYRSVSE – Present in all but PDE4B5 TDIDIATE – Present in all isoforms 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1-1 1.99 1.31% 2.59 21.63% 
1-2 2.01 2.63% 2.82 23.56% 
2-1 5.10 0.88% 2.38 22.58% 
2-2 5.11 2.14% 2.57 27.07% 
3-1 3.20 3.88% 2.79 17.83% 
3-2 3.13 2.12% 2.96 21.68% 
4-1 3.03 0.97% 3.01 15.28% 
4-2 3.02 0.83% 3.09 14.94% 
5-1 5.76 2.80% 2.66 26.81% 
5-2 5.76 1.67% 2.41 22.98% 
Average 3.81 37.37% 2.73 19.82% 
 
VNPQEESYQK – Present in PDE4B1, 3 and 4 NSPCFFR – Unique to PDE4B3 
Replicate Average per Replicate (pmol/µL) CoV Average per Replicate (pmol/µL) CoV 
1-1 4.40 38.63% 0.05 56.73% 
1-2 5.45 17.81% 0.03 45.54% 
2-1 4.02 4.56% 0.02 58.03% 
2-2 3.81 10.66% 0.02 60.36% 
3-1 5.29 14.43% 0.03 56.89% 
3-2 4.99 14.94% 0.03 68.71% 
4-1 6.43 2.24% 0.03 78.22% 
4-2 6.21 4.43% 0.02 56.77% 
5-1 4.80 9.24% 0.02 57.79% 
5-2 5.06 6.85% 0.02 49.71% 
Average 5.05 20.43% 0.02 65.15% 
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Figure 5-18: The quantity of each PDE4B3 target peptide detected during the 
spiked digestion of PDE4B3 transfected HEK293 IP on a QTrap 4000.  The 
amount of each PDE4B3 target peptide detected during the spiked digestion of 
25 µL of PDE4B3 transfected HEK293 IP is shown. In brief, this single quantity, 
per peptide, was calculated through comparing the peak areas for three MRM 
transitions per peptide, per replicate, and the values averaged. A CoV value was 
determined for this averaged value. This bar chart helps to visualise the 
variation detected between each peptide and replicate. 
 
From assessing the data shown on Table 5-9 and Figure 5-18, the levels of 
peptide NSPCFFR detected (digested with Arg-C) were seen to be extremely low. 
While this peptide contained a Cys residue, the amount of peptide detected was 
lower than expected, suggesting an inefficient digestion may have been 
responsible. Further Arg-C based digest optimisations should therefore be 
performed prior to the re-analysis of PDE4B3. Indeed, when the raw data 
obtained for peptide NSPCFFR was investigated (data not shown), no analyte 
peaks were detected, and background noise had instead been integrated, 
explaining the large CoV values obtained (with an average CoV value of 65.15%). 
Due to peptide NSPCFFR not being detected during this spiked digestion, and 
thus variation existing between the quantities of each peptide detected, an 
ANOVA based statistical analysis was not performed. 
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Figure 5-19: A typical peak detected for peptide VNPQEESYQK, fragment 
KQYS, during the spiked digestion of PDE4B3 on a QTrap 4000.  A typical XIC 
spectra obtained for each VNPQEESYQK transition, in this case showing fragment 
KQYS. In addition to the low peak heights detected (<300 counts per second), 
the peaks were dwarfed by the background noise detected during these LC-MRM 
experiments.  
 
In an attempt to further explain the variability of the data obtained during the 
analysis of PDE4B3 (Table 5-9), the individual XIC spectra were reviewed for 
each peptide and each replicate. From this review, the peak heights obtained 
for peptide VNPQEESYQK were noted to be considerably lower than those 
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achieved for the same peptide during the analysis of PDE4B isoform PDE4B1 
(data not shown). While each transition of peptide VNPQEESYQK achieved a peak 
height greater than 1x105 during the analysis of PDE4B1, each achieved a peak 
height of less than 300 cps during the analysis of PDE4B3 (Figure 5-19). As low 
peak heights were achieved for both the IS and the target peptide, it would 
appear that an inefficient proteolytic digestion was not at fault. A more likely 
explanation was the inefficient recovery of peptide VNPQEESYQK from the gel, 
or an incomplete re-suspension of peptide VNPQEESYQK after drying. 
 
When the data obtained from the Glu-C catalysed digestion of PDE4B3 alone was 
analysed, the data appeared just as variable (Table 5-9). While the levels of 
peptides TDIDIATE and TIQTYRSVSE were similar for replicates one, three and 
four, replicates two and five identified levels of peptide TIQTYRSVSE 87% and 
110% higher, respectively, than the average quantity detected for peptide 
TDIDIATE. As the XIC spectra for each of the replicates appeared normal (data 
not shown), it may have been easy to attribute this quantitation pattern to the 
amount of AQUA peptide present within the sample being less than intended. 
The MS signal response to the AQUA peptide however was constant throughout 
this batch, if slightly decreasing (Figure 5-20), making this variation hard to 
explain. 
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Figure 5-20: The MS signal intensity detected for both the TIQTYRSVSE IS and 
target peptide, over the duration of the PDE4B3 batch.  Shown on this graph 
are the peak areas detected for both TIQTYRSVSE and TIQTYR*SVSE, fragment 
ion Y2, over the duration of a PDE4B3 LC-MS/MS run. Interestingly, the IS signal 
intensity appears consistent, if slightly decreasing, while the target peptide 
response detected appears to increase during the analysis of replicates two and 
five. 
 
5.5 Conclusion 
Unlike the four A-Raf isoforms, where each contained a shared stretch of N-
terminal sequence and the protein isoforms were differentiated on unique C-
terminal sequence, each of the PDE4B isoforms contained a shared C-terminal, 
and were differentiated on a small amount of unique N-terminal sequence. In 
some ways this has made the quantification of the PDE4B isoforms more 
complicated, as a C-terminal peptide could not be selected as a last resort. 
 
As long-PDE4B isoforms PDE4B1 and PDE4B3 PDE4B had the most unique 
sequence, it was possible to select unique AQUA peptides suitable for their 
quantification. While the literature would also suggest PDE4B4 to be a long-
PDE4B isoform, no consensus sequence has as yet been published for this 
isozyme, and indeed its expression in Homo sapiens had as yet to be proven. 
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Assuming PDE4B4 was indeed expressed, then it would certainly contain both 
UCRs 1, 2 and the PDE4B shared catalytic domain, requiring its quantification so 
as to enable a subtraction based quantification to be performed on short and 
super-short PDE4B isoforms PDE4B2 and PDE4B5, respectively. A peptide was 
thus selected from UCR1, present in long-PDE4B isoforms PDE4B1, PDE4B3 and 
PDE4B4, which through the subtraction of the quantitation values obtained for 
PDE4B1 and PDE4B3, should enable PDE4B4 alone to be quantified. Likewise, 
when the selection of a peptide unique to PDE4B2 could not be identified, a 
peptide was instead selected from the N-terminal of UCR2, present in each of 
the PDE4B isoforms but super-short PDE4B isoform PDE4B5, and thus enabling 
PDE4B2 alone to be quantified though the subtraction of the quantitation value 
obtained for PDE4B isoforms PDE4B1, PDE4B3 and PDE4B4. Finally, through 
selecting a peptide located in the C-terminal of each of the five PDE4B isoforms, 
the quantification of super-short PDE4B isoform PDE4B5 was possible, again 
based on the subtraction of the known quantitation values for each of the four 
other PDE4B isoforms. 
 
In order to allow a spiked digest based analysis on each of the PDE4B isoforms, 
PDE4B1, PDE4B2 and PDE4B3 were transferred from Celltech pEE7 plasmids to 
higher copy number pcDNA3 and pcDNA3.1(+) vectors. The PDE4B plasmids were 
then FLAG-tagged so as to enable sample enrichment. Each plasmid was then 
amplified, transfected into HEK293 cells, over-expressed, and 
immunoprecipitated, ready for quantitation. 
 
Each of the five PDE4B AQUA peptides were characterised and an MRM based MS 
acquisition method developed. During the spiked digest based analysis of the 
three PDE4B isozymes, several points of interest were noted. Firstly, the LC-
MS/MS equipment took a significantly longer amount of time to equilibrate than 
was previously thought; suggesting that in future more blanks and system 
suitability tests should be run prior to the batch being submitted. Furthermore, 
with the improvements in sensitivity offered by the QTrap 4000 and QTrap 5500 
over the API 2000, an increase in co-eluting peaks was also realised. In future it 
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may be prudent to reduce the MS background through restricting the Q1 and Q3 
transmission windows to unit resolution. 
 
Finally, the Arg-C catalysed digestion of PDE4B3 was discovered to be 
incomplete. Further optimisation of this critical step should therefore be 
undertaken prior to the analysis being repeated. 
 
Several problems were encountered during the development of this quantitative 
technique, however. Firstly, despite the limited regions of unique sequence 
expressed within each of the PDE4B isoforms, it was possible to select an AQUA 
peptide suitable for the quantification of each. Secondly, each of these AQUA 
peptides selected was successfully characterised, a single MRM based acquisition 
method developed, and each target peptide and IS detected during the spiked 
digestion of the PDE4B isoforms. Finally, when the flawed and erroneous data 
had been explained, and thus could be removed, the spiked digest data obtained 
was accurate, both between peptides and indeed between proteases (trypsin 
and Glu-C).  
 
In conclusion, further to additional optimisation, the acquisition method 
developed here should be suitable for the detection and quantification of 
endogenous PDE4B populations; assuming a sensitive triple quadrupole based MS 
is available and that further steps are taken to purify the sample, so as to 
reduce the presence of interfering peaks which led to inaccurate quantitative 
data throughout this project. 
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6 Absolute Quantification of the SERCA 2 Group of 
Protein Isoforms 
6.1 Introduction 
6.1.1 P-Type ATPase 
P-type pumps constitute a superfamily of integrated membrane ATPases which 
are responsible for transporting ions and lipids across the cellular membrane 
based upon the hydrolysis of ATP (Palmgren and Nissen, 2011, Olesen et al., 
2007). Indeed, the activity of P-type ATPases are thought to account for 
approximately one-third of the energy usage in humans (Rolfe and Brown, 1997). 
The action of such pumps are thus thought to be of critical importance within 
the body, enabling homeostasis of heavy metals and the asymmetric distribution 
of lipid within the membrane (Olesen et al., 2007). Early work conducted on P-
type ATPases by Skou, found that by adding radiolabelled ADP to a Na+/K+ pump 
assay, that small amounts of radiolabelled ATP could be obtained. Skou thus 
rationalised that the intermediate step in the breakdown of ATP must be “the 
formation of a phosphorylated enzyme in which the phosphate is bound” (Skou, 
1960, Palmgren and Nissen, 2011). Two distinct conformational states of 
phosphorylated ATPase intermediate were later identified, Enzyme1-P (E1-P) 
which can be dephosphorylated through the addition of ADP, but which is 
insensitive to K+, and Enzyme2-P (E2-P) which is sensitive to K+ but insensitive to 
ADP (Whittam and Wheeler, 1970, Palmgren and Nissen, 2011). It is now known 
that the pumps E1 state can be phosphorylated to yield E1-P, and that following a 
change in conformation from E1-P to E2-P, that a simultaneous movement of ions 
across the cell membrane will occur. Likewise, when the E2-P state is 
dephosphorylated back to E2, the change in conformation from E2 to E1, will 
cause the simultaneous movement of ions (Albers, 1967), as is depicted on 
Figure 6-1. 
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Figure 6-1: The cycle of changes in conformation undergone by P-type 
ATPases, enabling the transportation of ions.  Depicted are the various 
conformations through which P-type ATPases will cycle while transporting ions 
both in and out of the cytoplasm. Conformational state “Enzyme1” initially 
accepts an ATP molecule, with which the nucleotide binding domain auto-
phosphorylates the phosphorylation domain of the enzyme, yielding an ADP 
molecule and through changing in conformation, transporting ions from the 
cytoplasm to the extracellular space. Conformational state “Enzyme2” is then 
dephosphorylated by the actuator domain, yielding an inorganic phosphorous 
(Pi), and in doing so changing in conformation back to “Enzyme1” while 
transporting ions from the extracellular space to the cytoplasm. It should be 
noted that Enzyme1 and Enzyme2 are simply names given to the various 
conformational states of the P-type ATPase, not separate biomolecules. 
 
In terms of structure, P-type ATPases have been shown to be elongated, with a 
length approximately three times that of their width. While the ATPases are 
embedded in the cell membrane, the majority of the protein forms a large 
cytoplasmic headpiece, with only a fraction of the protein exposed outside of 
the cell (Palmgren and Nissen, 2011). P-type ATPases have been shown to 
contain five functionally and structurally distinct domains, three of which are 
located within the exposed cytoplasmic headpiece, including the actuator, 
nucleotide binding and phosphorylation domains, while two are embedded in the 
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membrane, including the transport and class specific support domains. The final 
domain contained within P-type ATPases is the regulatory domain, which 
depending on the specific ATPase, can be located on either the C- or N-terminal 
and is capable of acting as an auto inhibitor to the ATPase pump molecule (Rolfe 
and Brown, 1997). 
 
During each cycle of the P-type ATPase pump mechanism, it is the nucleotide 
binding domain which is responsible for phosphorylating the ATPase at the 
phosphorylation domain, while subsequent dephosphorylation is performed by 
the actuator domain (Rolfe and Brown, 1997). 
 
6.1.2 Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 
One such group of P-type ATPases are the P2A-ATPase family of Ca2+ ion 
transporters (Olesen et al., 2007), an evolutionarily conserved group of P-type 
ATPases which are thought to be present in all living organisms, from yeast to 
mammalian systems (Brandl et al., 1987). While these pumps most likely evolved 
as a mechanism for exporting Ca2+ ions against steep transmembrane gradients 
(Devés and Brodie, 1981), their main function in mammalian cells is in the 
relaxation of muscle cells by Ca2+ ion transport from the sarcoplasm, post-action 
potential, back into the sarcoplasmic reticulum. Muscle cells contract by 
releasing Ca2+ from the sarcoplasmic reticulum into the sarcoplasm, where they 
combine with troponin, so as to establish a cross-link between actin and myosin. 
For relaxation to occur, those same Ca2+ ions must dissociate from the myofibrils 
and be pumped back into the sarcoplasmic reticulum (Berchtold et al., 2000). 
 
P2A-ATPase, or sarcoplasmic /endoplasmic reticulum calcium ATPase (SERCA), 
can also found in the endoplasmic reticulum (ER) of both muscle and non-muscle 
cells where it is responsible for maintaining calcium homeostasis by exporting 
two Ca2+ ions into the lumen of the endoplasmic reticulum per hydrolysed ATP 
molecule, counter-transporting four H+ ions into the cytoplasm in the process 
(Skou, 1960, Whittam and Wheeler, 1970). 
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While just one SERCA gene has been identified in invertebrates (Periasamy and 
Kalyanasundaram, 2007), three have been described in mammalian systems. 
Each of these three genes are highly conserved and are located on different 
chromosomes, giving rise to three separate SERCA families (SERCA1-3) and some 
11 protein isoforms (Pegoraro et al., 2011). Each isoform is thought to vary in its 
affinity towards Ca2+, its Ca2+ turnover rate, and its tissue expression pattern, 
suggesting each may contribute to the unique physiological state of the tissue in 
which it is expressed (Periasamy and Kalyanasundaram, 2007).  
 
SERCA1 has two known isoforms, SERCA1a, which encodes a 994 amino acid 
protein in adult fast-twitch skeletal muscle cells, and SERCA1b, which encodes a 
1011 amino acid protein involved in the differentiation and growth of skeletal 
myogenic tissue in foetal populations  (Brandl et al., 1987, Periasamy and 
Kalyanasundaram, 2007).  
 
SERCA2, meanwhile, has three known protein isoforms and one recently 
described mRNA transcript. The first of these, SERCA2a, encodes a 997 amino 
acid protein which is expressed predominantly in both cardiac and slow-twitch 
skeletal muscle cells (MacLennan et al., 1985), while SERCA2b encodes a 1042 
amino acid protein which is expressed in all tissues at a low level (Delabastie et 
al., 1990). SERCA2c encodes a 999 amino acid protein which is thought to be 
expressed in both heart and skeletal muscle cells (Dally et al., 2006, Periasamy 
and Kalyanasundaram, 2007). A SERCA2d transcript has also recently been 
described, which while having not yet been shown to yield a functional protein is 
thought to encode a 1007 amino acid protein (Kimura et al., 2005). Indeed, 
SERCA2 is thought to be the most studied of the P2A-ATPase families, especially 
in regard to its regulation (Albers, 1967).  
 
SERCA3 has six known isoforms, SERCA3a, which encodes a 999 amino acid 
protein, SERCA3b, which encodes a 1042 amino acid protein, SERCA3c, which 
encodes a 1029 amino acid protein, SERCA3d, which encodes a 1044 amino acid 
protein, SERCA3e, which encodes a 1052 amino acid protein, and SERCA3f, which 
encodes a 1033 amino acid protein (Dally et al., 2010). Unlike the isoforms of 
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both SERCA1 and SERCA2, the function and tissue specific distribution pattern of 
each SERCA3 isoform has yet to be assessed. High levels of SERCA3 expression 
have however been documented in several non-muscle cells, including platelets, 
mast cells, T cells, epithelial cells, fibroblast cells, and endothelial cells 
(Pegoraro et al., 2011). 
 
A small number of transmembrane-bound proteins capable of regulating the 
activity of SERCA have previously been identified; these including 
phospholamban, capable of regulating cardiac P2A-ATPase SERCA2a, and 
sarcolipin, capable of regulating fast-twitch skeletal muscle P2A-ATPase 
SERCA1a (MacLennan et al., 2003). These proteins are thought to act by 
interfering with a membrane-spanning segment (M2) of the transport domain 
within SERCA, stabilising the ATPase in its low affinity Ca2+ binding 
conformational state (E2) (Palmgren and Nissen, 2011).  
 
A recent study into the activity of sarcolipin on SERCA1a within rat muscle, 
found that the over expression of this protein caused a significant reduction in 
both twitch and tetanic peak force amplitude, a reduction in the maximum rate 
of contraction and relaxation, and increased fatigability with repeated electrical 
stimulation. This suggested that the over-expression of sarcolipin impaired the 
actions of SERCA1a, which as a result led to the depletion of the sarcoplasmic 
reticulum Ca2+ stores (Devés and Brodie, 1981). 
 
6.1.2.1 SERCA2 
SERCA2 is thought to be oldest of the SERCA P2A-ATPase Ca2+ pumps, and as such 
is widely distributed throughout nature (Devés and Brodie, 1981). Indeed, this 
may partially explain why it has the greatest number of modulator factors of all 
the SERCA ATPase families. 
 
The gene which encodes SERCA2 in humans is thought to contain some 26 exons, 
with each of the four SERCA2 isoforms containing the first 20 exons prior to 
exhibiting a unique C-terminal transcription pattern. SERCA2a has been shown to 
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splice out exons 21, 23, 24 and 25, combining exon 20 and exon 22 before 
terminating during the translation of exon 26. SERCA2b meanwhile has been 
found to be coded for by three different mRNAs, each of which has been shown 
to remove only exon 21, therefore combining exons 20 and 22 before terminating 
during the translation of exon 23 (Brini and Carafoli, 2009), while SERCA2c has 
been shown to splice out exons 21 and 23, combining exons 20 and 22 before 
terminating during the translation of exon 24. Finally, assuming SERCA2d is 
expressed (Albers, 1967), this recently discovered isoform has been predicted to 
contain exon 21, and to terminate just six amino acids into exon 22 (as a result 
of the alternative reading frame utilised during the translation of this exon) 
(Dally et al., 2010, Kimura et al., 2005), as is shown on Figure 6-2. 
 
 
Figure 6-2: The exon expression patterns of each of the SERCA2 isoforms.  
The pattern of exons expressed by each of the SERCA2 isoforms, where SERCA2a 
contains exons 20, 22 and 26, splicing out exons 21, 23, 24 and 25, while 
SERCA2b contains exons 20, 22 and 23, splicing out exon 21. SERCA2c contains 
exons 20, 22 and 24, splicing out exons 21 and 23, while SERCA2d contains exons 
20, 21 and 22. The letter T is used to indicate the introns termination site. 
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It is because of this mRNA sequence homology that the first 993 amino acids of 
each SERCA2 isoform are identical, each differentiated based solely upon a 
unique C-terminal. SERCA2a has been detailed to contain a unique four amino 
acid C-terminal, resulting from the incorporation of exon 26, while SERCA2b has 
been found to contain a 49 amino acid unique C-terminal, resulting from the 
inclusion of exon 23. SERCA2c had been found to contain a six amino acid unique 
C-terminal resulting from the inclusion of exon 24, while SERCA2d is predicted to 
express a 54 amino acid unique C-terminal, resulting from the inclusion of exons 
21 and 22, with exon 22 being translated based on an alternative reading frame 
(Delabastie et al., 1990). 
 
6.1.2.1.1 SERCA2a 
SERCA2a is thought to be expressed in both cardiac and slow-twitch skeletal 
muscle cells (MacLennan et al., 1985). It is also thought to be the major Ca2+ 
ATPase within the heart, accounting for more than 50% of the total membrane 
protein within the sarcoplasmic reticulum and thus is responsible ensuring 
normal contractility in the working myocardium (Dally et al., 2010). 
 
A recent study into cardiac dysfunction led to an experiment being conducted in 
transgenic mice in which either SERCA1a or SERCA2a was over-expressed. It was 
found that even when the mRNA encoding SERCA2a was increased 2-4 fold that 
only a 20 – 30% increase in endogenous SERCA2a expression was detected, 
leading to both an increase in the velocity at which Ca2+ was transported into the 
sarcoplasmic reticulum and an increase in maximum rate of contraction and 
relaxation within the heart. When SERCA1a was over-expressed by 2-2.5 fold 
however, the expression of SERCA2a was seen to drop by 50%, also leading to a 
decrease in L-type Ca2+ channel expression. This would suggest that SERCA2a can 
be substituted by SERCA1a within the heart, and that isoform specificity is not 
absolute (Periasamy and Huke, 2001). Furthermore, a study conducted into the 
intracellular location of the SERCA2 isoforms within human cardiomyocytes 
found SERCA2a to be present in both transverse and longitudinal immunostaining 
assays. This would suggest that SERCA2a is widely expressed throughout the 
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sarcoplasmic reticulum, including those locations which are in close proximity to 
the T-tubules (Whittam and Wheeler, 1970). 
 
6.1.2.1.2 SERCA2b 
SERCA2b is thought to be expressed at a low level in both muscle and non-
muscle cells and as such is thought to fulfil a house-keeping role in maintaining 
cellular Ca2+ levels (Lytton et al., 1992, Delabastie et al., 1990). It has been 
suggested however that the expression of SERCA2b may be induced in response 
to cellular stress (Wang et al., 2011). 
 
When both SERCA2a and SERCA2b were compared in terms of their ability to 
transport Ca2+, SERCA2b was found to have a twofold higher affinity towards Ca2+ 
than SERCA2a, but also to have a 50% lower Ca2+ turnover rate (Wang et al., 
2011). This variation in both affinity and Ca2+ turnover is thought to result from 
the varying C-terminal sequences expressed by each isoform, where the 49 
amino acids unique to SERCA2b are mostly hydrophobic and have been shown to 
create an extra transmembrane segment within the structure of the protein, 
shifting the C-terminal of the isoform from the cytoplasm to the lumen. This 
change in conformation is thought to stabilise SERCA2b within its Ca2+ binding 
conformation (E1), accounting for the high Ca2+ binding affinity of this isoform 
(Pegoraro et al., 2011).  
 
The ability of SERCA2b to act as a substitute for SERCA2a within cardiac muscle 
cells has also been investigated. On assessing the expression levels of SERCA2 
within SERCA2a −/− transgenic mice, the expression levels of SERCA2b were seen 
to increase, however the overall expression of SERCA2 within the cell was only 
50% of that of the wild type. In 40% of cases, this resulted in embryonic or 
neonatal mortality, while those specimens which did survive showed mild 
concentric hypertrophy and impaired relaxation and contraction kinetics (Ver 
Heyen et al., 2001).  
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In regard to the intracellular expression pattern of SERCA2b, SERCA2b was 
detected only during the transverse immunostaining of human cardiomyocytes, 
suggesting the expression of this protein may be restricted to those areas of the 
sarcoplasmic reticulum which run parallel to both the actin and myosin, but not 
those areas which are in close proximity to the T-tubules (Whittam and Wheeler, 
1970). 
 
6.1.2.1.3 SERCA2c 
SERCA2c is thought to be expressed in both heart and skeletal muscle cells and is 
thought to exist only in Homo sapiens (Whittam and Wheeler, 1970, Dally et al., 
2006, Periasamy and Kalyanasundaram, 2007). While very little data has been 
published detailing the specific function of SERCA2c, SERCA2c is thought to have 
a lower binding affinity for Ca2+ than either SERCA2a or SERCA2b, but to have a 
high Ca2+ turnover rate, similar to that of SERCA2b (Whittam and Wheeler, 
1970). 
 
In regard to the intracellular expression pattern of SERCA2c, SERCA2c was found 
to be restricted to the intercalated discs and the subplasmalemmal areas of 
human cardiomyocytes. Indeed, these are the areas of the cell where the 
cytoplasmic Ca2+ concentrations are highest, which helps to explain both the 
expression of SERCA2c in those areas and the lower binding affinity of this 
isoform towards Ca2+ (Skou, 1960, Whittam and Wheeler, 1970).  
 
Proceeding from the end of exon 20 (the point at which SERCA2d differentiates 
through the inclusion of exon 21) SERCA2c incorporates exon 22 (present in 
SERCA2a, b & c) before terminating during the translation of exon 24 (which 
provided SERCA2c with its unique six amino acid c-terminal). 
 
6.1.2.1.4 SERCA2d 
A new SERCA2 mRNA has recently been described, SERCA2d, which is predicted 
to code for a 1007 amino acid protein. Unlike SERCA2a, b and c, SERCA2d 
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contains exon 21, leading to a frame shift in the translation of exon 22, 
transcribing a unique C-terminal before encountering a premature stop codon 
(Kimura et al., 2005). The predicted protein sequence for SERCA2d has been 
described by both (Berchtold et al., 2000) and (Albers, 1967), however, no 
protein product has as yet been identified for this isoform. 
 
6.1.2.1.5 SERCA2 Oxidation as a Disease Biomarker 
Nitric oxide (NO) is produced within the body through the degradation of Arg to 
L-citrulline based upon the action of nitric oxide synthase (NOS) (Knyushko et 
al., 2005). Indeed both NO and L-citrulline are of great biological importance, 
with L-citrulline being involved in the efficient removal of ammonia from the 
body and NO being involved in the modulation of blood flow, thrombosis, and 
neural activity (Luiking et al., 2010). NO can however react with a mitochondrial 
by-product superoxide (O2•−) to form a powerful oxidant, peroxynitrite (ONOO-), 
capable of nitrating tyrosine residues to 3-nitrotyrosine. Indeed 3-nitrotyrosine 
modified proteins have been observed in over 80 different pathologies in a 
variety of tissues (Ischiropoulos, 1998).   
 
The levels of 3-nitrotyrosine modified SERCA2a (nitrated at both Tyr294 and 
Tyr295) within skeletal muscle has recently been shown to increase with age, 
with young adults expressing 1.0 ± 0.5 mol of nitrotyrosine/mol of SERCA2a, in 
comparison to the elderly where 3.5 ± 0.7 mol of nitrotyrosine/mol of SERCA2a 
has been measured. This correlates to a 40% loss in Ca-ATPase activity (Knyushko 
et al., 2005). The nitration of SERCA2a within cardiac muscle has also been 
investigated because mitochondria account for approximately 1/3 of the volume 
of a cardiomyocyte, and the potential for peroxynitrate to modify SERCA2a 
(which accounts for up to 50% of the total membrane protein within the 
sarcoplasmic reticulum (Dally et al., 2010)) is increased (Lokuta et al., 2005). 
This study found that nitrated SERCA2a was increased in dilated cardiomyopathy 
(DCM) related heart failure as a result of Ca2+ pump failure (Lokuta et al., 2005). 
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6.2 Project Aims 
In addition to developing a technique capable of quantifying each of the SERCA2 
isoforms in a range of tissues, a peptide will also be selected which is capable of 
quantifying the frequency at which SERCA2 is nitrated. Therefore, the 
development of a SERCA2 based quantitative technique should allow for the 
assessment of: (i) Which SERCA2a isoforms are expressed within a tissue, and 
whether SERCA2d is translated into a functional protein (by detecting isoform 
specific target peptides). (ii) The concentration at which each SERCA2 isoform is 
expressed (by detecting both the isoform specific target and synthetic AQUA 
peptide), and (iii) How both the SERCA isoform expression ratios, and the 
frequency at which SERCA2 is nitrated, vary under different physiological 
conditions. As such, during this part of the project I aim to: (i) Screen each of 
the previously detailed SERCA2 isoforms, identifying and selecting suitable AQUA 
peptides for the absolute quantification of each protein, and (ii) Screen SERCA2 
with the aim of identifying a suitable AQUA peptide for the absolute 
quantification of nitrated Tyr294 and Tyr295. 
 
6.3 SERCA2 Specific Methods 
6.3.1 3-Nitrotyrosine Generation 
Some 25 pmol of AQUA peptide GLNQDCCVVYR was reduced and alkylated, with 
DTT and IAA, respectively. The alkylated peptide was nitrated with either: (i) 3-
Morpholinosydnonimine hydrochloride (SIN-1) for one hour at 37 oC, as has been 
described by (Richards et al., 2006); (ii) Tetranitromethane (TNM) for one hour 
at 37 oC, as has been described by (Yamada et al., 1990), or with (iii) Sodium 
nitrite (NaNO2) for one hour at 37 oC, as has been described by (Ohshima et al., 
1990). Each reaction was performed at a 1:1 ratio, a 1:500 ratio and a 1:1000 
ratio of peptide to nitrating agent (mol:mol), prior to undergoing a Zip-Tip based 
cleanup and a MALDI-ToF based analysis on an Ultraflex II. 
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6.4 Results and Discussion 
6.4.1 AQUA Peptide Selection 
While each of the five PDE4B isoforms had unique N-terminals, with PDE4B1 
containing 93 residues of unique sequence, PDE4B2 containing 39 residues of 
unique sequence, PDE4B3 containing 78 residues of unique sequence and PDE4B5 
containing 15 residues of unique sequence, the SERCA2 isoforms are much more 
homologous, with SERCA2a containing only four residues of unique sequence, 
SERCA2b containing 49 residues of unique sequence, SERCA2c containing only 6 
residues of unique sequence and SERCA2d predicted to contain 54 residues of 
unique sequence, making the selection of suitable AQUA peptides increasingly 
difficult. 
 
While the A-Raf family of protein isoforms were also differentiated based upon 
unique C-terminal sequence, A-Raf WT contained an extensive unique C-terminal 
sequence and A-Raf Short contained intronic sequence, each reducing the 
homology of those particular isoforms, and thus increasing the likelihood of a 
suitable AQUA peptide being identified. 
 
Through the use of the AQUA peptide selection workflow, four AQUA peptides 
were selected for the quantification of each of the four SERCA2 isoforms and a 
single additional AQUA peptide selected for the quantification of nitrated 
SERCA2 (Table 6-1). 
 
Table 6-1: The AQUA peptides selected for the quantification of each of the 
SERCA2 isoforms and nitrated SERCA2.  Each of the AQUA peptides selected for 
the quantification of each of the four PDE4B isoforms. 
Peptide Protease Present in: Comments: 
NYLEPAILE Trypsin SERCA2a 
As this peptide has an N-terminal Asn residue, then it should be 
ordered with extended sequence to the N-terminal and cleaved 
with trypsin during sample preparation. 
FVARNYLEPGK Lys-C SERCA2b Located within the unique C-terminal of SERCA2b. 
NYLEPVLSSEL Trypsin SERCA2c 
As this peptide has an N-terminal Asn residue, then it should be 
ordered with extended sequence to the N-terminal and cleaved 
with trypsin during sample preparation. 
CVSAHLP Asp-N SERCA2d Located within the unique C-terminal of SERCA2d. 
IRGAIYYF Glu-C All four SERCA2 
isoforms 
Cleaved with Chymotrypsin, which has documented to undergo 
non-specific proteolytic cleavage. 
279 
 
6.4.2 SERCA2 Nitration  
As pre-nitrated Fmoc SPPS Tyr residues are commercially available, it should be 
possible to chemically synthesise a pre-nitrated version of AQUA peptide 
IRGAIYYF. If an accurate quantification is to be undertaken on the frequency at 
which each Tyr residue is nitrated in vivo however, several nitrated AQUA 
peptide species must be synthesised, one of which is only nitrated at Tyr294, one 
which is only nitrated at Tyr295, one which is nitrated at both Tyr294 and Tyr295, 
and one which is nitrated at neither Tyr294 or Tyr295. For this quantitative 
technique to be validated however, an intact nitrated SERCA2 protein must also 
be produced. 
 
Due to the various pathologies in which 3-nitrotyrosine modified proteins have 
been observed (Ischiropoulos, 1998), several techniques already exist which 
enable the nitration of intact proteins under relatively mild conditions (Gow et 
al., 1997), these include the application of SIN-1, TNM or NaNO2. Of these three 
nitration methods, the process through which SIN-1 is applied to the nitration of 
Tyr best mimics that which occurs in vivo. In brief, when SIN-1 is introduced to a 
sample with a pH greater than pH 7 (Bohn and Schönafinger, 1989), SIN-1 
spontaneously decomposes. In doing so, it consumes oxygen and releases 
equimolar volumes of both NO and O2.− (Richards et al., 2006, Ashki et al., 
2008). SIN-1 based nitration has, however, been found to increase the level of 3-
nitrotyrosine in HepG2 cells from 23.2% to just 59.2% (Yasuda et al., 2007) and 
thus is somewhat inefficient. 
 
While TNM is used in the manufacture of explosives, the technique through 
which TNM is applied to the nitration of Tyr is also considered mild, in that the 
reaction is conducted under mild pHs, ionic strengths and temperatures 
(Subbarao and Kenkare, 1977). Indeed TNM is  seen as being the method of 
choice for protein nitration (Ischiropoulos, 1998). While TNM is thought to react 
specifically with Tyr, oxidation of Cys has also been documented (Sokolovsky et 
al., 1966). It is therefore imperative that Cys residues are blocked with IAA prior 
to the application of TNM. Indeed, while Trp and Met can also readily undergo 
oxidation, their oxidation has not been recorded during TNM based Tyr nitration. 
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Furthermore, as none of the AQUA peptides selected for the quantification of 
SERCA2 contain either Trp or Met, the use of this nitrating agent would appear 
ideal. 
 
As TNM has been documented as being carcinogenic, any un-reacted TNM will be 
quenched through the application of 2-mercaptoethanol (Klevan and Tse, 1983), 
which is capable of quenching TNM, but will not to reverse the nitration 
(Subbarao and Kenkare, 1977). 
 
Finally, the acidification of NaNO2 can also be applied to the nitration of Tyr. 
This technique had been found to yield efficiencies of up to 90% when the two 
components are combined at an equimolar ratio (Radabaugh et al., 2008). While 
this reaction is conducted at a pH lower than pH 1, and thus is not particularly 
mild, this method of nitration is both less toxic than TNM and more efficient 
than SIN-1 (Oldreive et al., 1998).   
 
6.4.2.1 Optimisation of Tyr Nitration  
In order to test the relative efficiency with which SIN-1, TNM and NaNO2 are 
capable of nitrating a Tyr containing peptide, A-Raf AQUA peptide 
GLNQDCCVVYR was subjected to nitration under three different ratios of 
peptide:nitrating agent (mol:mol), including 1:1, 1:500 and 1:1000. 
 
While only an unmodified parent ion peak was detected during the SIN-1 based 
nitration (data not shown), confirming this technique to be too inefficient for 
the nitration of SERCA2, the spectra obtained from the TNM based nitration 
contained no peaks (data not shown), not even those of the unmodified parent 
ion. This would suggest the TNM was either too harsh for use in the nitration of 
the Tyr containing peptide, possibly degrading the peptide into smaller 
constituents (though none were identified on the mass spectrum), or that the 
TNM interfered with the Zip Tip based purification of the nitrated peptide, 
explaining the blank spectrum. 
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The NaNO2 based nitration of AQUA peptide GLNQDCCVVYR appeared more 
suitable however, yielding three previously unidentified peaks with mass 
increases of +14 Da, +29 Da and +45 Da, as is shown on Figure 6-3. While the +45 
Da and +29 Da peaks are indicative of nitration, with the +49 Da increase 
equating to the addition of NO2 and the loss of a hydrogen, and the +29 Da 
increase equating to the addition of NO, and the loss of a hydrogen, the +14 Da 
peak is somewhat unexpected. While +14 Da would suggest the addition of 
nitrogen, nitrogen has a valency of three and thus its binding to a single carbon 
atom on the Tyr residue would be unfavourable. Instead, the +14 Da increase 
may indicate an ortho-quinone like oxidation product of the Tyr residue 
(Steinmann et al., 2012), as is shown on Figure 6-4. An alternative theory has 
also been proposed in which both the +29 and +14 Da peaks actually related to 
the decomposition of the +45 Da nitrated peak during the MALDI-ToF based 
analysis (Lee et al., 2007).  
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Figure 6-3: The nitration of alkylated AQUA peptide GLNQDCCVVYR, through 
the acidification of NaNO2.  So as to test the efficiency with which NaNO2 
nitrates Tyr residues within a peptide, an existing Tyr containing AQUA peptide, 
GLNQDCCVVYR, originally selected for the quantification of A-Raf isoforms A-Raf 
WT, DA-Raf-1 and DA-Raf-2, was modified. As can be seen above, when the 
unmodified peptide, the processing control (exposed to TFA, vacuum centrifuged 
to completion and purified via Zip Tip) and the 1:1 (mol:mol) NaNO2 nitrated 
peptide were analysed via MALDI-ToF, each was found to yield only the 
GLNQDCCVVYR parent ion. When both the 1:500 and 1:1000 NaNO2 nitrated 
peptides were analysed however, the parent ion was no longer detectable, 
instead being replaced with three peaks, one at +14 Da, one at +29 Da and one 
at +45 Da. 
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Figure 6-4: The possible nitration products of AQUA peptide GLNQDCCVVYR, 
when exposed to acidified NaNO2.  When AQUA peptide GLNQDCCVVYR was 
nitrated with NaNO2, three previously undetected peaks were identified, 
including one at +45 Da, most likely resulting from the production of 3-
nitrotyrosine, one at +29 Da, most likely from to the introduction of an NO group 
and the loss of hydrogen. Finally a +14 Da peak was identified, which may result 
from either the production of ortho-quinone or from the MALDI-ToF based 
degradation of either the +29 or +45 Da peaks. 
 
In conclusion, of the three nitrating agents applied to the nitration of AQUA 
peptide GLNQDCCVVYR, including SIN-1, TNM and NaNO2, only NaNO2 has been 
shown to yield nitrated tyrosine. While this reaction may not be complete, or 
may be complete but undergoes degradation during MALDI-ToF, this technique 
should be capable of creating a small amount of nitrated SERCA2, suitable for 
use in the optimisation of the AQUA based quantification. 
 
6.5 Conclusion 
As the SERCA2 family of proteins was the last of the three groups of isoforms to 
be analysed, much less work has been completed for SERCA2 than either A-Raf 
or PDE4B. This group of protein isoforms has, however, proven both interesting 
and unique, requiring the selection of longer than necessary AQUA peptides, 
which are co-digested with the target protein, due to the presence of N-terminal 
Asn residues, the use of Chymotrypsin, a protease which has yet to be utilised 
during this study, and the selection of an AQUA peptide unique to SERCA2d, a 
predicted protein isoform which as yet has not been proven to yield a functional 
protein. 
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Furthermore, due to the description of nitrated Tyr294 and Tyr295 in various 
physiological conditions, a peptide sequence was also selected which is capable 
of quantifying the various nitrated and un-nitrated states at which SERCA2 
isoforms may present, enabling the ratio of SERCA2 nitration to be assessed 
under a range of physiological conditions. 
 
The development of this AQUA based technique for the quantification of the 
SERCA2 isoforms can thus be seen as successful, with a single AQUA peptide 
having been selected for the quantification of each protein species. 
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7 Conclusion 
From the outset, the aims of this project have been to identify several families 
of protein isoforms, and to select suitable AQUA peptides for the quantification 
of each.  Following the development of an MRM based LC-MS acquisition method 
capable of quantifying each protein isoform within a single LC-MS run, it was 
intended that a HEK293 cell lysate would be analysed, enabling the detection 
and quantification of each endogenous protein isoform. 
 
While three families of protein isoforms have been analysed during this project, 
the rate at which work has progressed on each has been variable. The first set of 
protein isoforms to be analysed were the four A-Raf protein isoforms, as 
described in Chapter 4, for which the majority of the project aims were 
fulfilled. Indeed, in addition to aligning the sequence of each A-Raf protein 
isoform and selecting an AQUA peptide suitable for the quantification of each, 
each AQUA peptide was also characterised and optimised; so as to enable the 
development of an MRM based MS acquisition method. Furthermore, upon 
performing SOE PCR on A-Raf Short, each A-Raf isoform was expressed in 
transfected HEK293 at a quantity suitable for detection during this project. Each 
transfected HEK293 cell lysate was subjected to FLAG-tag immunoprecipitation, 
and the enriched protein used as a basis for single isoform based spiked digests, 
so as to assess the reproducibility of this quantitative technique. Finally, the 
optimised A-Raf MS acquisition method was applied to the quantification of both 
non-immunoprecipitated exogenous A-Raf expression in HEK293, and endogenous 
A-Raf expression in HEK293, though both of these analyses failed detected either 
A-Raf isoform, due to the limitations of the mass spectrometer utilised. 
 
The second set of protein isoforms to be analysed meanwhile were the four 
confirmed and one predicted PDE4B protein isoforms, as described in Chapter 5, 
and while the same level of progress was not achieved, the protein sequence for 
each PDE4B isoform was aligned, and a suitable AQUA peptide selected for the 
quantification of each. Each of the PDE4B AQUA peptides were then 
characterised and optimised; so as to enable the development of an MRM based 
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MS acquisition method. Furthermore, upon transferring each PDE4B insert to 
pcDNA3 or pcDNA3.1(+), and FLAG-tagging each insert, so as to enable a rapid 
enrichment, each PDE4B isoform was expressed in transfected HEK293 at a level 
suitable for detection during this project. Finally, each transfected HEK293 cell 
lysate was FLAG-tag immunoprecipitated, using the enriched protein as a basis 
for single isoform based spiked digests, so as to assess the reproducibility of this 
quantitative technique. Indeed, while the MS acquisition method developed for 
the quantification of PDE4B was complete, this technique was not applied to the 
absolute quantification of endogenous PDE4B expression, due both to the 
negative results obtained from the endogenous A-Raf quantification, but also as 
a result of time constraints. 
 
Finally, the last set of protein isoforms to be analysed were the three confirmed 
and one predicted SERCA2 protein isoforms, as detailed in Chapter 6, and while 
this set of protein isoforms was explored only in brief, due to time constraints, 
the sequence for each SERCA2 isoform was aligned, and a suitable AQUA peptide 
selected for the quantification of each. Furthermore, an AQUA peptide was also 
selected for the quantification of nitrated SERCA2, a PTM which has been linked 
to more than 80 different pathologies in a variety of Homo sapiens tissues 
(Ischiropoulos, 1998). 
 
Indeed, of the 11 confirmed protein isoforms and two predicted protein isoforms 
explored during this study, it has been possible to select a suitable AQUA 
peptide for the quantification of each, although each family of protein isoforms 
presented the author with unique challenges. For example, when the four A-Raf 
protein isoforms were explored, each of which exhibited a homologous N-
terminal, and three of which were translated from a truncated version of the A-
Raf WT mRNA, it was necessary to explore the quantification of unique C-
terminal peptides, subtraction based quantification, the selection of peptides 
which included reactive amino acids and the selection of peptides cleaved 
through the use of non-ideal proteases. To the author’s knowledge no 
publications have yet explored the quantification of an entire family of protein 
isoforms, nor the use of such intricate peptide selection techniques, such as 
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subtraction based quantification, thus this work significantly advancing the field 
of absolute protein quantification. 
 
Furthermore, when assessing the four confirmed PDE4B protein isoforms, and the 
one predicted PDE4B protein isoform, each of which exhibited a homologous C-
terminal and was differentiated based upon a unique N-terminal, it was 
necessary to explore the use of several proteases, so as to maximise the number 
of candidate peptides which could be generated from the limited amounts of 
unique sequence. In addition, where a suitable AQUA peptide was not identified, 
subtraction based quantification was again employed. As was previously 
mentioned, to the author’s knowledge the use of subtraction based 
quantification has not yet been explored in an AQUA based quantification. 
Furthermore, this specific set of protein isoforms provided the author with an 
opportunity to develop an AQUA based quantitative technique which should 
enable the confirmation of a predicted protein, a process which is more 
commonly based upon either immunoblotting (Shepherd et al., 2003), or LC-MS ( 
through analysing a cell lysate with the aim of identifying each of the proteins 
contained within) (Lamontagne et al., 2010). Indeed while the MS sensitivity 
achieved during this project did not allow for the exploration of endogenous 
protein expression levels, this technique should enable others to both quantify 
endogenous PDE4B expression, but also to confirm the existence of PDE4B4. 
 
Indeed, utilising an AQUA based approach to confirm a predicted protein has 
several advantages over both immunoblotting and LC-MS. For example, if an 
antibody is to be raised against a predicted protein, a biomolecule which shares 
a certain amount of sequence homology must serve as an antigen (such as a 
protein isoform generated from the same pre-mRNA), restricting the use of this 
technique. Furthermore, any proteins which do share a degree of homology must 
have a significantly different MW to that of the predicted protein, if a 
differentiation is to be achieved. Finally, LC-MS based proteomic analyses are 
most commonly performed through the use of bottom-up based proteomics 
(Zhang et al., 2010), a technique through which only those peptides which are 
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present in each of the protein isoforms will be detected, rendering highly 
homologous proteins indistinguishable (Wu et al., 2009). 
 
Finally, when the three confirmed SERCA2 protein isoforms, and one predicted 
SERCA2 protein isoform were explored, each of which exhibited a homologous 
993 amino acid N-terminal and was differentiated based upon a region of unique 
C-terminal sequence (ranging from 4 to 54 amino acids in length), it was again 
necessary to explore the selection of unique C-terminal peptides, the use of 
several non-ideal proteases, and indeed the selection of longer than necessary 
AQUA peptides which require a proteolytic digestion step to yield the final AQUA 
product. To the author’s knowledge no data has yet been published which 
explores the use of AQUA peptides which require a proteolytic digest step, 
however, this technique is somewhat similar to both PSAQ and QconCAT. 
 
While QconCAT utilises an artificial protein, constructed of several Qpeptides, 
and thus also requires a proteolytic digest step, this technique would be non-
ideal for use on C-terminal peptides as C-terminal peptides require only a single 
digest step, while each Qpeptide would require two, reducing the accuracy of 
this technique. In the case of PSAQ, while the digest efficiency of both the 
target and labelled proteins would be identical, the in vitro synthesis and 
subsequent quantification of the labelled protein would require considerable 
effort so as to enable the quantification of a single target peptide. 
 
As such, while the quantitative techniques explored during this study have been 
based upon existing technologies, the further development of these methods has 
enabled their application in a completely different field of research, the 
exploration and quantitation of protein isoforms. Indeed while previously the 
selection of proteotypic peptides has been the cornerstone of a successful AQUA 
quantitation, this project has shown that both non-ideal peptides and non-ideal 
proteases may be utilised so as to enable a quantitative analysis. Finally, while 
the overall aim of this project, the absolute quantification of endogenous 
protein isoforms, was not achieved, the factor limiting this achievement was the 
MS instrumentation available for use. 
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7.1 Significance of this Research 
Increasingly complex sets of proteins have being quantified through the use of 
synthetic, isotopically-labelled, internal standards since the first description of 
AQUA in 2003 (Gerber et al., 2003a). Initially this form of quantitative analysis 
was restricted to the quantification of single protein species (Gerber et al., 
2007, Gerber et al., 2003a). Two such low-abundance proteins were quantified 
in an unspecified whole yeast lysate (Sir2 and Sir4), for which protein expression 
levels of 1,750 molecules per cell and 1,150 molecules per cell were identified, 
respectively (Gerber et al., 2003a). 
 
More recently QconCAT was applied to the absolute quantitation of 27 proteins 
involved in the glycolytic pathway of Saccharomyces cerevisiae (Carroll et al., 
2011). From this study, protein expression levels of between 14,000 and 10 
million molecules per cell were identified (Carroll et al., 2011). Furthermore, 
work is underway to quantify at least 4,000 proteins from Saccharomyces 
cerevisiae, again based upon the use of QconCAT (Brownridge et al., 2011), 
suggesting the field of quantitative proteomics may still be in its infancy. 
 
Fewer sets of protein isoforms have thus far been quantified however, and to 
the author’s knowledge, the absolute quantitation of a complete family of 
protein isoforms has yet to be explored. Those families of protein isoforms which 
have been quantified include: (i) Three of five known sucrose synthase isoforms 
from the root nodules of Medicago truncatula, for which concentrations of 
between 0.3 and 160 fmol/µg of protein were identified (Wienkoop et al., 2008), 
and (ii) Several members of the Cytochrome P450 superfamily of protein 
isoforms in human liver microsomes, from which a LLOQ of approximately 20 
fmol was achieved (a value which is defined as being three times the LoD 
(Addona et al., 2009)) (Wang et al., 2008b). 
 
During this study three complete sets of protein isoforms have been explored, A-
Raf, PDE4B and SERCA2. However, when a HEK293 cell lysate was probed to 
assess its endogenous expression of A-Raf, none of the four A-Raf isoforms was 
identified. The failure of this experiment can be traced to two main problems. 
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Firstly, the majority of the work completed during this project was conducted on 
an API 2000 MS, an instrument with a LoD for Reserpine of 50 pg, relatively 
insensitive in comparison to most modern triple quadrupole based mass 
spectrometers. Secondly, when a limited amount of instrument time became 
available on a QTrap 5500, the sub-optimal instrument parameters set in the A-
Raf MRM acquisition method failed to fully utilise the sensitivity offered by this 
device, which has a LoD for Reserpine of just 50 fg.  
 
To better explain, when the API 2000 A-Raf MRM based acquisition method was 
imported to an optimised QTrap 4000 MS, the LoD for AQUA peptide 
GLNQDCCVVYR fell from 5 pmol to just 15 fmol, comparable to the femtomolar 
levels of protein expression detected during other published quantitative 
analyses (Wang et al., 2008b, Wienkoop et al., 2008). Based upon this increase 
in sensitivity, if the QTrap 5500 were fully optimised, the LoD for GLNQDCCVVYR 
should fall to just 5 fmol, increasing the likelihood of endogenous A-Raf being 
detected. Indeed AB SCIEX has just recently released a new QTrap instrument, 
the QTrap 6500, which offers a 10 x increase in sensitivity over the QTrap 5500. 
This would suggest that a LoD as low as 500 amol could be achieved for A-Raf 
limiting peptide GLNQDCCVVYR. Indeed the only factor limiting the 
quantification of endogenous A-Raf expression is the sensitivity offered by the 
MS instrument utilised, which if not detectable on either the QTrap 5500 or 
QTrap 6500, should be detectable upon the release of new instrumentation in 
the future. 
 
Despite the poor LoDs achieved during this study, this AQUA based quantitative 
technique still offers researchers many advantages over other methods of 
isoform quantitation, including antibody based techniques such as western 
blotting, gene expression based techniques such as qPCR, and general LC-MS 
based quantitative techniques. Regarding quantitation based on the use of an 
antibody, each targeted protein isoform must present with significantly different 
MW’s, if each isoform is to be differentiated. Furthermore, if mRNA expression is 
to be used as an indicator of protein concentration, it should be noted that not 
all mRNAs are translated into functional proteins, and that those which are may 
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be translated at different rates. Finally, if a non-isoform specific LC-MS based 
quantitative method is used, only those peptides which are present in multiple 
protein isoforms will be detected, rendering highly homologous proteins 
indistinguishable (Wu et al., 2009).  
 
The description of this AQUA based technique for the quantitation of protein 
isoforms thus offers researchers a new tool to both confirm the expression of 
predicted proteins, and to quantify known protein isoforms. 
  
7.2 Further Research 
While the mass spectrometers available for use during the development of this 
quantitative method have hindered progress, it is the author’s opinion that 
several other aspects of this project could be improved upon.  
 
Firstly, when Cys containing AQUA peptides GLNQDCCVVYR, VPTVCVDMSTNRQQ, 
DYFECSLSK and NSPCFFR were ordered, each was intentionally selected with a 
reduced sulfhydryl group, so as to ensure both the synthetic peptide and the 
target protein were alkylated with an equal efficiency. Upon reviewing the 
efficiency of the IAA based alkylation however, the reaction appeared complete. 
Instead, through choosing to reduce and alkylate each of the Cys containing 
AQUA peptide separately, considerable sample losses were incurred, most likely 
as a result of non specific peptide binding (Speicher et al., 2000). If each Cys 
containing AQUA peptide was to be re-ordered pre-alkylated, each should enable 
a more reliable quantitation.  
 
Secondly, when an AQUA based protein quantification is conducted on a complex 
protein sample such as a cell lysate, an alternative method of protein 
purification may be more appropriate. While 1D-SDS-PAGE enables the number 
of proteins permitted to the proteolytic digest step to be reduced considerably, 
it relies upon the excision of a single gel band for each protein isoform, which 
are then combined and digested in a single tube, a process which is prone to 
both inter-gel variability and human error. Furthermore, only a relatively small 
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number of samples can be run on a single 1D-SDS-PAGE gel, where a 4-12% Bis-
Tris gel contains 10 wells, in which only five samples were run, leaving a blank 
well between each sample so as to prevent mixing. A suitable sample cleanup 
technique may instead be solid-phase extraction, a method which enables 
sample multiplexing, orthogonal sample purification and faster sample cleanup 
and elution (Nissum et al., 2004).  
 
Thirdly, when complex samples such as mixed isoform spiked digests and HEK293 
cell lysates were analysed, additional MRM peaks were detected which often 
interfered with the integration of either the IS or analyte peaks. These peaks 
most likely resulted from the detection of proteolytic peptides with m/z’s 
similar to those of targeted peptides, where the Q1 and Q3 MS transmission 
windows used during this study were set to permit ions within 1.2 ± 0.2 amu of 
the target m/z to reach the collision cell/detector. A method for reducing the 
number of interfering peaks may be to modify the Q1 and Q3 transmission 
window parameters, so as to permit only those ions within 0.7 ± 0.1 amu of the 
target m/z to reach the collision cell/detector. Alternatively SISCAPA based 
peptide purification could also be applied to reduce the complexity of the 
lysate, post-proteolytic digestion. Through reducing the complexity of the 
peptide sample, fewer undesirable MRM peaks should be detected, while 
lowering the background MS noise detected. 
 
Aside from the improvements detailed above, the overall aims behind the 
development of this quantitative method included (i) The identification of which 
protein isoforms from a particular protein family are expressed within a given 
tissue. (ii) The accurate quantification each isoform detected, and (iii) The 
detection of changes in the isoform expression ratio under different 
physiological conditions. These aims thus set the scene for any future work 
which may be conducted upon the completion of this project. 
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7.3 Final Conclusion 
While comparative and quantitative proteomic technologies have not yet 
progressed to the same extent as genomic and transcriptomic technologies in 
their ability to access differential gene expression (Roulhac et al., 2011), new 
mass spectrometers and analytical quantitative techniques are being released 
regularly, offering increased sensitivity, dynamic range, resolution and 
specificity to the field of proteomics. 
 
Indeed proteomics only progressed beyond the limitations of 2DGE in the early 
1990s with the description of soft biomolecule ionisation, enabling proteomic 
analyses to be performed based upon the use of mass spectrometry (Falk et al., 
2006). Even then, proteomic research has required the development of a whole 
new range of complex multi-stage mass spectrometers, so as to enable peptide 
fragmentation, peptide/protein sequencing and PTM identification (Domon and 
Aebersold, 2006). 
 
In regard to quantitative proteomics, the first MS based quantitative technique, 
15N labelling, was described as recently as 1999 (Oda et al., 1999), while the 
first stable isotopically labelled internal standard based absolute quantitative 
technique was described less than a decade ago (Gerber et al., 2003a).  
 
Building upon these successes, this project has explored the use of stable 
isotopically labelled internal standard peptides so as to enable the 
quantification of complete families of protein isoforms, and in doing so has 
investigated the use of novel non-ideal peptide selection criteria. 
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